WO2014119617A1 - Amidine compound and salt thereof - Google Patents

Amidine compound and salt thereof Download PDF

Info

Publication number
WO2014119617A1
WO2014119617A1 PCT/JP2014/051966 JP2014051966W WO2014119617A1 WO 2014119617 A1 WO2014119617 A1 WO 2014119617A1 JP 2014051966 W JP2014051966 W JP 2014051966W WO 2014119617 A1 WO2014119617 A1 WO 2014119617A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
optionally substituted
substituted
methyl
added
Prior art date
Application number
PCT/JP2014/051966
Other languages
French (fr)
Japanese (ja)
Inventor
正弘 竹林
康裕 筒井
歩夢 森
加藤 智也
宣知 藤野
Original Assignee
富山化学工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富山化学工業株式会社 filed Critical 富山化学工業株式会社
Publication of WO2014119617A1 publication Critical patent/WO2014119617A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms

Definitions

  • the present invention relates to a novel amidine compound having an antifungal activity or a salt thereof, and an antifungal agent containing them.
  • Non-patent Document 1 Serious deep mycosis such as invasive candidiasis is often a fatal disease.
  • the main defense mechanism on the host organism side against fungi such as Candida is considered to be due to non-specific immunity by neutrophils. If this defense mechanism is functioning normally, there is little risk of infection with fungi.
  • the number of patients with underlying diseases such as malignant tumors and AIDS that cause a decline in the immune function of this living body, frequent use of anticancer drugs and immunosuppressants, heavy use of antibacterial antibiotics and steroid hormones, and long-term focus
  • amphotericin B has a very strong bactericidal action, but has side-effects such as nephrotoxicity and is limited in clinical use. Since flucytosine has problems such as resistance, it is rarely used alone at present. Caspofungin and Micafungin are weakly active against the genus Cryptococcus.
  • Non-Patent Document 2 All other drugs are collectively referred to as azole antifungal agents, and their bactericidal action tends to be generally inferior to that of amphotericin B, but is currently most frequently used due to the balance between efficacy and safety.
  • Non-patent Document 3 The problem of resistance has a serious impact on the management of patients with deep mycosis, which is steadily increasing (Non-patent Document 3).
  • onychomycosis caused by ringworm is a kind of superficial mycosis and is an intractable disease that requires 3 to 6 months for its treatment.
  • itraconazole and terbinafine are used for the treatment.
  • both drugs cannot be said to have a sufficient cure rate, and recurrence has been observed (Non-patent Documents 4 and 5).
  • Terbinafine must be taken every day for 6 months, and it has been pointed out that medication compliance is poor due to long-term administration (Non-patent Document 6).
  • side effects were observed in approximately 10% or more of both drugs, and abnormal laboratory values such as liver function test values were confirmed in about 5% of patients.
  • Itraconazole is known to show drug interactions with many other drugs.
  • amidine compounds of the present invention or salts thereof having antifungal activity against pathogenic fungi, and antifungal agents containing them have never been known so far.
  • An object of the present invention is to provide a novel compound that exhibits excellent antifungal activity against pathogenic fungi including Candida, Aspergillus, and ringworm, and is useful as a pharmaceutical.
  • R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, or an optionally substituted C 2- 6 alkenyl group, optionally substituted C 2-6 alkynyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 alkoxy group, optionally substituted A C 1-6 alkylamino group, an optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, a substituted Arylthio group which may be substituted, aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, protected Good amino group, An optionally
  • Z 1 and Z 2 are the same or different and are each a nitrogen atom or a general formula CR c wherein R c is a hydrogen atom, a halogen atom, a cyano group, a nitro group, or an optionally substituted C 1-6 alkyl.
  • R 1 and R 2 are the same or different and are each a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, a substituted An optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted C 1-6 alkylamino group , An optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, an optionally substituted arylthio group, Aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, amino group which may be protected, protected May A hydroxyl group or an
  • R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2 ⁇ A 6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted monocyclic heterocyclic group; or An optionally substituted cyclic amino group formed by R 4 and R 5 together with the nitrogen atom to which they are attached;
  • X 1 is a sulfur atom, a methylene group, or a group represented by the general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group.
  • Z 1 and Z 2 are the same or different and are a nitrogen atom or a group represented by the formula CH;
  • the compound represented by the general formula [1] or a salt thereof has excellent antifungal activity and is useful as an antifungal agent.
  • the compound represented by the general formula [1] or a salt thereof is excellent in safety and is useful as an antifungal agent against Candida, Aspergillus, and Trichophyton.
  • a halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • C 1-6 alkyl group means, for example, linear or branched C 1 such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl and hexyl groups.
  • -6 means an alkyl group.
  • the C 1-6 alkylene group means a linear or branched C 1-6 alkylene group such as methylene, ethylene, propylene, butylene and hexylene groups.
  • C 2-6 alkenyl group means, for example, linear or branched C 2-6 alkenyl such as vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, 1,3-butadienyl, pentenyl and hexenyl groups Means a group.
  • C 2-6 alkynyl group for example, ethynyl, propynyl, butynyl, straight or branched C 2-6 alkynyl group such as pentynyl and hexynyl groups.
  • C 3-8 cycloalkyl group means a C 3-8 cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
  • An aryl group means, for example, a phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, dihydronaphthyl, benzocycloheptyl, dihydro-5H-benzocycloheptenyl or 5H-benzocycloheptenyl group.
  • the Al C 1-6 alkyl group for example, refers to a benzyl, diphenylmethyl, trityl, Al C 1-6 alkyl groups such as phenethyl and naphthylmethyl groups.
  • C 1-6 alkoxy group means, for example, linear or branched C groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy groups Means a 1-6 alkyloxy group;
  • the al C 1-6 alkoxy group means an al C 1-6 alkyloxy group such as benzyloxy, phenethyloxy and naphthylmethyloxy groups.
  • An aryloxy group means, for example, a phenoxy or naphthyloxy group.
  • the C 1-6 alkoxy C 1-6 alkyl group means, for example, a C 1-6 alkyloxy C 1-6 alkyl group such as methoxymethyl and 1-ethoxyethyl group.
  • the ar C 1-6 alkoxy C 1-6 alkyl group means an ar C 1-6 alkyloxy C 1-6 alkyl group such as benzyloxymethyl and phenethyloxymethyl groups.
  • the C 2-12 alkanoyl group for example, means acetyl, propionyl, valeryl, a linear or branched C 2-12 alkanoyl group such as isovaleryl and pivaloyl groups.
  • An aroyl group means, for example, a benzoyl or naphthoyl group.
  • the heterocyclic carbonyl group means, for example, nicotinoyl, thenoyl, pyrrolidinocarbonyl or furoyl group.
  • the ( ⁇ -substituted) aminoacetyl group is, for example, an amino acid (glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, arginine, lysine, histidine, hydroxylysine. , Phenylalanine, tyrosine, tryptophan, proline and hydroxyproline and the like.)
  • the N-terminus derived from ( ⁇ -substituted) aminoacetyl group may be protected.
  • Acyl group means, for example, formyl group, succinyl group, glutaryl group, maleoyl group, phthaloyl group, C 2-12 alkanoyl group, aroyl group, heterocyclic carbonyl group or ( ⁇ -substituted) aminoacetyl group.
  • Acyl C 1-6 alkyl group for example, means an acyl C 1-6 alkyl group such as acetyl, methyl, benzoyl methyl and 1-benzoyl ethyl.
  • acyloxy C 1-6 alkyl group for example, means acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, a benzoyloxy methyl and 1- acyloxy C 1-6 alkyl group such as (benzoyloxy) ethyl.
  • C 1-6 alkoxycarbonyl group means, for example, linear or branched C 1-6 such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl and 1,1-dimethylpropoxycarbonyl groups.
  • the al C 1-6 alkoxycarbonyl group means an al C 1-6 alkyloxycarbonyl group such as benzyloxycarbonyl and phenethyloxycarbonyl groups.
  • An aryloxycarbonyl group means, for example, a phenyloxycarbonyl or naphthyloxycarbonyl group.
  • the C 1-6 alkylamino group is, for example, a linear or branched group such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino, tert-butylamino, pentylamino and hexylamino groups. It means a branched C 1-6 alkylamino group.
  • di (C 1-6 alkyl) amino group examples include dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, di (tert-butyl) amino, dipentylamino, dihexylamino, (ethyl) (methyl)
  • linear or branched di (C 1-6 alkyl) amino groups such as amino and (methyl) (propyl) amino groups are meant.
  • the C 1-6 alkylthio group means, for example, a C 1-6 alkylthio group such as methylthio, ethylthio and propylthio groups.
  • An arylthio group means, for example, a phenylthio or naphthylthio group.
  • the C 1-6 alkylsulfonyl group means, for example, a C 1-6 alkylsulfonyl group such as methylsulfonyl, ethylsulfonyl and propylsulfonyl groups.
  • An arylsulfonyl group means, for example, a benzenesulfonyl, p-toluenesulfonyl or naphthalenesulfonyl group.
  • the C 1-6 alkylsulfonyloxy group means a C 1-6 alkylsulfonyloxy group such as methylsulfonyloxy, trifluoromethylsulfonyloxy and ethylsulfonyloxy groups.
  • the arylsulfonyloxy group means, for example, benzenesulfonyloxy or p-toluenesulfonyloxy group.
  • a silyl group means, for example, a trimethylsilyl, triethylsilyl or tributylsilyl group.
  • Monocyclic nitrogen-containing heterocyclic groups include, for example, azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, dihydropyrrolyl, piperidyl, tetrahydropyridyl, pyridyl, homopiperidinyl, octahydroazosinyl, imidazolidinyl, imidazolinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, It means a monocyclic nitrogen-containing heterocyclic group containing only a nitrogen atom as a hetero atom forming the ring, such as pyrazolyl, piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, homopiperazinyl, triazinyl, triazolyl and tetrazolyl groups.
  • the monocyclic oxygen-containing heterocyclic group means, for example, a tetrahydrofuranyl, furanyl, tetrahydropyranyl or pyranyl group.
  • the monocyclic sulfur-containing heterocyclic group means, for example, a thienyl group.
  • the monocyclic nitrogen-containing / oxygen heterocyclic group is, for example, a monocyclic nitrogen-containing / oxygen containing only a nitrogen atom and an oxygen atom as hetero atoms forming the ring, such as oxazolyl, isoxazolyl, oxadiazolyl and morpholinyl groups. Means a heterocyclic group.
  • a monocyclic nitrogen-containing / sulfur heterocyclic group forms the ring such as thiazolyl, isothiazolyl, thiadiazolyl, thiomorpholinyl, 1-oxidethiomorpholinyl and 1,1-dioxidethiomorpholinyl groups
  • the monocyclic heterocyclic group is a monocyclic nitrogen-containing heterocyclic group, a monocyclic oxygen-containing heterocyclic group, a monocyclic sulfur-containing heterocyclic group, or a monocyclic nitrogen-containing / oxygen heterocyclic group. It means a group or a monocyclic nitrogen-containing / sulfur heterocyclic group.
  • Bicyclic nitrogen-containing heterocyclic groups include, for example, indolinyl, indolyl, isoindolinyl, isoindolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, tetrahydroquinolinyl, quinolyl, tetrahydroisoquinolinyl, isoquinolinyl, Bicyclic nitrogen-containing heterocyclic groups containing only a nitrogen atom as a hetero atom forming the ring, such as quinolidinyl, cinnolinyl, phthalazinyl, quinazolinyl, dihydroquinoxalinyl, quinoxalinyl, naphthyridinyl, purinyl, pteridinyl and quinuclidinyl groups Means.
  • bicyclic oxygen-containing heterocyclic group examples include 2,3-dihydrobenzofuranyl, benzofuranyl, isobenzofuranyl, chromanyl, chromenyl, isochromanyl, 1,3-benzodioxolyl, 1,3- It means a bicyclic oxygen-containing heterocyclic group containing only an oxygen atom as a hetero atom forming the ring, such as benzodioxanyl and 1,4-benzodioxanyl groups.
  • the bicyclic sulfur-containing heterocyclic group is, for example, a bicyclic sulfur-containing heterocyclic ring containing only a sulfur atom as a hetero atom forming the ring, such as 2,3-dihydrobenzothienyl and benzothienyl groups.
  • Bicyclic nitrogen-containing / oxygen heterocyclic groups include, for example, benzoxazolyl, benzisoxazolyl, benzooxadiazolyl, benzomorpholinyl, dihydropyranopyridyl, dihydrodioxynopyridyl and dihydropyridyl.
  • Bicyclic nitrogen-containing / oxygen heterocyclic group containing only a nitrogen atom and an oxygen atom as the hetero atoms forming the ring, such as a dooxazinyl group.
  • Bicyclic nitrogen-containing / sulfur heterocyclic groups are, for example, bicyclic compounds containing nitrogen and sulfur atoms as hetero atoms forming the ring such as benzothiazolyl, benzisothiazolyl and benzothiadiazolyl groups. This means a nitrogen-containing / sulfur heterocyclic group.
  • a bicyclic heterocyclic group is a bicyclic nitrogen-containing heterocyclic group, a bicyclic oxygen-containing heterocyclic group, a bicyclic sulfur-containing heterocyclic group, or a bicyclic nitrogen-containing group. -An oxygen heterocyclic group or a bicyclic nitrogen-containing / sulfur heterocyclic group.
  • the heterocyclic group means a monocyclic heterocyclic group or a bicyclic heterocyclic group.
  • Cyclic amino groups include, for example, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrrolyl, dihydropyrrolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, thiazolinyl, thiazolidinyl, dihydrothiadiazyl, Including one or more nitrogen atoms as a hetero atom forming the ring, such as homomorpholinyl, thiomorpholinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzomorpholinyl, dihydropyridoxazinyl and quinuclidinyl, Means a 3-, 4-, 5-, 6- or 7-membered, fused or bridged cyclic amino group which may contain one or more oxygen or sulfur
  • Amino protecting groups and imino protecting groups include all groups that can be used as protecting groups for conventional amino and imino groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 696-926, 2007, John Wiley & Sons (John Wiley & Sons, INC.). Specifically, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an acyl group, a C 1-6 alkoxycarbonyl group, an ar C 1-6 alkoxycarbonyl group, an aryloxycarbonyl group, Examples thereof include a C 1-6 alkylsulfonyl group, an arylsulfonyl group, and a silyl group.
  • Hydroxyl protecting groups include all groups that can be used as protecting groups for conventional hydroxyl groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 16-299, 2007, John Wiley & Sons (John Wiley & Sons, INC.).
  • a C 1-6 alkyl group a C 2-6 alkenyl group, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an ar C 1-6 alkoxy C 1- 1 6 alkyl group, acyl group, C 1-6 alkoxycarbonyl group, al C 1-6 alkoxycarbonyl group, C 1-6 alkylsulfonyl group, arylsulfonyl group, silyl group, tetrahydrofuranyl group or tetrahydropyranyl group .
  • the carboxyl protecting group includes all groups that can be used as protecting groups for ordinary carboxyl groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 533-643, 2007, John Wiley & Sons (John Wiley & Sons, INC.). Specifically, a C 1-6 alkyl group, a C 2-6 alkenyl group, an aryl group, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an ar C 1-6 alkoxy C 1 Examples include a -6 alkyl group, an acyl C 1-6 alkyl group, an acyloxy C 1-6 alkyl group, and a silyl group.
  • Examples of the leaving group include a halogen atom, a C 1-6 alkylsulfonyloxy group or an arylsulfonyloxy group.
  • Examples of the aliphatic hydrocarbons include pentane, hexane, cyclohexane, and decahydronaphthalene.
  • Examples of halogenated hydrocarbons include methylene chloride, chloroform or dichloroethane.
  • Examples of alcohols include methanol, ethanol, propanol, 2-propanol, butanol, and 2-methyl-2-propanol.
  • Examples of ethers include diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran, anisole, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, and diethylene glycol diethyl ether.
  • ketones include acetone, 2-butanone, and 4-methyl-2-pentanone.
  • esters include methyl acetate, ethyl acetate, propyl acetate, and butyl acetate.
  • amides include N, N-dimethylformamide, N, N-dimethylacetamide, and 1-methyl-2-pyrrolidone.
  • aromatic hydrocarbons include benzene, toluene, and xylene.
  • Substituent group A1 Halogen atom, a cyano group, a nitro group, one or more C 1-6 alkyl carbamoyl group which may be substituted with a group, optionally substituted with one or more groups selected from Substituent Group A2 C 1 A -6 alkoxy group, a C 1-6 alkylamino group optionally substituted with one or more groups selected from Substituent Group A2, and a substituent substituted with one or more groups selected from Substituent Group A2 A good di (C 1-6 alkyl) amino group, an aryl group which may be substituted with one or more groups selected from Substituent Group B1, and one or more groups selected from Substituent Group B1 A monocyclic heterocyclic group which may be substituted, a bicyclic heterocyclic group which may be substituted with one or more groups selected from substituent group B1, an amino group which may be protected, a protected group Optionally imino groups, optionally protected hydro A xyl
  • Substituent group A2 A halogen atom, a cyano group, a carbamoyl group, a C 1-6 alkyl group, a C 1-6 alkoxy group, an optionally protected amino group, an optionally protected hydroxyl group, and an optionally protected carboxyl group;
  • Substituent group B1 A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2.
  • Substituent group C1 A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2.
  • a C 1-6 alkylamino group which may be substituted, a di (C 1-6 alkyl) amino group which may be substituted with one or more groups selected from the substituent group A2, and a substituent group A2.
  • C optionally substituted with one or more groups 1-6 alkylthio group
  • C 3-8 cycloalkyl group optionally substituted with one or more groups selected from substituent group C2, substituted with one or more groups selected from substituent group C2 Or an aroyl group, an al C 1-6 alkyl group which may be substituted with one or more groups selected from substituent group C2, and one or more groups selected from substituent group C2.
  • Substituent group C2 Substituted with one or more groups selected from a halogen atom, a cyano group, a nitro group, an oxo group, an adamantyl group, a carbamoyl group optionally substituted with one or more C 1-6 alkyl groups, and substituent group A2.
  • a C 1-6 alkyl group which may be substituted with one or more, a C 2-6 alkenyl group which may be substituted with one or more groups selected from substituent group A2, and one or more selected from substituent group A2
  • a C 2-6 alkynyl group which may be substituted with one group, a C 1-6 alkoxy group which may be substituted with one or more groups selected from substituent group A2, and a group selected from substituent group A2
  • Substituted with two or more groups A C 1-6 alkylamino group which may be optionally substituted with one or more groups selected from substituent group A2, and a di (C 1-6 alkyl) amino group which may be substituted with 1 or more groups selected from substituent group A2.
  • Substituent group D1 A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2.
  • a C 1-6 alkylamino group which may be substituted a di (C 1-6 alkyl) amino group which may be substituted with one or more groups selected from substituent group A2, and a substituent group B1 C optionally substituted with one or more groups 3-8 cycloalkyl group, amino group which may be protected, imino group which may be protected, hydroxyl group which may be protected, carboxyl group which may be protected.
  • the amino group and the C 1-6 alkylthio group may be substituted with one or more groups selected from the substituent group A1.
  • the C 3-8 cycloalkyl group, aryloxy group, arylthio group, aryl group, monocyclic heterocyclic group and bicyclic heterocyclic group represented by R 1 and R 2 are selected from the substituent group B1. It may be substituted with more than one group.
  • R 3 dihydrobenzocyclobutenyl, indanyl, indenyl, tetrahydronaphthyl, dihydronaphthyl, benzocycloheptyl, dihydro-5H-benzocycloheptenyl, 5H-benzocycloheptenyl, hexahydrobenzo
  • the cyclooctenyl group, tetrahydrobenzocyclooctenyl group, dihydrobenzocyclooctenyl group, tetrahydromethanonaphthyl group and tetrahydroethanonaphthyl group may be substituted with one or more groups selected from the substituent group C1.
  • the C 1-6 alkyl group, C 2-6 alkenyl group and C 2-6 alkynyl group of R 4 and R 5 may be substituted with one or more groups selected from the substituent group A1.
  • the C 3-8 cycloalkyl group, aryl group and monocyclic heterocyclic group of R 4 and R 5 may be substituted with one or more groups selected from substituent group B1.
  • the cyclic amino group of R 4 and R 5 may be substituted with one or more groups selected from the substituent group D1.
  • the C 1-6 alkyl group of R a may be substituted with one or more groups selected from Substituent Group A1.
  • the C 1-6 alkyl group of R b may be substituted with one or more groups selected from Substituent Group A1.
  • the C 1-6 alkylthio group may be substituted with one or more groups selected from Substituent Group A1.
  • the C 3-8 cycloalkyl group, aryloxy group, arylthio group, aryl group, monocyclic heterocyclic group and bicyclic heterocyclic group of R c are one or more selected from the substituent group B1. It may be substituted with a group.
  • preferable compounds include the following compounds.
  • R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or a substituted
  • the compound is an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group or an optionally substituted aryl group.
  • Compounds are preferred.
  • R 1 and R 2 are the same or different and are each a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted
  • a compound that is a compound having a C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, or an optionally substituted C 1-6 alkoxy group is more preferable. More preferred is a compound wherein R 1 and R 2 are the same or different and each is a halogen atom, an optionally substituted C 1-6 alkyl group or an optionally substituted C 3-8 cycloalkyl group.
  • R 1 and R 2 may be the same or different and each may be a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-8 cycloalkyl group or an optionally substituted More preferred are compounds that are good C 1-6 alkoxy groups.
  • R 1 and R 2 are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more halogen atoms, or C 3 which may be substituted with one or more halogen atoms Even more preferred are compounds that are -8 cycloalkyl groups.
  • R 3 is an optionally substituted dihydrobenzocyclobutenyl group, an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted benzocycloheptyl group, a substituted
  • a compound which is an optionally substituted hexahydrobenzocyclooctenyl group or an optionally substituted tetrahydromethanonaphthyl group is preferred.
  • a compound in which R 3 is an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group or an optionally substituted benzocycloheptyl group is more preferable.
  • R 3 is represented by the general formula [X] "Wherein R 6 is the same or different and is a group selected from substituent group C1; R 7 is the same or different and is a group selected from substituent group C1; n is an integer of 2 to 6 M1 represents an integer of 0 to 10; m2 represents an integer of 0 to 3. ”is more preferable.
  • m 1 R 6 s are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more groups selected from Substituent Group A2, or one selected from Substituent Group A2
  • a compound which is a C 1-6 alkoxy group which may be substituted with the above groups is preferred.
  • a compound in which m1 R 6 s are the same or different and each is a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group is more preferable.
  • m1 pieces of R 6 are the same or different, compounds which are C 1-6 alkyl group is more preferred.
  • m2 R 7 s are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more groups selected from Substituent Group A2, or one selected from Substituent Group A2
  • a compound which is a C 1-6 alkoxy group which may be substituted with the above groups is preferred.
  • a compound in which m 2 R 7 s are the same or different and each is a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group is more preferable.
  • a compound in which m1 represents an integer of 0 to 4 is preferable.
  • a compound in which m1 represents an integer of 0 to 2 is more preferable.
  • a compound in which m2 is 0 or 1 is preferable.
  • a compound in which m2 is 0 is more preferable.
  • n 3, 4 or 5 are preferred.
  • R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2 ⁇
  • a compound which is a 6 alkynyl group or an optionally substituted C 3-8 cycloalkyl group is preferred.
  • a compound in which R 4 and R 5 are the same or different and each is a C 1-6 alkyl group which may be substituted with a hydrogen atom or one or more groups selected from substituent group A1 is more preferable. More preferred are compounds in which R 4 and R 5 are the same or different and are a hydrogen atom or a C 1-6 alkyl group.
  • a compound in which X 1 is a C 1-6 alkylene group or a group represented by the general formula NR a , wherein R a has the same meaning as described above is preferable. More preferred is a compound in which X 1 is a methylene group or a group represented by the general formula NR a1 , wherein R a1 represents a hydrogen atom or an imino protecting group. A compound in which X 1 is a methylene group is more preferable.
  • Z 1 and Z 2 are the same or different and is a group represented by the general formula CR c "wherein R c has the same meaning as described above" is preferable.
  • Z 1 and Z 2 may be the same or different and have the general formula CR c1 , wherein R c1 is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, a substituted An optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group or a substituted group
  • the aryl group which may be made is a group represented by "is more preferable.
  • Z 1 and Z 2 are the same or different and have the general formula CR c2 "wherein R c2 is a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group or an optionally substituted C 1
  • R c2 is a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group or an optionally substituted C 1
  • a compound represented by the formula “ 3-8 cycloalkyl group” is more preferred.
  • Z 1 and Z 2 are the same or different and have the general formula CR c3 , wherein R c3 is a hydrogen atom, a halogen atom, a C 1-6 alkyl group which may be substituted with one or more halogen atoms, or A compound having a group represented by “denotes a C 3-8 cycloalkyl group which may be substituted with one or more halogen atoms” is even more preferable. Most preferred are compounds wherein Z 1 and Z 2 are groups represented by the formula CH.
  • a compound in which Z 3 is a group represented by the general formula CR b "wherein R b has the same meaning as described above" is preferable.
  • a compound in which Z 3 is a group represented by the formula CH is more preferable.
  • preferable compounds include the following compounds.
  • R 1, R 2, two of Z 1 of R c and Z 2 of R c are the same or different, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, optionally substituted
  • a compound having an optionally substituted C 3-8 cycloalkyl group or an optionally substituted C 1-6 alkoxy group, and the other two being a hydrogen atom is preferable.
  • R 1, R 2, two of Z 1 of R c and Z 2 of R c are the same or different, substituted is also C 1-6 alkyl group, the other two are hydrogen atom
  • R 1 and R 2 are the same or different, a C 1-6 alkyl group, R c and Z 2 of R c of Z 1 is, compounds and more preferably a hydrogen atom.
  • preferable compounds include the following compounds. N ′-(5-Bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl)- N-ethyl-N-methylimidoformamide, N ′-(5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- Thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalene-2) -Yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide
  • An antifungal agent means a substance capable of acting on a pathogenic fungus and suppressing or sterilizing its growth. It may be something that suppresses fungal growth or kills some fungi to reduce their number.
  • pathogenic fungi examples include yeast-like fungi, filamentous fungi, and zygomycetes.
  • yeast-like fungi include Candida (Candida albicans, Candida glabrata, Candida giermondii, Candida crusei, Candida parapsilosis, Candida tropicalis, etc.), Cryptococcus genus (such as Cryptococcus neoformans), Examples include the genus Malassezia (such as Malassezia fullfur) and the genus Trichosporon (such as Trichosporon and Asahi).
  • Aspergillus Aspergillus fumigatus, Aspergillus tereus, Aspergillus niger, Aspergillus flavus, etc.
  • Genus Fusarium such as Fusarium solani
  • genus Schedosporum such as skedosporum apiospermum
  • Microsporium such as Microsporum canis
  • Examples of the zygomycete include the genus Mucor (Mucor plum plumus, etc.), the genus Rhizopus (such as Rhizopus oryzae), and the genus Absidia (such as Absidia cholinebifera).
  • the antifungal agent of the present invention exhibits an excellent antifungal action against bacterial species such as Candida, Aspergillus and ringworm, and more excellent antifungal action against ringworm .
  • the antifungal agent of the present invention is a bacterial species such as Candida albicans, Aspergillus fumigatus, Trichophyton rubulum, Trichophyton mentagrophytes, Malassezia furfur, and Cryptococcus neoformans. Excellent antifungal activity.
  • the compound represented by the general formula [1] or a salt thereof exhibits excellent safety.
  • Safety is evaluated by various tests, for example, cytotoxicity test, hERG test, repeated dose toxicity test, cytochrome P450 (CYP) activity inhibition test, metabolism-dependent inhibition test, in vivo mouse micronucleus It can be evaluated by various safety tests selected from a test and an in vivo rat liver UDS test.
  • Examples of the salt of the compound represented by the general formula [1] include a salt of a commonly known basic group such as amino group or acidic group such as hydroxyl or carboxyl group.
  • salts in basic groups include salts with mineral acids such as hydrochloric acid, hydrobromic acid, nitric acid and sulfuric acid; formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid , Salts with organic carboxylic acids such as tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid Is mentioned.
  • mineral acids such as hydrochloric acid, hydrobromic acid, nitric acid and sulfuric acid
  • formic acid acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid
  • Salts with organic carboxylic acids
  • Salts in acidic groups include, for example, salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and trimethylamine, triethylamine, tributylamine, pyridine, N, N— Nitrogen-containing organic bases such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine and N, N′-dibenzylethylenediamine And a salt thereof.
  • alkali metals such as sodium and potassium
  • alkaline earth metals such as calcium and magnesium
  • ammonium salts and trimethylamine, triethylamine, tributylamine, pyridine, N, N— Nitrogen-containing organic bases such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethy
  • preferred salts include pharmacologically acceptable salts.
  • the present invention when isomers (for example, optical isomers, geometric isomers, tautomers, etc.) exist, the present invention includes those isomers, It includes solvates, hydrates and crystals of various shapes.
  • the compound of the present invention is produced by combining methods known per se, and can be produced, for example, according to the production method shown below.
  • N-ethyl-N-methylformamide, N-methylformamide, and the like are known as compounds of the general formula [3].
  • the compound of the general formula [1] can be produced by reacting the compound of the general formula [2] with the compound of the general formula [3] in the presence of an activator.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture.
  • Preferable solvents include halogenated hydrocarbons.
  • Examples of the activator used in this reaction include oxalyl chloride, phosphoryl chloride and p-toluenesulfonyl chloride.
  • the amount of the activator used may be 1 to 20 times mol, preferably 1 to 5 times mol, of the compound of the general formula [2].
  • the amount of the compound of the general formula [3] used may be 1 to 20 times mol, preferably 1 to 5 times mol for the compound of the general formula [2].
  • This reaction may be carried out at ⁇ 50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
  • Compounds of general formula [5] include 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 2-bromo-1- (2,3-dihydro-1H-indene- 5-yl) ethanone is known.
  • the compound of the general formula [1a] can be produced by reacting the compound of the general formula [4] with the compound of the general formula [5]. This reaction may be carried out by the method described in International Publication No. 05/115382 pamphlet and US Patent No. 20060052420 or a method based thereon.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture.
  • Preferred solvents include alcohols.
  • the amount of the compound of the general formula [5] used may be 1 to 20 times mol, preferably 1 to 5 times mol for the compound of the general formula [4]. This reaction may be carried out at ⁇ 50 to 200 ° C., preferably 0 to 150 ° C., for 10 minutes to 48 hours.
  • the compound of the general formula [Ab] can be produced by reacting the compound of the general formula [Aa] with dithiophosphoric acid O, O′-diethyl or the like in the presence of an acid.
  • This reaction is the method described in WO 06/137658 and the Journal of Medicinal Chemistry, 1990, Vol. 33, p.2715-2720, or a similar method. Just do it.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture.
  • Preferable solvents include esters.
  • acids used in this reaction include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrogen chloride and hydrogen bromide; organic carboxylic acids such as acetic acid, trichloroacetic acid and trifluoroacetic acid; and methanesulfonic acid and Examples thereof include organic sulfonic acids such as p-toluenesulfonic acid.
  • a preferred acid is hydrogen chloride.
  • the amount of the acid used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of the general formula [Aa].
  • the amount of dithiophosphoric acid O, O′-diethyl used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of general formula [Aa]. This reaction may be carried out at ⁇ 50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
  • the compound of the general formula [2a] can be produced by reducing the compound of the general formula [Ac]. This reaction was performed by Richard C. Richard C. Larock et al., Comprehensive Organic Transformations, 2nd edition, pages 823-827, 1999, John Wiley & Sons , INC.) Or a method similar thereto. Specific examples include a catalytic hydrogenation reaction using a metal catalyst and a reduction reaction using a metal such as iron or zinc.
  • the solvent used is not particularly limited as long as it does not adversely affect the reaction.
  • the metal catalyst used in this reaction include palladium metal such as palladium-carbon and palladium black; palladium salts such as palladium oxide and palladium hydroxide; nickel metal such as Raney nickel; and platinum salts such as platinum oxide.
  • the amount of the metal catalyst used may be 0.001 to 5 times (w / w), preferably 0.01 to 1 times (w / w) of the compound of the general formula [Ac].
  • the hydrogen source include hydrogen; formic acid; formate salts such as sodium formate, ammonium formate and triethylammonium formate; cyclohexene; and cyclohexadiene.
  • the amount of the hydrogen source used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the general formula [Ac]. This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
  • the solvent used is not particularly limited as long as it does not adversely affect the reaction, but water, halogenated hydrocarbons, alcohols, Examples include ethers, ketones, esters, amides, aromatic hydrocarbons, nitriles such as acetonitrile, and water, and these may be used as a mixture.
  • the metal used in this reaction include iron, zinc, tin, and tin (II) chloride.
  • the amount of the metal used may be 1 to 50 times mol, preferably 1 to 10 times mol, of the compound of the general formula [Ac].
  • Examples of the acid that is optionally used in this reaction include hydrogen chloride, hydrogen bromide, acetic acid, and ammonium chloride.
  • the amount of the acid used may be 0.001 to 100 times (v / w), preferably 0.01 to 20 times (v / w) of the compound of the general formula [Ac]. This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
  • R d is a protected amino group
  • the compound of the general formula [2a] can be produced by deprotecting the amino protecting group of the compound of the general formula [Cc].
  • Deprotection of amino protecting groups is described, for example, in W.W. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 696-868, 2007, John Wiley & Sons (John Wiley & Sons, INC.).
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons, sulfoxides such as dimethyl sulfoxide and water, and these may be used as a mixture.
  • a preferred solvent is dimethyl sulfoxide.
  • Examples of the base used in this reaction include organic bases such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, pyridine, dimethylaminopyridine and triethylamine; sodium hydride, sodium hydroxide, potassium hydroxide, Examples thereof include inorganic bases such as sodium hydrogen carbonate, potassium carbonate and sodium carbonate. Preferred bases include sodium hydroxide and potassium hydroxide.
  • the amount of the base used may be 1 to 50 times mol, preferably 1 to 10 times mol, of the compound of the general formula [Da].
  • the amount of the compound of the general formula [Db] used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of the general formula [Da]. This reaction may be carried out at ⁇ 50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. Nitriles such as acetonitrile, sulfoxides such as dimethyl sulfoxide, and water, and these may be used as a mixture.
  • the amount of the base used may be 1 to 50 times mol, preferably 2 to 5 times mol, of the compound of the general formula [Ea].
  • the ligands optionally used in this reaction include trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; triarylphosphine such as triphenylphosphine and tritolylphosphine Trialkyl phosphites such as trimethyl phosphite, triethyl phosphite and tributyl phosphite; tricycloalkyl phosphites such as tricyclohexyl phosphite; triaryl phosphites such as triphenyl phosphite; 1,3- Imidazolium salts such as bis (2,4,6-trimethylphenyl) imidazolium chloride; acetylacetone and octafluoroacetylacetate Diketones such as trimethylamine, triethylamine, trip
  • the palladium catalyst used in this reaction examples include metal palladium such as palladium-carbon and palladium black; inorganic palladium salts such as palladium chloride; organic palladium salts such as palladium acetate; tetrakis (triphenylphosphine) palladium (0), Bis (tri-tert-butylphosphine) palladium (0), bis (triphenylphosphine) palladium (II) chloride, 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) chloride, (E) -di ( ⁇ -Acetate) bis (o- (di-o-tolylphosphino) benzyl) dipalladium (II) and tris (dibenzylideneacetone) dipalladium (0) (II And polymer supported di (acetato) such as a polymer immobilized organopalladium complex such as dicyclohex
  • the amount of acrylonitrile used may be 1 to 50 times mol, preferably 1 to 2 times mol, of the compound of general formula [Ea]. This reaction is preferably carried out at 40 to 170 ° C. for 1 minute to 24 hours in an inert gas (eg, nitrogen, argon) atmosphere.
  • an inert gas eg, nitrogen, argon
  • the compound of the general formula [Caa] can be produced by reducing the compound of the general formula [Eb].
  • Examples of the reduction reaction include a catalytic hydrogenation reaction using a metal catalyst.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. , Nitriles such as acetonitrile, carboxylic acids such as acetic acid, heteroaromatics such as pyridine and water, and these may be used as a mixture.
  • Examples of the metal catalyst used in this reaction include palladium metal such as palladium-carbon and palladium black; palladium salts such as palladium oxide and palladium hydroxide; nickel metals such as Raney nickel and platinum salts such as platinum oxide. It is done.
  • the amount of the metal catalyst used may be 0.001 to 5 times (w / w), preferably 0.01 to 1 times (w / w) of the compound of the general formula [Eb].
  • Examples of the reducing agent include hydrogen; formic acid; formate salts such as sodium formate, ammonium formate and triethylammonium formate; cyclohexene and cyclohexadiene.
  • the amount of the reducing agent used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the general formula [Eb]. This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
  • (F-1) As a compound of the general formula [Fa], ethyl cyanoacetate or methyl cyanoacetate is known.
  • the compound of the general formula [Fb] is produced by reacting the compound of the general formula [Ea] with the compound of the general formula [Fa] in the presence of a base, in the presence or absence of a ligand, and in the presence of a palladium catalyst. can do.
  • the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. Nitriles such as acetonitrile, sulfoxides such as dimethyl sulfoxide, and water, and these may be used as a mixture.
  • Examples of the base used in this reaction include inorganic bases such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate and tripotassium phosphate; organic bases such as triethylamine and diisopropylethylamine.
  • the amount of the base used may be 1 to 50 times mol, preferably 2 to 5 times mol, of the compound of the general formula [Ea].
  • the ligands optionally used in this reaction include trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; triarylphosphine such as triphenylphosphine and tritolylphosphine Trialkyl phosphites such as trimethyl phosphite, triethyl phosphite and tributyl phosphite; tricycloalkyl phosphites such as tricyclohexyl phosphite; triaryl phosphites such as triphenyl phosphite; 1,3- Imidazolium salts such as bis (2,4,6-trimethylphenyl) imidazolium chloride; acetylacetone and octafluoroacetylacetate Diketones such as trimethylamine, triethylamine, trip
  • Examples of the palladium catalyst used in this reaction include metal palladium such as palladium-carbon and palladium black; inorganic palladium salts such as palladium chloride; organic palladium salts such as palladium acetate; tetrakis (triphenylphosphine) palladium (0), Bis (tri-tert-butylphosphine) palladium (0), bis (triphenylphosphine) palladium (II) chloride, 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) chloride and tris (dibenzylideneacetone)
  • Organopalladium complexes such as dipalladium (0) and polymer-supported bis (acetate) triphenylphosphine palladium (II) and polymer-supported di (acetate) dicyclohexylphenylphosphine palladium (II)
  • the amount of the compound of the general formula [Fa] used may be 1 to 50 times mol, preferably 1 to 2 times mol for the compound of the general formula [Ea]. This reaction is preferably carried out at 40 to 170 ° C. for 1 minute to 96 hours in an inert gas (eg, nitrogen, argon) atmosphere.
  • an inert gas eg, nitrogen, argon
  • the compound of the general formula [Cab] can be produced by subjecting the compound of the general formula [Fb] to a decarboxylation reaction.
  • This reaction is carried out by a method known per se, for example, the method described in New Experimental Chemistry Course, Vol. 15, [II], edited by The Chemical Society of Japan, pages 808-811 (1977, Maruzen) or a method analogous thereto. Just do it.
  • a compound that can take the form of a salt can also be used as a salt.
  • examples of such salts include the same salts as the salts of the compound of the general formula [1].
  • a compound having a substituent that can be protected such as an amino group, a hydroxyl group, or a carboxyl group, is previously protected with a normal protecting group.
  • these protecting groups can be removed by a method known per se.
  • formulation adjuvants such as excipients, carriers and diluents usually used for formulation may be appropriately mixed.
  • excipients such as excipients, carriers and diluents usually used for formulation
  • these are tablets, capsules, powders, syrups, granules, pills, suspensions, emulsions, solutions, powder formulations, suppositories, eye drops, nasal drops, ear drops, It can be administered orally or parenterally in the form of a patch, ointment or injection.
  • the administration method, the dosage, and the number of administrations can be appropriately selected according to the age, weight and symptoms of the patient. In general, for adults, oral administration or parenteral administration (for example, injection, infusion, administration to the rectal site, etc.), 0.01 to 1000 mg / kg daily may be divided into 1 to several doses. Good.
  • Test Example The susceptibility test of fungi to the test substance was performed by a micro liquid dilution method according to the Clinical and Laboratory Standards Institute method.
  • the microplate was prepared by the following method.
  • the medium used for the sensitivity test was RPMI1640 (RPMI / MOPS) adjusted to pH 7.0 with 0.165 mol / L morpholinepropanesulfonic acid (MOPS) and 50% sodium hydroxide.
  • the test substance was dissolved in DMSO, diluted 2-fold serially with DMSO on a 96-well microplate, and then dispensed at 1 ⁇ L into a 96-well microplate.
  • Trichophyton rubrum NBRC 5467 stored at ⁇ 80 ° C. was diluted with RPMI / MOPS to prepare an inoculum (about 2 ⁇ 10 3 CFU / mL). 199 ⁇ L of the inoculum solution was dispensed into each well to prepare a microplate containing a predetermined concentration of the test substance, medium and cells. C. albicans and A. fumigatus were cultured at 35 ° C. for 2 days. T. rubrum was cultured at 35 ° C for 4 days. After completion of the culture, the MIC was visually determined. The MIC of C. albicans and A. fumigatus was the lowest concentration at which about 50% growth inhibition was observed compared to the growth control without addition of the test substance. The MIC of T. rubrum was set to the lowest concentration at which about 80% growth inhibition was observed compared to the growth control with no test substance added. The results are shown in Tables 1 to 3.
  • the carrier in silica gel column chromatography is Kanto Chemical Co., Inc., silica gel 60 (spherical, 63-210 ⁇ m);
  • the carrier in DIOL type silica gel chromatography is Chromatrex DIOL MB 100- manufactured by Fuji Silysia Chemical Ltd. 75/200;
  • the carrier in DNH silica gel chromatography is Chromatrex DNHDMB 100-75 / 200 (110 ⁇ m) manufactured by Fuji Silysia Chemical Ltd.
  • the mixing ratio in the eluent is a volume ratio.
  • DMSO dimethyl sulfoxide
  • DMSO-d 6 heavy dimethyl sulfoxide s: singlet d: doublet dd: double doublet m: multiplet
  • Reference example 2 A mixture of 2.5 g of (2-bromo-5-methyl-4-nitrophenyl) acetonitrile, 2.3 mL of dithiophosphoric acid O, O′-diethyl and 7.5 mL of a 4.9 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 1 day. . The solid was collected by filtration to obtain 2.1 g of 2- (2-bromo-5-methyl-4-nitrophenyl) ethanethioamide as a yellow solid.
  • Reference example 4 (2-Bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 200 mg, ethanol 2.0 mL and water 2.0 mL To the mixture, 76 mg of iron powder and 72 mg of ammonium chloride were added and heated to reflux for 30 minutes. Ethanol 2.0mL was added to the reaction mixture, and it heated and refluxed for 30 minutes. The reaction mixture was cooled to room temperature, ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration.
  • reaction mixture is cooled to room temperature, toluene is added, the solid is collected by filtration, and the dark brown solid 2- (2,5-dimethyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydro 0.29 g of naphthalen-2-yl) -1,3-thiazole was obtained.
  • reaction mixture was cooled to room temperature, ethyl acetate, methanol and water were added, and insoluble materials were removed by filtration.
  • organic layer of the filtrate was separated, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 19 A mixture of 1.72 g of 4-chloro-1-methyl-2-nitrobenzene, 1.68 g of potassium hydroxide, 2.89 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 5 mL of dimethyl sulfoxide was stirred at room temperature for 2 hours. To the reaction mixture, 1.68 g of potassium hydroxide was added and stirred for 2 hours and 30 minutes. Saturated aqueous sodium hydrogen carbonate solution and ethyl acetate were added to the reaction mixture.
  • Reference Example 24 A mixture of 0.40 g of (2-fluoro-5-methyl-4-nitrophenyl) acetonitrile, 0.49 mL of dithiophosphoric acid O, O′-diethyl and 2 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 12 hours and 30 minutes. did. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 28 A mixture of 5.5 g of sodium hydroxide, 3.2 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 18 mL of dimethyl sulfoxide was stirred at 30 ° C. for 5 minutes. To the reaction mixture was added 2.8 g of 4- (difluoromethoxy) -1-methyl-2-nitrobenzene in 10 mL of dimethyl sulfoxide, and the mixture was stirred at 30 ° C. for 1 hour. Ice water, toluene and ethyl acetate were added to the reaction mixture, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated and the aqueous layer was extracted with toluene.
  • Reference Example 31 A mixture of 0.84 g of 4-methoxy-1-methyl-2-nitrobenzene, 1.20 g of sodium hydroxide, 1.45 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 5 mL of dimethyl sulfoxide was stirred at room temperature for 6 hours. Water and toluene were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 38 A mixture of 0.50 g of (5-methyl-4-nitro-2- (propan-2-yloxy) phenyl) acetonitrile, 0.51 mL of dithiophosphoric acid O, O′-diethyl and 5.0 mL of 5 mol / L hydrogen chloride-ethyl acetate solution The mixture was stirred at room temperature for 1 hour and 15 minutes and allowed to stand for 14 hours. The reaction mixture was evaporated under reduced pressure. A mixture of the obtained brown oily substance, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone (0.65 g) and ethanol (5.0 mL) was heated to reflux for 2 hours and 30 minutes.
  • the reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure.
  • a mixture of 0.40 g of the obtained yellow oil, 30 mg of ammonium chloride, 0.16 g of iron powder, 8.0 mL of ethanol and 2.0 mL of water was heated to reflux for 3 hours.
  • To the reaction mixture were added 0.33 g of the obtained yellow oil, 30 mg of ammonium chloride and 0.16 g of iron powder, and the mixture was heated to reflux for 1 hour.
  • Reference Example 40 4-Bromo-2-methyl-5- (propan-2-yl) aniline 0.50 g, ethyl cyanoacetate 0.70 mL, bis (tri-tert-butylphosphine) palladium (0) 56 mg, tripotassium phosphate 1.40 g and toluene 10 mL of the mixture was heated to reflux under a nitrogen atmosphere for 3 hours 30 minutes. The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 42 A mixture of 150 mg of hydrochloride of (4-amino-5-methyl-2- (propan-2-yl) phenyl) acetonitrile, 158 ⁇ L of dithiophosphoric acid O, O′-diethyl and 3 mL of 5 mol / L hydrogen chloride-ethyl acetate solution, The mixture was stirred at room temperature for 5 hours and then allowed to stand for 14 hours. To the reaction mixture, 84 ⁇ L of dithiophosphoric acid O, O′-diethyl was added and stirred for 3 hours. To the reaction mixture, 84 ⁇ L of dithiophosphoric acid O, O′-diethyl was added and stirred for 2 hours.
  • Reference Example 45 4-bromo-5- (tert-butyl) -2-methylaniline 0.50 g, ethyl cyanoacetate 0.66 mL, bis (tri-tert-butylphosphine) palladium (0) 53 mg, tripotassium phosphate 1.31 g and toluene 10 mL The mixture was heated to reflux under a nitrogen atmosphere for 3 hours 30 minutes. To the reaction mixture, 0.66 mL of ethyl cyanoacetate, 53 mg of bis (tri-tert-butylphosphine) palladium (0), 10 mL of toluene and 3 mL of dioxane were added, and the mixture was heated to reflux for 6 hours under a nitrogen atmosphere.
  • Reaction B To a suspension of 0.11 g of sodium hydroxide in 0.30 mL of dimethylsulfoxide was added 53 ⁇ L of (phenylthio) acetonitrile and 0.20 mL of dimethylsulfoxide in 50 mg of 4- (difluoromethyl) -1-methyl-2-nitrobenzene at room temperature. After stirring for 20 minutes, toluene and water were added to obtain reaction mixture B. Reaction mixture A and reaction mixture B were added to ice water. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 51 0.10 g 2- (2- (difluoromethyl) -5-methyl-4-nitrophenyl) ethanethioamide, 0.15 g 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and A mixture of 2.0 mL of ethanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, iron powder (64 mg), ammonium chloride (12 mg) and water (0.50 mL) were added, and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled to room temperature, ethyl acetate, methanol and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration.
  • Reference Example 56 A mixture of 6.48 g of sodium hydroxide, 10 g of 1-bromo-4-methyl-2-nitrobenzene, 11.6 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 50 mL of dimethyl sulfoxide was stirred at room temperature for 88 hours. To the reaction mixture, 13 g of potassium tert-butoxide was added under ice cooling, and the mixture was stirred for 2 hours under ice cooling. Water and ethyl acetate were added to the reaction mixture.
  • Reference Example 70 A mixture of 0.60 g of (2-methyl-4-nitro-5- (propan-2-yloxy) phenyl) acetonitrile, 0.61 mL of dithiophosphoric acid O, O′-diethyl and 6.0 mL of 5 mol / L hydrogen chloride-ethyl acetate solution The mixture was stirred at room temperature for 1 hour and 15 minutes and allowed to stand for 12 hours. The solvent of the reaction mixture was distilled off under reduced pressure to obtain a yellow solid. A mixture of the obtained yellow solid, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 0.78 g and ethanol 6.0 mL was heated to reflux for 2 hours 30 minutes.
  • Reference Example 72 A mixture of 2.54 g of 1- (difluoromethoxy) -4-methyl-2-nitrobenzene, 5.00 g of sodium hydroxide, 2.90 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 25 mL of dimethyl sulfoxide is stirred at 30 to 40 ° C. for 2 hours. Stir. The reaction mixture was ice-cooled, water and ethyl acetate were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 75 4-bromo-5-methyl-2- (propan-2-yl) aniline 500 mg, ethyl cyanoacetate 702 ⁇ L, bis (tri-tert-butylphosphine) palladium (0) 56 mg, tripotassium phosphate 1.40 g and toluene 10 mL The mixture was heated to reflux under a nitrogen atmosphere for 5 hours. The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 80 A mixture of N- (2- (tert-butyl) -5-methylphenyl) -1,1-diphenylmethanimine (3.0 g), 2 mol / L hydrochloric acid (2.5 mL) and tetrahydrofuran (30 mL) was stirred at room temperature for 4 hours and 30 minutes. To the reaction mixture, 2 mL of 6 mol / L hydrochloric acid was added and stirred for 9 hours. To the reaction mixture was added 2 mL of 6 mol / L hydrochloric acid, and the mixture was allowed to stand for 15 hours. Toluene and water were added to the reaction mixture.
  • the aqueous layer was separated, and the organic layer was extracted with 1 mol / L hydrochloric acid.
  • the aqueous layer and the extract were combined, and 10% aqueous potassium carbonate solution and ethyl acetate were added.
  • the organic layer was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to obtain 0.78 g of 2- (tert-butyl) -5-methylaniline as a pale red oil.
  • a mixture of the obtained black oily substance, 0.47 mL of dithiophosphoric acid O, O′-diethyl and 4 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 19 hours.
  • To the reaction mixture were added ethyl acetate and saturated aqueous sodium hydrogen carbonate solution.
  • the organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Reference Example 91 In the same manner as in Reference Example 10, from 90 mg of 2- (2,5-dichloro-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole, 72 mg of 2,5-dichloro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
  • Reference Example 93 1.40 g of N ′-(4- (cyanomethyl) -2,6-dimethylphenyl) -N-ethyl-N-methylimidoformamide hydrochloride, 40 mL of 5 mol / L hydrogen chloride-ethyl acetate solution and dithiophosphoric acid O, O ′ -A mixture of 1.25 mL of diethyl was stirred at room temperature for 5 hours and allowed to stand for 14 hours. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with chloroform.
  • Reference Example 94 4-bromo-2,3-dimethylaniline 2.00 g, ethyl cyanoacetate 3.20 mL, tris (dibenzylideneacetone) dipalladium (0) 275 mg, tri-tert-butylphosphonium tetrafluoroborate 348 mg, tripotassium phosphate 6.37 g
  • the mixture of toluene and 40 mL was heated to reflux for 4 hours and 10 minutes under a nitrogen atmosphere.
  • To the reaction mixture was added 260 mg of bis (tri-tert-butylphosphine) palladium (0), and the mixture was heated to reflux for 3 hours.
  • the reaction mixture was cooled to room temperature and ice water and ethyl acetate were added.
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate.
  • the organic layer and the extract were combined, washed successively with 1 mol / L hydrochloric acid and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
  • Reference Example 96 A mixture of 150 mg of (4-amino-2,3-dimethylphenyl) acetonitrile hydrochloride, 181 ⁇ L of dithiophosphoric acid O, O′-diethyl and 3 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 5 hours, and 12 hours Left to stand. To the reaction mixture, 97 ⁇ L of dithiophosphoric acid O, O′-diethyl was added and stirred for 3 hours, and 97 ⁇ L of dithiophosphoric acid O, O′-diethyl was added and stirred for 2 hours.
  • the mixture was stirred at 90-100 ° C. for 1 hour.
  • To the reaction mixture was added 0.12 mL of 2,2,7,7-tetramethyl-4-((trimethylsilyl) oxy) -3,6-dioxa-2,7-disilaoct-4-ene, and the mixture was stirred at 90-100 ° C. for 3 hours. Stir for 30 minutes.
  • To the reaction mixture 1.6 mL of dioxane and 0.80 mL of 1 mol / L hydrochloric acid were added, and the mixture was stirred at 70 to 80 ° C. for 1 hour.
  • the reaction mixture was cooled to room temperature, adjusted to pH 2 with a 1 mol / L aqueous sodium hydroxide solution, and ethyl acetate was added to the reaction mixture.
  • the organic layer was separated, washed successively with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Reaction B 1- (5,6,7,8,9,10-hexahydrobenzo [8] annulen-2-yl) -2-hydroxyethanone in a suspension of 170 mg of acetonitrile in 1.4 mL of acetonitrile under ice cooling Then, 0.23 g of triphenylphosphine and 0.28 g of carbon tetrabromide were added, and the mixture was stirred for 20 minutes under ice-cooling and for 15 minutes at room temperature, and then ethyl acetate and water were added to obtain a reaction mixture B. Reaction mixture A and reaction mixture B were combined.
  • Example 1 Under a nitrogen atmosphere, 54 ⁇ L of oxalyl chloride was added to a solution of N-ethyl-N-methylformamide 55 mg in chloroform 1.0 mL, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 131 mg of 5-bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A chloroform 1.0 mL solution was added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture.
  • the organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 2 In the same manner as in Example 1, 5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl ) Methyl) aniline from 90 mg, N ′-(5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole-2) 70 mg of hydrochloride of -yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
  • Example 3 2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.13 g and N-methylformamide 2.6
  • 0.11 g of p-toluenesulfonyl chloride was added and stirred at room temperature for 16 hours.
  • Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture.
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate.
  • Example 4 In the same manner as in Example 3, 2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) From 114 mg of aniline to N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl as a white solid 66 mg of phenyl) -N-ethylimidoformamide hydrochloride was obtained.
  • Example 5 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 200 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalene A mixture of -2-yl) ethanone 186 mg and methanol 2 mL was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, water and ethyl acetate were added, and the pH was adjusted to 9.5 with a saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 6 According to the same procedure as in Example 5, 0.36 g of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- ( From 0.48 g of 5,6,7,8-tetrahydronaphthalen-2-yl) propan-1-one to N ′-(2,5-dimethyl-4-((5-methyl-4- (5,6 , 7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide hydrochloride 0.25 g was obtained.
  • Example 7 In the same manner as in Example 5, 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 100 mg, 2-bromo-1- (5 , 5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) ethanone from 108 mg of white solid N ′-(2,5-dimethyl-4-((4- (5 Of 5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide 142 mg of hydrochloride was obtained.
  • Example 8 In the same manner as in Example 5, 200 mg of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (indane -5-yl) ethanone to 175 mg of light yellow solid N ′-(4-((4- (indan-5-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) 245 mg of hydrochloride salt of -N-ethyl-N-methylimidoformamide was obtained.
  • Example 9 In the same manner as in Example 5, 100 mg of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (benzo From 94 mg of cycloheptan-2-yl) ethanone to N ′-(2,5-dimethyl-4-((4- (benzocycloheptan-2-yl) -1,3-thiazol-2-yl) methyl as a white solid 124 mg of phenyl) -N-ethyl-N-methylimidoformamide hydrochloride was obtained.
  • Example 10 0.12 mL of oxalyl chloride was added to a 2.4 mL chloroform solution of 0.14 g N-isopropyl-N-methylformamide and stirred at room temperature for 20 minutes. To the reaction mixture, 2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.24 g of chloroform was added. 2.4 mL solution was added and stirred at room temperature for 4 hours. The solvent of the reaction mixture was distilled off under reduced pressure. Ethanol was added to the obtained residue, and the solvent was distilled off under reduced pressure.
  • Example 11 In the same manner as in Example 1, 2,5-dimethyl-4- (2- (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) N '-(2,5-dimethyl-4- (2- (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole-2) from 82 mg of ethyl) aniline 87 mg of hydrochloride of -yl) ethyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
  • Example 12 To a solution of N-ethyl-N-methylformamide 48 mg in chloroform 1.0 mL was added oxalyl chloride 48 ⁇ L, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 5-amino-4-methyl-2-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile 0.10. A solution of g in chloroform (3.0 mL) was added, and the mixture was stirred at room temperature for 1 hour. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 13 To a solution of 33 mg of N-ethyl-N-methylformamide in 1 mL of chloroform was added 32 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture, 92 mg of 5-chloro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 15 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 14 30 ⁇ L of oxalyl chloride was added to 1 mL of chloroform in 30 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 82 mg of 5-fluoro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 15 To a solution of 36 mg of N-ethyl-N-methylformamide in 5 mL of methylene chloride was added 36 ⁇ L of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 85 mg of 4-methyl-6-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) biphenyl-3-amine. Methylene chloride (2 mL) was added, and the mixture was stirred at room temperature for 3 hours. Ice water and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture.
  • Example 16 34 ⁇ L of oxalyl chloride was added to 1 mL of chloroform in 34 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 30 minutes.
  • a solution of 79 mg of aniline in 1 mL of chloroform was added, and the mixture was stirred at room temperature for 30 minutes.
  • the solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 17 To a solution of 27 mg of N-ethyl-N-methylformamide in 1 mL of chloroform was added 26 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 75 mg of 5-methoxy-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. Chloroform 2mL solution was added and stirred at room temperature for 5 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 18 2- (5-Methyl-4-nitro-2- (trifluoromethyl) phenyl) ethanethioamide 0.12 g, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 0.16 g
  • a mixture of ethanol and 2.0 mL was heated to reflux for 1 hour.
  • the reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. Hexane was added to the obtained residue, and the solid was collected by filtration to obtain a light brown solid.
  • a mixture of the obtained light brown solid, water 0.6 mL, ethanol 2.4 mL, iron powder 58 mg and ammonium chloride 11 mg was heated to reflux for 1 hour.
  • the reaction mixture was cooled to room temperature, ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration.
  • the organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and activated carbon was added.
  • the insoluble material was removed by filtration, and the solvent was evaporated under reduced pressure to give a yellow oil.
  • 17 ⁇ L of oxalyl chloride was added to a 1.0 mL chloroform solution of 18 mg N-ethyl-N-methylformamide and stirred at room temperature for 10 minutes.
  • Example 19 To a solution of 107 mg of N-ethyl-N-methylformamide in 1.5 mL of chloroform was added 105 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 2-methyl-5- (propan-2-yloxy) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl. ) Methyl) aniline (240 mg) in chloroform (1.5 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 20 To a solution of N-ethyl-N-methylformamide 27 mg in 1 mL of chloroform was added 27 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture, 56 mg of 5-ethynyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline Chloroform 1mL solution was added and stirred at room temperature for 30 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 21 To a solution of 42 mg of N-ethyl-N-methylformamide in 1 mL of methylene chloride was added 42 ⁇ L of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture was added 2-methyl-5- (propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- under ice cooling. A solution of thiazol-2-yl) methyl) aniline hydrochloride (100 mg) in methylene chloride (10 mL) was added, and the mixture was stirred at room temperature for 50 minutes.
  • Example 22 Reaction A: To 1 mL of methylene chloride in 41 mg of N-ethyl-N-methylformamide was added 40 ⁇ L of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was stirred under ice cooling with 5- (tert-butyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole- 2-yl) methyl) aniline hydrochloride (100 mg) in methylene chloride (10 mL) was added, and the mixture was stirred at room temperature for 50 minutes.
  • reaction B 40 ⁇ L of oxalyl chloride was added to 2 mL of methylene chloride in 41 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 20 minutes to obtain a reaction mixture B. Under ice-cooling, reaction mixture B was added to reaction mixture A and stirred at room temperature for 10 minutes. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 23 To a 1.0 mL chloroform solution of 26 mg N-ethyl-N-methylformamide was added 26 ⁇ L oxalyl chloride, and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture, 5- (difluoromethyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) A solution of aniline (58 mg) in chloroform (1.0 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 24 To a solution of N-ethyl-N-methylformamide 32 mg in 1 mL of chloroform was added 31 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 85 mg of 2-fluoro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 25 To a solution of N-ethyl-N-methylformamide 25 mg in 1 mL of chloroform was added 25 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was charged with 2-amino-4-methyl-5-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile 52 mg. In chloroform (2 mL) and stirred at room temperature for 2 hours. To the reaction mixture, chloroform and a saturated aqueous sodium hydrogen carbonate solution were added.
  • Example 26 To a solution of N-ethyl-N-methylformamide 13 mg in 1 mL of chloroform was added 13 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 37 mg of 2-chloro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. Chloroform 2mL solution was added and stirred at room temperature for 5 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 27 27 ⁇ L of oxalyl chloride was added to 1 mL of chloroform in 28 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 5 minutes. To the reaction mixture, 77 mg of 2-methoxy-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 28 To a 2.0 mL solution of 84 mg of N-ethyl-N-methylformamide in chloroform was added 82 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 5-methyl-2- (propan-2-yloxy) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl. ) 206 mg of methyl) aniline hydrochloride was added and stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 29 To a 1.5 mL chloroform solution of 101 mg N-ethyl-N-methylformamide was added 100 ⁇ L oxalyl chloride, and the mixture was stirred at room temperature for 5 minutes. To the reaction mixture was added 2- (difluoromethoxy) -5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) A solution of aniline 233 mg in chloroform 1.5 mL was added, and the mixture was stirred at room temperature for 40 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the obtained residue.
  • Reaction B 70 ⁇ L of oxalyl chloride was added to 2 mL of methylene chloride in 71 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 1 hour.
  • 2 mL of a methylene chloride solution of light yellow solid obtained in Reaction A and 28 ⁇ L of triethylamine were added under ice cooling, and the mixture was stirred for 25 minutes under ice cooling. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture.
  • reaction B To 1 mL of methylene chloride in 12 mg of N-ethyl-N-methylformamide was added 12 ⁇ L of oxalyl chloride, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was added to a mixture of the pale yellow solid obtained in reaction A, 12 ⁇ L of triethylamine and 1 mL of methylene chloride, and stirred at room temperature for 30 minutes to obtain reaction mixture B.
  • Reaction C 12 ⁇ L of oxalyl chloride was added to 1 mL of methylene chloride in 12 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 15 minutes to obtain a reaction mixture C.
  • Reaction mixture C was added to reaction mixture B and stirred at room temperature for 30 minutes.
  • a 10% aqueous potassium carbonate solution was added to the reaction mixture.
  • the organic layer was separated and the aqueous layer was extracted with chloroform. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 32 15 ⁇ L of oxalyl chloride was added to a solution of N-ethyl-N-methylformamide 15 mg in 1 mL of chloroform and stirred at room temperature for 10 minutes. To the reaction mixture, 2,5-difluoro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 41 mg chloroform 2 mL The solution was added and stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 33 24 ⁇ L of oxalyl chloride was added to 1 mL of chloroform in 24 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 10 minutes.
  • 2,5-dichloro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 72 mg chloroform 2 mL
  • the solution was added and stirred at room temperature for 15 minutes.
  • the solvent of the reaction mixture was distilled off under reduced pressure.
  • Example 34 2- (4-((((Ethyl (methyl) amino) methylene) amino) -3,5-dimethylphenyl) ethanethioamide 100 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalene-2- Yl) A mixture of 98 mg of ethanone and 5 mL of methanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. To the obtained residue, ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate.
  • Example 35 To a solution of 42 mg of N-ethyl-N-methylformamide in 5 mL of methylene chloride was added 42 ⁇ L of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 40 minutes. To the reaction mixture was added 2,3-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) under ice cooling. A solution of 85 mg of aniline in 5 mL of methylene chloride was added, and the mixture was stirred for 1 hour and 30 minutes under ice cooling. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture.
  • Example 36 0.10 g of hydrochloride of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide, 2-bromo-1- (1,2,3,4-tetrahydro
  • a mixture of 0.11, 4-methanonaphthalen-6-yl) ethanone and 2.0 mL of methanol was heated to reflux for 2 hours.
  • the reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added.
  • the organic layer was separated, dried over anhydrous magnesium sulfate, and activated carbon was added. The insoluble material was removed by filtration, and the solvent was distilled off under reduced pressure.
  • Example 37 0.12 g of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (2-methyl-2,3-dihydro
  • Example 38 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 67 mg, 2-bromo-1- (2,2-dimethyl-2,3- A mixture of 53 mg of dihydro-1H-inden-5-yl) ethanone and 2.0 mL of methanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 39 2- (4-(((Ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 0.29 g, 1- (bicyclo [4.2.0] octa-1,3 , 5-trien-3-yl) -2-bromoethanone and 4.4 mL of methanol were heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 40 2- (4-((((Ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 0.14 g, 2-bromo-1- (5,6,7,8,9 , 10-hexahydrobenzo [8] annulen-2-yl) ethanone and a mixture of methanol 2.0 mL were heated to reflux for 1 hour 35 minutes. The reaction mixture is cooled to room temperature, 0.13 g of 2-bromo-1- (5,6,7,8,9,10-hexahydrobenzo [8] annulen-2-yl) ethanone and 2.0 mL of methanol are added, and 1 Heated to reflux for hours.
  • the reaction mixture was cooled to room temperature, and saturated aqueous sodium hydrogen carbonate solution, saturated aqueous sodium chloride solution and ethyl acetate were added.
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate.
  • the organic layer and the extract were combined, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
  • the solvent was distilled off.
  • the compound represented by the general formula [1] or a salt thereof has excellent antifungal activity and is useful as an antifungal agent.
  • the compound represented by the general formula [1] or a salt thereof is excellent in safety and is useful as an antifungal agent against Candida, Aspergillus, and Trichophyton.

Abstract

A compound that can be represented by general formula or a salt of such a compound is useful as an antifungal agent. (In the formula, R1 and R2 may be the same as or different from each other and each represent a halogen atom, a C1-6 alkyl group that may be substituted, or the like; R3 represents an indanyl group that may be substituted, an indenyl group that may be substituted, a dihydronaphthyl group that may be substituted, a tetrahydronaphthyl group that may be substituted, or the like; R4 and R5 may be the same as or different from each other and each represent a hydrogen atom, a C1-6 alkyl group that may be substituted, or the like; X1 represents a C1-6 alkylene group or the like; Z1 and Z2 may be the same as or different from each other and each represent a nitrogen atom, the group represented by the formula CH, or the like; and Z3 represents a nitrogen atom, the group represented by the formula CH, or the like.)

Description

アミジン化合物またはその塩Amidine compound or salt thereof
 本発明は、抗真菌活性を有する新規なアミジン化合物またはその塩、およびそれらを含有する抗真菌剤に関する。 The present invention relates to a novel amidine compound having an antifungal activity or a salt thereof, and an antifungal agent containing them.
 侵襲性カンジダ症などの重篤な深在性真菌症は、しばしば致死的疾患となる。本来、カンジダなどの真菌に対する宿主生体側の主要な防御機構は、好中球による非特異免疫によると考えられている。この防御機構が正常に機能している場合には真菌に感染する危険性は少ない。しかしながら、近年、この生体の免疫機能の低下をもたらす悪性腫瘍およびエイズなどの基礎疾患を有する患者数の増加、制癌剤・免疫抑制剤などの繁用、抗菌抗生物質・ステロイドホルモンの多用、長期にわたる中心静脈栄養および静脈カテーテルの使用などにより深在性真菌症に罹患する危険が増大している(非特許文献1)。 Serious deep mycosis such as invasive candidiasis is often a fatal disease. Originally, the main defense mechanism on the host organism side against fungi such as Candida is considered to be due to non-specific immunity by neutrophils. If this defense mechanism is functioning normally, there is little risk of infection with fungi. In recent years, however, the number of patients with underlying diseases such as malignant tumors and AIDS that cause a decline in the immune function of this living body, frequent use of anticancer drugs and immunosuppressants, heavy use of antibacterial antibiotics and steroid hormones, and long-term focus There is an increased risk of suffering from deep mycosis due to the use of parenteral nutrition and intravenous catheters (Non-patent Document 1).
 このような深在性真菌症の薬剤は、アムホテリシンB、フルシトシン、ミコナゾール、フルコナゾール、イトラコナゾール、ボリコナゾール、ポサコナゾール、カスポファンギンおよびミカファンギンの9種類にすぎない。アムホテリシンBは、殺菌作用が非常に強いが、腎毒性などの副作用の問題があり、臨床使用には制約がある。フルシトシンは、耐性化するなどの問題があるため、現在では単独で使用されることは稀である。カスポファンギンおよびミカファンギンは、クリプトコッカス属に対する活性が弱い。その他の薬剤は、いずれもアゾール系抗真菌剤と総称され、その真菌に対する殺菌作用は、アムホテリシンBのそれに比べて一般に劣る傾向にあるが、有効性と安全性の兼ね合いから、現在、最も多用されている(非特許文献2)。 There are only nine such drugs for deep mycosis: amphotericin B, flucytosine, miconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin and micafungin. Amphotericin B has a very strong bactericidal action, but has side-effects such as nephrotoxicity and is limited in clinical use. Since flucytosine has problems such as resistance, it is rarely used alone at present. Caspofungin and Micafungin are weakly active against the genus Cryptococcus. All other drugs are collectively referred to as azole antifungal agents, and their bactericidal action tends to be generally inferior to that of amphotericin B, but is currently most frequently used due to the balance between efficacy and safety. (Non-Patent Document 2).
 現在、フルコナゾールの反復投与を受けたエイズ患者の口腔咽頭カンジダ症病巣から、フルコナゾール耐性カンジダ・アルビカンス(Candida albicans)が、高頻度に検出されている。しかも、耐性株の多くは、イトラコナゾールおよびその他のアゾール系薬剤にも交叉耐性を示す。さらに、慢性粘膜皮膚カンジダ症または深在性カンジダ症を発症した非エイズ患者についても、耐性株の分離が報告されている(非特許文献3)。耐性の問題は、増加の一途を辿っている深在性真菌症患者のマネジメントに深刻な影響を与える(非特許文献3)。 Currently, fluconazole-resistant Candida albicans is frequently detected in the oropharyngeal candidiasis lesions of AIDS patients who have been repeatedly administered fluconazole. Moreover, many resistant strains are also cross-resistant to itraconazole and other azole drugs. Furthermore, isolation of resistant strains has also been reported for non-AIDS patients who developed chronic mucocutaneous candidiasis or deep candidiasis (Non-patent Document 3). The problem of resistance has a serious impact on the management of patients with deep mycosis, which is steadily increasing (Non-patent Document 3).
 一方、白癬菌によって引き起こされる爪白癬症は表在性真菌症の1種であり、その治療に3~6ケ月を要する難治性の疾患である。現在、イトラコナゾールおよびテルビナフィンがその治療に用いられている。
 しかし両薬剤とも、治癒率が十分であるとはいえず、再発が認められている(非特許文献4、5)。テルビナフィンは、6ケ月間毎日服用しなければならず、長期投与に起因する服薬コンプライアンスの悪さも指摘されている(非特許文献6)。さらに、副作用も両薬剤ともおおよそ10%以上に認められ、5%程度の患者では肝機能検査値をはじめとした臨床検査値異常が確認されている。イトラコナゾールは、他の多くの薬剤と薬物相互作用を示すことが知られている。
On the other hand, onychomycosis caused by ringworm is a kind of superficial mycosis and is an intractable disease that requires 3 to 6 months for its treatment. Currently, itraconazole and terbinafine are used for the treatment.
However, both drugs cannot be said to have a sufficient cure rate, and recurrence has been observed (Non-patent Documents 4 and 5). Terbinafine must be taken every day for 6 months, and it has been pointed out that medication compliance is poor due to long-term administration (Non-patent Document 6). Furthermore, side effects were observed in approximately 10% or more of both drugs, and abnormal laboratory values such as liver function test values were confirmed in about 5% of patients. Itraconazole is known to show drug interactions with many other drugs.
 既存の薬剤よりも治癒率が優れ、再発率が低く、投与期間が短縮され、安全性および薬物相互作用が改善された抗真菌剤が強く望まれている。
 病原性真菌に対して抗真菌活性を有する本発明のアミジン化合物またはその塩、およびそれらを含有する抗真菌剤は、これまでに一切知られていない。
There is a strong need for antifungal agents that have better cure rates, lower recurrence rates, shorter administration periods, and improved safety and drug interactions than existing drugs.
The amidine compounds of the present invention or salts thereof having antifungal activity against pathogenic fungi, and antifungal agents containing them have never been known so far.
国際公開第00/46184号パンフレットInternational Publication No. 00/46184 Pamphlet 国際公開第2004/037239号パンフレットInternational Publication No. 2004/037239 Pamphlet
 本発明の課題は、カンジダ属菌やアスペルギルス属菌、白癬菌属菌をはじめとする病原性真菌に対して優れた抗真菌活性を示し、医薬品として有用な新規化合物を提供することにある。 An object of the present invention is to provide a novel compound that exhibits excellent antifungal activity against pathogenic fungi including Candida, Aspergillus, and ringworm, and is useful as a pharmaceutical.
 このような状況下において、本発明者らは、鋭意検討を行った結果、一般式[1]
Figure JPOXMLDOC01-appb-C000002
「式中、RおよびRは、同一または異なって、水素原子、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基を;
は、置換されていてもよいジヒドロベンゾシクロブテニル基、置換されていてもよいインダニル基、置換されていてもよいインデニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいジヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいジヒドロ-5H-ベンゾシクロヘプテニル基、置換されていてもよい5H-ベンゾシクロヘプテニル基、置換されていてもよいヘキサヒドロベンゾシクロオクテニル基、置換されていてもよいテトラヒドロベンゾシクロオクテニル基、置換されていてもよいジヒドロベンゾシクロオクテニル基、置換されていてもよいテトラヒドロメタノナフチル基または置換されていてもよいテトラヒドロエタノナフチル基を;
およびRは、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいアリール基または置換されていてもよい単環の複素環式基;または、
およびRは、それらが結合する窒素原子と一緒になって形成される、置換されていてもよい環状アミノ基を;
は、硫黄原子、C1-6アルキレン基または一般式NR「式中、Rは、水素原子、置換されていてもよいC1-6アルキル基またはイミノ保護基を示す。」で表される基を;
およびZは、同一または異なって、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基を示す。」で表される基を;
は、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子または置換されていてもよいC1-6アルキル基を示す。」で表される基を意味する。」で表される化合物またはその塩が、優れた抗真菌活性を有し、抗真菌剤として有用であることを見出した。
Under such circumstances, the present inventors have conducted extensive studies, and as a result, the general formula [1]
Figure JPOXMLDOC01-appb-C000002
In the formula, R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, or an optionally substituted C 2- 6 alkenyl group, optionally substituted C 2-6 alkynyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 alkoxy group, optionally substituted A C 1-6 alkylamino group, an optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, a substituted Arylthio group which may be substituted, aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, protected Good amino group, An optionally protected hydroxyl group or an optionally protected carboxyl group;
R 3 is an optionally substituted dihydrobenzocyclobutenyl group, an optionally substituted indanyl group, an optionally substituted indenyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted Good dihydronaphthyl group, optionally substituted benzocycloheptyl group, optionally substituted dihydro-5H-benzocycloheptenyl group, optionally substituted 5H-benzocycloheptenyl group, substituted May be a hexahydrobenzocyclooctenyl group, an optionally substituted tetrahydrobenzocyclooctenyl group, an optionally substituted dihydrobenzocyclooctenyl group, an optionally substituted tetrahydromethanonaphthyl group or a substituted An optionally tetrahydroethanonaphthyl group;
R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− A 6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted monocyclic heterocyclic group; or
R 4 and R 5 are an optionally substituted cyclic amino group formed together with the nitrogen atom to which they are attached;
X 1 represents a sulfur atom, a C 1-6 alkylene group or a general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group. The group represented;
Z 1 and Z 2 are the same or different and are each a nitrogen atom or a general formula CR c wherein R c is a hydrogen atom, a halogen atom, a cyano group, a nitro group, or an optionally substituted C 1-6 alkyl. A group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1 -6 alkoxy group, optionally substituted C 1-6 alkylamino group, optionally substituted di (C 1-6 alkyl) amino group, optionally substituted C 1-6 alkylthio group, substituted Aryloxy group which may be substituted, arylthio group which may be substituted, aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic which may be substituted Heterocyclic A group represented by a group, an optionally protected amino group, an optionally protected hydroxyl group or an optionally protected carboxyl group;
Z 3 represents a nitrogen atom or a group represented by the general formula CR b wherein R b represents a hydrogen atom, a halogen atom or an optionally substituted C 1-6 alkyl group. It has been found that the compound represented by the above or a salt thereof has excellent antifungal activity and is useful as an antifungal agent.
 さらに本発明者らは、鋭意検討を行った結果、一般式[1]において、
およびRが、同一または異なって、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基;
が、置換されていてもよいインダニル基、置換されていてもよいインデニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいジヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいジヒドロ-5H-ベンゾシクロヘプテニル基または置換されていてもよい5H-ベンゾシクロヘプテニル基;
およびRが、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいアリール基または置換されていてもよい単環の複素環式基;または、
およびRが、それらが結合する窒素原子と一緒になって形成される、置換されていてもよい環状アミノ基;
が、硫黄原子、メチレン基または一般式NR「式中、Rは、水素原子、置換されていてもよいC1-6アルキル基またはイミノ保護基を示す。」で表される基;
およびZが、同一または異なって、窒素原子または式CHで表される基;
が、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子または置換されていてもよいC1-6アルキル基を示す。」で表される基である化合物またはその塩が、優れた抗真菌活性を有し、抗真菌剤として有用であることを見出し、本発明を完成した。
Furthermore, as a result of intensive studies, the present inventors have found that in the general formula [1],
R 1 and R 2 are the same or different and are each a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, a substituted An optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted C 1-6 alkylamino group , An optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, an optionally substituted arylthio group, Aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, amino group which may be protected, protected May A hydroxyl group or an optionally protected carboxyl group;
R 3 is an optionally substituted indanyl group, an optionally substituted indenyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted dihydronaphthyl group, an optionally substituted benzocyclo group. A heptyl group, an optionally substituted dihydro-5H-benzocycloheptenyl group or an optionally substituted 5H-benzocycloheptenyl group;
R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− A 6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted monocyclic heterocyclic group; or
An optionally substituted cyclic amino group formed by R 4 and R 5 together with the nitrogen atom to which they are attached;
X 1 is a sulfur atom, a methylene group, or a group represented by the general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group. ;
Z 1 and Z 2 are the same or different and are a nitrogen atom or a group represented by the formula CH;
A compound in which Z 3 is a nitrogen atom or a group represented by the general formula CR b , wherein R b represents a hydrogen atom, a halogen atom or an optionally substituted C 1-6 alkyl group, or The salt was found to have excellent antifungal activity and useful as an antifungal agent, and the present invention was completed.
 一般式[1]で表される化合物またはその塩は、優れた抗真菌活性を有し、抗真菌剤として有用である。また、別の態様では、一般式[1]で表される化合物またはその塩は、安全性にも優れ、カンジダ属菌、アスペルギルス属菌および白癬菌属菌に対する抗真菌剤として有用である。 The compound represented by the general formula [1] or a salt thereof has excellent antifungal activity and is useful as an antifungal agent. In another embodiment, the compound represented by the general formula [1] or a salt thereof is excellent in safety and is useful as an antifungal agent against Candida, Aspergillus, and Trichophyton.
 本発明について以下に詳述する。
 本明細書において、特にことわらない限り、各用語は、次の意味を有する。
 ハロゲン原子とは、フッ素原子、塩素原子、臭素原子またはヨウ素原子を意味する。
 C1-6アルキル基とは、たとえば、メチル、エチル、プロピル、イソプロピル、ブチル、sec-ブチル、イソブチル、tert-ブチル、ペンチル、イソペンチルおよびヘキシル基などの直鎖状または分枝鎖状のC1-6アルキル基を意味する。
 C1-6アルキレン基とは、メチレン、エチレン、プロピレン、ブチレンおよびヘキシレン基などの直鎖状または分枝鎖状のC1-6アルキレン基を意味する。
 C2-6アルケニル基とは、たとえば、ビニル、アリル、プロペニル、イソプロペニル、ブテニル、イソブテニル、1,3-ブタジエニル、ペンテニルおよびヘキセニル基などの直鎖状または分枝鎖状のC2-6アルケニル基を意味する。
 C2-6アルキニル基とは、たとえば、エチニル、プロピニル、ブチニル、ペンチニルおよびヘキシニル基などの直鎖状または分枝鎖状のC2-6アルキニル基を意味する。
 C3-8シクロアルキル基とは、たとえば、シクロプロピル、シクロブチル、シクロペンチルおよびシクロヘキシル基などのC3-8シクロアルキル基を意味する。
 アリール基とは、たとえば、フェニル、ナフチル、インダニル、インデニル、テトラヒドロナフチル、ジヒドロナフチル、ベンゾシクロヘプチル、ジヒドロ-5H-ベンゾシクロヘプテニルまたは5H-ベンゾシクロヘプテニル基を意味する。
 アルC1-6アルキル基とは、たとえば、ベンジル、ジフェニルメチル、トリチル、フェネチルおよびナフチルメチル基などのアルC1-6アルキル基を意味する。
The present invention is described in detail below.
In this specification, unless otherwise stated, each term has the following meaning.
A halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
C 1-6 alkyl group means, for example, linear or branched C 1 such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl and hexyl groups. -6 means an alkyl group.
The C 1-6 alkylene group means a linear or branched C 1-6 alkylene group such as methylene, ethylene, propylene, butylene and hexylene groups.
C 2-6 alkenyl group means, for example, linear or branched C 2-6 alkenyl such as vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, 1,3-butadienyl, pentenyl and hexenyl groups Means a group.
The C 2-6 alkynyl group, for example, ethynyl, propynyl, butynyl, straight or branched C 2-6 alkynyl group such as pentynyl and hexynyl groups.
C 3-8 cycloalkyl group means a C 3-8 cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
An aryl group means, for example, a phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, dihydronaphthyl, benzocycloheptyl, dihydro-5H-benzocycloheptenyl or 5H-benzocycloheptenyl group.
The Al C 1-6 alkyl group, for example, refers to a benzyl, diphenylmethyl, trityl, Al C 1-6 alkyl groups such as phenethyl and naphthylmethyl groups.
 C1-6アルコキシ基とは、たとえば、メトキシ、エトキシ、プロポキシ、イソプロポキシ、ブトキシ、イソブトキシ、sec-ブトキシ、tert-ブトキシ、ペンチルオキシおよびヘキシルオキシ基などの直鎖状または分枝鎖状のC1-6アルキルオキシ基を意味する。
 アルC1-6アルコキシ基とは、たとえば、ベンジルオキシ、フェネチルオキシおよびナフチルメチルオキシ基などのアルC1-6アルキルオキシ基を意味する。
 アリールオキシ基とは、たとえば、フェノキシまたはナフチルオキシ基を意味する。
 C1-6アルコキシC1-6アルキル基とは、たとえば、メトキシメチルおよび1-エトキシエチル基などのC1-6アルキルオキシC1-6アルキル基を意味する。
 アルC1-6アルコキシC1-6アルキル基とは、たとえば、ベンジルオキシメチルおよびフェネチルオキシメチル基などのアルC1-6アルキルオキシC1-6アルキル基を意味する。
C 1-6 alkoxy group means, for example, linear or branched C groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy groups Means a 1-6 alkyloxy group;
The al C 1-6 alkoxy group means an al C 1-6 alkyloxy group such as benzyloxy, phenethyloxy and naphthylmethyloxy groups.
An aryloxy group means, for example, a phenoxy or naphthyloxy group.
The C 1-6 alkoxy C 1-6 alkyl group means, for example, a C 1-6 alkyloxy C 1-6 alkyl group such as methoxymethyl and 1-ethoxyethyl group.
The ar C 1-6 alkoxy C 1-6 alkyl group means an ar C 1-6 alkyloxy C 1-6 alkyl group such as benzyloxymethyl and phenethyloxymethyl groups.
 C2-12アルカノイル基とは、たとえば、アセチル、プロピオニル、バレリル、イソバレリルおよびピバロイル基などの直鎖状または分枝鎖状のC2-12アルカノイル基を意味する。
 アロイル基とは、たとえば、ベンゾイルまたはナフトイル基を意味する。
 複素環式カルボニル基とは、たとえば、ニコチノイル、テノイル、ピロリジノカルボニルまたはフロイル基を意味する。
 (α-置換)アミノアセチル基とは、たとえば、アミノ酸(グリシン、アラニン、バリン、ロイシン、イソロイシン、セリン、トレオニン、システイン、メチオニン、アスパラギン酸、グルタミン酸、アスパラギン、グルタミン、アルギニン、リジン、ヒスチジン、ヒドロキシリジン、フェニルアラニン、チロシン、トリプトファン、プロリンおよびヒドロキシプロリンなどのアミノ酸が挙げられる。)から誘導されるN末端が保護されていてもよい(α-置換)アミノアセチル基を意味する。
 アシル基とは、たとえば、ホルミル基、スクシニル基、グルタリル基、マレオイル基、フタロイル基、C2-12アルカノイル基、アロイル基、複素環式カルボニル基または(α-置換)アミノアセチル基を意味する。
The C 2-12 alkanoyl group, for example, means acetyl, propionyl, valeryl, a linear or branched C 2-12 alkanoyl group such as isovaleryl and pivaloyl groups.
An aroyl group means, for example, a benzoyl or naphthoyl group.
The heterocyclic carbonyl group means, for example, nicotinoyl, thenoyl, pyrrolidinocarbonyl or furoyl group.
The (α-substituted) aminoacetyl group is, for example, an amino acid (glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, arginine, lysine, histidine, hydroxylysine. , Phenylalanine, tyrosine, tryptophan, proline and hydroxyproline and the like.) The N-terminus derived from (α-substituted) aminoacetyl group may be protected.
Acyl group means, for example, formyl group, succinyl group, glutaryl group, maleoyl group, phthaloyl group, C 2-12 alkanoyl group, aroyl group, heterocyclic carbonyl group or (α-substituted) aminoacetyl group.
 アシルC1-6アルキル基とは、たとえば、アセチルメチル、ベンゾイルメチルおよび1-ベンゾイルエチル基などのアシルC1-6アルキル基を意味する。
 アシルオキシC1-6アルキル基とは、たとえば、アセトキシメチル、プロピオニルオキシメチル、ピバロイルオキシメチル、ベンゾイルオキシメチルおよび1-(ベンゾイルオキシ)エチル基などのアシルオキシC1-6アルキル基を意味する。
 C1-6アルコキシカルボニル基とは、たとえば、メトキシカルボニル、エトキシカルボニル、イソプロポキシカルボニル、tert-ブトキシカルボニルおよび1,1-ジメチルプロポキシカルボニル基などの直鎖状または分枝鎖状のC1-6アルキルオキシカルボニル基を意味する。
 アルC1-6アルコキシカルボニル基とは、たとえば、ベンジルオキシカルボニルおよびフェネチルオキシカルボニル基などのアルC1-6アルキルオキシカルボニル基を意味する。
 アリールオキシカルボニル基とは、たとえば、フェニルオキシカルボニルまたはナフチルオキシカルボニル基を意味する。
Acyl C 1-6 alkyl group, for example, means an acyl C 1-6 alkyl group such as acetyl, methyl, benzoyl methyl and 1-benzoyl ethyl.
And acyloxy C 1-6 alkyl group, for example, means acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, a benzoyloxy methyl and 1- acyloxy C 1-6 alkyl group such as (benzoyloxy) ethyl.
C 1-6 alkoxycarbonyl group means, for example, linear or branched C 1-6 such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl and 1,1-dimethylpropoxycarbonyl groups. Means an alkyloxycarbonyl group;
The al C 1-6 alkoxycarbonyl group means an al C 1-6 alkyloxycarbonyl group such as benzyloxycarbonyl and phenethyloxycarbonyl groups.
An aryloxycarbonyl group means, for example, a phenyloxycarbonyl or naphthyloxycarbonyl group.
 C1-6アルキルアミノ基とは、たとえば、メチルアミノ、エチルアミノ、プロピルアミノ、イソプロピルアミノ、ブチルアミノ、sec-ブチルアミノ、tert-ブチルアミノ、ペンチルアミノおよびヘキシルアミノ基などの直鎖状または分枝鎖状のC1-6アルキルアミノ基を意味する。
 ジ(C1-6アルキル)アミノ基とは、たとえば、ジメチルアミノ、ジエチルアミノ、ジプロピルアミノ、ジイソプロピルアミノ、ジブチルアミノ、ジ(tert-ブチル)アミノ、ジペンチルアミノ、ジヘキシルアミノ、(エチル)(メチル)アミノおよび(メチル)(プロピル)アミノ基などの直鎖状または分枝鎖状のジ(C1-6アルキル)アミノ基を意味する。
The C 1-6 alkylamino group is, for example, a linear or branched group such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino, tert-butylamino, pentylamino and hexylamino groups. It means a branched C 1-6 alkylamino group.
Examples of the di (C 1-6 alkyl) amino group include dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, di (tert-butyl) amino, dipentylamino, dihexylamino, (ethyl) (methyl) By linear or branched di (C 1-6 alkyl) amino groups such as amino and (methyl) (propyl) amino groups are meant.
 C1-6アルキルチオ基とは、たとえば、メチルチオ、エチルチオおよびプロピルチオ基などのC1-6アルキルチオ基を意味する。
 アリールチオ基とは、たとえば、フェニルチオまたはナフチルチオ基を意味する。
 C1-6アルキルスルホニル基とは、たとえば、メチルスルホニル、エチルスルホニルおよびプロピルスルホニル基などのC1-6アルキルスルホニル基を意味する。
 アリールスルホニル基とは、たとえば、ベンゼンスルホニル、p-トルエンスルホニルまたはナフタレンスルホニル基を意味する。
 C1-6アルキルスルホニルオキシ基とは、たとえば、メチルスルホニルオキシ、トリフルオロメチルスルホニルオキシおよびエチルスルホニルオキシ基などのC1-6アルキルスルホニルオキシ基を意味する。
 アリールスルホニルオキシ基とは、たとえば、ベンゼンスルホニルオキシまたはp-トルエンスルホニルオキシ基を意味する。
The C 1-6 alkylthio group means, for example, a C 1-6 alkylthio group such as methylthio, ethylthio and propylthio groups.
An arylthio group means, for example, a phenylthio or naphthylthio group.
The C 1-6 alkylsulfonyl group means, for example, a C 1-6 alkylsulfonyl group such as methylsulfonyl, ethylsulfonyl and propylsulfonyl groups.
An arylsulfonyl group means, for example, a benzenesulfonyl, p-toluenesulfonyl or naphthalenesulfonyl group.
The C 1-6 alkylsulfonyloxy group means a C 1-6 alkylsulfonyloxy group such as methylsulfonyloxy, trifluoromethylsulfonyloxy and ethylsulfonyloxy groups.
The arylsulfonyloxy group means, for example, benzenesulfonyloxy or p-toluenesulfonyloxy group.
 シリル基とは、たとえば、トリメチルシリル、トリエチルシリルまたはトリブチルシリル基を意味する。 A silyl group means, for example, a trimethylsilyl, triethylsilyl or tributylsilyl group.
 単環の含窒素複素環式基とは、たとえば、アゼチジニル、ピロリジニル、ピロリニル、ピロリル、ジヒドロピロリル、ピペリジル、テトラヒドロピリジル、ピリジル、ホモピペリジニル、オクタヒドロアゾシニル、イミダゾリジニル、イミダゾリニル、イミダゾリル、ピラゾリジニル、ピラゾリニル、ピラゾリル、ピペラジニル、ピラジニル、ピリダジニル、ピリミジニル、ホモピペラジニル、トリアジニル、トリアゾリルおよびテトラゾリル基などの該環を形成する異項原子として窒素原子のみを含む単環の含窒素複素環式基を意味する。
 単環の含酸素複素環式基とは、たとえば、テトラヒドロフラニル、フラニル、テトラヒドロピラニルまたはピラニル基を意味する。
 単環の含硫黄複素環式基とは、たとえば、チエニル基を意味する。
 単環の含窒素・酸素複素環式基とは、たとえば、オキサゾリル、イソオキサゾリル、オキサジアゾリルおよびモルホリニル基などの該環を形成する異項原子として窒素原子および酸素原子のみを含む単環の含窒素・酸素複素環式基を意味する。
 単環の含窒素・硫黄複素環式基とは、たとえば、チアゾリル、イソチアゾリル、チアジアゾリル、チオモルホリニル、1-オキシドチオモルホリニルおよび1,1-ジオキシドチオモルホリニル基などの該環を形成する異項原子として窒素原子および硫黄原子のみを含む単環の含窒素・硫黄複素環式基を意味する。
 単環の複素環式基とは、単環の含窒素複素環式基、単環の含酸素複素環式基、単環の含硫黄複素環式基、単環の含窒素・酸素複素環式基または単環の含窒素・硫黄複素環式基を意味する。
Monocyclic nitrogen-containing heterocyclic groups include, for example, azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, dihydropyrrolyl, piperidyl, tetrahydropyridyl, pyridyl, homopiperidinyl, octahydroazosinyl, imidazolidinyl, imidazolinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, It means a monocyclic nitrogen-containing heterocyclic group containing only a nitrogen atom as a hetero atom forming the ring, such as pyrazolyl, piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, homopiperazinyl, triazinyl, triazolyl and tetrazolyl groups.
The monocyclic oxygen-containing heterocyclic group means, for example, a tetrahydrofuranyl, furanyl, tetrahydropyranyl or pyranyl group.
The monocyclic sulfur-containing heterocyclic group means, for example, a thienyl group.
The monocyclic nitrogen-containing / oxygen heterocyclic group is, for example, a monocyclic nitrogen-containing / oxygen containing only a nitrogen atom and an oxygen atom as hetero atoms forming the ring, such as oxazolyl, isoxazolyl, oxadiazolyl and morpholinyl groups. Means a heterocyclic group.
A monocyclic nitrogen-containing / sulfur heterocyclic group forms the ring such as thiazolyl, isothiazolyl, thiadiazolyl, thiomorpholinyl, 1-oxidethiomorpholinyl and 1,1-dioxidethiomorpholinyl groups This means a monocyclic nitrogen-containing / sulfur heterocyclic group containing only nitrogen and sulfur atoms as hetero atoms.
The monocyclic heterocyclic group is a monocyclic nitrogen-containing heterocyclic group, a monocyclic oxygen-containing heterocyclic group, a monocyclic sulfur-containing heterocyclic group, or a monocyclic nitrogen-containing / oxygen heterocyclic group. It means a group or a monocyclic nitrogen-containing / sulfur heterocyclic group.
 二環式の含窒素複素環式基とは、たとえば、インドリニル、インドリル、イソインドリニル、イソインドリル、ベンズイミダゾリル、インダゾリル、ベンゾトリアゾリル、キノリル、テトラヒドロキノリニル、キノリル、テトラヒドロイソキノリニル、イソキノリニル、キノリジニル、シンノリニル、フタラジニル、キナゾリニル、ジヒドロキノキサリニル、キノキサリニル、ナフチリジニル、プリニル、プテリジニルおよびキヌクリジニル基などの該環を形成する異項原子として窒素原子のみを含む二環式の含窒素複素環式基を意味する。
 二環式の含酸素複素環式基とは、たとえば、2,3-ジヒドロベンゾフラニル、ベンゾフラニル、イソベンゾフラニル、クロマニル、クロメニル、イソクロマニル、1,3-ベンゾジオキソリル、1,3-ベンゾジオキサニルおよび1,4-ベンゾジオキサニル基などの該環を形成する異項原子として酸素原子のみを含む二環式の含酸素複素環式基を意味する。
 二環式の含硫黄複素環式基とは、たとえば、2,3-ジヒドロベンゾチエニルおよびベンゾチエニル基などの該環を形成する異項原子として硫黄原子のみを含む二環式の含硫黄複素環式基を意味する。
 二環式の含窒素・酸素複素環式基とは、たとえば、ベンゾオキサゾリル、ベンゾイソオキサゾリル、ベンゾオキサジアゾリル、ベンゾモルホリニル、ジヒドロピラノピリジル、ジヒドロジオキシノピリジルおよびジヒドロピリドオキサジニル基などの該環を形成する異項原子として窒素原子および酸素原子のみを含む二環式の含窒素・酸素複素環式基を意味する。
 二環式の含窒素・硫黄複素環式基とは、たとえば、ベンゾチアゾリル、ベンゾイソチアゾリルおよびベンゾチアジアゾリル基などの該環を形成する異項原子として窒素原子および硫黄原子を含む二環式の含窒素・硫黄複素環式基を意味する。
 二環式の複素環式基とは、二環式の含窒素複素環式基、二環式の含酸素複素環式基、二環式の含硫黄複素環式基、二環式の含窒素・酸素複素環式基または二環式の含窒素・硫黄複素環式基を意味する。
Bicyclic nitrogen-containing heterocyclic groups include, for example, indolinyl, indolyl, isoindolinyl, isoindolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, tetrahydroquinolinyl, quinolyl, tetrahydroisoquinolinyl, isoquinolinyl, Bicyclic nitrogen-containing heterocyclic groups containing only a nitrogen atom as a hetero atom forming the ring, such as quinolidinyl, cinnolinyl, phthalazinyl, quinazolinyl, dihydroquinoxalinyl, quinoxalinyl, naphthyridinyl, purinyl, pteridinyl and quinuclidinyl groups Means.
Examples of the bicyclic oxygen-containing heterocyclic group include 2,3-dihydrobenzofuranyl, benzofuranyl, isobenzofuranyl, chromanyl, chromenyl, isochromanyl, 1,3-benzodioxolyl, 1,3- It means a bicyclic oxygen-containing heterocyclic group containing only an oxygen atom as a hetero atom forming the ring, such as benzodioxanyl and 1,4-benzodioxanyl groups.
The bicyclic sulfur-containing heterocyclic group is, for example, a bicyclic sulfur-containing heterocyclic ring containing only a sulfur atom as a hetero atom forming the ring, such as 2,3-dihydrobenzothienyl and benzothienyl groups. Means a formula group.
Bicyclic nitrogen-containing / oxygen heterocyclic groups include, for example, benzoxazolyl, benzisoxazolyl, benzooxadiazolyl, benzomorpholinyl, dihydropyranopyridyl, dihydrodioxynopyridyl and dihydropyridyl. It means a bicyclic nitrogen-containing / oxygen heterocyclic group containing only a nitrogen atom and an oxygen atom as the hetero atoms forming the ring, such as a dooxazinyl group.
Bicyclic nitrogen-containing / sulfur heterocyclic groups are, for example, bicyclic compounds containing nitrogen and sulfur atoms as hetero atoms forming the ring such as benzothiazolyl, benzisothiazolyl and benzothiadiazolyl groups. This means a nitrogen-containing / sulfur heterocyclic group.
A bicyclic heterocyclic group is a bicyclic nitrogen-containing heterocyclic group, a bicyclic oxygen-containing heterocyclic group, a bicyclic sulfur-containing heterocyclic group, or a bicyclic nitrogen-containing group. -An oxygen heterocyclic group or a bicyclic nitrogen-containing / sulfur heterocyclic group.
 複素環式基とは、単環の複素環式基または二環式の複素環式基を意味する。 The heterocyclic group means a monocyclic heterocyclic group or a bicyclic heterocyclic group.
 環状アミノ基とは、たとえば、アジリジニル、アゼチジニル、ピロリジニル、ピペリジニル、ホモピペリジニル、ピロリル、ジヒドロピロリル、ピラゾリル、ピラゾリニル、ピラゾリジニル、イミダゾリル、イミダゾリニル、イミダゾリジニル、チアゾリニル、チアゾリジニル、ジヒドロチアジアゾリル、ピペラジニル、ホモピペラジニル、モルホリニル、ホモモルホリニル、チオモルホリニル、テトラヒドロキノリニル、テトラヒドロイソキノリニル、ベンゾモルホリニル、ジヒドロピリドオキサジニルおよびキヌクリジニルなどの該環を形成する異項原子として一つ以上の窒素原子を含み、さらに一つ以上の酸素原子または硫黄原子を含んでもよい3員、4員、5員、6員もしくは7員環、縮合環または架橋環の環状アミノ基を意味する。 Cyclic amino groups include, for example, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrrolyl, dihydropyrrolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, thiazolinyl, thiazolidinyl, dihydrothiadiazyl, Including one or more nitrogen atoms as a hetero atom forming the ring, such as homomorpholinyl, thiomorpholinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzomorpholinyl, dihydropyridoxazinyl and quinuclidinyl, Means a 3-, 4-, 5-, 6- or 7-membered, fused or bridged cyclic amino group which may contain one or more oxygen or sulfur atoms .
 アミノ保護基およびイミノ保護基としては、通常のアミノ基およびイミノ基の保護基として使用し得るすべての基を含み、たとえば、W.グリーン(W.Greene)ら、プロテクティブ・グループス・イン・オーガニック・シンセシス(Protective Groups in Organic Synthesis)第4版、第696~926頁、2007年、ジョン・ウィリイ・アンド・サンズ社(John Wiley & Sons,INC.)に記載されている基が挙げられる。具体的には、アルC1-6アルキル基、C1-6アルコキシC1-6アルキル基、アシル基、C1-6アルコキシカルボニル基、アルC1-6アルコキシカルボニル基、アリールオキシカルボニル基、C1-6アルキルスルホニル基、アリールスルホニル基またはシリル基が挙げられる。 Amino protecting groups and imino protecting groups include all groups that can be used as protecting groups for conventional amino and imino groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 696-926, 2007, John Wiley & Sons (John Wiley & Sons, INC.). Specifically, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an acyl group, a C 1-6 alkoxycarbonyl group, an ar C 1-6 alkoxycarbonyl group, an aryloxycarbonyl group, Examples thereof include a C 1-6 alkylsulfonyl group, an arylsulfonyl group, and a silyl group.
 ヒドロキシル保護基としては、通常のヒドロキシル基の保護基として使用し得るすべての基を含み、たとえば、W.グリーン(W.Greene)ら、プロテクティブ・グループス・イン・オーガニック・シンセシス(Protective Groups in Organic Synthesis)第4版、第16~299頁、2007年、ジョン・ウィリイ・アンド・サンズ社(John Wiley & Sons,INC.)に記載されている基が挙げられる。具体的には、たとえば、C1-6アルキル基、C2-6アルケニル基、アルC1-6アルキル基、C1-6アルコキシC1-6アルキル基、アルC1-6アルコキシC1-6アルキル基、アシル基、C1-6アルコキシカルボニル基、アルC1-6アルコキシカルボニル基、C1-6アルキルスルホニル基、アリールスルホニル基、シリル基、テトラヒドロフラニル基またはテトラヒドロピラニル基が挙げられる。 Hydroxyl protecting groups include all groups that can be used as protecting groups for conventional hydroxyl groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 16-299, 2007, John Wiley & Sons (John Wiley & Sons, INC.). Specifically, for example, a C 1-6 alkyl group, a C 2-6 alkenyl group, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an ar C 1-6 alkoxy C 1- 1 6 alkyl group, acyl group, C 1-6 alkoxycarbonyl group, al C 1-6 alkoxycarbonyl group, C 1-6 alkylsulfonyl group, arylsulfonyl group, silyl group, tetrahydrofuranyl group or tetrahydropyranyl group .
 カルボキシル保護基としては、通常のカルボキシル基の保護基として使用し得るすべての基を含み、たとえば、W.グリーン(W.Greene)ら、プロテクティブ・グループス・イン・オーガニック・シンセシス(Protective Groups in Organic Synthesis)第4版、第533~643頁、2007年、ジョン・ウィリイ・アンド・サンズ社(John Wiley & Sons,INC.)に記載されている基が挙げられる。具体的には、C1-6アルキル基、C2-6アルケニル基、アリール基、アルC1-6アルキル基、C1-6アルコキシC1-6アルキル基、アルC1-6アルコキシC1-6アルキル基、アシルC1-6アルキル基、アシルオキシC1-6アルキル基またはシリル基が挙げられる。 The carboxyl protecting group includes all groups that can be used as protecting groups for ordinary carboxyl groups. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 533-643, 2007, John Wiley & Sons (John Wiley & Sons, INC.). Specifically, a C 1-6 alkyl group, a C 2-6 alkenyl group, an aryl group, an ar C 1-6 alkyl group, a C 1-6 alkoxy C 1-6 alkyl group, an ar C 1-6 alkoxy C 1 Examples include a -6 alkyl group, an acyl C 1-6 alkyl group, an acyloxy C 1-6 alkyl group, and a silyl group.
 脱離基としては、たとえば、ハロゲン原子、C1-6アルキルスルホニルオキシ基またはアリールスルホニルオキシ基が挙げられる。 Examples of the leaving group include a halogen atom, a C 1-6 alkylsulfonyloxy group or an arylsulfonyloxy group.
 脂肪族炭化水素類としては、たとえば、ペンタン、ヘキサン、シクロヘキサンまたはデカヒドロナフタレンが挙げられる。
 ハロゲン化炭化水素類としては、たとえば、塩化メチレン、クロロホルムまたはジクロロエタンが挙げられる。
 アルコール類としては、たとえば、メタノール、エタノール、プロパノール、2-プロパノール、ブタノールまたは2-メチル-2-プロパノールが挙げられる。
 エーテル類としては、たとえば、ジエチルエーテル、ジイソプロピルエーテル、ジオキサン、テトラヒドロフラン、アニソール、エチレングリコールジメチルエーテル、ジエチレングリコールジメチルエーテルまたはジエチレングリコールジエチルエーテルが挙げられる。
Examples of the aliphatic hydrocarbons include pentane, hexane, cyclohexane, and decahydronaphthalene.
Examples of halogenated hydrocarbons include methylene chloride, chloroform or dichloroethane.
Examples of alcohols include methanol, ethanol, propanol, 2-propanol, butanol, and 2-methyl-2-propanol.
Examples of ethers include diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran, anisole, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, and diethylene glycol diethyl ether.
 ケトン類としては、たとえば、アセトン、2-ブタノンまたは4-メチル-2-ペンタノンが挙げられる。
 エステル類としては、たとえば、酢酸メチル、酢酸エチル、酢酸プロピルまたは酢酸ブチルが挙げられる。
 アミド類としては、たとえば、N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミドまたは1-メチル-2-ピロリドンが挙げられる。
 芳香族炭化水素類としては、たとえば、ベンゼン、トルエンまたはキシレンが挙げられる。
Examples of ketones include acetone, 2-butanone, and 4-methyl-2-pentanone.
Examples of the esters include methyl acetate, ethyl acetate, propyl acetate, and butyl acetate.
Examples of amides include N, N-dimethylformamide, N, N-dimethylacetamide, and 1-methyl-2-pyrrolidone.
Examples of aromatic hydrocarbons include benzene, toluene, and xylene.
 本明細書において、各置換基群は、次の意味を有する。 In the present specification, each substituent group has the following meaning.
 置換基群A1:
ハロゲン原子、シアノ基、ニトロ基、1つ以上のC1-6アルキル基で置換されていてもよいカルバモイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルアミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいジ(C1-6アルキル)アミノ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいアリール基、置換基群B1から選ばれる1つ以上の基で置換されていてもよい単環の複素環式基、置換基群B1から選ばれる1つ以上の基で置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいイミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group A1:
Halogen atom, a cyano group, a nitro group, one or more C 1-6 alkyl carbamoyl group which may be substituted with a group, optionally substituted with one or more groups selected from Substituent Group A2 C 1 A -6 alkoxy group, a C 1-6 alkylamino group optionally substituted with one or more groups selected from Substituent Group A2, and a substituent substituted with one or more groups selected from Substituent Group A2 A good di (C 1-6 alkyl) amino group, an aryl group which may be substituted with one or more groups selected from Substituent Group B1, and one or more groups selected from Substituent Group B1 A monocyclic heterocyclic group which may be substituted, a bicyclic heterocyclic group which may be substituted with one or more groups selected from substituent group B1, an amino group which may be protected, a protected group Optionally imino groups, optionally protected hydro A xyl group, an optionally protected carboxyl group.
 置換基群A2:
ハロゲン原子、シアノ基、カルバモイル基、C1-6アルキル基、C1-6アルコキシ基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group A2:
A halogen atom, a cyano group, a carbamoyl group, a C 1-6 alkyl group, a C 1-6 alkoxy group, an optionally protected amino group, an optionally protected hydroxyl group, and an optionally protected carboxyl group;
 置換基群B1:
ハロゲン原子、シアノ基、ニトロ基、オキソ基、1つ以上のC1-6アルキル基で置換されていてもよいカルバモイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルアミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいジ(C1-6アルキル)アミノ基、保護されていてもよいアミノ基、保護されていてもよいイミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group B1:
A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2. A C 1-6 alkyl group, which may be substituted with one or more groups selected from the substituent group A2, and a C 1-6 alkoxy group which may be substituted with one or more groups selected from the substituent group A2. An optionally substituted C 1-6 alkylamino group, a di (C 1-6 alkyl) amino group optionally substituted with one or more groups selected from Substituent Group A2, an optionally protected amino group, An imino group which may be protected, a hydroxyl group which may be protected, a carboxyl group which may be protected.
 置換基群C1:
ハロゲン原子、シアノ基、ニトロ基、オキソ基、1つ以上のC1-6アルキル基で置換されていてもよいカルバモイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルケニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルキニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルアミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいジ(C1-6アルキル)アミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルチオ基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいC3-8シクロアルキル基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいアロイル基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいアルC1-6アルキル基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいアリールオキシ基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいアリールチオ基、置換基群C2から選ばれる1つ以上の基で置換されていてもよいアリール基、置換基群C2から選ばれる1つ以上の基で置換されていてもよい単環の複素環式基、置換基群C2から選ばれる1つ以上の基で置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいイミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group C1:
A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2. A C 1-6 alkyl group, a C 2-6 alkenyl group optionally substituted with one or more groups selected from Substituent Group A2, and one or more groups selected from Substituent Group A2 A C 2-6 alkynyl group which may be optionally substituted with one or more groups selected from substituent group A2, and a C 1-6 alkoxy group which may be substituted with one or more groups selected from substituent group A2. A C 1-6 alkylamino group which may be substituted, a di (C 1-6 alkyl) amino group which may be substituted with one or more groups selected from the substituent group A2, and a substituent group A2. C optionally substituted with one or more groups 1-6 alkylthio group, C 3-8 cycloalkyl group optionally substituted with one or more groups selected from substituent group C2, substituted with one or more groups selected from substituent group C2 Or an aroyl group, an al C 1-6 alkyl group which may be substituted with one or more groups selected from substituent group C2, and one or more groups selected from substituent group C2. A good aryloxy group, an arylthio group which may be substituted with one or more groups selected from substituent group C2, an aryl group which may be substituted with one or more groups selected from substituent group C2, A monocyclic heterocyclic group which may be substituted with one or more groups selected from group C2, and a bicyclic complex which may be substituted with one or more groups selected from substituent group C2. Cyclic groups, optionally protected amino groups, Which may be an imino group, a protected or unprotected hydroxyl groups, protected or unprotected carboxyl group.
 置換基群C2:
ハロゲン原子、シアノ基、ニトロ基、オキソ基、アダマンチル基、1つ以上のC1-6アルキル基で置換されていてもよいカルバモイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルスルホニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-12アルカノイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルケニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルキニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルアミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいジ(C1-6アルキル)アミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルチオ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいC3-8シクロアルキル基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいアリールオキシ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいアリールチオ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいアリール基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいアルC1-6アルコキシ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよい単環の複素環式基、置換基群B1から選ばれる1つ以上の基で置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいイミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group C2:
Substituted with one or more groups selected from a halogen atom, a cyano group, a nitro group, an oxo group, an adamantyl group, a carbamoyl group optionally substituted with one or more C 1-6 alkyl groups, and substituent group A2. An optionally substituted C 1-6 alkylsulfonyl group, one or more groups selected from substituent group A2 and a C 2-12 alkanoyl group optionally substituted by one or more groups selected from substituent group A2. A C 1-6 alkyl group which may be substituted with one or more, a C 2-6 alkenyl group which may be substituted with one or more groups selected from substituent group A2, and one or more selected from substituent group A2 A C 2-6 alkynyl group which may be substituted with one group, a C 1-6 alkoxy group which may be substituted with one or more groups selected from substituent group A2, and a group selected from substituent group A2 Substituted with two or more groups A C 1-6 alkylamino group which may be optionally substituted with one or more groups selected from substituent group A2, and a di (C 1-6 alkyl) amino group which may be substituted with 1 or more groups selected from substituent group A2. A C 1-6 alkylthio group which may be substituted with one or more groups, a C 3-8 cycloalkyl group which may be substituted with one or more groups selected from substituent group B1, and a substituent group B1 An aryloxy group optionally substituted with one or more selected groups, an arylthio group optionally substituted with one or more groups selected from substituent group B1, and one or more selected from substituent group B1 An aryl group which may be substituted with the above group, an al C 1-6 alkoxy group which may be substituted with one or more groups selected from substituent group B1, and one or more groups selected from substituent group B1 Monocyclic optionally substituted with groups A cyclic group, a bicyclic heterocyclic group optionally substituted with one or more groups selected from substituent group B1, an amino group which may be protected, an imino group which may be protected A hydroxyl group which may be protected, a carboxyl group which may be protected.
 置換基群D1:
ハロゲン原子、シアノ基、ニトロ基、オキソ基、1つ以上のC1-6アルキル基で置換されていてもよいカルバモイル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルケニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC2-6アルキニル基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキルアミノ基、置換基群A2から選ばれる1つ以上の基で置換されていてもよいジ(C1-6アルキル)アミノ基、置換基群B1から選ばれる1つ以上の基で置換されていてもよいC3-8シクロアルキル基、保護されていてもよいアミノ基、保護されていてもよいイミノ基、保護されていてもよいヒドロキシル基、保護されていてもよいカルボキシル基。
Substituent group D1:
A halogen atom, a cyano group, a nitro group, an oxo group, a carbamoyl group that may be substituted with one or more C 1-6 alkyl groups, and a substituent that is substituted with one or more groups selected from Substituent Group A2. A C 1-6 alkyl group, a C 2-6 alkenyl group optionally substituted with one or more groups selected from Substituent Group A2, and one or more groups selected from Substituent Group A2 A C 2-6 alkynyl group which may be optionally substituted with one or more groups selected from substituent group A2, and a C 1-6 alkoxy group which may be substituted with one or more groups selected from substituent group A2. A C 1-6 alkylamino group which may be substituted, a di (C 1-6 alkyl) amino group which may be substituted with one or more groups selected from substituent group A2, and a substituent group B1 C optionally substituted with one or more groups 3-8 cycloalkyl group, amino group which may be protected, imino group which may be protected, hydroxyl group which may be protected, carboxyl group which may be protected.
 RおよびRのC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、C1-6アルキルアミノ基、ジ(C1-6アルキル)アミノ基およびC1-6アルキルチオ基は、置換基群A1から選ばれる1つ以上の基で置換されてもよい。
 RおよびRのC3-8シクロアルキル基、アリールオキシ基、アリールチオ基、アリール基、単環の複素環式基および二環式の複素環式基は、置換基群B1から選ばれる1つ以上の基で置換されてもよい。
C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 1-6 alkoxy group, C 1-6 alkylamino group, di (C 1-6 alkyl) of R 1 and R 2 The amino group and the C 1-6 alkylthio group may be substituted with one or more groups selected from the substituent group A1.
The C 3-8 cycloalkyl group, aryloxy group, arylthio group, aryl group, monocyclic heterocyclic group and bicyclic heterocyclic group represented by R 1 and R 2 are selected from the substituent group B1. It may be substituted with more than one group.
のジヒドロベンゾシクロブテニル基、インダニル基、インデニル基、テトラヒドロナフチル基、ジヒドロナフチル基、ベンゾシクロヘプチル基、ジヒドロ-5H-ベンゾシクロヘプテニル基、5H-ベンゾシクロヘプテニル基、ヘキサヒドロベンゾシクロオクテニル基、テトラヒドロベンゾシクロオクテニル基、ジヒドロベンゾシクロオクテニル基、テトラヒドロメタノナフチル基およびテトラヒドロエタノナフチル基は、置換基群C1から選ばれる1つ以上の基で置換されてもよい。 R 3 dihydrobenzocyclobutenyl, indanyl, indenyl, tetrahydronaphthyl, dihydronaphthyl, benzocycloheptyl, dihydro-5H-benzocycloheptenyl, 5H-benzocycloheptenyl, hexahydrobenzo The cyclooctenyl group, tetrahydrobenzocyclooctenyl group, dihydrobenzocyclooctenyl group, tetrahydromethanonaphthyl group and tetrahydroethanonaphthyl group may be substituted with one or more groups selected from the substituent group C1.
 RおよびRのC1-6アルキル基、C2-6アルケニル基およびC2-6アルキニル基は、置換基群A1から選ばれる1つ以上の基で置換されてもよい。
 RおよびRのC3-8シクロアルキル基、アリール基および単環の複素環式基は、置換基群B1から選ばれる1つ以上の基で置換されてもよい。
 RおよびRの環状アミノ基は、置換基群D1から選ばれる1つ以上の基で置換されてもよい。
The C 1-6 alkyl group, C 2-6 alkenyl group and C 2-6 alkynyl group of R 4 and R 5 may be substituted with one or more groups selected from the substituent group A1.
The C 3-8 cycloalkyl group, aryl group and monocyclic heterocyclic group of R 4 and R 5 may be substituted with one or more groups selected from substituent group B1.
The cyclic amino group of R 4 and R 5 may be substituted with one or more groups selected from the substituent group D1.
 RのC1-6アルキル基は、置換基群A1から選ばれる1つ以上の基で置換されてもよい。 The C 1-6 alkyl group of R a may be substituted with one or more groups selected from Substituent Group A1.
 RのC1-6アルキル基は、置換基群A1から選ばれる1つ以上の基で置換されてもよい。 The C 1-6 alkyl group of R b may be substituted with one or more groups selected from Substituent Group A1.
 RのC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、C1-6アルキルアミノ基、ジ(C1-6アルキル)アミノ基およびC1-6アルキルチオ基は、置換基群A1から選ばれる1つ以上の基で置換されてもよい。
 RのC3-8シクロアルキル基、アリールオキシ基、アリールチオ基、アリール基、単環の複素環式基および二環式の複素環式基は、置換基群B1から選ばれる1つ以上の基で置換されてもよい。
A C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino group, a di (C 1-6 alkyl) amino group of R c and The C 1-6 alkylthio group may be substituted with one or more groups selected from Substituent Group A1.
The C 3-8 cycloalkyl group, aryloxy group, arylthio group, aryl group, monocyclic heterocyclic group and bicyclic heterocyclic group of R c are one or more selected from the substituent group B1. It may be substituted with a group.
 本発明の一般式[1]の化合物において、好ましい化合物としては、以下の化合物が挙げられる。 In the compound of the general formula [1] of the present invention, preferable compounds include the following compounds.
 RおよびRが、同一または異なって、水素原子、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基または置換されていてもよいアリール基である化合物である化合物が好ましい。
 RおよびRが、同一または異なって、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基または置換されていてもよいC1-6アルコキシ基である化合物である化合物がより好ましい。
 RおよびRが、同一または異なって、ハロゲン原子、置換されていてもよいC1-6アルキル基または置換されていてもよいC3-8シクロアルキル基である化合物がさらに好ましい。
 RおよびRが、同一または異なって、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC3-8シクロアルキル基または置換されていてもよいC1-6アルコキシ基である化合物である化合物がより好ましい。
 RおよびRが、同一または異なって、ハロゲン原子、1つ以上のハロゲン原子で置換されていてもよいC1-6アルキル基または1つ以上のハロゲン原子で置換されていてもよいC3-8シクロアルキル基である化合物がよりさらに好ましい。
R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or a substituted The compound is an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group or an optionally substituted aryl group. Compounds are preferred.
R 1 and R 2 are the same or different and are each a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted A compound that is a compound having a C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, or an optionally substituted C 1-6 alkoxy group is more preferable.
More preferred is a compound wherein R 1 and R 2 are the same or different and each is a halogen atom, an optionally substituted C 1-6 alkyl group or an optionally substituted C 3-8 cycloalkyl group.
R 1 and R 2 may be the same or different and each may be a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-8 cycloalkyl group or an optionally substituted More preferred are compounds that are good C 1-6 alkoxy groups.
R 1 and R 2 are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more halogen atoms, or C 3 which may be substituted with one or more halogen atoms Even more preferred are compounds that are -8 cycloalkyl groups.
 Rが、置換されていてもよいジヒドロベンゾシクロブテニル基、置換されていてもよいインダニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいヘキサヒドロベンゾシクロオクテニル基または置換されていてもよいテトラヒドロメタノナフチル基である化合物が好ましい。
 Rが、置換されていてもよいインダニル基、置換されていてもよいテトラヒドロナフチル基または置換されていてもよいベンゾシクロヘプチル基である化合物がより好ましい。
 別の態様として、Rが、一般式[X]
Figure JPOXMLDOC01-appb-C000003
「式中、Rは、同一または異なって、置換基群C1から選ばれる基を;Rは、同一または異なって、置換基群C1から選ばれる基を;nは、2~6の整数を;m1は、0~10の整数を;m2は、0~3の整数を示す。」で表される基である化合物がより好ましい。
R 3 is an optionally substituted dihydrobenzocyclobutenyl group, an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted benzocycloheptyl group, a substituted A compound which is an optionally substituted hexahydrobenzocyclooctenyl group or an optionally substituted tetrahydromethanonaphthyl group is preferred.
A compound in which R 3 is an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group or an optionally substituted benzocycloheptyl group is more preferable.
In another embodiment, R 3 is represented by the general formula [X]
Figure JPOXMLDOC01-appb-C000003
"Wherein R 6 is the same or different and is a group selected from substituent group C1; R 7 is the same or different and is a group selected from substituent group C1; n is an integer of 2 to 6 M1 represents an integer of 0 to 10; m2 represents an integer of 0 to 3. ”is more preferable.
 m1個のRが、同一または異なって、ハロゲン原子、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基または置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基である化合物が好ましい。
 m1個のRが、同一または異なって、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基である化合物がより好ましい。
 m1個のRが、同一または異なって、C1-6アルキル基である化合物がさらに好ましい。
m 1 R 6 s are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more groups selected from Substituent Group A2, or one selected from Substituent Group A2 A compound which is a C 1-6 alkoxy group which may be substituted with the above groups is preferred.
A compound in which m1 R 6 s are the same or different and each is a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group is more preferable.
m1 pieces of R 6 are the same or different, compounds which are C 1-6 alkyl group is more preferred.
 m2個のRが、同一または異なって、ハロゲン原子、置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルキル基または置換基群A2から選ばれる1つ以上の基で置換されていてもよいC1-6アルコキシ基である化合物が好ましい。
 m2個のRが、同一または異なって、ハロゲン原子、C1-6アルキル基またはC1-6アルコキシ基である化合物がより好ましい。
m2 R 7 s are the same or different and each is a halogen atom, a C 1-6 alkyl group which may be substituted with one or more groups selected from Substituent Group A2, or one selected from Substituent Group A2 A compound which is a C 1-6 alkoxy group which may be substituted with the above groups is preferred.
A compound in which m 2 R 7 s are the same or different and each is a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group is more preferable.
 m1が、0~4の整数を示す化合物が好ましい。
 m1が、0~2の整数を示す化合物がより好ましい。
A compound in which m1 represents an integer of 0 to 4 is preferable.
A compound in which m1 represents an integer of 0 to 2 is more preferable.
 m2が、0または1である化合物が好ましい。
 m2が、0である化合物がより好ましい。
A compound in which m2 is 0 or 1 is preferable.
A compound in which m2 is 0 is more preferable.
 nが、3、4または5である化合物が好ましい。
 nが、3または4である化合物がより好ましい。
 nが、3である化合物がさらに好ましい。
Compounds in which n is 3, 4 or 5 are preferred.
A compound in which n is 3 or 4 is more preferable.
More preferred are compounds wherein n is 3.
 RおよびRが、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基または置換されていてもよいC3-8シクロアルキル基である化合物が好ましい。
 RおよびRが、同一または異なって、水素原子または置換基群A1から選ばれる1つ以上の基で置換されてもよいC1-6アルキル基である化合物がより好ましい。
 RおよびRが、同一または異なって、水素原子またはC1-6アルキル基である化合物がさらに好ましい。
R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− A compound which is a 6 alkynyl group or an optionally substituted C 3-8 cycloalkyl group is preferred.
A compound in which R 4 and R 5 are the same or different and each is a C 1-6 alkyl group which may be substituted with a hydrogen atom or one or more groups selected from substituent group A1 is more preferable.
More preferred are compounds in which R 4 and R 5 are the same or different and are a hydrogen atom or a C 1-6 alkyl group.
 Xが、C1-6アルキレン基または一般式NR「式中、Rは、前記と同様の意味を有する。」で表される基である化合物が好ましい。
 Xが、メチレン基または一般式NRa1「式中、Ra1は、水素原子またはイミノ保護基を示す。」で表される基である化合物がより好ましい。
 Xが、メチレン基である化合物がさらに好ましい。
A compound in which X 1 is a C 1-6 alkylene group or a group represented by the general formula NR a , wherein R a has the same meaning as described above is preferable.
More preferred is a compound in which X 1 is a methylene group or a group represented by the general formula NR a1 , wherein R a1 represents a hydrogen atom or an imino protecting group.
A compound in which X 1 is a methylene group is more preferable.
 ZおよびZが、同一または異なって、一般式CR「式中、Rは、前記と同様の意味を有する。」で表される基である化合物が好ましい。
 ZおよびZが、同一または異なって、一般式CRc1「式中、Rc1は、水素原子、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基または置換されていてもよいアリール基を示す。」で表される基である化合物がより好ましい。
 ZおよびZが、同一または異なって、一般式CRc2「式中、Rc2は、水素原子、ハロゲン原子、置換されていてもよいC1-6アルキル基または置換されていてもよいC3-8シクロアルキル基を示す。」で表される基である化合物がさらに好ましい。
 ZおよびZが、同一または異なって、一般式CRc3「式中、Rc3は、水素原子、ハロゲン原子、1つ以上のハロゲン原子で置換されていてもよいC1-6アルキル基または1つ以上のハロゲン原子で置換されていてもよいC3-8シクロアルキル基を示す。」で表される基である化合物がよりさらに好ましい。
 ZおよびZが、式CHで表される基である化合物が最も好ましい。
A compound in which Z 1 and Z 2 are the same or different and is a group represented by the general formula CR c "wherein R c has the same meaning as described above" is preferable.
Z 1 and Z 2 may be the same or different and have the general formula CR c1 , wherein R c1 is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, a substituted An optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group or a substituted group The aryl group which may be made is a group represented by "is more preferable.
Z 1 and Z 2 are the same or different and have the general formula CR c2 "wherein R c2 is a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group or an optionally substituted C 1 A compound represented by the formula “ 3-8 cycloalkyl group” is more preferred.
Z 1 and Z 2 are the same or different and have the general formula CR c3 , wherein R c3 is a hydrogen atom, a halogen atom, a C 1-6 alkyl group which may be substituted with one or more halogen atoms, or A compound having a group represented by “denotes a C 3-8 cycloalkyl group which may be substituted with one or more halogen atoms” is even more preferable.
Most preferred are compounds wherein Z 1 and Z 2 are groups represented by the formula CH.
 Zが、一般式CR「式中、Rは、前記と同様の意味を有する。」で表される基である化合物が好ましい。
 Zが、式CHで表される基である化合物がより好ましい。
A compound in which Z 3 is a group represented by the general formula CR b "wherein R b has the same meaning as described above" is preferable.
A compound in which Z 3 is a group represented by the formula CH is more preferable.
 別の態様として、本発明の一般式[1]の化合物において、好ましい化合物としては、以下の化合物が挙げられる。
 R、R、ZのRおよびZのRのうちの二つが、同一または異なって、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC3-8シクロアルキル基または置換されていてもよいC1-6アルコキシ基であり、他の二つが、水素原子である化合物が好ましい。
 R、R、ZのRおよびZのRのうちの二つが、同一または異なって、置換されていてもよいC1-6アルキル基であり、他の二つが、水素原子である化合物がより好ましい。
 RおよびRが、同一または異なって、C1-6アルキル基であり、ZのRおよびZのRが、水素原子である化合物がさらに好ましい。
As another aspect, in the compound of the general formula [1] of the present invention, preferable compounds include the following compounds.
R 1, R 2, two of Z 1 of R c and Z 2 of R c are the same or different, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, optionally substituted A compound having an optionally substituted C 3-8 cycloalkyl group or an optionally substituted C 1-6 alkoxy group, and the other two being a hydrogen atom is preferable.
R 1, R 2, two of Z 1 of R c and Z 2 of R c are the same or different, substituted is also C 1-6 alkyl group, the other two are hydrogen atom The compound which is is more preferable.
R 1 and R 2 are the same or different, a C 1-6 alkyl group, R c and Z 2 of R c of Z 1 is, compounds and more preferably a hydrogen atom.
 別の態様として、本発明の一般式[1]の化合物において、好ましい化合物としては、以下の化合物が挙げられる。
 N’-(5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(5-シクロプロピル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((5-メチル-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(4-((4-(インダン-5-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(ベンゾシクロヘプタン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチル-N-(プロパン-2-イル)イミドホルムアミド、N’-(5-クロロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(5-(ジフルオロメトキシ)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N-エチル-N’-(5-メトキシ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミド、N-エチル-N-メチル-N’-(2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)-5-(トリフルオロメチル)フェニル)イミドホルムアミド、N-エチル-N’-(5-エチニル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミド、N-エチル-N-メチル-N’-(2-メチル-5-(プロパン-2-イル)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)イミドホルムアミド、N’-(5-(ジフルオロメチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(1,2,3,4-テトラヒドロ-1,4-メタノナフタレン-6-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(2,5-ジメチル-4-((4-(2-メチル-2,3-ジヒドロ-1H-インデン-5-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(4-((4-(2,2-ジメチル-2,3-ジヒドロ-1H-インデン-5-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミド、N’-(4-((4-(ビシクロ[4.2.0]オクタ-1,3,5-トリエン-3-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミド、N-エチル-N’-(4-((4-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-メチルイミドホルムアミド。
As another aspect, in the compound of the general formula [1] of the present invention, preferable compounds include the following compounds.
N ′-(5-Bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl)- N-ethyl-N-methylimidoformamide, N ′-(5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- Thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalene-2) -Yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (5,6,7,8- Tetrahydronaphthalen-2-yl) -1,3-thiazole- 2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((5-methyl-4- (5,6,7,8-tetrahydronaphthalene) -2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(4-((4- (indan-5-yl) -1 , 3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (benzocycloheptane -2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (5 6,7,8-tetrahydronaphthalene-2- Yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methyl-N- (propan-2-yl) imidoformamide, N ′-(5-chloro-2-methyl-4-(( 4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(5- (Difluoromethoxy) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl -N-methylimidoformamide, N-ethyl-N '-(5-methoxy-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- Thiazol-2-yl) methyl) phenyl -N-methylimidoformamide, N-ethyl-N-methyl-N '-(2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- Thiazol-2-yl) methyl) -5- (trifluoromethyl) phenyl) imidoformamide, N-ethyl-N ′-(5-ethynyl-2-methyl-4-((4- (5,6,7, 8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide, N-ethyl-N-methyl-N ′-(2-methyl-5- ( Propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) imidoformamide, N′- (5- (difluoromethyl)- -Methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide N ′-(2,5-dimethyl-4-((4- (1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) -1,3-thiazol-2-yl) Methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(2,5-dimethyl-4-((4- (2-methyl-2,3-dihydro-1H-inden-5-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide, N ′-(4-((4- (2,2-dimethyl-2,3-dihydro-1H -Inden-5-yl) -1,3-thiazole-2- L) methyl) -2,5-dimethylphenyl) -N-ethyl-N-methylimidoformamide, N ′-(4-((4- (bicyclo [4.2.0] octa-1,3,5- Trien-3-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N-ethyl-N-methylimidoformamide, N-ethyl-N ′-(4-(( 4- (5,6,7,8,9,10-hexahydrobenzo [8] annulen-2-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N -Methylimidoformamide.
 抗真菌剤とは、病原性真菌に作用して、その生育を抑制または殺菌する能力を持つ物質を意味する。真菌の繁殖を抑えたり、一部の真菌を殺してその数を減少させたりするようなものでもよい。 An antifungal agent means a substance capable of acting on a pathogenic fungus and suppressing or sterilizing its growth. It may be something that suppresses fungal growth or kills some fungi to reduce their number.
 病原性真菌とは、たとえば、酵母様真菌、糸状真菌および接合菌などを挙げることができる。酵母様真菌として、たとえば、カンジダ属(カンジダ・アルビカンス、カンジダ・グラブラータ、カンジダ・ギリエルモンディ、カンジダ・クルセイ、カンジダ・パラプシローシスおよびカンジダ・トロピカリスなど)、クリプトコッカス属(クリプトコッカス・ネオフォルマンスなど)、マラセチア属(マラセチア・フルフルなど)、トリコスポロン属(トリコスポロン・アサヒなど)が挙げられる。糸状真菌として、たとえば、アスペルギルス属(アスペルギルス・フミガーツス、アスペルギルス・テレウス、アスペルギルス・ニゲール、アスペルギルス・フラバスなど)、白癬菌属(トリコフィトン・ルブルム、トリコフィトン・メンタグロファィテス、トリコフィトン・トンズランスなど)、フサリウム属(フサリウム・ソラニなど)、スケドスポリウム属(スケドスポリウム・アピオスペルマムなど)および小胞子菌属(ミクロスポルム・カニスなど)が挙げられる。接合菌として、たとえば、ムーコル属(ムーコル・プルムベウスなど)、リゾプス属(リゾプス・オリゼなど)およびアブシディア属(アブシディア・コリンビフェラなど)が挙げられる。
 本発明の抗真菌剤は、カンジダ属菌、アスペルギルス属菌および白癬菌属菌などの菌種に対して優れた抗真菌作用を示し、白癬菌属菌に対してより優れた抗真菌作用を示す。
 また、別の態様では、本発明の抗真菌剤は、カンジダ・アルビカンス、アスペルギルス・フミガーツス、トリコフィトン・ルブルム、トリコフィトン・メンタグロファィテス、マラセチア・フルフル、およびクリプトコッカス・ネオフォルマンスなどの菌種に対して優れた抗真菌作用を示す。
Examples of pathogenic fungi include yeast-like fungi, filamentous fungi, and zygomycetes. Examples of yeast-like fungi include Candida (Candida albicans, Candida glabrata, Candida giermondii, Candida crusei, Candida parapsilosis, Candida tropicalis, etc.), Cryptococcus genus (such as Cryptococcus neoformans), Examples include the genus Malassezia (such as Malassezia fullfur) and the genus Trichosporon (such as Trichosporon and Asahi). As the filamentous fungi, for example, Aspergillus (Aspergillus fumigatus, Aspergillus tereus, Aspergillus niger, Aspergillus flavus, etc.) , Genus Fusarium (such as Fusarium solani), genus Schedosporum (such as skedosporum apiospermum) and genus Microsporium (such as Microsporum canis). Examples of the zygomycete include the genus Mucor (Mucor plum plumus, etc.), the genus Rhizopus (such as Rhizopus oryzae), and the genus Absidia (such as Absidia cholinebifera).
The antifungal agent of the present invention exhibits an excellent antifungal action against bacterial species such as Candida, Aspergillus and ringworm, and more excellent antifungal action against ringworm .
In another aspect, the antifungal agent of the present invention is a bacterial species such as Candida albicans, Aspergillus fumigatus, Trichophyton rubulum, Trichophyton mentagrophytes, Malassezia furfur, and Cryptococcus neoformans. Excellent antifungal activity.
 一般式[1]で表される化合物またはその塩は、優れた安全性を示す。安全性は、種々の試験によって評価されるが、たとえば、細胞毒性試験、hERG試験、反復投与毒性試験、シトクロムP450(CYP)活性阻害試験、代謝依存性阻害試験、インビボ(in vivo)マウス小核試験およびインビボ(in vivo)ラット肝UDS試験などから選ばれる各種安全性試験などで評価することができる。 The compound represented by the general formula [1] or a salt thereof exhibits excellent safety. Safety is evaluated by various tests, for example, cytotoxicity test, hERG test, repeated dose toxicity test, cytochrome P450 (CYP) activity inhibition test, metabolism-dependent inhibition test, in vivo mouse micronucleus It can be evaluated by various safety tests selected from a test and an in vivo rat liver UDS test.
 一般式[1]の化合物の塩としては、通常知られているアミノ基などの塩基性基またはヒドロキシルもしくはカルボキシル基などの酸性基における塩を挙げることができる。 Examples of the salt of the compound represented by the general formula [1] include a salt of a commonly known basic group such as amino group or acidic group such as hydroxyl or carboxyl group.
 塩基性基における塩としては、たとえば、塩酸、臭化水素酸、硝酸および硫酸などの鉱酸との塩;ぎ酸、酢酸、クエン酸、シュウ酸、フマル酸、マレイン酸、コハク酸、リンゴ酸、酒石酸、アスパラギン酸、トリクロロ酢酸およびトリフルオロ酢酸などの有機カルボン酸との塩;ならびにメタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メシチレンスルホン酸およびナフタレンスルホン酸などのスルホン酸との塩が挙げられる。 Examples of salts in basic groups include salts with mineral acids such as hydrochloric acid, hydrobromic acid, nitric acid and sulfuric acid; formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid , Salts with organic carboxylic acids such as tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid Is mentioned.
 酸性基における塩としては、たとえば、ナトリウムおよびカリウムなどのアルカリ金属との塩;カルシウムおよびマグネシウムなどのアルカリ土類金属との塩;アンモニウム塩;ならびにトリメチルアミン、トリエチルアミン、トリブチルアミン、ピリジン、N、N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、ジシクロヘキシルアミン、プロカイン、ジベンジルアミン、N-ベンジル-β-フェネチルアミン、1-エフェナミンおよびN、N'-ジベンジルエチレンジアミンなどの含窒素有機塩基との塩などが挙げられる。 Salts in acidic groups include, for example, salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and trimethylamine, triethylamine, tributylamine, pyridine, N, N— Nitrogen-containing organic bases such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine and N, N′-dibenzylethylenediamine And a salt thereof.
 上記した塩の中で、好ましい塩としては、薬理学的に許容される塩が挙げられる。 Among the above-mentioned salts, preferred salts include pharmacologically acceptable salts.
 一般式[1]の化合物またはその塩において、異性体(たとえば、光学異性体、幾何異性体および互変異性体など)が存在する場合、本発明は、それらの異性体を包含し、また、溶媒和物、水和物および種々の形状の結晶を包含するものである。 In the compound of the general formula [1] or a salt thereof, when isomers (for example, optical isomers, geometric isomers, tautomers, etc.) exist, the present invention includes those isomers, It includes solvates, hydrates and crystals of various shapes.
 次に、本発明化合物の製造法について説明する。
 本発明化合物は、自体公知の方法を組み合わせることにより製造されるが、たとえば、次に示す製造法にしたがって製造することができる。
Next, the manufacturing method of this invention compound is demonstrated.
The compound of the present invention is produced by combining methods known per se, and can be produced, for example, according to the production method shown below.
[製造法1]
Figure JPOXMLDOC01-appb-I000004
「式中、R、R、R、R、R、X、Z、ZおよびZは、前記と同様の意味を有する。」
[Production Method 1]
Figure JPOXMLDOC01-appb-I000004
“Wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , Z 1 , Z 2 and Z 3 have the same meaning as described above.
 一般式[3]の化合物として、N-エチル-N-メチルホルムアミドおよびN-メチルホルムアミドなどが知られている。
 一般式[1]の化合物は、活性化剤の存在下、一般式[2]の化合物を一般式[3]の化合物と反応させることにより製造することができる。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、脂肪族炭化水素類、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類および水が挙げられ、これらは混合して使用してもよい。好ましい溶媒としては、ハロゲン化炭化水素類が挙げられる。
 この反応において、使用される活性化剤としては、たとえば、塩化オキサリル、塩化ホスホリルおよびp-トルエンスルホニルクロリドなどが挙げられる。
 活性化剤の使用量は、一般式[2]の化合物に対して1~20倍モルであればよく、好ましくは、1~5倍モルである。
 一般式[3]の化合物の使用量は、一般式[2]の化合物に対して1~20倍モルであればよく、好ましくは、1~5倍モルである。
 この反応は、-50~200℃、好ましくは0~50℃で10分間~48時間実施すればよい。
N-ethyl-N-methylformamide, N-methylformamide, and the like are known as compounds of the general formula [3].
The compound of the general formula [1] can be produced by reacting the compound of the general formula [2] with the compound of the general formula [3] in the presence of an activator.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture. Preferable solvents include halogenated hydrocarbons.
Examples of the activator used in this reaction include oxalyl chloride, phosphoryl chloride and p-toluenesulfonyl chloride.
The amount of the activator used may be 1 to 20 times mol, preferably 1 to 5 times mol, of the compound of the general formula [2].
The amount of the compound of the general formula [3] used may be 1 to 20 times mol, preferably 1 to 5 times mol for the compound of the general formula [2].
This reaction may be carried out at −50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
[製造法2]
Figure JPOXMLDOC01-appb-I000005
「式中、Lは、脱離基を;R、R、R、R、R、R、X、ZおよびZは、前記と同様の意味を有する。」
[Production Method 2]
Figure JPOXMLDOC01-appb-I000005
“Wherein L 1 represents a leaving group; R 1 , R 2 , R 3 , R 4 , R 5 , R b , X 1 , Z 1 and Z 2 have the same meaning as described above.
 一般式[5]の化合物として、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノンおよび2-ブロモ-1-(2,3-ジヒドロ-1H-インデン-5-イル)エタノンなどが知られている。
 一般式[1a]の化合物は、一般式[4]の化合物を一般式[5]の化合物と反応させることにより製造することができる。
 この反応は、国際公開第05/115382号パンフレットおよび米国特許第20060052420などに記載された方法またはそれに準じた方法で行えばよい。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、脂肪族炭化水素類、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類および水が挙げられ、これらは混合して使用してもよい。好ましい溶媒としては、アルコール類が挙げられる。
 一般式[5]の化合物の使用量は、一般式[4]の化合物に対して1~20倍モルであればよく、好ましくは、1~5倍モルである。
 この反応は、-50~200℃、好ましくは0~150℃で10分間~48時間実施すればよい。
Compounds of general formula [5] include 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 2-bromo-1- (2,3-dihydro-1H-indene- 5-yl) ethanone is known.
The compound of the general formula [1a] can be produced by reacting the compound of the general formula [4] with the compound of the general formula [5].
This reaction may be carried out by the method described in International Publication No. 05/115382 pamphlet and US Patent No. 20060052420 or a method based thereon.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture. Preferred solvents include alcohols.
The amount of the compound of the general formula [5] used may be 1 to 20 times mol, preferably 1 to 5 times mol for the compound of the general formula [4].
This reaction may be carried out at −50 to 200 ° C., preferably 0 to 150 ° C., for 10 minutes to 48 hours.
 このようにして得られた一般式[1a]および[1]の化合物またはそれらの塩は、たとえば、縮合、付加、酸化、還元、転位、置換、ハロゲン化、脱水もしくは加水分解などの自体公知の反応に付すことによって、またはそれらの反応を適宜組み合わせることによって、他の一般式[1]の化合物またはその塩に誘導することができる。 The thus obtained compounds of the general formulas [1a] and [1] or salts thereof are known per se such as, for example, condensation, addition, oxidation, reduction, rearrangement, substitution, halogenation, dehydration or hydrolysis. By subjecting to a reaction or by appropriately combining these reactions, it can be derived into other compounds of the general formula [1] or salts thereof.
 次に、本発明化合物の製造原料の製造法について説明する。 Next, a method for producing a raw material for producing the compound of the present invention will be described.
[製造法A]
Figure JPOXMLDOC01-appb-I000006
「式中、R、R、R、R、L、X、ZおよびZは、前記と同様の意味を有する。」
[Production method A]
Figure JPOXMLDOC01-appb-I000006
“Wherein R 1 , R 2 , R 3 , R b , L 1 , X 1 , Z 1 and Z 2 have the same meaning as described above.
(A-1)
 一般式[Ab]の化合物は、酸の存在下、一般式[Aa]の化合物をジチオリン酸 O,O’-ジエチルなどと反応させることによって製造することができる。
 この反応は、国際公開第06/137658号パンフレットおよびジャーナル・オブ・メディシナル・ケミストリー(Journal of Medicinal Chemistry)、1990年、第33巻、p.2715-2720などに記載された方法またはそれに準じた方法で行えばよい。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、脂肪族炭化水素類、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類および水が挙げられ、これらは混合して使用してもよい。好ましい溶媒としては、エステル類が挙げられる。
 この反応において、使用される酸としては、たとえば、塩酸、硫酸、リン酸、塩化水素および臭化水素などの無機酸;酢酸、トリクロロ酢酸およびトリフルオロ酢酸などの有機カルボン酸;ならびにメタンスルホン酸およびp-トルエンスルホン酸などの有機スルホン酸などが挙げられる。好ましい酸としては、塩化水素が挙げられる。
 酸の使用量は、一般式[Aa]の化合物に対して1~50倍モルであればよく、好ましくは、1~5倍モルである。
 ジチオリン酸 O,O’-ジエチルの使用量は、一般式[Aa]の化合物に対して1~50倍モルであればよく、好ましくは、1~5倍モルである。
 この反応は、-50~200℃、好ましくは0~50℃で10分間~48時間実施すればよい。
(A-1)
The compound of the general formula [Ab] can be produced by reacting the compound of the general formula [Aa] with dithiophosphoric acid O, O′-diethyl or the like in the presence of an acid.
This reaction is the method described in WO 06/137658 and the Journal of Medicinal Chemistry, 1990, Vol. 33, p.2715-2720, or a similar method. Just do it.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons and water, and these may be used as a mixture. Preferable solvents include esters.
Examples of acids used in this reaction include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrogen chloride and hydrogen bromide; organic carboxylic acids such as acetic acid, trichloroacetic acid and trifluoroacetic acid; and methanesulfonic acid and Examples thereof include organic sulfonic acids such as p-toluenesulfonic acid. A preferred acid is hydrogen chloride.
The amount of the acid used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of the general formula [Aa].
The amount of dithiophosphoric acid O, O′-diethyl used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of general formula [Aa].
This reaction may be carried out at −50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
(A-2)
 一般式[Ac]の化合物は、製造法2に準じて製造することができる。
(A-2)
The compound of general formula [Ac] can be manufactured according to the manufacturing method 2.
(A-3)
 一般式[2a]の化合物は、一般式[Ac]の化合物を還元することにより製造できる。この反応は、リチャード C.ラロック(Richard C. Larock)ら、コンプレヘンシブ・オーガニック・トランスフォーメーションズ(Comprehensive Organic Transformations)、第2版、第823~827頁、1999年、ジョン・ウィリイ・アンド・サンズ社(John Wiley & Sons,INC.)に記載された方法またはそれに準じた方法で行えばよい。具体的には、金属触媒を用いる接触水素添加反応および鉄または亜鉛などの金属を用いる還元反応などが挙げられる。
(A-3)
The compound of the general formula [2a] can be produced by reducing the compound of the general formula [Ac]. This reaction was performed by Richard C. Richard C. Larock et al., Comprehensive Organic Transformations, 2nd edition, pages 823-827, 1999, John Wiley & Sons , INC.) Or a method similar thereto. Specific examples include a catalytic hydrogenation reaction using a metal catalyst and a reduction reaction using a metal such as iron or zinc.
 一般式[Ac]の化合物を接触水素添加反応に付す場合、使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、たとえば、水、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、アセトニトリルなどのニトリル類、酢酸などのカルボン酸類、ピリジンなどのヘテロ芳香族類および水が挙げられ、これらは混合して使用してもよい。
 この反応に使用される金属触媒としては、たとえば、パラジウム-炭素およびパラジウム黒などの金属パラジウム;酸化パラジウムおよび水酸化パラジウムなどのパラジウム塩;ラネーニッケルなどのニッケル金属;ならびに酸化白金などの白金塩などが挙げられる。金属触媒の使用量は、一般式[Ac]の化合物に対して0.001~5倍量(w/w)であればよく、好ましくは、0.01~1倍量(w/w)である。
 水素源としては、たとえば、水素;ギ酸;ギ酸ナトリウム、ギ酸アンモニウムおよびギ酸トリエチルアンモニウムなどのギ酸塩;シクロヘキセン;ならびにシクロヘキサジエンなどが挙げられる。水素源の使用量は、一般式[Ac]の化合物に対して2~100倍モルであればよく、好ましくは、2~10倍モルである。
 この反応は、0~200℃、好ましくは、0~100℃で1分間~24時間実施すればよい。
When the compound of the general formula [Ac] is subjected to a catalytic hydrogenation reaction, the solvent used is not particularly limited as long as it does not adversely affect the reaction. For example, water, halogenated hydrocarbons, alcohols , Ethers, ketones, esters, amides, aromatic hydrocarbons, nitriles such as acetonitrile, carboxylic acids such as acetic acid, heteroaromatics such as pyridine, and water, which are used as a mixture May be.
Examples of the metal catalyst used in this reaction include palladium metal such as palladium-carbon and palladium black; palladium salts such as palladium oxide and palladium hydroxide; nickel metal such as Raney nickel; and platinum salts such as platinum oxide. Can be mentioned. The amount of the metal catalyst used may be 0.001 to 5 times (w / w), preferably 0.01 to 1 times (w / w) of the compound of the general formula [Ac].
Examples of the hydrogen source include hydrogen; formic acid; formate salts such as sodium formate, ammonium formate and triethylammonium formate; cyclohexene; and cyclohexadiene. The amount of the hydrogen source used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the general formula [Ac].
This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
 一般式[Ac]の化合物を金属を用いる還元反応に付す場合、使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、水、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、アセトニトリルなどのニトリル類および水が挙げられ、これらは混合して使用してもよい。
 この反応に用いられる金属としては、たとえば、鉄、亜鉛、スズおよび塩化スズ(II)などが挙げられる。金属の使用量は、一般式[Ac]の化合物に対して1~50倍モルであればよく、好ましくは、1~10倍モルである。
 この反応において所望により用いられる酸としては、たとえば、塩化水素、臭化水素、酢酸および塩化アンモニウムなどが挙げられる。酸の使用量は、一般式[Ac]の化合物に対して0.001~100倍量(v/w)であればよく、好ましくは、0.01~20倍量(v/w)である。
 この反応は、0~200℃、好ましくは、0~100℃で1分間~24時間実施すればよい。
When the compound of the general formula [Ac] is subjected to a reduction reaction using a metal, the solvent used is not particularly limited as long as it does not adversely affect the reaction, but water, halogenated hydrocarbons, alcohols, Examples include ethers, ketones, esters, amides, aromatic hydrocarbons, nitriles such as acetonitrile, and water, and these may be used as a mixture.
Examples of the metal used in this reaction include iron, zinc, tin, and tin (II) chloride. The amount of the metal used may be 1 to 50 times mol, preferably 1 to 10 times mol, of the compound of the general formula [Ac].
Examples of the acid that is optionally used in this reaction include hydrogen chloride, hydrogen bromide, acetic acid, and ammonium chloride. The amount of the acid used may be 0.001 to 100 times (v / w), preferably 0.01 to 20 times (v / w) of the compound of the general formula [Ac].
This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
[製造法B]
Figure JPOXMLDOC01-appb-I000007
「式中、R、R、R、R、X、ZおよびZは、前記と同様の意味を有する。」
[Production method B]
Figure JPOXMLDOC01-appb-I000007
“Wherein R 1 , R 2 , R 4 , R 5 , X 1 , Z 1 and Z 2 have the same meaning as described above.
(B-1)
 一般式[Ba]の化合物は、製造法A-3に準じて製造することができる。
(B-1)
The compound of the general formula [Ba] can be produced according to production method A-3.
(B-2)
 一般式[Bb]の化合物は、製造法1に準じて製造することができる。
(B-2)
The compound of general formula [Bb] can be manufactured according to the manufacturing method 1.
(B-3)
 一般式[4a]の化合物は、製造法A-1に準じて製造することができる。
(B-3)
The compound of the general formula [4a] can be produced according to production method A-1.
[製造法C]
Figure JPOXMLDOC01-appb-I000008
「式中、Rは、保護されていてもよいアミノ基を;R、R、R、L、X、ZおよびZは、前記と同様の意味を有する。」
[Production Method C]
Figure JPOXMLDOC01-appb-I000008
“Wherein R d represents an amino group which may be protected; R 1 , R 2 , R b , L 1 , X 1 , Z 1 and Z 2 have the same meaning as described above.
(C-1)
 一般式[Cb]の化合物は、製造法A-1に準じて製造することができる。
(C-1)
The compound of the general formula [Cb] can be produced according to production method A-1.
(C-2)
 一般式[Cc]の化合物は、製造法2に準じて製造することができる。
(C-2)
The compound of the general formula [Cc] can be produced according to Production Method 2.
(C-3)
 Rが保護されているアミノ基である場合、一般式[2a]の化合物は、一般式[Cc]の化合物のアミノ保護基を脱保護することにより製造することができる。
 アミノ保護基の脱保護は、たとえば、W.グリーン(W.Greene)ら、プロテクティブ・グループス・イン・オーガニック・シンセシス(Protective Groups in Organic Synthesis)第4版、第696~868頁、2007年、ジョン・ウィリイ・アンド・サンズ社(John Wiley & Sons,INC.)に記載の方法などが挙げられる。
(C-3)
When R d is a protected amino group, the compound of the general formula [2a] can be produced by deprotecting the amino protecting group of the compound of the general formula [Cc].
Deprotection of amino protecting groups is described, for example, in W.W. W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pages 696-868, 2007, John Wiley & Sons (John Wiley & Sons, INC.).
[製造法D]
Figure JPOXMLDOC01-appb-I000009
「式中、Lは、脱離基またはアリールチオ基を;R、R、ZおよびZは、前記と同様の意味を有する。」
[Production Method D]
Figure JPOXMLDOC01-appb-I000009
“Wherein L 2 represents a leaving group or an arylthio group; R 1 , R 2 , Z 1 and Z 2 have the same meaning as described above.
 一般式[Da]の化合物として、1,4-ジメチル-2-ニトロベンゼンおよび4-ブロモ-1-メチル-2-ニトロベンゼンなどが知られている。
 一般式[Db]の化合物として、クロロアセトニトリル、(フェニルチオ)アセトニトリル、4-クロロフェノキシアセトニトリルおよび2-((シアノメチル)スルファニル)安息香酸などが知られている。
 一般式[Aaa]の化合物は、塩基の存在下、一般式[Da]の化合物を一般式[Db]の化合物と反応させることにより製造することができる。
 この反応は、米国特許第2003229130およびザ・ジャーナル・オブ・オーガニック・ケミストリー(The Journal of Organic Chemistry)、1984年、第49巻、p.1494~1499などに記載された方法またはそれに準じた方法で行えばよい。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、脂肪族炭化水素類、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、ジメチルスルホキシドなどのスルホキシド類および水が挙げられ、これらは混合して使用してもよい。好ましい溶媒としては、ジメチルスルホキシドが挙げられる。
 この反応において、使用される塩基としては、たとえば、ナトリウムメトキシド、ナトリウムエトキシド、カリウムtert-ブトキシド、ピリジン、ジメチルアミノピリジンおよびトリエチルアミンなどの有機塩基;水素化ナトリウム、水酸化ナトリウム、水酸化カリウム、炭酸水素ナトリウム、炭酸カリウムおよび炭酸ナトリウムなどの無機塩基などが挙げられる。好ましい塩基としては、水酸化ナトリウムおよび水酸化カリウムが挙げられる。
 塩基の使用量は、一般式[Da]の化合物に対して1~50倍モルであればよく、好ましくは、1~10倍モルである。
 一般式[Db]の化合物の使用量は、一般式[Da]の化合物に対して、1~50倍モルであればよく、好ましくは、1~5倍モルである。
 この反応は、-50~200℃、好ましくは0~50℃で10分間~48時間実施すればよい。
As compounds of the general formula [Da], 1,4-dimethyl-2-nitrobenzene, 4-bromo-1-methyl-2-nitrobenzene and the like are known.
As compounds of the general formula [Db], chloroacetonitrile, (phenylthio) acetonitrile, 4-chlorophenoxyacetonitrile, 2-((cyanomethyl) sulfanyl) benzoic acid and the like are known.
The compound of the general formula [Aaa] can be produced by reacting the compound of the general formula [Da] with the compound of the general formula [Db] in the presence of a base.
This reaction is carried out by a method described in US 2003229130 and The Journal of Organic Chemistry, 1984, Vol. 49, p. Just do it.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides , Aromatic hydrocarbons, sulfoxides such as dimethyl sulfoxide and water, and these may be used as a mixture. A preferred solvent is dimethyl sulfoxide.
Examples of the base used in this reaction include organic bases such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, pyridine, dimethylaminopyridine and triethylamine; sodium hydride, sodium hydroxide, potassium hydroxide, Examples thereof include inorganic bases such as sodium hydrogen carbonate, potassium carbonate and sodium carbonate. Preferred bases include sodium hydroxide and potassium hydroxide.
The amount of the base used may be 1 to 50 times mol, preferably 1 to 10 times mol, of the compound of the general formula [Da].
The amount of the compound of the general formula [Db] used may be 1 to 50 times mol, preferably 1 to 5 times mol, of the compound of the general formula [Da].
This reaction may be carried out at −50 to 200 ° C., preferably 0 to 50 ° C., for 10 minutes to 48 hours.
[製造法E]
Figure JPOXMLDOC01-appb-I000010
「式中、Lは、脱離基を;R、R、R、ZおよびZは、前記と同様の意味を有する。」
[Production Method E]
Figure JPOXMLDOC01-appb-I000010
“Wherein L 3 represents a leaving group; R 1 , R 2 , R d , Z 1 and Z 2 have the same meaning as described above.
(E-1)
 一般式[Ea]の化合物として、N-(4-ヨード-2,5-ジメチルフェニル)アセトアミド、(4-ヨード-2,5-ジメチルフェニル)アミンおよびN-(4-ブロモ-2,5-ジメチルフェニル)アセトアミドなどが知られている。
 一般式[Eb]の化合物は、塩基の存在下または不存在下、リガンドの存在下または不存在下、パラジウム触媒の存在下、一般式[Ea]の化合物をアクリロニトリルと反応させることにより製造することができる。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、アセトニトリルなどのニトリル類、ジメチルスルホキシドなどのスルホキシド類および水が挙げられ、これらは混合して使用してもよい。
 この反応において所望により用いられる塩基としては、たとえば、水素化ナトリウム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸カリウム、炭酸セシウムおよびリン酸三カリウムなどの無機塩基;酢酸ナトリウム、酢酸カリウム、ナトリウム=tert-ブトキシド、トリエチルアミン、ジイソプロピルエチルアミン、トリブチルアミンおよびN,N-ジシクロヘキシルメチルアミンなどの有機塩基などが挙げられる。
 塩基の使用量は、一般式[Ea]の化合物に対して1~50倍モルであればよく、好ましくは、2~5倍モルである。
(E-1)
As compounds of general formula [Ea], N- (4-iodo-2,5-dimethylphenyl) acetamide, (4-iodo-2,5-dimethylphenyl) amine and N- (4-bromo-2,5- Dimethylphenyl) acetamide and the like are known.
The compound of the general formula [Eb] is produced by reacting the compound of the general formula [Ea] with acrylonitrile in the presence or absence of a base, in the presence or absence of a ligand, and in the presence of a palladium catalyst. Can do.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. Nitriles such as acetonitrile, sulfoxides such as dimethyl sulfoxide, and water, and these may be used as a mixture.
Examples of the base optionally used in this reaction include inorganic bases such as sodium hydride, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate and tripotassium phosphate; sodium acetate, potassium acetate, sodium = tert-butoxide And organic bases such as triethylamine, diisopropylethylamine, tributylamine and N, N-dicyclohexylmethylamine.
The amount of the base used may be 1 to 50 times mol, preferably 2 to 5 times mol, of the compound of the general formula [Ea].
 この反応において所望により用いられるリガンドとしては、トリメチルホスフィンおよびトリ-tert-ブチルホスフィンなどのトリアルキルホスフィン類;トリシクロヘキシルホスフィンなどのトリシクロアルキルホスフィン類;トリフェニルホスフィンおよびトリトリルホスフィンなどのトリアリールホスフィン類;トリメチルホスファイト、トリエチルホスファイトおよびトリブチルホスファイトなどのトリアルキルホスファイト類;トリシクロヘキシルホスファイトなどのトリシクロアルキルホスファイト類;トリフェニルホスファイトなどのトリアリールホスファイト類;1,3-ビス(2,4,6-トリメチルフェニル)イミダゾリウムクロリドなどのイミダゾリウム塩;アセチルアセトンおよびオクタフルオロアセチルアセトンなどのジケトン類;トリメチルアミン、トリエチルアミン、トリプロピルアミンおよびトリイソプロピルアミンなどのアミン類;1,1’-ビス(ジフェニルホスフィノ)フェロセン、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフチル、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル、2-ジシクロヘキシルホスフィノ-2’,4’,6’-トリイソプロピルビフェニル、2-(ジ-tert-ブチルホスフィノ)-2’,4’,6’-トリイソプロピルビフェニルならびに2-(ジ-tert-ブチルホスフィノ)ビフェニルなどが挙げられ、これらは組み合わせて使用してもよい。
 リガンドの使用量は、一般式[Ea]の化合物に対して0.00001~1倍モルであればよく、好ましくは、0.001~0.1倍モルである。
The ligands optionally used in this reaction include trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; triarylphosphine such as triphenylphosphine and tritolylphosphine Trialkyl phosphites such as trimethyl phosphite, triethyl phosphite and tributyl phosphite; tricycloalkyl phosphites such as tricyclohexyl phosphite; triaryl phosphites such as triphenyl phosphite; 1,3- Imidazolium salts such as bis (2,4,6-trimethylphenyl) imidazolium chloride; acetylacetone and octafluoroacetylacetate Diketones such as trimethylamine, triethylamine, tripropylamine and triisopropylamine; 1,1′-bis (diphenylphosphino) ferrocene, 2,2′-bis (diphenylphosphino) -1,1 '-Binaphthyl, 2-dicyclohexylphosphino-2', 6'-dimethoxybiphenyl, 2-dicyclohexylphosphino-2 ', 4', 6'-triisopropylbiphenyl, 2- (di-tert-butylphosphino)- Examples thereof include 2 ′, 4 ′, 6′-triisopropylbiphenyl and 2- (di-tert-butylphosphino) biphenyl, and these may be used in combination.
The amount of the ligand used may be 0.00001 to 1-fold mol, preferably 0.001 to 0.1-fold mol based on the compound of the general formula [Ea].
 この反応に用いられるパラジウム触媒としては、たとえば、パラジウム-炭素およびパラジウム黒などの金属パラジウム;塩化パラジウムなどの無機パラジウム塩;酢酸パラジウムなどの有機パラジウム塩;テトラキス(トリフェニルホスフィン)パラジウム(0)、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)、ビス(トリフェニルホスフィン)パラジウム(II)クロリド、1,1’-ビス(ジフェニルホスフィノ)フェロセンパラジウム(II)クロリド、(E)-ジ(μ-アセタート)ビス(o-(ジ-o-トリルホスフィノ)ベンジル)ジパラジウム(II)およびトリス(ジベンジリデンアセトン)ジパラジウム(0)などの有機パラジウム錯体ならびにポリマー担持ビス(アセタート)トリフェニルホスフィンパラジウム(II)およびポリマー担持ジ(アセタート)ジシクロヘキシルフェニルホスフィンパラジウム(II)などのポリマー固定化有機パラジウム錯体などが挙げられ、これらは組み合わせて使用してもよい。
 パラジウム触媒の使用量は、一般式[Ea]の化合物に対して0.00001~1倍モルであればよく、好ましくは、0.001~0.1倍モルである。
Examples of the palladium catalyst used in this reaction include metal palladium such as palladium-carbon and palladium black; inorganic palladium salts such as palladium chloride; organic palladium salts such as palladium acetate; tetrakis (triphenylphosphine) palladium (0), Bis (tri-tert-butylphosphine) palladium (0), bis (triphenylphosphine) palladium (II) chloride, 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) chloride, (E) -di ( μ-Acetate) bis (o- (di-o-tolylphosphino) benzyl) dipalladium (II) and tris (dibenzylideneacetone) dipalladium (0) (II And polymer supported di (acetato) such as a polymer immobilized organopalladium complex such as dicyclohexylphenylphosphine palladium (II) and the like, may be used these in combination.
The amount of the palladium catalyst used may be 0.00001 to 1 times mol, preferably 0.001 to 0.1 times mol for the compound of the general formula [Ea].
 アクリロニトリルの使用量は、一般式[Ea]の化合物に対して1~50倍モルであればよく、好ましくは、1~2倍モルである。
 この反応は、好ましくは、不活性気体(たとえば、窒素、アルゴン)雰囲気下、40~170℃で、1分間~24時間実施すればよい。
The amount of acrylonitrile used may be 1 to 50 times mol, preferably 1 to 2 times mol, of the compound of general formula [Ea].
This reaction is preferably carried out at 40 to 170 ° C. for 1 minute to 24 hours in an inert gas (eg, nitrogen, argon) atmosphere.
(E-2)
 一般式[Caa]の化合物は、一般式[Eb]の化合物を還元することにより製造することができる。
 還元反応としては、たとえば、金属触媒を用いる接触水素添加反応が挙げられる。
 この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、アセトニトリルなどのニトリル類、酢酸などのカルボン酸類、ピリジンなどのヘテロ芳香族類および水が挙げられ、これらは混合して使用してもよい。
 この反応に使用される金属触媒としては、たとえば、パラジウム-炭素およびパラジウム黒などの金属パラジウム;酸化パラジウムおよび水酸化パラジウムなどのパラジウム塩;ラネーニッケルなどのニッケル金属ならびに酸化白金などの白金塩などが挙げられる。金属触媒の使用量は、一般式[Eb]の化合物に対して0.001~5倍量(w/w)であればよく、好ましくは、0.01~1倍量(w/w)である。
 還元剤としては、たとえば、水素;ギ酸;ギ酸ナトリウム、ギ酸アンモニウムおよびギ酸トリエチルアンモニウムなどのギ酸塩;シクロヘキセンならびにシクロヘキサジエンなどが挙げられる。還元剤の使用量は、一般式[Eb]の化合物に対して2~100倍モルであればよく、好ましくは、2~10倍モルである。
 この反応は、0~200℃、好ましくは、0~100℃で1分間~24時間実施すればよい。
(E-2)
The compound of the general formula [Caa] can be produced by reducing the compound of the general formula [Eb].
Examples of the reduction reaction include a catalytic hydrogenation reaction using a metal catalyst.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. , Nitriles such as acetonitrile, carboxylic acids such as acetic acid, heteroaromatics such as pyridine and water, and these may be used as a mixture.
Examples of the metal catalyst used in this reaction include palladium metal such as palladium-carbon and palladium black; palladium salts such as palladium oxide and palladium hydroxide; nickel metals such as Raney nickel and platinum salts such as platinum oxide. It is done. The amount of the metal catalyst used may be 0.001 to 5 times (w / w), preferably 0.01 to 1 times (w / w) of the compound of the general formula [Eb].
Examples of the reducing agent include hydrogen; formic acid; formate salts such as sodium formate, ammonium formate and triethylammonium formate; cyclohexene and cyclohexadiene. The amount of the reducing agent used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the general formula [Eb].
This reaction may be carried out at 0 to 200 ° C., preferably 0 to 100 ° C. for 1 minute to 24 hours.
[製造法F]
Figure JPOXMLDOC01-appb-I000011
「式中、Rは、置換されていてもよいC1-6アルキル基または置換されていてもよいC2-6アルケニル基を;R、R、R、L、ZおよびZは、前記と同様の意味を有する。」
[Production Method F]
Figure JPOXMLDOC01-appb-I000011
“Wherein R e represents an optionally substituted C 1-6 alkyl group or an optionally substituted C 2-6 alkenyl group; R 1 , R 2 , R d , L 3 , Z 1 and Z 2 has the same meaning as described above.
(F-1)
 一般式[Fa]の化合物として、シアノ酢酸エチルまたはシアノ酢酸メチルなどが知られている。
 一般式[Fb]の化合物は、塩基の存在下、リガンドの存在下または不存在下、パラジウム触媒の存在下、一般式[Ea]の化合物を一般式[Fa]の化合物と反応させることにより製造することができる。
  この反応で使用される溶媒としては、反応に悪影響を及ぼさないものであれば特に限定されないが、ハロゲン化炭化水素類、アルコール類、エーテル類、ケトン類、エステル類、アミド類、芳香族炭化水素類、アセトニトリルなどのニトリル類、ジメチルスルホキシドなどのスルホキシド類および水が挙げられ、これらは混合して使用してもよい。
(F-1)
As a compound of the general formula [Fa], ethyl cyanoacetate or methyl cyanoacetate is known.
The compound of the general formula [Fb] is produced by reacting the compound of the general formula [Ea] with the compound of the general formula [Fa] in the presence of a base, in the presence or absence of a ligand, and in the presence of a palladium catalyst. can do.
The solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, but halogenated hydrocarbons, alcohols, ethers, ketones, esters, amides, aromatic hydrocarbons. Nitriles such as acetonitrile, sulfoxides such as dimethyl sulfoxide, and water, and these may be used as a mixture.
 この反応において用いられる塩基としては、たとえば、炭酸水素ナトリウム、炭酸ナトリウム、炭酸カリウム、炭酸セシウムおよびリン酸三カリウムなどの無機塩基;トリエチルアミンおよびジイソプロピルエチルアミンなどの有機塩基などが挙げられる。塩基の使用量は、一般式[Ea]の化合物に対して1~50倍モルであればよく、好ましくは、2~5倍モルである。 Examples of the base used in this reaction include inorganic bases such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate and tripotassium phosphate; organic bases such as triethylamine and diisopropylethylamine. The amount of the base used may be 1 to 50 times mol, preferably 2 to 5 times mol, of the compound of the general formula [Ea].
 この反応において所望により用いられるリガンドとしては、トリメチルホスフィンおよびトリ-tert-ブチルホスフィンなどのトリアルキルホスフィン類;トリシクロヘキシルホスフィンなどのトリシクロアルキルホスフィン類;トリフェニルホスフィンおよびトリトリルホスフィンなどのトリアリールホスフィン類;トリメチルホスファイト、トリエチルホスファイトおよびトリブチルホスファイトなどのトリアルキルホスファイト類;トリシクロヘキシルホスファイトなどのトリシクロアルキルホスファイト類;トリフェニルホスファイトなどのトリアリールホスファイト類;1,3-ビス(2,4,6-トリメチルフェニル)イミダゾリウムクロリドなどのイミダゾリウム塩;アセチルアセトンおよびオクタフルオロアセチルアセトンなどのジケトン類;トリメチルアミン、トリエチルアミン、トリプロピルアミンおよびトリイソプロピルアミンなどのアミン類;1,1’-ビス(ジフェニルホスフィノ)フェロセン、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフチル、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル、2-ジシクロヘキシルホスフィノ-2’,4’,6’-トリイソプロピルビフェニル、2-(ジ-tert-ブチルホスフィノ)-2’,4’,6’-トリイソプロピルビフェニル、2-(ジ-tert-ブチルホスフィノ)ビフェニルならびにトリ-tert-ブチルホスホニウムテトラフルオロボラートなどが挙げられ、これらは組み合わせて使用してもよい。
 リガンドの使用量は、一般式[Ea]の化合物に対して0.00001~1倍モルであればよく、好ましくは、0.001~0.1倍モルである。
The ligands optionally used in this reaction include trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; triarylphosphine such as triphenylphosphine and tritolylphosphine Trialkyl phosphites such as trimethyl phosphite, triethyl phosphite and tributyl phosphite; tricycloalkyl phosphites such as tricyclohexyl phosphite; triaryl phosphites such as triphenyl phosphite; 1,3- Imidazolium salts such as bis (2,4,6-trimethylphenyl) imidazolium chloride; acetylacetone and octafluoroacetylacetate Diketones such as trimethylamine, triethylamine, tripropylamine and triisopropylamine; 1,1′-bis (diphenylphosphino) ferrocene, 2,2′-bis (diphenylphosphino) -1,1 '-Binaphthyl, 2-dicyclohexylphosphino-2', 6'-dimethoxybiphenyl, 2-dicyclohexylphosphino-2 ', 4', 6'-triisopropylbiphenyl, 2- (di-tert-butylphosphino)- Examples include 2 ', 4', 6'-triisopropylbiphenyl, 2- (di-tert-butylphosphino) biphenyl, and tri-tert-butylphosphonium tetrafluoroborate, which may be used in combination. .
The amount of the ligand used may be 0.00001 to 1-fold mol, preferably 0.001 to 0.1-fold mol based on the compound of the general formula [Ea].
 この反応に用いられるパラジウム触媒としては、たとえば、パラジウム-炭素およびパラジウム黒などの金属パラジウム;塩化パラジウムなどの無機パラジウム塩;酢酸パラジウムなどの有機パラジウム塩;テトラキス(トリフェニルホスフィン)パラジウム(0)、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)、ビス(トリフェニルホスフィン)パラジウム(II)クロリド、1,1’-ビス(ジフェニルホスフィノ)フェロセンパラジウム(II)クロリドおよびトリス(ジベンジリデンアセトン)ジパラジウム(0)などの有機パラジウム錯体ならびにポリマー担持ビス(アセタート)トリフェニルホスフィンパラジウム(II)およびポリマー担持ジ(アセタート)ジシクロヘキシルフェニルホスフィンパラジウム(II)などのポリマー固定化有機パラジウム錯体などが挙げられ、これらは組み合わせて使用してもよい。
 パラジウム触媒の使用量は、一般式[Ea]の化合物に対して0.00001~1倍モルであればよく、好ましくは、0.001~0.1倍モルである。
Examples of the palladium catalyst used in this reaction include metal palladium such as palladium-carbon and palladium black; inorganic palladium salts such as palladium chloride; organic palladium salts such as palladium acetate; tetrakis (triphenylphosphine) palladium (0), Bis (tri-tert-butylphosphine) palladium (0), bis (triphenylphosphine) palladium (II) chloride, 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) chloride and tris (dibenzylideneacetone) Organopalladium complexes such as dipalladium (0) and polymer-supported bis (acetate) triphenylphosphine palladium (II) and polymer-supported di (acetate) dicyclohexylphenylphosphine palladium (II) A mer-immobilized organic palladium complex may be used, and these may be used in combination.
The amount of the palladium catalyst used may be 0.00001 to 1 times mol, preferably 0.001 to 0.1 times mol for the compound of the general formula [Ea].
 一般式[Fa]の化合物の使用量は、一般式[Ea]の化合物に対して1~50倍モルであればよく、好ましくは、1~2倍モルである。
 この反応は、好ましくは、不活性気体(たとえば、窒素、アルゴン)雰囲気下、40~170℃で、1分間~96時間実施すればよい。
The amount of the compound of the general formula [Fa] used may be 1 to 50 times mol, preferably 1 to 2 times mol for the compound of the general formula [Ea].
This reaction is preferably carried out at 40 to 170 ° C. for 1 minute to 96 hours in an inert gas (eg, nitrogen, argon) atmosphere.
(F-2)
 一般式[Cab]の化合物は、一般式[Fb]の化合物を脱炭酸反応に付すことによって製造することができる。
 この反応は、自体公知の方法、例えば、新実験化学講座、第15巻、[II]、日本化学会編、第808~811頁(1977年、丸善)に記載の方法またはそれに準じた方法で実施すればよい。
(F-2)
The compound of the general formula [Cab] can be produced by subjecting the compound of the general formula [Fb] to a decarboxylation reaction.
This reaction is carried out by a method known per se, for example, the method described in New Experimental Chemistry Course, Vol. 15, [II], edited by The Chemical Society of Japan, pages 808-811 (1977, Maruzen) or a method analogous thereto. Just do it.
 上記した製造法で使用される化合物において、塩の形態を取り得る化合物は、塩として使用することもできる。それらの塩としては、たとえば、一般式[1]の化合物の塩と同様の塩が挙げられる。 In the compounds used in the above production method, a compound that can take the form of a salt can also be used as a salt. Examples of such salts include the same salts as the salts of the compound of the general formula [1].
 上記した製造法で使用される化合物において、異性体(たとえば、光学異性体、幾何異性体および互変異性体など)が存在する場合、これらの異性体も使用することができる。また、溶媒和物、水和物および種々の形状の結晶が存在する場合、これらの溶媒和物、水和物および種々の形状の結晶も使用することができる。 In the compounds used in the above production method, when there are isomers (for example, optical isomers, geometric isomers, tautomers, etc.), these isomers can also be used. Also, when solvates, hydrates and crystals of various shapes are present, these solvates, hydrates and crystals of various shapes can also be used.
 また、上記した製造法で使用される化合物において、保護し得る置換基、たとえば、アミノ基、ヒドロキシル基またはカルボキシル基などを有している化合物は、予めこれらの基を通常の保護基で保護しておき、反応後、自体公知の方法でこれらの保護基を脱離することもできる。 In addition, in the compounds used in the above-described production method, a compound having a substituent that can be protected, such as an amino group, a hydroxyl group, or a carboxyl group, is previously protected with a normal protecting group. In addition, after the reaction, these protecting groups can be removed by a method known per se.
 本発明の一般式[1]の化合物を医薬として用いる場合、通常、製剤化に使用される賦形剤、担体および希釈剤などの製剤補助剤を適宜混合してもよい。これらは、常法にしたがって、錠剤、カプセル剤、散剤、シロップ剤、顆粒剤、丸剤、懸濁剤、乳剤、液剤、粉体製剤、坐剤、点眼剤、点鼻剤、点耳剤、貼付剤、軟膏剤または注射剤などの形態で、経口または非経口で投与することができる。また投与方法、投与量および投与回数は、患者の年齢、体重および症状に応じて適宜選択することができる。通常、成人に対しては、経口または非経口(たとえば、注射、点滴および直腸部位への投与など)投与により、1日、0.01~1000mg/kgを1回から数回に分割して投与すればよい。 When the compound of the general formula [1] of the present invention is used as a medicine, formulation adjuvants such as excipients, carriers and diluents usually used for formulation may be appropriately mixed. These are tablets, capsules, powders, syrups, granules, pills, suspensions, emulsions, solutions, powder formulations, suppositories, eye drops, nasal drops, ear drops, It can be administered orally or parenterally in the form of a patch, ointment or injection. In addition, the administration method, the dosage, and the number of administrations can be appropriately selected according to the age, weight and symptoms of the patient. In general, for adults, oral administration or parenteral administration (for example, injection, infusion, administration to the rectal site, etc.), 0.01 to 1000 mg / kg daily may be divided into 1 to several doses. Good.
 次に、本発明の代表的化合物の有用性を以下の試験例で説明する。 Next, the usefulness of the representative compounds of the present invention will be explained by the following test examples.
試験例
 真菌の被験物質に対する感受性試験はClinical and Laboratory Standards Institute法に準じた微量液体希釈法により行った。マイクロプレートは以下の方法で調製した。
 感受性試験に用いる培地は、0.165mol/Lモルホリンプロパンスルホン酸(MOPS)および50%水酸化ナトリウムにてpH7.0に調整したRPMI1640(RPMI/MOPS)とした。被験物質をDMSOに溶解し、96ウェルマイクロプレート上でDMSOを用いて2倍段階希釈後、96ウェルマイクロプレートに1μLずつ分注した。サブロー寒天培地にて35℃一晩培養したCandida albicans TIMM 1623を滅菌生理食塩液に懸濁した。細胞数を生物顕微鏡で計数し、菌懸濁液をRPMI/MOPSで希釈し、接種菌液(約1×103 cells/mL)を調製した。あるいは、-80℃に保存されているC. albicans TIMM 1623をRPMI/MOPSで希釈し、接種菌液(約1×103 CFU/mL)を調製した。5℃に保存されているAspergillus fumigatus TIMM 0063をRPMI/MOPSで希釈し、接種菌液(約1×104 CFU/mL)を調製した。-80℃に保存されているTrichophyton rubrum NBRC 5467をRPMI/MOPSで希釈し、接種菌液(約2×103 CFU/mL)を調製した。接種菌液199μLを各ウェルに分注し、所定濃度の被験物質、培地および菌体が含まれるマイクロプレートを作製した。
 C. albicans及びA. fumigatusは35℃で2日間培養した。T. rubrumは35℃で4日間培養した。培養終了後、目視によりMIC判定を行った。C. albicans及びA. fumigatusのMICは、被験物質無添加の発育対照に比べ約50%の生育阻害が見られる最も低い濃度とした。T. rubrumのMICは、被験物質無添加の発育対照に比べ約80%の生育阻害が見られる最も低い濃度とした。結果を表1~3に示す。
Test Example The susceptibility test of fungi to the test substance was performed by a micro liquid dilution method according to the Clinical and Laboratory Standards Institute method. The microplate was prepared by the following method.
The medium used for the sensitivity test was RPMI1640 (RPMI / MOPS) adjusted to pH 7.0 with 0.165 mol / L morpholinepropanesulfonic acid (MOPS) and 50% sodium hydroxide. The test substance was dissolved in DMSO, diluted 2-fold serially with DMSO on a 96-well microplate, and then dispensed at 1 μL into a 96-well microplate. Candida albicans TIMM 1623 cultured overnight at 35 ° C. on a Sabouraud agar medium was suspended in sterile physiological saline. The number of cells was counted with a biological microscope, and the bacterial suspension was diluted with RPMI / MOPS to prepare an inoculated bacterial solution (about 1 × 10 3 cells / mL). Alternatively, C. albicans TIMM 1623 stored at −80 ° C. was diluted with RPMI / MOPS to prepare an inoculum (about 1 × 10 3 CFU / mL). Aspergillus fumigatus TIMM 0063 stored at 5 ° C. was diluted with RPMI / MOPS to prepare an inoculum (about 1 × 10 4 CFU / mL). Trichophyton rubrum NBRC 5467 stored at −80 ° C. was diluted with RPMI / MOPS to prepare an inoculum (about 2 × 10 3 CFU / mL). 199 μL of the inoculum solution was dispensed into each well to prepare a microplate containing a predetermined concentration of the test substance, medium and cells.
C. albicans and A. fumigatus were cultured at 35 ° C. for 2 days. T. rubrum was cultured at 35 ° C for 4 days. After completion of the culture, the MIC was visually determined. The MIC of C. albicans and A. fumigatus was the lowest concentration at which about 50% growth inhibition was observed compared to the growth control without addition of the test substance. The MIC of T. rubrum was set to the lowest concentration at which about 80% growth inhibition was observed compared to the growth control with no test substance added. The results are shown in Tables 1 to 3.
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000014
Figure JPOXMLDOC01-appb-T000014
 つぎに、本発明を参考例および実施例を挙げて説明するが、本発明はこれらに限定されるものではない。 Next, the present invention will be described with reference examples and examples, but the present invention is not limited thereto.
 特に記載のない場合、シリカゲルカラムクロマトグラフィーにおける担体は、関東化学株式会社、シリカゲル60(球状、63-210μm);DIOL型シリカゲルクロマトグラフィーにおける担体は、富士シリシア化学株式会社製クロマトレックスDIOL MB 100-75/200;DNH型シリカゲルクロマトグラフィーにおける担体は、富士シリシア化学株式会社製クロマトレックスDNH MB 100-75/200 (110μm)である。 Unless otherwise specified, the carrier in silica gel column chromatography is Kanto Chemical Co., Inc., silica gel 60 (spherical, 63-210 μm); the carrier in DIOL type silica gel chromatography is Chromatrex DIOL MB 100- manufactured by Fuji Silysia Chemical Ltd. 75/200; The carrier in DNH silica gel chromatography is Chromatrex DNHDMB 100-75 / 200 (110 μm) manufactured by Fuji Silysia Chemical Ltd.
 溶離液における混合比は、容量比である。 The mixing ratio in the eluent is a volume ratio.
 各実施例において各略号は、以下の意味を有する。
DMSO:ジメチルスルホキシド
DMSO-d:重ジメチルスルホキシド
s:シングレット
d:ダブレット
dd:ダブルダブレット
m:マルチプレット
In each example, each abbreviation has the following meaning.
DMSO: dimethyl sulfoxide DMSO-d 6 : heavy dimethyl sulfoxide s: singlet d: doublet dd: double doublet m: multiplet
参考例1
Figure JPOXMLDOC01-appb-I000015
窒素雰囲気下、水酸化ナトリウム10.4g、4-ブロモ-1-メチル-2-ニトロベンゼン5.5gおよびジメチルスルホキシド26mLの混合物に(フェニルチオ)アセトニトリル4.6gのジメチルスルホキシド26mL溶液を30℃以下で滴下し、室温で2時間撹拌した。反応混合物に酢酸エチルおよび水を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=90:10-50:50]で精製後、ジイソプロピルエーテルを加え、固形物を濾取し、緑色固体の(2-ブロモ-5-メチル-4-ニトロフェニル)アセトニトリル2.5gを得た。
1H-NMR(CDCl3)δ値:2.61(3H,s),3.88(2H,s),7.56(1H,s),8.24(1H,s).
Reference example 1
Figure JPOXMLDOC01-appb-I000015
Under a nitrogen atmosphere, a solution of 4.6 mL of (phenylthio) acetonitrile in 26 mL of dimethyl sulfoxide was added dropwise at 30 ° C. or lower to a mixture of 10.4 g of sodium hydroxide, 5.5 g of 4-bromo-1-methyl-2-nitrobenzene and 26 mL of dimethyl sulfoxide. For 2 hours. Ethyl acetate and water were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 90: 10-50: 50], diisopropyl ether was added, and the solid was collected by filtration to give a green solid (2-bromo 2.5 g of -5-methyl-4-nitrophenyl) acetonitrile was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.61 (3H, s), 3.88 (2H, s), 7.56 (1H, s), 8.24 (1H, s).
参考例2
Figure JPOXMLDOC01-appb-I000016
(2-ブロモ-5-メチル-4-ニトロフェニル)アセトニトリル2.5g、ジチオリン酸 O,O’-ジエチル2.3mLおよび4.9mol/L塩化水素-酢酸エチル溶液7.5mLの混合物を室温で1日撹拌した。固形物を濾取し、黄色固体の2-(2-ブロモ-5-メチル-4-ニトロフェニル)エタンチオアミド2.1gを得た。
1H-NMR(CDCl3)δ値:2.59(3H,s),4.19(2H,s),6.79-6.98(1H,broad),7.38-7.50(1H,broad),7.46(1H,s),8.24(1H,s).
Reference example 2
Figure JPOXMLDOC01-appb-I000016
A mixture of 2.5 g of (2-bromo-5-methyl-4-nitrophenyl) acetonitrile, 2.3 mL of dithiophosphoric acid O, O′-diethyl and 7.5 mL of a 4.9 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 1 day. . The solid was collected by filtration to obtain 2.1 g of 2- (2-bromo-5-methyl-4-nitrophenyl) ethanethioamide as a yellow solid.
1 H-NMR (CDCl 3 ) δ value: 2.59 (3H, s), 4.19 (2H, s), 6.79-6.98 (1H, broad), 7.38-7.50 (1H, broad), 7.46 (1H, s), 8.24 (1H, s).
参考例3
Figure JPOXMLDOC01-appb-I000017
窒素雰囲気下、2-(2-ブロモ-5-メチル-4-ニトロフェニル)エタンチオアミド1.0g,2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.96gおよびメタノール5.0mLの混合物を2時間加熱還流した。反応混合物を室温まで冷却後、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、活性炭を加えた。不溶物を濾去後、減圧下で溶媒を留去し、褐色油状物の2-(2-ブロモ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール1.6gを得た。
1H-NMR(CDCl3)δ値:1.78-1.87(4H,m),2.54(3H,s),2.75-2.88(4H,m),4.55(2H,s),7.11(1H,d,J=8.0Hz),7.33(1H,s),7.36(1H,s),7.55-7.63(2H,m),8.25(1H,s).
Reference example 3
Figure JPOXMLDOC01-appb-I000017
Under nitrogen atmosphere, 2- (2-bromo-5-methyl-4-nitrophenyl) ethanethioamide 1.0 g, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 0.96 g A mixture of methanol and 5.0 mL was heated to reflux for 2 hours. The reaction mixture was cooled to room temperature, and ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then activated carbon was added. The insoluble material was removed by filtration, and the solvent was distilled off under reduced pressure to give 2- (2-bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalene) as a brown oil. 1.6 g of -2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.87 (4H, m), 2.54 (3H, s), 2.75-2.88 (4H, m), 4.55 (2H, s), 7.11 (1H, d, J = 8.0Hz), 7.33 (1H, s), 7.36 (1H, s), 7.55-7.63 (2H, m), 8.25 (1H, s).
参考例4
Figure JPOXMLDOC01-appb-I000018
2-(2-ブロモ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール200mg、エタノール2.0mLおよび水2.0mLの混合物に、鉄粉76mgおよび塩化アンモニウム72mgを加え、30分間加熱還流した。反応混合物にエタノール2.0mLを加え、30分間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加え、不溶物を濾去した。濾液の有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=3:1]で精製し、黄色油状物の5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン136mgを得た。
1H-NMR(CDCl3)δ値:1.75-1.86(4H,m),2.10(3H,s),2.73-2.87(4H,m),3.58-3.73(2H,broad),4.39(2H,s),6.91(1H,s),7.05(1H,s),7.10(1H,d,J=7.8Hz),7.25(1H,s),7.55-7.59(1H,m),7.62(1H,s).
Reference example 4
Figure JPOXMLDOC01-appb-I000018
2- (2-Bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 200 mg, ethanol 2.0 mL and water 2.0 mL To the mixture, 76 mg of iron powder and 72 mg of ammonium chloride were added and heated to reflux for 30 minutes. Ethanol 2.0mL was added to the reaction mixture, and it heated and refluxed for 30 minutes. The reaction mixture was cooled to room temperature, ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 3: 1], and yellow oil 5-bromo-2-methyl-4-((4- (5,6,7,8 -Tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 136 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.75-1.86 (4H, m), 2.10 (3H, s), 2.73-2.87 (4H, m), 3.58-3.73 (2H, broad), 4.39 (2H, s ), 6.91 (1H, s), 7.05 (1H, s), 7.10 (1H, d, J = 7.8Hz), 7.25 (1H, s), 7.55-7.59 (1H, m), 7.62 (1H, s) .
参考例5
Figure JPOXMLDOC01-appb-I000019
手法A:窒素雰囲気下、2-(2-ブロモ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール200mg、トルエン3.8mLおよび水0.2mLの混合物に、シクロプロピルボロン酸61mg、リン酸三カリウム340mgおよびビス(トリシクロヘキシルホスフィン)パラジウム(II)ジクロリド33mgを加え、6時間加熱還流した。反応混合物を室温まで冷却し、トルエンおよび水を加え、不溶物を濾去した。濾液の有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去し、褐色油状物0.25gを得た。
手法B:窒素雰囲気下、2-(2-ブロモ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール200mg、トルエン3.8mLおよび水0.2mLの混合物に、シクロプロピルボロン酸61mg、リン酸三カリウム340mg、酢酸パラジウム(II)5.1mgおよび2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル18mgを加え、6時間加熱還流した。反応混合物を室温まで冷却し、トルエンおよび水を加え、不溶物を濾去した。濾液の有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去し、褐色油状物0.27gを得た。
手法AおよびBで得られた褐色油状物を併せ、シリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=99:1-94:6]で精製し、褐色油状物の2-(2-シクロプロピル-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.38gを得た。
1H-NMR(CDCl3)δ値:0.67-0.73(2H,m),0.96-1.03(2H,m),1.78-1.86(4H,m),1.95-2.03(1H,m),2.56(3H,s),2.75-2.87(4H,m),4.59(2H,s),7.11(1H,d,J=8.0Hz),7.24(1H,s),7.30(1H,s),7.55-7.59(1H,m),7.60(1H,s),7.69(1H,s).
Reference Example 5
Figure JPOXMLDOC01-appb-I000019
Method A: 200 mg of 2- (2-bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole under nitrogen atmosphere To a mixture of 3.8 mL of toluene and 0.2 mL of water were added 61 mg of cyclopropylboronic acid, 340 mg of tripotassium phosphate and 33 mg of bis (tricyclohexylphosphine) palladium (II) dichloride, and the mixture was heated to reflux for 6 hours. The reaction mixture was cooled to room temperature, toluene and water were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to obtain 0.25 g of a brown oil.
Method B: 200 mg of 2- (2-bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole under nitrogen atmosphere To a mixture of 3.8 mL of toluene and 0.2 mL of water, 61 mg of cyclopropylboronic acid, 340 mg of tripotassium phosphate, 5.1 mg of palladium (II) acetate and 18 mg of 2-dicyclohexylphosphino-2 ′, 6′-dimethoxybiphenyl were added. Heated to reflux for hours. The reaction mixture was cooled to room temperature, toluene and water were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to obtain 0.27 g of a brown oil.
The brown oils obtained in Methods A and B were combined and purified by silica gel column chromatography [hexane: ethyl acetate gradient elution = 99: 1-94: 6] to give 2- (2-cyclopropyl) as a brown oil. There was obtained 0.38 g of -5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole.
1 H-NMR (CDCl 3 ) δ value: 0.67-0.73 (2H, m), 0.96-1.03 (2H, m), 1.78-1.86 (4H, m), 1.95-2.03 (1H, m), 2.56 (3H , s), 2.75-2.87 (4H, m), 4.59 (2H, s), 7.11 (1H, d, J = 8.0Hz), 7.24 (1H, s), 7.30 (1H, s), 7.55-7.59 ( 1H, m), 7.60 (1H, s), 7.69 (1H, s).
参考例6
Figure JPOXMLDOC01-appb-I000020
参考例4と同様にして、2-(2-シクロプロピル-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.19gより、5-シクロプロピル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン90mgを得た。
1H-NMR(CDCl3)δ値:0.54-0.60(2H,m),0.80-0.86(2H,m),1.79-1.89(5H,m),2.14(3H,s),2.76-2.86(4H,m),3.40-3.80(2H,broad),4.44(2H,s),6.38(1H,s),6.98(1H,s),7.10(1H,d,J=8.0Hz),7.23(1H,s),7.55-7.60(1H,m),7.62(1H,s).
Reference Example 6
Figure JPOXMLDOC01-appb-I000020
2- (2-Cyclopropyl-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole as in Reference Example 4 From 0.19 g, 5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 90 mg Got.
1 H-NMR (CDCl 3 ) δ value: 0.54-0.60 (2H, m), 0.80-0.86 (2H, m), 1.79-1.89 (5H, m), 2.14 (3H, s), 2.76-2.86 (4H , m), 3.40-3.80 (2H, broad), 4.44 (2H, s), 6.38 (1H, s), 6.98 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.23 (1H, s), 7.55-7.60 (1H, m), 7.62 (1H, s).
参考例7
Figure JPOXMLDOC01-appb-I000021
水酸化ナトリウム81.5gのジメチルスルホキシド900mL懸濁液に、氷冷下で、2,5-ジメチルニトロベンゼン88.0gおよび(フェニルチオ)アセトニトリル110gを加え、室温で3時間撹拌した。反応混合物に、氷冷下で、酢酸エチルおよび水を加え、濃塩酸でpH7.9に調整した。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、10%炭酸カリウム水溶液、1mol/L塩酸および飽和塩化ナトリウム水溶液で順次洗浄し、有機層を無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、褐色固体の(2,5-ジメチル-4-ニトロフェニル)アセトニトリル82.4gを得た。
1H-NMR(CDCl3)δ値:2.38(3H,s),2.59(3H,s),3.71(2H,s),7.37(1H,s),7.85(1H,s).
Reference Example 7
Figure JPOXMLDOC01-appb-I000021
To a suspension of 81.5 g of sodium hydroxide in 900 mL of dimethyl sulfoxide, 88.0 g of 2,5-dimethylnitrobenzene and 110 g of (phenylthio) acetonitrile were added under ice cooling, and the mixture was stirred at room temperature for 3 hours. Ethyl acetate and water were added to the reaction mixture under ice cooling, and the pH was adjusted to 7.9 with concentrated hydrochloric acid. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined and washed successively with 10% aqueous potassium carbonate, 1 mol / L hydrochloric acid and saturated aqueous sodium chloride. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration to obtain 82.4 g of (2,5-dimethyl-4-nitrophenyl) acetonitrile as a brown solid.
1 H-NMR (CDCl 3 ) δ value: 2.38 (3H, s), 2.59 (3H, s), 3.71 (2H, s), 7.37 (1H, s), 7.85 (1H, s).
参考例8
Figure JPOXMLDOC01-appb-I000022
参考例2と同様にして、(2,5-ジメチル-4-ニトロフェニル)アセトニトリル500mgより、2-(2,5-ジメチル-4-ニトロフェニル)エタンチオアミド512mgを得た。
1H-NMR(CDCl3)δ値:2.37(3H,s),2.58(3H,s),4.11(2H,s),6.43-6.72(1H,broad),7.18(1H,s),7.41-7.68(1H,broad),7.86(1H,s).
Reference Example 8
Figure JPOXMLDOC01-appb-I000022
In the same manner as in Reference Example 2, 512 mg of 2- (2,5-dimethyl-4-nitrophenyl) ethanethioamide was obtained from 500 mg of (2,5-dimethyl-4-nitrophenyl) acetonitrile.
1 H-NMR (CDCl 3 ) δ value: 2.37 (3H, s), 2.58 (3H, s), 4.11 (2H, s), 6.43-6.72 (1H, broad), 7.18 (1H, s), 7.41 7.68 (1H, broad), 7.86 (1H, s).
参考例9
Figure JPOXMLDOC01-appb-I000023
2-(2,5-ジメチル-4-ニトロフェニル)エタンチオアミド0.23g、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.26gおよびメタノール5.2mLの混合物を2時間加熱還流した。反応混合物に、2-(2,5-ジメチル-4-ニトロフェニル)エタンチオアミド0.05gを加え、1時間加熱還流した。反応混合物を室温まで冷却し、トルエンを加え、固形物を濾取し、暗褐色固体の2-(2,5-ジメチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.29gを得た。
1H-NMR(DMSO-d6)δ値:1.72-1.78(4H,m),2.38(3H,s),2.48(3H,s),2.70-2.79(4H,m),4.46(2H,s),7.09(1H,d,J=8.3Hz),7.45(1H,s),7.59-7.63(2H,m),7.87(1H,s),7.89(1H,s).
Reference Example 9
Figure JPOXMLDOC01-appb-I000023
Mixture of 0.23 g of 2- (2,5-dimethyl-4-nitrophenyl) ethanethioamide, 0.26 g of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 5.2 mL of methanol Was heated to reflux for 2 hours. To the reaction mixture, 0.05 g of 2- (2,5-dimethyl-4-nitrophenyl) ethanethioamide was added and heated to reflux for 1 hour. The reaction mixture is cooled to room temperature, toluene is added, the solid is collected by filtration, and the dark brown solid 2- (2,5-dimethyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydro 0.29 g of naphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.72-1.78 (4H, m), 2.38 (3H, s), 2.48 (3H, s), 2.70-2.79 (4H, m), 4.46 (2H, s ), 7.09 (1H, d, J = 8.3Hz), 7.45 (1H, s), 7.59-7.63 (2H, m), 7.87 (1H, s), 7.89 (1H, s).
参考例10
Figure JPOXMLDOC01-appb-I000024
2-(2,5-ジメチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.29gの水1.2mL懸濁液に、エタノール4.8mL、鉄粉0.11gおよび塩化アンモニウム20mgを加え、2時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加え、不溶物を濾去した。濾液の有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去し、黄色油状物の2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン172mgを得た。
1H-NMR(CDCl3)δ値:1.79-1.84(4H,m),2.14(3H,s),2.21(3H,s),2.76-2.86(4H,m),3.52-3.60(2H,broad),4.24(2H,s),6.55(1H,s),6.96(1H,s),7.10(1H,d,J=8.0Hz),7.22(1H,s),7.54-7.59(1H,m),7.62(1H,s).
Reference Example 10
Figure JPOXMLDOC01-appb-I000024
To a 1.2 mL water suspension of 0.29 g 2- (2,5-dimethyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole, Ethanol 4.8mL, iron powder 0.11g and ammonium chloride 20mg were added, and it heated and refluxed for 2 hours. The reaction mixture was cooled to room temperature, ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure to give 2,5-dimethyl-4-((4- ( There was obtained 172 mg of 5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline.
1 H-NMR (CDCl 3 ) δ value: 1.79-1.84 (4H, m), 2.14 (3H, s), 2.21 (3H, s), 2.76-2.86 (4H, m), 3.52-3.60 (2H, broad ), 4.24 (2H, s), 6.55 (1H, s), 6.96 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.22 (1H, s), 7.54-7.59 (1H, m) , 7.62 (1H, s).
参考例11
Figure JPOXMLDOC01-appb-I000025
(2,5-ジメチル-4-ニトロフェニル)アセトニトリル16.0gの水160mL懸濁液に、エタノール160mL、鉄粉14.1gおよび塩化アンモニウム13.5gを加え、1時間30分間加熱還流した。反応混合物を室温まで冷却し、不溶物を濾去し、減圧下で溶媒を留去した。得られた溶液に、酢酸エチルを加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒留去した。得られた残留物に、25%エタノール水溶液を加え、固形物を濾取し、淡黄色固体の(4-アミノ-2,5-ジメチルフェニル)アセトニトリル12.9gを得た。
1H-NMR(CDCl3)δ値:2.13(3H,s),2.23(3H,s),3.54(2H,s),3.50-3.68(2H,broad),6.52(1H,s),6.98(1H,s).
Reference Example 11
Figure JPOXMLDOC01-appb-I000025
160 mL of ethanol, 14.1 g of iron powder and 13.5 g of ammonium chloride were added to a suspension of 16.0 g of (2,5-dimethyl-4-nitrophenyl) acetonitrile in 160 mL of water, and the mixture was heated to reflux for 1 hour and 30 minutes. The reaction mixture was cooled to room temperature, insolubles were filtered off, and the solvent was distilled off under reduced pressure. Ethyl acetate was added to the resulting solution. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. A 25% aqueous ethanol solution was added to the obtained residue, and the solid was collected by filtration to obtain 12.9 g of (4-amino-2,5-dimethylphenyl) acetonitrile as a pale yellow solid.
1 H-NMR (CDCl 3 ) δ value: 2.13 (3H, s), 2.23 (3H, s), 3.54 (2H, s), 3.50-3.68 (2H, broad), 6.52 (1H, s), 6.98 ( 1H, s).
参考例12
Figure JPOXMLDOC01-appb-I000026
N-エチル-N-メチルホルムアミド3.81gのクロロホルム15mL溶液に、氷冷下で、塩化オキサリル3.75mLを加え、20℃で1時間撹拌した。反応混合物に、(4-アミノ-2,5-ジメチルフェニル)アセトニトリル5.00gのクロロホルム20mL溶液を30分間で滴下し、室温で20分間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチル=3:1]で精製した。得られた油状物に5.1mol/L塩化水素-酢酸エチル溶液80mLおよびジチオリン酸 O,O’-ジエチル7.34mLを加え、室温で7時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル1.47mLを加え、5日間撹拌した。反応混合物の上層を取り除き、酢酸エチルを加え、固形物を濾取し、淡灰色固体の2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩8.70gを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.29(3H,m),2.25-2.32(6H,m),3.22-3.30(3H,m),3.58-3.70(2H,m),3.82(2H,s),7.10-7.16(1H,m),7.17(1H,s),8.25-8.43(1H,m),9.33-9.44(1H,broad),9.49-9.61(1H,broad),10.67-10.88(1H,m).
Reference Example 12
Figure JPOXMLDOC01-appb-I000026
To a solution of 3.81 g of N-ethyl-N-methylformamide in 15 mL of chloroform was added 3.75 mL of oxalyl chloride under ice cooling, and the mixture was stirred at 20 ° C. for 1 hour. To the reaction mixture, a solution of 5.00 g of (4-amino-2,5-dimethylphenyl) acetonitrile in 20 mL of chloroform was added dropwise over 30 minutes, and the mixture was stirred at room temperature for 20 minutes. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate = 3: 1]. To the obtained oil were added 5.1 mL / L hydrogen chloride-ethyl acetate solution (80 mL) and dithiophosphoric acid O, O′-diethyl (7.34 mL), and the mixture was stirred at room temperature for 7 hours. To the reaction mixture, 1.47 mL of dithiophosphoric acid O, O′-diethyl was added and stirred for 5 days. The upper layer of the reaction mixture was removed, ethyl acetate was added, the solid was collected by filtration, and light gray solid 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethane. 8.70 g of thioamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.29 (3H, m), 2.25-2.32 (6H, m), 3.22-3.30 (3H, m), 3.58-3.70 (2H, m), 3.82 (2H, s), 7.10-7.16 (1H, m), 7.17 (1H, s), 8.25-8.43 (1H, m), 9.33-9.44 (1H, broad), 9.49-9.61 (1H, broad), 10.67 -10.88 (1H, m).
参考例13
Figure JPOXMLDOC01-appb-I000027
N-(4-ヨード-2,5-ジメチルフェニル)アセトアミド0.50g、テトラキス(トリフェニルホスフィン)パラジウム(0)20mg、トリエチルアミン482μL、アクリロニトリル136μLおよびN,N-ジメチルホルムアミド5mLの混合物を、窒素雰囲気下、2時間加熱還流した。反応混合物を室温まで冷却し、水およびクロロホルムを加えた。有機層を分取し、水層をクロロホルムで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、白色固体のN-(4-(2-シアノエテニル)-2,5-ジメチルフェニル)アセトアミド0.29gを得た。
1H-NMR(CDCl3)δ値:2.22(3H,s),2.25(3H,s),2.37(3H,s),5.73(1H,d,J=16.5Hz),6.92-7.07(1H,broad),7.28(1H,s),7.61(1H,d,J=16.5Hz),7.88(1H,s).
Reference Example 13
Figure JPOXMLDOC01-appb-I000027
A mixture of 0.50 g of N- (4-iodo-2,5-dimethylphenyl) acetamide, 20 mg of tetrakis (triphenylphosphine) palladium (0), 482 μL of triethylamine, 136 μL of acrylonitrile and 5 mL of N, N-dimethylformamide was added under a nitrogen atmosphere. And heated to reflux for 2 hours. The reaction mixture was cooled to room temperature and water and chloroform were added. The organic layer was separated and the aqueous layer was extracted with chloroform. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the resulting residue, and the solid was collected by filtration to obtain 0.29 g of N- (4- (2-cyanoethenyl) -2,5-dimethylphenyl) acetamide as a white solid.
1 H-NMR (CDCl 3 ) δ value: 2.22 (3H, s), 2.25 (3H, s), 2.37 (3H, s), 5.73 (1H, d, J = 16.5 Hz), 6.92-7.07 (1H, broad), 7.28 (1H, s), 7.61 (1H, d, J = 16.5Hz), 7.88 (1H, s).
参考例14
Figure JPOXMLDOC01-appb-I000028
N-(4-(2-シアノエテニル)-2,5-ジメチルフェニル)アセトアミド150mg、10%パラジウム-炭素20mg、エタノール5mLおよびN,N-ジメチルホルムアミド5mLの混合物を、水素雰囲気下、室温で2時間撹拌した。不溶物を濾去し、減圧下で溶媒留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、白色固体のN-(4-(2-シアノエチル)-2,5-ジメチルフェニル)アセトアミド115mgを得た。
1H-NMR(CDCl3)δ値:2.20(3H,s),2.22(3H,s),2.28(3H,s),2.55(2H,t,J=7.6Hz),2.91(2H,t,J=7.6Hz),6.84-6.94(1H,broad),6.98(1H,s),7.59(1H,s).
Reference Example 14
Figure JPOXMLDOC01-appb-I000028
A mixture of 150 mg of N- (4- (2-cyanoethenyl) -2,5-dimethylphenyl) acetamide, 20 mg of 10% palladium-carbon, 5 mL of ethanol and 5 mL of N, N-dimethylformamide was stirred at room temperature for 2 hours under a hydrogen atmosphere. Stir. The insoluble material was removed by filtration, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration to obtain 115 mg of white solid N- (4- (2-cyanoethyl) -2,5-dimethylphenyl) acetamide.
1 H-NMR (CDCl 3 ) δ value: 2.20 (3H, s), 2.22 (3H, s), 2.28 (3H, s), 2.55 (2H, t, J = 7.6 Hz), 2.91 (2H, t, J = 7.6Hz), 6.84-6.94 (1H, broad), 6.98 (1H, s), 7.59 (1H, s).
参考例15
Figure JPOXMLDOC01-appb-I000029
N-(4-(2-シアノエチル)-2,5-ジメチルフェニル)アセトアミド113mg、ジチオリン酸 O,O’-ジエチル165μLおよび5mol/L塩化水素-酢酸エチル溶液2mLの混合物を、室温で14時間撹拌した。反応混合物に、ジチオリン酸 O,O’-ジエチル248μLを加え、5時間撹拌した。反応混合物に、ジチオリン酸 O,O’-ジエチル248μLを加え、5時間撹拌した。反応混合物に、酢酸エチル、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、淡灰色固体のN-(4-(3-アミノ-3-チオキソプロピル)-2,5-ジメチルフェニル)アセトアミド114mgを得た。
1H-NMR(CDCl3)δ値:2.19(3H,s),2.20(3H,s),2.30(3H,s),2.86(2H,t,J=7.7Hz),3.05(2H,t,J=7.7Hz),6.79-6.95(2H,broad),7.02(1H,s),7.20-7.35(1H,broad),7.46(1H,s).
Reference Example 15
Figure JPOXMLDOC01-appb-I000029
A mixture of 113 mg of N- (4- (2-cyanoethyl) -2,5-dimethylphenyl) acetamide, 165 μL of dithiophosphoric acid O, O′-diethyl and 2 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 14 hours. did. To the reaction mixture, 248 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 5 hours. To the reaction mixture, 248 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 5 hours. To the reaction mixture were added ethyl acetate, chloroform and 10% aqueous potassium carbonate solution. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration to obtain 114 mg of N- (4- (3-amino-3-thioxopropyl) -2,5-dimethylphenyl) acetamide as a light gray solid. It was.
1 H-NMR (CDCl 3 ) δ value: 2.19 (3H, s), 2.20 (3H, s), 2.30 (3H, s), 2.86 (2H, t, J = 7.7 Hz), 3.05 (2H, t, J = 7.7Hz), 6.79-6.95 (2H, broad), 7.02 (1H, s), 7.20-7.35 (1H, broad), 7.46 (1H, s).
参考例16
Figure JPOXMLDOC01-appb-I000030
N-(4-(3-アミノ-3-チオキソプロピル)-2,5-ジメチルフェニル)アセトアミド100mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン101mgおよびエタノール5mLの混合物を、70℃で2時間撹拌した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、淡黄色固体のN-(2,5-ジメチル-4-(2-(4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)エチル)フェニル)アセトアミド134mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.86(4H,m),2.16-2.24(6H,m),2.30(3H,s),2.74-2.88(4H,m),3.04-3.16(2H,m),3.23-3.33(2H,m),6.77-6.87(1H,broad),7.03(1H,s),7.11(1H,d,J=7.9Hz),7.25(1H,s),7.54(1H,s),7.58(1H,d,J=7.9Hz),7.62(1H,s).
Reference Example 16
Figure JPOXMLDOC01-appb-I000030
N- (4- (3-amino-3-thioxopropyl) -2,5-dimethylphenyl) acetamide 100 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone A mixture of 101 mg and 5 mL of ethanol was stirred at 70 ° C. for 2 hours. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid matter was collected by filtration. 134 mg of -2-yl) -1,3-thiazol-2-yl) ethyl) phenyl) acetamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.86 (4H, m), 2.16-2.24 (6H, m), 2.30 (3H, s), 2.74-2.88 (4H, m), 3.04-3.16 (2H , m), 3.23-3.33 (2H, m), 6.77-6.87 (1H, broad), 7.03 (1H, s), 7.11 (1H, d, J = 7.9Hz), 7.25 (1H, s), 7.54 ( 1H, s), 7.58 (1H, d, J = 7.9Hz), 7.62 (1H, s).
参考例17
Figure JPOXMLDOC01-appb-I000031
N-(2,5-ジメチル-4-(2-(4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)エチル)フェニル)アセトアミド100mg、ジオキサン2mL、濃塩酸1mLおよび水1mLの混合物を、3時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去し、淡黄色油状物の2,5-ジメチル-4-(2-(4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)エチル)アニリン113mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.12(3H,s),2.23(3H,s),2.75-2.88(4H,m),2.98-3.06(2H,m),3.22-3.29(2H,m),3.41-3.55(2H,broad),6.51(1H,s),6.89(1H,s),7.10(1H,d,J=8.0Hz),7.25(1H,s),7.58(1H,d,J=8.0Hz),7.62(1H,s).
Reference Example 17
Figure JPOXMLDOC01-appb-I000031
N- (2,5-dimethyl-4- (2- (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) ethyl) phenyl) acetamide 100 mg A mixture of 2 mL of dioxane, 1 mL of concentrated hydrochloric acid and 1 mL of water was heated to reflux for 3 hours. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to give 2,5-dimethyl-4- (2- (4- (5,6,7,8) as a pale yellow oil. -Tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) ethyl) aniline (113 mg) was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.12 (3H, s), 2.23 (3H, s), 2.75-2.88 (4H, m), 2.98-3.06 (2H, m ), 3.22-3.29 (2H, m), 3.41-3.55 (2H, broad), 6.51 (1H, s), 6.89 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.25 (1H, s), 7.58 (1H, d, J = 8.0Hz), 7.62 (1H, s).
参考例18
Figure JPOXMLDOC01-appb-I000032
5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン0.26g、シアン化亜鉛0.22g、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)64mgおよびN,N-ジメチルホルムアミド2.6mLの混合物を、窒素雰囲気下、120~130℃で4時間撹拌した。反応混合物にビス(トリ-tert-ブチルホスフィン)パラジウム(0)64mgを加え、窒素雰囲気下、140~150℃で4時間30分間撹拌した。反応混合物を室温まで冷却し、酢酸エチル、メタノールおよび水を加え、不溶物を濾去した。濾液の有機層を分取し、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=17:3-1:1]で精製し、白色固体の5-アミノ-4-メチル-2-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル0.20gを得た。
1H-NMR(DMSO-d6)δ値:1.70-1.78(4H,m),2.10(3H,s),2.68-2.80(4H,m),4.33(2H,s),5.38(2H,s),6.94(1H,s),7.06-7.13(1H,m),7.17(1H,s),7.58-7.65(2H,m),7.84(1H,s).
Reference Example 18
Figure JPOXMLDOC01-appb-I000032
5-bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.26 g, zinc cyanide A mixture of 0.22 g, 64 mg of bis (tri-tert-butylphosphine) palladium (0) and 2.6 mL of N, N-dimethylformamide was stirred at 120 to 130 ° C. for 4 hours under a nitrogen atmosphere. To the reaction mixture, 64 mg of bis (tri-tert-butylphosphine) palladium (0) was added, and the mixture was stirred at 140 to 150 ° C. for 4 hours and 30 minutes under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, ethyl acetate, methanol and water were added, and insoluble materials were removed by filtration. The organic layer of the filtrate was separated, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 17: 3-1: 1], and 5-amino-4-methyl-2-((4- (5 , 6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile (0.20 g).
1 H-NMR (DMSO-d 6 ) δ value: 1.70-1.78 (4H, m), 2.10 (3H, s), 2.68-2.80 (4H, m), 4.33 (2H, s), 5.38 (2H, s ), 6.94 (1H, s), 7.06-7.13 (1H, m), 7.17 (1H, s), 7.58-7.65 (2H, m), 7.84 (1H, s).
参考例19
Figure JPOXMLDOC01-appb-I000033
4-クロロ-1-メチル-2-ニトロベンゼン1.72g、水酸化カリウム1.68g、2-((シアノメチル)スルファニル)安息香酸2.89gおよびジメチルスルホキシド5mLの混合物を、室温で2時間撹拌した。反応混合物に水酸化カリウム1.68gを加え、2時間30分間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、飽和炭酸水素ナトリウム水溶液および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-4:1]で精製し、赤色固体の(2-クロロ-5-メチル-4-ニトロフェニル)アセトニトリル0.90gを得た。
1H-NMR(CDCl3)δ値:2.64(3H,s),3.89(2H,s),7.56(1H,s),8.08(1H,s).
Reference Example 19
Figure JPOXMLDOC01-appb-I000033
A mixture of 1.72 g of 4-chloro-1-methyl-2-nitrobenzene, 1.68 g of potassium hydroxide, 2.89 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 5 mL of dimethyl sulfoxide was stirred at room temperature for 2 hours. To the reaction mixture, 1.68 g of potassium hydroxide was added and stirred for 2 hours and 30 minutes. Saturated aqueous sodium hydrogen carbonate solution and ethyl acetate were added to the reaction mixture. The organic layer was separated, washed successively with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate gradient elution = 9: 1-4: 1] to give a red solid (2-chloro-5-methyl-4-nitrophenyl) acetonitrile 0.90. g was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.64 (3H, s), 3.89 (2H, s), 7.56 (1H, s), 8.08 (1H, s).
参考例20
Figure JPOXMLDOC01-appb-I000034
参考例2と同様にして、(2-クロロ-5-メチル-4-ニトロフェニル)アセトニトリル0.90gより、2-(2-クロロ-5-メチル-4-ニトロフェニル)エタンチオアミド0.76gを得た。
1H-NMR(CDCl3)δ値:2.61(3H,s),4.17(2H,s),6.74-7.06(1H,broad),7.38-7.62(1H,broad),7.46(1H,s),8.08(1H,s).
Reference Example 20
Figure JPOXMLDOC01-appb-I000034
In the same manner as in Reference Example 2, 0.76 g of 2- (2-chloro-5-methyl-4-nitrophenyl) ethanethioamide was obtained from 0.90 g of (2-chloro-5-methyl-4-nitrophenyl) acetonitrile. .
1 H-NMR (CDCl 3 ) δ value: 2.61 (3H, s), 4.17 (2H, s), 6.74-7.06 (1H, broad), 7.38-7.62 (1H, broad), 7.46 (1H, s), 8.08 (1H, s).
参考例21
Figure JPOXMLDOC01-appb-I000035
2-(2-クロロ-5-メチル-4-ニトロフェニル)エタンチオアミド245mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン253mgおよびメタノール3mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、淡黄色固体の2-(2-クロロ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール360mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.61(3H,s),2.74-2.94(4H,m),5.35(2H,s),7.21(1H,d,J=8.1Hz),7.51(1H,s),7.75(1H,dd,J=8.1,2.2Hz),7.87-7.91(1H,m),8.08(1H,s),8.17(1H,s).
Reference Example 21
Figure JPOXMLDOC01-appb-I000035
A mixture of 245 mg of 2- (2-chloro-5-methyl-4-nitrophenyl) ethanethioamide, 253 mg of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 3 mL of methanol The mixture was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration to give 2- (2-chloro-5-methyl-4-nitrobenzyl) -4- (5,6,7,8- 360 mg of tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.61 (3H, s), 2.74-2.94 (4H, m), 5.35 (2H, s), 7.21 (1H, d, J = 8.1Hz), 7.51 (1H, s), 7.75 (1H, dd, J = 8.1, 2.2Hz), 7.87-7.91 (1H, m), 8.08 (1H, s), 8.17 (1H, s).
参考例22
Figure JPOXMLDOC01-appb-I000036
参考例10と同様にして、2-(2-クロロ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール100mgより、5-クロロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン92mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.88(4H,m),2.11(3H,s),2.70-3.00(4H,m),3.50-3.82(2H,broad),4.37(2H,s),6.73(1H,s),7.03(1H,s),7.09(1H,d,J=7.8Hz),7.24(1H,s),7.53-7.60(1H,m),7.62(1H,s).
Reference Example 22
Figure JPOXMLDOC01-appb-I000036
In the same manner as in Reference Example 10, 2- (2-chloro-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 100 mg Thus, 92 mg of 5-chloro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.76-1.88 (4H, m), 2.11 (3H, s), 2.70-3.00 (4H, m), 3.50-3.82 (2H, broad), 4.37 (2H, s) ), 6.73 (1H, s), 7.03 (1H, s), 7.09 (1H, d, J = 7.8Hz), 7.24 (1H, s), 7.53-7.60 (1H, m), 7.62 (1H, s) .
参考例23
Figure JPOXMLDOC01-appb-I000037
参考例19と同様にして、4-フルオロ-1-メチル-2-ニトロベンゼン2.32gより、(2-フルオロ-5-メチル-4-ニトロフェニル)アセトニトリル0.51gを得た。
1H-NMR(CDCl3)δ値:2.62(3H,s),3.84(2H,s),7.49(1H,d,J=7.1Hz),7.79(1H,d,J=9.2Hz).
Reference Example 23
Figure JPOXMLDOC01-appb-I000037
In the same manner as in Reference Example 19, 0.52-g of (2-fluoro-5-methyl-4-nitrophenyl) acetonitrile was obtained from 2.32 g of 4-fluoro-1-methyl-2-nitrobenzene.
1 H-NMR (CDCl 3 ) δ value: 2.62 (3H, s), 3.84 (2H, s), 7.49 (1H, d, J = 7.1 Hz), 7.79 (1H, d, J = 9.2 Hz).
参考例24
Figure JPOXMLDOC01-appb-I000038
(2-フルオロ-5-メチル-4-ニトロフェニル)アセトニトリル0.40g、ジチオリン酸 O,O’-ジエチル0.49mLおよび5mol/L塩化水素-酢酸エチル溶液2mLの混合物を、室温で12時間30分間撹拌した。反応混合物に酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-2:1]で精製し、赤色固体の2-(2-フルオロ-5-メチル-4-ニトロフェニル)エタンチオアミド400mgを得た。
1H-NMR(CDCl3)δ値:2.60(3H,s),4.07(2H,s),6.69-7.11(1H,broad),7.41(1H,d,J=7.3Hz),7.38-7.58(1H,broad),7.79(1H,d,J=9.3Hz).
Reference Example 24
Figure JPOXMLDOC01-appb-I000038
A mixture of 0.40 g of (2-fluoro-5-methyl-4-nitrophenyl) acetonitrile, 0.49 mL of dithiophosphoric acid O, O′-diethyl and 2 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 12 hours and 30 minutes. did. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-2: 1] to give 2- (2-fluoro-5-methyl-4-nitrophenyl) as a red solid. Ethanethioamide 400 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.60 (3H, s), 4.07 (2H, s), 6.69-7.11 (1H, broad), 7.41 (1H, d, J = 7.3 Hz), 7.38-7.58 ( 1H, broad), 7.79 (1H, d, J = 9.3Hz).
参考例25
Figure JPOXMLDOC01-appb-I000039
参考例9と同様にして、2-(2-フルオロ-5-メチル-4-ニトロフェニル)エタンチオアミド228mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン253mgより、2-(2-フルオロ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール294mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.87(4H,m),2.60(3H,s),2.74-2.93(4H,m),5.27(2H,s),7.21(1H,d,J=7.8Hz),7.52(1H,s),7.75(1H,dd,J=7.8,1.7Hz),7.80(1H,d,J=9.3Hz),7.88(1H,s),8.06(1H,d,J=7.3Hz).
Reference Example 25
Figure JPOXMLDOC01-appb-I000039
In the same manner as in Reference Example 9, 228 mg of 2- (2-fluoro-5-methyl-4-nitrophenyl) ethanethioamide and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) From 253 mg of ethanone, 294 mg of 2- (2-fluoro-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.76-1.87 (4H, m), 2.60 (3H, s), 2.74-2.93 (4H, m), 5.27 (2H, s), 7.21 (1H, d, J = 7.8Hz), 7.52 (1H, s), 7.75 (1H, dd, J = 7.8,1.7Hz), 7.80 (1H, d, J = 9.3Hz), 7.88 (1H, s), 8.06 (1H, d , J = 7.3Hz).
参考例26
Figure JPOXMLDOC01-appb-I000040
参考例10と同様にして、2-(2-フルオロ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール90mgより、5-フルオロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン82mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.88(4H,m),2.10(3H,s),2.73-2.90(4H,m),3.58-3.80(2H,broad),4.27(2H,s),6.42(1H,d,J=11.2Hz),6.98(1H,d,J=8.2Hz),7.09(1H,d,J=8.2Hz),7.25(1H,s),7.56(1H,dd,J=7.8,1.9Hz),7.61(1H,s).
Reference Example 26
Figure JPOXMLDOC01-appb-I000040
In the same manner as in Reference Example 10, 2- (2-fluoro-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 90 mg Thus, 82 mg of 5-fluoro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.78-1.88 (4H, m), 2.10 (3H, s), 2.73-2.90 (4H, m), 3.58-3.80 (2H, broad), 4.27 (2H, s ), 6.42 (1H, d, J = 11.2Hz), 6.98 (1H, d, J = 8.2Hz), 7.09 (1H, d, J = 8.2Hz), 7.25 (1H, s), 7.56 (1H, dd , J = 7.8, 1.9Hz), 7.61 (1H, s).
参考例27
Figure JPOXMLDOC01-appb-I000041
2-(2-ブロモ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール100mg、テトラキス(トリフェニルホスフィン)パラジウム(0)13mg、フェニルホウ酸30mg、炭酸カリウム62mg、ジオキサン5mLおよび水2mLの混合物を、窒素雰囲気下、3時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび水を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=100:0-10:1]で精製し、淡黄色油状物を得た。参考例10と同様にして、得られた淡黄色油状物より、4-メチル-6-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ビフェニル-3-アミン86mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.86(4H,m),2.20(3H,s),2.73-2.86(4H,m),3.58-3.72(2H,m),4.21(2H,s),6.63(1H,s),7.08(1H,d,J=7.7Hz),7.11(1H,s),7.21(1H,s),7.23-7.38(5H,m),7.53(1H,d,J=7.7Hz),7.57(1H,s).
Reference Example 27
Figure JPOXMLDOC01-appb-I000041
2- (2-Bromo-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 100 mg, tetrakis (triphenylphosphine) palladium A mixture of (0) 13 mg, phenylboric acid 30 mg, potassium carbonate 62 mg, dioxane 5 mL and water 2 mL was heated to reflux under a nitrogen atmosphere for 3 hours. The reaction mixture was cooled to room temperature and ethyl acetate and water were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 100: 0-10: 1] to obtain a pale yellow oil. In the same manner as in Reference Example 10, 4-methyl-6-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole- 86 mg of 2-yl) methyl) biphenyl-3-amine were obtained.
1 H-NMR (CDCl 3 ) δ value: 1.76-1.86 (4H, m), 2.20 (3H, s), 2.73-2.86 (4H, m), 3.58-3.72 (2H, m), 4.21 (2H, s ), 6.63 (1H, s), 7.08 (1H, d, J = 7.7Hz), 7.11 (1H, s), 7.21 (1H, s), 7.23-7.38 (5H, m), 7.53 (1H, d, J = 7.7Hz), 7.57 (1H, s).
参考例28
Figure JPOXMLDOC01-appb-I000042
水酸化ナトリウム5.5g、2-((シアノメチル)スルファニル)安息香酸3.2gおよびジメチルスルホキシド18mLの混合物を、30℃で5分間撹拌した。反応混合物に4-(ジフルオロメトキシ)-1-メチル-2-ニトロベンゼン2.8gのジメチルスルホキシド10mL溶液を加え、30℃で1時間撹拌した。反応混合物に氷水、トルエンおよび酢酸エチルを加え、不溶物を濾去した。濾液の有機層を分取し、水層をトルエンで抽出した。有機層および抽出液を併せ、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、活性炭を加えた。不溶物を濾去し、減圧下で溶媒を留去し、褐色油状物の(2-(ジフルオロメトキシ)-5-メチル-4-ニトロフェニル)アセトニトリル1.6gを得た。
1H-NMR(CDCl3)δ値:2.63(3H,s),3.82(2H,s),6.65(1H,t,J=71.8Hz),7.53(1H,s),7.85(1H,s).
Reference Example 28
Figure JPOXMLDOC01-appb-I000042
A mixture of 5.5 g of sodium hydroxide, 3.2 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 18 mL of dimethyl sulfoxide was stirred at 30 ° C. for 5 minutes. To the reaction mixture was added 2.8 g of 4- (difluoromethoxy) -1-methyl-2-nitrobenzene in 10 mL of dimethyl sulfoxide, and the mixture was stirred at 30 ° C. for 1 hour. Ice water, toluene and ethyl acetate were added to the reaction mixture, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated and the aqueous layer was extracted with toluene. The organic layer and the extract were combined, washed sequentially with water and a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and then activated carbon was added. The insoluble material was removed by filtration, and the solvent was distilled off under reduced pressure to obtain 1.6 g of (2- (difluoromethoxy) -5-methyl-4-nitrophenyl) acetonitrile as a brown oil.
1 H-NMR (CDCl 3 ) δ value: 2.63 (3H, s), 3.82 (2H, s), 6.65 (1H, t, J = 71.8 Hz), 7.53 (1H, s), 7.85 (1H, s) .
参考例29
Figure JPOXMLDOC01-appb-I000043
(2-(ジフルオロメトキシ)-5-メチル-4-ニトロフェニル)アセトニトリル0.36g、ジチオリン酸 O,O’-ジエチル0.14mLおよび4mol/L塩化水素-酢酸エチル溶液3.0mLの混合物を、室温で4時間撹拌した。減圧下で溶媒を留去し、褐色油状物を得た。得られた褐色油状物、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.46gおよびエタノール4mLの混合物を、1時間30分間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=19:1-17:3]で精製し、褐色油状物の2-(2-(ジフルオロメトキシ)-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.23gを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.57(3H,s),2.74-2.86(4H,m),4.48(2H,s),6.62(1H,t,J=72.8Hz),7.11(1H,d,J=7.8Hz),7.31(1H,s),7.37(1H,s),7.51-7.60(2H,m),7.87(1H,s).
Reference Example 29
Figure JPOXMLDOC01-appb-I000043
A mixture of 0.36 g of (2- (difluoromethoxy) -5-methyl-4-nitrophenyl) acetonitrile, 0.14 mL of dithiophosphoric acid O, O′-diethyl and 3.0 mL of 4 mol / L hydrogen chloride-ethyl acetate solution was added at room temperature to 4 Stir for hours. The solvent was distilled off under reduced pressure to obtain a brown oil. A mixture of the obtained brown oil, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone (0.46 g) and ethanol (4 mL) was heated to reflux for 1 hour and 30 minutes. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 19: 1-17: 3] to give 2- (2- (difluoromethoxy) -5-methyl-4 as a brown oil. -Nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole (0.23 g) was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.57 (3H, s), 2.74-2.86 (4H, m), 4.48 (2H, s), 6.62 (1H, t, J = 72.8Hz), 7.11 (1H, d, J = 7.8Hz), 7.31 (1H, s), 7.37 (1H, s), 7.51-7.60 (2H, m), 7.87 (1H, s).
参考例30
Figure JPOXMLDOC01-appb-I000044
参考例4と同様にして、2-(2-(ジフルオロメトキシ)-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.23gより、5-(ジフルオロメトキシ)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン80mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.11(3H,s),2.74-2.86(4H,m),3.69(2H,s),4.29(2H,s),6.46(1H,t,J=74.2Hz),6.50(1H,s),7.03(1H,s),7.09(1H,d,J=8.1Hz),7.20-7.40(1H,m),7.53-7.58(1H,m),7.60(1H,s).
Reference Example 30
Figure JPOXMLDOC01-appb-I000044
In the same manner as in Reference Example 4, 2- (2- (difluoromethoxy) -5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3 -From 0.23 g of thiazole, 5- (difluoromethoxy) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) 80 mg of methyl) aniline were obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.11 (3H, s), 2.74-2.86 (4H, m), 3.69 (2H, s), 4.29 (2H, s), 6.46 (1H, t, J = 74.2Hz), 6.50 (1H, s), 7.03 (1H, s), 7.09 (1H, d, J = 8.1Hz), 7.20-7.40 (1H, m), 7.53-7.58 (1H, m), 7.60 (1H, s).
参考例31
Figure JPOXMLDOC01-appb-I000045
4-メトキシ-1-メチル-2-ニトロベンゼン0.84g、水酸化ナトリウム1.20g、2-((シアノメチル)スルファニル)安息香酸1.45gおよびジメチルスルホキシド5mLの混合物を、室温で6時間撹拌した。反応混合物に水およびトルエンを加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-4:1]で精製し、淡黄色固体の(2-メトキシ-5-メチル-4-ニトロフェニル)アセトニトリル0.14gを得た。
1H-NMR(CDCl3)δ値:2.57(3H,s),3.73(2H,s),3.93(3H,s),7.37(1H,s),7.53(1H,s).
Reference Example 31
Figure JPOXMLDOC01-appb-I000045
A mixture of 0.84 g of 4-methoxy-1-methyl-2-nitrobenzene, 1.20 g of sodium hydroxide, 1.45 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 5 mL of dimethyl sulfoxide was stirred at room temperature for 6 hours. Water and toluene were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-4: 1] to give (2-methoxy-5-methyl-4-nitrophenyl) acetonitrile as a pale yellow solid. 0.14 g was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.57 (3H, s), 3.73 (2H, s), 3.93 (3H, s), 7.37 (1H, s), 7.53 (1H, s).
参考例32
Figure JPOXMLDOC01-appb-I000046
参考例15と同様にして、(2-メトキシ-5-メチル-4-ニトロフェニル)アセトニトリル0.12gより、2-(2-メトキシ-5-メチル-4-ニトロフェニル)エタンチオアミド102mgを得た。
1H-NMR(CDCl3)δ値:2.56(3H,s),3.95(3H,s),4.08(2H,s),7.21-7.35(2H,broad),7.32(1H,s),7.58(1H,s).
Reference Example 32
Figure JPOXMLDOC01-appb-I000046
In the same manner as in Reference Example 15, 102 mg of 2- (2-methoxy-5-methyl-4-nitrophenyl) ethanethioamide was obtained from 0.12 g of (2-methoxy-5-methyl-4-nitrophenyl) acetonitrile.
1 H-NMR (CDCl 3 ) δ value: 2.56 (3H, s), 3.95 (3H, s), 4.08 (2H, s), 7.21-7.35 (2H, broad), 7.32 (1H, s), 7.58 ( 1H, s).
参考例33
Figure JPOXMLDOC01-appb-I000047
参考例21と同様にして、2-(2-メトキシ-5-メチル-4-ニトロフェニル)エタンチオアミド100mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン105mgより、2-(2-メトキシ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール140mgを得た。
1H-NMR(DMSO-d6)δ値:1.69-1.80(4H,m),2.44(3H,s),2.65-2.83(4H,m),3.88(3H,s),4.37(2H,s),7.06-7.12(1H,m),7.47(1H,s),7.58-7.67(3H,m),7.83(1H,s).
Reference Example 33
Figure JPOXMLDOC01-appb-I000047
In the same manner as in Reference Example 21, 100 mg of 2- (2-methoxy-5-methyl-4-nitrophenyl) ethanethioamide and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) From 105 mg of ethanone, 140 mg of 2- (2-methoxy-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.69-1.80 (4H, m), 2.44 (3H, s), 2.65-2.83 (4H, m), 3.88 (3H, s), 4.37 (2H, s ), 7.06-7.12 (1H, m), 7.47 (1H, s), 7.58-7.67 (3H, m), 7.83 (1H, s).
参考例34
Figure JPOXMLDOC01-appb-I000048
参考例4と同様にして、2-(2-メトキシ-5-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール140mgより、5-メトキシ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン75mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.85(4H,m),2.09(3H,s),2.72-2.88(4H,m),3.53-3.71(2H,broad),3.77(3H,s),4.25(2H,s),6.29(1H,s),6.95(1H,s),7.08(1H,d,J=7.8Hz),7.20(1H,s),7.56(1H,dd,J=8.0,1.7Hz),7.62(1H,s).
Reference Example 34
Figure JPOXMLDOC01-appb-I000048
In the same manner as in Reference Example 4, 2- (2-methoxy-5-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 140 mg Thus, 75 mg of 5-methoxy-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.76-1.85 (4H, m), 2.09 (3H, s), 2.72-2.88 (4H, m), 3.53-3.71 (2H, broad), 3.77 (3H, s ), 4.25 (2H, s), 6.29 (1H, s), 6.95 (1H, s), 7.08 (1H, d, J = 7.8Hz), 7.20 (1H, s), 7.56 (1H, dd, J = 8.0, 1.7Hz), 7.62 (1H, s).
参考例35
Figure JPOXMLDOC01-appb-I000049
1-メチル-2-ニトロ-4-(トリフルオロメチル)ベンゼン1.0g、クロロアセトニトリル0.30mLおよびN,N-ジメチルホルムアミド20mLの混合物に、-15~-10℃でカリウムtert-ブトキシド1.1gを加え、-20~-10℃で1時間50分間撹拌した。反応混合物にクロロアセトニトリル90μLを加え、0~10℃で1時間撹拌した。反応混合物に水およびトルエンを加え、6mol/L塩酸でpH2に調整した。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=49:1-4:1]で精製し、褐色油状物の(5-メチル-4-ニトロ-2-(トリフルオロメチル)フェニル)アセトニトリル0.19gを得た。
1H-NMR(CDCl3)δ値:2.74(3H,s),4.01(2H,s),7.73(1H,s),8.34(1H,s).
Reference Example 35
Figure JPOXMLDOC01-appb-I000049
To a mixture of 1.0 g of 1-methyl-2-nitro-4- (trifluoromethyl) benzene, 0.30 mL of chloroacetonitrile and 20 mL of N, N-dimethylformamide, 1.1 g of potassium tert-butoxide was added at −15 to −10 ° C. The mixture was stirred at -20 to -10 ° C for 1 hour and 50 minutes. To the reaction mixture, 90 μL of chloroacetonitrile was added and stirred at 0 to 10 ° C. for 1 hour. Water and toluene were added to the reaction mixture, and the pH was adjusted to 2 with 6 mol / L hydrochloric acid. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 49: 1-4: 1] to give (5-methyl-4-nitro-2- (trifluoromethyl) as a brown oil. 0.19 g of phenyl) acetonitrile was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.74 (3H, s), 4.01 (2H, s), 7.73 (1H, s), 8.34 (1H, s).
参考例36
Figure JPOXMLDOC01-appb-I000050
参考例24と同様にして、(5-メチル-4-ニトロ-2-(トリフルオロメチル)フェニル)アセトニトリル0.19gより、2-(5-メチル-4-ニトロ-2-(トリフルオロメチル)フェニル)エタンチオアミド0.116gを得た。
1H-NMR(CDCl3)δ値:2.70(3H,s),4.20(2H,s),6.60-6.90(1H,broad),7.35-7.54(1H,broad),7.67(1H,s),8.33(1H,s).
Reference Example 36
Figure JPOXMLDOC01-appb-I000050
In the same manner as in Reference Example 24, from 0.19 g of (5-methyl-4-nitro-2- (trifluoromethyl) phenyl) acetonitrile, 2- (5-methyl-4-nitro-2- (trifluoromethyl) phenyl ) 0.116 g of ethanethioamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.70 (3H, s), 4.20 (2H, s), 6.60-6.90 (1H, broad), 7.35-7.54 (1H, broad), 7.67 (1H, s), 8.33 (1H, s).
参考例37
Figure JPOXMLDOC01-appb-I000051
参考例31と同様にして、4-メチル-3-ニトロフェニル=プロパン-2-イル=エーテル2.20gより、(5-メチル-4-ニトロ-2-(プロパン-2-イルオキシ)フェニル)アセトニトリル1.03gを得た。
1H-NMR(CDCl3)δ値:1.40(6H,d,J=6.1Hz),2.56(3H,s),3.70(2H,s),4.61-4.71(1H,m),7.35(1H,s),7.52(1H,s).
Reference Example 37
Figure JPOXMLDOC01-appb-I000051
In the same manner as in Reference Example 31, from 2.20 g of 4-methyl-3-nitrophenyl = propan-2-yl ether, (5-methyl-4-nitro-2- (propan-2-yloxy) phenyl) acetonitrile 1.03 g was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.40 (6H, d, J = 6.1 Hz), 2.56 (3H, s), 3.70 (2H, s), 4.61-4.71 (1H, m), 7.35 (1H, s), 7.52 (1H, s).
参考例38
Figure JPOXMLDOC01-appb-I000052
(5-メチル-4-ニトロ-2-(プロパン-2-イルオキシ)フェニル)アセトニトリル0.50g、ジチオリン酸 O,O’-ジエチル0.51mLおよび5mol/L塩化水素-酢酸エチル溶液5.0mLの混合物を、室温で1時間15分間撹拌し、14時間静置した。反応混合物を減圧下で溶媒留去した。得られた褐色油状物、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.65gおよびエタノール5.0mLの混合物を、2時間30分間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=100:0-3:1]で精製し、黄色油状物0.73gを得た。得られた黄色油状物0.40g、塩化アンモニウム30mg、鉄粉0.16g、エタノール8.0mLおよび水2.0mLの混合物を、3時間加熱還流した。反応混合物に、得られた黄色油状物0.33g、塩化アンモニウム30mgおよび鉄粉0.16gを加え、1時間加熱還流した。反応混合物を室温まで冷却し、不溶物を濾去し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=4:1]で精製し、暗緑色油状物の2-メチル-5-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン240mgを得た。
1H-NMR(CDCl3)δ値:1.27(6H,d,J=6.1Hz),1.76-1.86(4H,m),2.09(3H,s),2.72-2.88(4H,m),3.50-3.76(2H,broad),4.24(2H,s),4.40-4.51(1H,m),6.96(1H,s),7.09(1H,d,J=8.0Hz),7.20(1H,s),7.56(1H,d,J=8.1Hz),7.62(1H,s).
Reference Example 38
Figure JPOXMLDOC01-appb-I000052
A mixture of 0.50 g of (5-methyl-4-nitro-2- (propan-2-yloxy) phenyl) acetonitrile, 0.51 mL of dithiophosphoric acid O, O′-diethyl and 5.0 mL of 5 mol / L hydrogen chloride-ethyl acetate solution The mixture was stirred at room temperature for 1 hour and 15 minutes and allowed to stand for 14 hours. The reaction mixture was evaporated under reduced pressure. A mixture of the obtained brown oily substance, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone (0.65 g) and ethanol (5.0 mL) was heated to reflux for 2 hours and 30 minutes. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 100: 0-3: 1] to obtain 0.73 g of a yellow oily substance. A mixture of 0.40 g of the obtained yellow oil, 30 mg of ammonium chloride, 0.16 g of iron powder, 8.0 mL of ethanol and 2.0 mL of water was heated to reflux for 3 hours. To the reaction mixture were added 0.33 g of the obtained yellow oil, 30 mg of ammonium chloride and 0.16 g of iron powder, and the mixture was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, insolubles were filtered off, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 4: 1] to give 2-methyl-5- (propan-2-yloxy) -4-((4- ( 240 mg of 5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.27 (6H, d, J = 6.1 Hz), 1.76-1.86 (4H, m), 2.09 (3H, s), 2.72-2.88 (4H, m), 3.50- 3.76 (2H, broad), 4.24 (2H, s), 4.40-4.51 (1H, m), 6.96 (1H, s), 7.09 (1H, d, J = 8.0Hz), 7.20 (1H, s), 7.56 (1H, d, J = 8.1Hz), 7.62 (1H, s).
参考例39
Figure JPOXMLDOC01-appb-I000053
5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン0.10g、トリメチルシリルアセチレン43μL、テトラクロロパラジウム(II)酸ナトリウム 三水和物2.1mg、トリ-tert-ブチルホスホニウムテトラフルオロボラート3.5mg、ヨウ化銅(I)2.3mgおよびN,N,N’,N’-テトラメチルエチレンジアミン0.5mLの混合物を、マイクロウェーブ反応装置を使用して130℃で10分間、140℃で20分間処理した。反応混合物に、トリメチルシリルアセチレン0.13mL、テトラクロロパラジウム(II)酸ナトリウム 三水和物2.1mg、トリ-tert-ブチルホスホニウムテトラフルオロボラート3.5mgおよびヨウ化銅(I)2.3mgを加え、マイクロウェーブ反応装置を使用して140℃で20分間処理した。反応混合物に、酢酸エチルおよび水を加え、不溶物を濾去した。濾液の有機層を分取し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、炭酸カリウム0.10gおよびメタノール2.0mLを加え、30分間撹拌し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-67:33]で精製し、褐色油状物の5-エチニル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン57mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.85(4H,m),2.15(3H,s),2.74-2.87(4H,m),3.18(1H,s),3.56-3.70(2H,broad),4.46(2H,s),6.86(1H,s),7.05(1H,s),7.10(1H,d,J=8.0Hz),7.24(1H,s),7.54-7.59(1H,m),7.62(1H,s).
Reference Example 39
Figure JPOXMLDOC01-appb-I000053
5-Bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.10 g, trimethylsilylacetylene 43 μL , Sodium tetrachloropalladium (II) trihydrate 2.1 mg, tri-tert-butylphosphonium tetrafluoroborate 3.5 mg, copper (I) iodide 2.3 mg and N, N, N ′, N′-tetramethyl A mixture of 0.5 mL of ethylenediamine was treated using a microwave reactor at 130 ° C. for 10 minutes and 140 ° C. for 20 minutes. To the reaction mixture, 0.13 mL of trimethylsilylacetylene, 2.1 mg of sodium tetrachloropalladium (II) trihydrate, 3.5 mg of tri-tert-butylphosphonium tetrafluoroborate and 2.3 mg of copper (I) iodide were added. Treated at 140 ° C. for 20 minutes using a reactor. Ethyl acetate and water were added to the reaction mixture, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, potassium carbonate (0.10 g) and methanol (2.0 mL) were added, stirred for 30 minutes, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-67: 33], and 5-ethynyl-2-methyl-4-((4- ( 5,6,7,8-Tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 57 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.85 (4H, m), 2.15 (3H, s), 2.74-2.87 (4H, m), 3.18 (1H, s), 3.56-3.70 (2H, broad) ), 4.46 (2H, s), 6.86 (1H, s), 7.05 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.24 (1H, s), 7.54-7.59 (1H, m) , 7.62 (1H, s).
参考例40
Figure JPOXMLDOC01-appb-I000054
4-ブロモ-2-メチル-5-(プロパン-2-イル)アニリン0.50g、シアノ酢酸エチル0.70mL、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)56mg、リン酸三カリウム1.40gおよびトルエン10mLの混合物を、窒素雰囲気下、3時間30分間加熱還流した。反応混合物を室温まで冷却し、水および酢酸エチルを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、淡黄色固体のエチル=(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)(シアノ)アセタートの塩酸塩0.58gを得た。
1H-NMR(CDCl3)δ値:1.21-1.32(9H,m),2.59(3H,s),3.06-3.15(1H,m),4.17-4.35(2H,m),4.94(1H,s),7.39(1H,s),7.63(1H,s),10.10-10.90(3H,broad).
Reference Example 40
Figure JPOXMLDOC01-appb-I000054
4-Bromo-2-methyl-5- (propan-2-yl) aniline 0.50 g, ethyl cyanoacetate 0.70 mL, bis (tri-tert-butylphosphine) palladium (0) 56 mg, tripotassium phosphate 1.40 g and toluene 10 mL of the mixture was heated to reflux under a nitrogen atmosphere for 3 hours 30 minutes. The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration. Hydrochloric acid of ethyl = (4-amino-5-methyl-2- (propan-2-yl) phenyl) (cyano) acetate as a pale yellow solid 0.58 g of salt was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.21-1.32 (9H, m), 2.59 (3H, s), 3.06-3.15 (1H, m), 4.17-4.35 (2H, m), 4.94 (1H, s ), 7.39 (1H, s), 7.63 (1H, s), 10.10-10.90 (3H, broad).
参考例41
Figure JPOXMLDOC01-appb-I000055
エチル=(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)(シアノ)アセタートの塩酸塩0.50g、塩化ナトリウム0.74g、水1mLおよびジメチルスルホキシド16mLの混合物を、150℃で40分間撹拌した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=4:1]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡黄色固体の(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)アセトニトリルの塩酸塩206mgを得た。
1H-NMR(DMSO-d6)δ値:1.18(6H,d,J=6.8Hz),2.31(3H,s),3.05-3.17(1H,m),4.04(2H,s),7.27(1H,s),7.41(1H,s),9.70-10.50(3H,broad).
Reference Example 41
Figure JPOXMLDOC01-appb-I000055
A mixture of 0.50 g of ethyl = (4-amino-5-methyl-2- (propan-2-yl) phenyl) (cyano) acetate, 0.74 g of sodium chloride, 1 mL of water and 16 mL of dimethyl sulfoxide at 150 ° C. Stir for 40 minutes. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 4: 1], 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration to give a pale yellow solid (4- 206 mg of amino-5-methyl-2- (propan-2-yl) phenyl) acetonitrile hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.18 (6H, d, J = 6.8 Hz), 2.31 (3H, s), 3.05-3.17 (1H, m), 4.04 (2H, s), 7.27 ( 1H, s), 7.41 (1H, s), 9.70-10.50 (3H, broad).
参考例42
Figure JPOXMLDOC01-appb-I000056
(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)アセトニトリルの塩酸塩150mg、ジチオリン酸 O,O’-ジエチル158μLおよび5mol/L塩化水素-酢酸エチル溶液3mLの混合物を、室温で5時間撹拌後、14時間静置した。反応混合物にジチオリン酸 O,O’-ジエチル84μLを加え、3時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル84μLを加え、2時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル316μLを加え、14時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル316μLを加え、10時間撹拌した。反応混合物に、10%炭酸カリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡褐色固体の2-(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)エタンチオアミドの塩酸塩166mgを得た。
1H-NMR(DMSO-d6)δ値:1.14(6H,d,J=6.6Hz),2.27(3H,s),3.17-3.25(1H,m),3.85(2H,s),7.13(1H,s),7.27(1H,s),9.26-9.38(1H,broad),9.50-9.59(1H,broad),9.60-10.20(3H,broad).
Reference Example 42
Figure JPOXMLDOC01-appb-I000056
A mixture of 150 mg of hydrochloride of (4-amino-5-methyl-2- (propan-2-yl) phenyl) acetonitrile, 158 μL of dithiophosphoric acid O, O′-diethyl and 3 mL of 5 mol / L hydrogen chloride-ethyl acetate solution, The mixture was stirred at room temperature for 5 hours and then allowed to stand for 14 hours. To the reaction mixture, 84 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 3 hours. To the reaction mixture, 84 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 2 hours. To the reaction mixture, 316 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 14 hours. To the reaction mixture, 316 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 10 hours. A 10% aqueous potassium carbonate solution and ethyl acetate were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration to give 2- (4-amino-5-methyl-2- (propan-2-yl) as a light brown solid. 166 mg of phenyl) ethanethioamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.14 (6H, d, J = 6.6 Hz), 2.27 (3H, s), 3.17-3.25 (1H, m), 3.85 (2H, s), 7.13 ( 1H, s), 7.27 (1H, s), 9.26-9.38 (1H, broad), 9.50-9.59 (1H, broad), 9.60-10.20 (3H, broad).
参考例43
Figure JPOXMLDOC01-appb-I000057
2-(4-アミノ-5-メチル-2-(プロパン-2-イル)フェニル)エタンチオアミドの塩酸塩100mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン88mgおよびエタノール3mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=10:1-5:1]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体の2-メチル-5-(プロパン-2-イル)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリンの塩酸塩137mgを得た。
1H-NMR(DMSO-d6)δ値:1.12(6H,d,J=6.8Hz),1.71-1.79(4H,m),2.31(3H,s),2.66-2.80(4H,m),3.19-3.31(1H,m),4.41(2H,s),7.09(1H,d,J=7.8Hz),7.30(1H,s),7.41(1H,s),7.59-7.64(2H,m),7.83(1H,s),9.80-10.30(3H,broad).
Reference Example 43
Figure JPOXMLDOC01-appb-I000057
2- (4-amino-5-methyl-2- (propan-2-yl) phenyl) ethanethioamide hydrochloride 100 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl ) A mixture of 88 mg ethanone and 3 mL ethanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 10: 1-5: 1], a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration. 2-methyl-5- (propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) as a white solid 137 mg of methyl) aniline hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.12 (6H, d, J = 6.8 Hz), 1.71-1.79 (4H, m), 2.31 (3H, s), 2.66-2.80 (4H, m), 3.19-3.31 (1H, m), 4.41 (2H, s), 7.09 (1H, d, J = 7.8Hz), 7.30 (1H, s), 7.41 (1H, s), 7.59-7.64 (2H, m) , 7.83 (1H, s), 9.80-10.30 (3H, broad).
参考例44
Figure JPOXMLDOC01-appb-I000058
5-(tert-ブチル)-2-メチルアニリンの塩酸塩1.50gのクロロホルム20mL溶液に、氷冷下で、トリメチルフェニルアンモニウム=ブロミド2.82gを加え、室温で8時間30分間撹拌した。反応混合物に、チオ硫酸ナトリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=5:1]で精製し、赤色油状物の4-ブロモ-5-(tert-ブチル)-2-メチルアニリン1.63gを得た。
1H-NMR(CDCl3)δ値:1.46(9H,s),2.09(3H,s),3.49-3.62(2H,broad),6.75(1H,s),7.25(1H,s).
Reference Example 44
Figure JPOXMLDOC01-appb-I000058
To a solution of 5- (tert-butyl) -2-methylaniline hydrochloride (1.50 g) in chloroform (20 mL) was added trimethylphenylammonium bromide (2.82 g) under ice cooling, and the mixture was stirred at room temperature for 8 hours and 30 minutes. A sodium thiosulfate aqueous solution was added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 5: 1] to obtain 1.63 g of red oil 4-bromo-5- (tert-butyl) -2-methylaniline.
1 H-NMR (CDCl 3 ) δ value: 1.46 (9H, s), 2.09 (3H, s), 3.49-3.62 (2H, broad), 6.75 (1H, s), 7.25 (1H, s).
参考例45
Figure JPOXMLDOC01-appb-I000059
4-ブロモ-5-(tert-ブチル)-2-メチルアニリン0.50g、シアノ酢酸エチル0.66mL、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)53mg、リン酸三カリウム1.31gおよびトルエン10mLの混合物を、窒素雰囲気下、3時間30分間加熱還流した。反応混合物にシアノ酢酸エチル0.66mL、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)53mg、トルエン10mLおよびジオキサン3mLを加え、窒素雰囲気下、6時間加熱還流した。反応混合物にビス(トリ-tert-ブチルホスフィン)パラジウム(0)53mgを加え、窒素雰囲気下、2時間加熱還流した。反応混合物を室温まで冷却し、水および酢酸エチルを加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=5:1-3:1]で精製し、淡黄色油状物のエチル=(4-アミノ-2-(tert-ブチル)-5-メチルフェニル)(シアノ)アセタート300mgを得た。
1H-NMR(CDCl3)δ値:1.28(3H,t,J=7.1Hz),1.41(9H,s),2.13(3H,s),3.58-3.72(2H,broad),4.19-4.35(2H,m),5.27(1H,s),6.70(1H,s),7.15(1H,s).
Reference Example 45
Figure JPOXMLDOC01-appb-I000059
4-bromo-5- (tert-butyl) -2-methylaniline 0.50 g, ethyl cyanoacetate 0.66 mL, bis (tri-tert-butylphosphine) palladium (0) 53 mg, tripotassium phosphate 1.31 g and toluene 10 mL The mixture was heated to reflux under a nitrogen atmosphere for 3 hours 30 minutes. To the reaction mixture, 0.66 mL of ethyl cyanoacetate, 53 mg of bis (tri-tert-butylphosphine) palladium (0), 10 mL of toluene and 3 mL of dioxane were added, and the mixture was heated to reflux for 6 hours under a nitrogen atmosphere. To the reaction mixture was added 53 mg of bis (tri-tert-butylphosphine) palladium (0), and the mixture was heated to reflux for 2 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 5: 1-3: 1], and ethyl of pale yellow oil = (4-amino-2- (tert-butyl) 300 mg of -5-methylphenyl) (cyano) acetate was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.28 (3H, t, J = 7.1 Hz), 1.41 (9H, s), 2.13 (3H, s), 3.58-3.72 (2H, broad), 4.19-4.35 ( 2H, m), 5.27 (1H, s), 6.70 (1H, s), 7.15 (1H, s).
参考例46
Figure JPOXMLDOC01-appb-I000060
参考例41と同様にして、エチル=(4-アミノ-2-(tert-ブチル)-5-メチルフェニル)(シアノ)アセタート300mgより、(4-アミノ-2-(tert-ブチル)-5-メチルフェニル)アセトニトリルの塩酸塩130mgを得た。
1H-NMR(CDCl3)δ値:1.42(9H,s),2.57(3H,s),3.96(2H,s),7.38(1H,s),7.71(1H,s),10.30-10.70(3H,broad).
Reference Example 46
Figure JPOXMLDOC01-appb-I000060
In the same manner as in Reference Example 41, from 300 mg of ethyl = (4-amino-2- (tert-butyl) -5-methylphenyl) (cyano) acetate, (4-amino-2- (tert-butyl) -5- 130 mg of methylphenyl) acetonitrile hydrochloride was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.42 (9H, s), 2.57 (3H, s), 3.96 (2H, s), 7.38 (1H, s), 7.71 (1H, s), 10.30-10.70 ( 3H, broad).
参考例47
Figure JPOXMLDOC01-appb-I000061
参考例42と同様にして、(4-アミノ-2-(tert-ブチル)-5-メチルフェニル)アセトニトリルの塩酸塩100mgより、淡黄色固体を得た。得られた淡黄色固体および2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン100mgより、参考例43と同様にして、5-(tert-ブチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリンの塩酸塩120mgを得た。
1H-NMR(DMSO-d6)δ値:1.37(9H,s),1.71-1.79(4H,m),2.29(3H,s),2.66-2.81(4H,m),4.60(2H,s),7.10(1H,d,J=7.6Hz),7.28(1H,s),7.54(1H,s),7.60-7.66(2H,m),7.83(1H,s),9.90-10.30(3H,broad).
Reference Example 47
Figure JPOXMLDOC01-appb-I000061
In the same manner as in Reference Example 42, a pale yellow solid was obtained from 100 mg of hydrochloride of (4-amino-2- (tert-butyl) -5-methylphenyl) acetonitrile. From the obtained pale yellow solid and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 100 mg, in the same manner as in Reference Example 43, 5- (tert-butyl) -2 120 mg of 4-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.37 (9H, s), 1.71-1.79 (4H, m), 2.29 (3H, s), 2.66-2.81 (4H, m), 4.60 (2H, s ), 7.10 (1H, d, J = 7.6Hz), 7.28 (1H, s), 7.54 (1H, s), 7.60-7.66 (2H, m), 7.83 (1H, s), 9.90-10.30 (3H, broad).
参考例48
Figure JPOXMLDOC01-appb-I000062
4-メチル-3-ニトロベンズアルデヒド1.4gのクロロホルム28mL溶液に、ビス(2-メトキシエチル)アミノサルファー=トリフルオリド3.1mLを加え、室温で4時間撹拌した。反応混合物に、飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去し、褐色油状物の4-(ジフルオロメチル)-1-メチル-2-ニトロベンゼン1.6gを得た。
1H-NMR(CDCl3)δ値:2.66(3H,s),6.69(1H,t,J=56.3Hz),7.47(1H,d,J=7.6Hz),7.66(1H,d,J=7.6Hz),8.13(1H,s).
Reference Example 48
Figure JPOXMLDOC01-appb-I000062
Bis (2-methoxyethyl) aminosulfur trifluoride (3.1 mL) was added to a chloroform (28 mL) solution of 4-methyl-3-nitrobenzaldehyde (1.4 g), and the mixture was stirred at room temperature for 4 hours. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to give a brown oily 4- (difluoromethyl) -1-methyl-2 -1.6 g of nitrobenzene were obtained.
1 H-NMR (CDCl 3 ) δ value: 2.66 (3H, s), 6.69 (1H, t, J = 56.3 Hz), 7.47 (1H, d, J = 7.6 Hz), 7.66 (1H, d, J = 7.6Hz), 8.13 (1H, s).
参考例49
Figure JPOXMLDOC01-appb-I000063
反応A:水酸化ナトリウム1.6gのジメチルスルホキシド4.4mL懸濁液に、(フェニルチオ)アセトニトリル0.77mLおよび4-(ジフルオロメチル)-1-メチル-2-ニトロベンゼン0.73gのジメチルスルホキシド2.9mL溶液を加え、室温で15分間撹拌した後、トルエンを加え、反応混合物Aを得た。
反応B:水酸化ナトリウム0.11gのジメチルスルホキシド0.30mL懸濁液に、(フェニルチオ)アセトニトリル53μLおよび4-(ジフルオロメチル)-1-メチル-2-ニトロベンゼン50mgのジメチルスルホキシド0.20mL溶液を加え、室温で20分間撹拌した後、トルエンおよび水を加え、反応混合物Bを得た。
氷水中に、反応混合物Aおよび反応混合物Bを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=19:1-3:1]で精製し、黄色油状物の(2-(ジフルオロメチル)-5-メチル-4-ニトロフェニル)アセトニトリル0.28gを得た。
1H-NMR(CDCl3)δ値:2.71(3H,s),4.02(2H,s),6.73(1H,t,J=54.4Hz),7.65(1H,s),8.14(1H,s).
Reference Example 49
Figure JPOXMLDOC01-appb-I000063
Reaction A: To a suspension of 1.6 g of sodium hydroxide in 4.4 mL of dimethyl sulfoxide, 0.77 mL of (phenylthio) acetonitrile and 2.9 mL of dimethyl sulfoxide in 0.73 g of 4- (difluoromethyl) -1-methyl-2-nitrobenzene were added, After stirring at room temperature for 15 minutes, toluene was added to obtain reaction mixture A.
Reaction B: To a suspension of 0.11 g of sodium hydroxide in 0.30 mL of dimethylsulfoxide was added 53 μL of (phenylthio) acetonitrile and 0.20 mL of dimethylsulfoxide in 50 mg of 4- (difluoromethyl) -1-methyl-2-nitrobenzene at room temperature. After stirring for 20 minutes, toluene and water were added to obtain reaction mixture B.
Reaction mixture A and reaction mixture B were added to ice water. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 19: 1-3: 1] to give (2- (difluoromethyl) -5-methyl-4-nitro as a yellow oil) 0.28 g of phenyl) acetonitrile was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.71 (3H, s), 4.02 (2H, s), 6.73 (1H, t, J = 54.4 Hz), 7.65 (1H, s), 8.14 (1H, s) .
参考例50
Figure JPOXMLDOC01-appb-I000064
参考例24と同様にして、(2-(ジフルオロメチル)-5-メチル-4-ニトロフェニル)アセトニトリル0.28gより、2-(2-(ジフルオロメチル)-5-メチル-4-ニトロフェニル)エタンチオアミド0.23gを得た。
1H-NMR(CDCl3)δ値:2.67(3H,s),4.20(2H,s),6.70-7.50(2H,m),6.86(1H,t,J=54.9Hz),7.54(1H,s),8.20(1H,s).
Reference Example 50
Figure JPOXMLDOC01-appb-I000064
In the same manner as in Reference Example 24, from 0.28 g of (2- (difluoromethyl) -5-methyl-4-nitrophenyl) acetonitrile, 2- (2- (difluoromethyl) -5-methyl-4-nitrophenyl) ethane 0.23 g of thioamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.67 (3H, s), 4.20 (2H, s), 6.70-7.50 (2H, m), 6.86 (1H, t, J = 54.9 Hz), 7.54 (1H, s), 8.20 (1H, s).
参考例51
Figure JPOXMLDOC01-appb-I000065
2-(2-(ジフルオロメチル)-5-メチル-4-ニトロフェニル)エタンチオアミド0.10g、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.15gおよびエタノール2.0mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、鉄粉64mg、塩化アンモニウム12mgおよび水0.50mLを加え、3時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチル、メタノールおよび飽和炭酸水素ナトリウム水溶液を加え、不溶物を濾去した。濾液の有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、活性炭を加えた。不溶物を濾去し、減圧下で溶媒を留去し、得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-3:1]で精製し、褐色油状物の5-(ジフルオロメチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン58mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.17(3H,s),2.74-2.87(4H,m),3.62-3.82(2H,broad),4.36(2H,s),6.88(1H,t,J=55.6Hz),6.90(1H,s),7.06(1H,s),7.10(1H,d,J=7.8Hz),7.25(1H,s),7.54-7.59(1H,m),7.60(1H,s).
Reference Example 51
Figure JPOXMLDOC01-appb-I000065
0.10 g 2- (2- (difluoromethyl) -5-methyl-4-nitrophenyl) ethanethioamide, 0.15 g 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and A mixture of 2.0 mL of ethanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, iron powder (64 mg), ammonium chloride (12 mg) and water (0.50 mL) were added, and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled to room temperature, ethyl acetate, methanol and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and activated carbon was added. The insoluble material was removed by filtration, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-3: 1] to give a brown oil Of 5- (difluoromethyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline Obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.17 (3H, s), 2.74-2.87 (4H, m), 3.62-3.82 (2H, broad), 4.36 (2H, s ), 6.88 (1H, t, J = 55.6Hz), 6.90 (1H, s), 7.06 (1H, s), 7.10 (1H, d, J = 7.8Hz), 7.25 (1H, s), 7.54-7.59 (1H, m), 7.60 (1H, s).
参考例52
Figure JPOXMLDOC01-appb-I000066
参考例19と同様にして、1-フルオロ-4-メチル-2-ニトロベンゼン2.32gより、(5-フルオロ-2-メチル-4-ニトロフェニル)アセトニトリル0.62gを得た。
1H-NMR(CDCl3)δ値:2.40(3H,s),3.74(2H,s),7.40(1H,d,J=11.0Hz),7.94(1H,d,J=7.3Hz).
Reference Example 52
Figure JPOXMLDOC01-appb-I000066
In the same manner as in Reference Example 19, 0.62-g of (5-fluoro-2-methyl-4-nitrophenyl) acetonitrile was obtained from 2.32 g of 1-fluoro-4-methyl-2-nitrobenzene.
1 H-NMR (CDCl 3 ) δ value: 2.40 (3H, s), 3.74 (2H, s), 7.40 (1H, d, J = 11.0 Hz), 7.94 (1 H, d, J = 7.3 Hz).
参考例53
Figure JPOXMLDOC01-appb-I000067
参考例15と同様にして、(5-フルオロ-2-メチル-4-ニトロフェニル)アセトニトリル600mgより、2-(5-フルオロ-2-メチル-4-ニトロフェニル)エタンチオアミド600mgを得た。
1H-NMR(CDCl3)δ値:2.38(3H,s),4.08(2H,s),6.42-6.74(1H,broad),7.19(1H,d,J=11.2Hz),7.28-7.64(1H,broad),7.93(1H,d,J=7.3Hz).
Reference Example 53
Figure JPOXMLDOC01-appb-I000067
In the same manner as in Reference Example 15, 600 mg of 2- (5-fluoro-2-methyl-4-nitrophenyl) ethanethioamide was obtained from 600 mg of (5-fluoro-2-methyl-4-nitrophenyl) acetonitrile.
1 H-NMR (CDCl 3 ) δ value: 2.38 (3H, s), 4.08 (2H, s), 6.42-6.74 (1H, broad), 7.19 (1H, d, J = 11.2 Hz), 7.28-7.64 ( 1H, broad), 7.93 (1H, d, J = 7.3Hz).
参考例54
Figure JPOXMLDOC01-appb-I000068
参考例9と同様にして、2-(5-フルオロ-2-メチル-4-ニトロフェニル)エタンチオアミド228mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン253mgより、2-(5-フルオロ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール300mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.87(4H,m),2.43(3H,s),2.74-2.90(4H,m),4.60-4.80(2H,broad),7.16(1H,d,J=7.9Hz),7.29(1H,s),7.39(1H,s),7.63(1H,d,J=7.9Hz),7.70(1H,s),7.94(1H,d,J=7.3Hz).
Reference Example 54
Figure JPOXMLDOC01-appb-I000068
In the same manner as in Reference Example 9, 228 mg of 2- (5-fluoro-2-methyl-4-nitrophenyl) ethanethioamide and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) From 253 mg of ethanone, 300 mg of 2- (5-fluoro-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.87 (4H, m), 2.43 (3H, s), 2.74-2.90 (4H, m), 4.60-4.80 (2H, broad), 7.16 (1H, d , J = 7.9Hz), 7.29 (1H, s), 7.39 (1H, s), 7.63 (1H, d, J = 7.9Hz), 7.70 (1H, s), 7.94 (1H, d, J = 7.3Hz ).
参考例55
Figure JPOXMLDOC01-appb-I000069
参考例10と同様にして、2-(5-フルオロ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール90mgより、2-フルオロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン85mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.86(4H,m),2.20(3H,s),2.72-2.88(4H,m),3.63-3.75(2H,broad),4.23(2H,s),6.63(1H,d,J=9.0Hz),6.91(1H,d,J=11.5Hz),7.10(1H,d,J=8.1Hz),7.24(1H,s),7.56(1H,dd,J=8.1,2.0Hz),7.61(1H,s).
Reference Example 55
Figure JPOXMLDOC01-appb-I000069
In the same manner as in Reference Example 10, 2- (5-fluoro-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 90 mg Thus, 85 mg of 2-fluoro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.76-1.86 (4H, m), 2.20 (3H, s), 2.72-2.88 (4H, m), 3.63-3.75 (2H, broad), 4.23 (2H, s ), 6.63 (1H, d, J = 9.0Hz), 6.91 (1H, d, J = 11.5Hz), 7.10 (1H, d, J = 8.1Hz), 7.24 (1H, s), 7.56 (1H, dd , J = 8.1, 2.0Hz), 7.61 (1H, s).
参考例56
Figure JPOXMLDOC01-appb-I000070
水酸化ナトリウム6.48g、1-ブロモ-4-メチル-2-ニトロベンゼン10g、2-((シアノメチル)スルファニル)安息香酸11.6gおよびジメチルスルホキシド50mLの混合物を、室温で88時間撹拌した。反応混合物に、氷冷下で、カリウムtert-ブトキシド13gを加え、氷冷下で2時間撹拌した。反応混合物に水および酢酸エチルを加えた。有機層を分取し、10%炭酸カリウム水溶液、1mol/L塩酸および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=4:1-2:1]で精製し、褐色固体の(5-ブロモ-2-メチル-4-ニトロフェニル)アセトニトリル1.12gを得た。
1H-NMR(CDCl3)δ値:2.39(3H,s),3.72(2H,s),7.74(1H,s),7.77(1H,s).
Reference Example 56
Figure JPOXMLDOC01-appb-I000070
A mixture of 6.48 g of sodium hydroxide, 10 g of 1-bromo-4-methyl-2-nitrobenzene, 11.6 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 50 mL of dimethyl sulfoxide was stirred at room temperature for 88 hours. To the reaction mixture, 13 g of potassium tert-butoxide was added under ice cooling, and the mixture was stirred for 2 hours under ice cooling. Water and ethyl acetate were added to the reaction mixture. The organic layer was separated, washed successively with 10% aqueous potassium carbonate solution, 1 mol / L hydrochloric acid and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate gradient elution = 4: 1-2: 1] to give (5-bromo-2-methyl-4-nitrophenyl) acetonitrile 1.12 as a brown solid. g was obtained.
1 H-NMR (CDCl 3 ) δ value: 2.39 (3H, s), 3.72 (2H, s), 7.74 (1H, s), 7.77 (1H, s).
参考例57
Figure JPOXMLDOC01-appb-I000071
参考例15と同様にして、(5-ブロモ-2-メチル-4-ニトロフェニル)アセトニトリル500mgより、2-(5-ブロモ-2-メチル-4-ニトロフェニル)エタンチオアミド0.42gを得た。
1H-NMR(DMSO-d6)δ値:2.31(3H,s),3.94(2H,s),7.73(1H,s),7.87(1H,s),9.35-9.49(1H,broad),9.61-9.73(1H,broad).
Reference Example 57
Figure JPOXMLDOC01-appb-I000071
In the same manner as in Reference Example 15, 0.42 g of 2- (5-bromo-2-methyl-4-nitrophenyl) ethanethioamide was obtained from 500 mg of (5-bromo-2-methyl-4-nitrophenyl) acetonitrile.
1 H-NMR (DMSO-d 6 ) δ value: 2.31 (3H, s), 3.94 (2H, s), 7.73 (1H, s), 7.87 (1H, s), 9.35-9.49 (1H, broad), 9.61-9.73 (1H, broad).
参考例58
Figure JPOXMLDOC01-appb-I000072
2-(5-ブロモ-2-メチル-4-ニトロフェニル)エタンチオアミド300mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン263mgおよびメタノール5mLの混合物を、1時間30分間加熱還流した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=5:1]で精製した。得られた油状物にジイソプロピルエーテルおよびヘキサンを加え、固形物を濾取し、淡黄色固体の2-(5-ブロモ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール390mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.87(4H,m),2.40(3H,s),2.75-2.88(4H,m),4.39(2H,s),7.11(1H,d,J=7.8Hz),7.31(1H,s),7.56(1H,d,J=7.8H),7.59(1H,s),7.64(1H,s),7.74(1H,s).
Reference Example 58
Figure JPOXMLDOC01-appb-I000072
A mixture of 300 mg of 2- (5-bromo-2-methyl-4-nitrophenyl) ethanethioamide, 263 mg of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 5 mL of methanol The mixture was heated to reflux for 1 hour and 30 minutes. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 5: 1]. Diisopropyl ether and hexane were added to the obtained oil, and the solid was collected by filtration to give 2- (5-bromo-2-methyl-4-nitrobenzyl) -4- (5,6,7, 390 mg of 8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.87 (4H, m), 2.40 (3H, s), 2.75-2.88 (4H, m), 4.39 (2H, s), 7.11 (1H, d, J = 7.8Hz), 7.31 (1H, s), 7.56 (1H, d, J = 7.8H), 7.59 (1H, s), 7.64 (1H, s), 7.74 (1H, s).
参考例59
Figure JPOXMLDOC01-appb-I000073
2-(5-ブロモ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.10g、シアン化亜鉛79mg、テトラキス(トリフェニルホスフィン)パラジウム(0)27mgおよびN,N-ジメチルホルムアミド2.0mLの混合物を、窒素雰囲気下、マイクロウェーブ反応装置を使用して140℃で10分間処理した。反応混合物に、テトラキス(トリフェニルホスフィン)パラジウム(0)13mgを加え、140℃で5分間処理した。反応混合物に、トルエンおよび水を加え、不溶物を濾去した。濾液の有機層を分取し、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-67:33]で精製し、黄色油状物の4-メチル-2-ニトロ-5-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル73mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.85(4H,m),2.58(3H,s),2.75-2.86(4H,m),4.47(2H,s),7.11(1H,d,J=7.6Hz),7.34(1H,s),7.51-7.57(2H,m),7.79(1H,s),8.17(1H,s).
Reference Example 59
Figure JPOXMLDOC01-appb-I000073
2- (5-Bromo-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 0.10 g, zinc cyanide 79 mg, tetrakis A mixture of 27 mg of (triphenylphosphine) palladium (0) and 2.0 mL of N, N-dimethylformamide was treated for 10 minutes at 140 ° C. using a microwave reactor under a nitrogen atmosphere. To the reaction mixture, 13 mg of tetrakis (triphenylphosphine) palladium (0) was added and treated at 140 ° C. for 5 minutes. Toluene and water were added to the reaction mixture, and insoluble materials were removed by filtration. The organic layer of the filtrate was separated, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-67: 33], and 4-methyl-2-nitro-5-((4- ( There was obtained 73 mg of 5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.85 (4H, m), 2.58 (3H, s), 2.75-2.86 (4H, m), 4.47 (2H, s), 7.11 (1H, d, J = 7.6Hz), 7.34 (1H, s), 7.51-7.57 (2H, m), 7.79 (1H, s), 8.17 (1H, s).
参考例60
Figure JPOXMLDOC01-appb-I000074
参考例10と同様にして、4-メチル-2-ニトロ-5-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル73mgより、2-アミノ-4-メチル-5-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル52mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.86(4H,m),2.33(3H,s),2.74-2.90(4H,m),4.26(2H,s),5.50-5.80(2H,broad),6.55(1H,s),7.10(1H,d,J=8.1Hz),7.24-7.30(2H,m),7.54-7.64(2H,m).
Reference Example 60
Figure JPOXMLDOC01-appb-I000074
In the same manner as in Reference Example 10, 4-methyl-2-nitro-5-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl ) From 73 mg of benzonitrile, 2-amino-4-methyl-5-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzo 52 mg of nitrile was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.86 (4H, m), 2.33 (3H, s), 2.74-2.90 (4H, m), 4.26 (2H, s), 5.50-5.80 (2H, broad ), 6.55 (1H, s), 7.10 (1H, d, J = 8.1Hz), 7.24-7.30 (2H, m), 7.54-7.64 (2H, m).
参考例61
Figure JPOXMLDOC01-appb-I000075
参考例31と同様にして、1-クロロ-4-メチル-2-ニトロベンゼン0.86gより、(5-クロロ-2-メチル-4-ニトロフェニル)アセトニトリル140mgを得た。
1H-NMR(CDCl3)δ値:2.41(3H,s),3.73(2H,s),7.60(1H,s),7.77(1H,s).
Reference Example 61
Figure JPOXMLDOC01-appb-I000075
In the same manner as in Reference Example 31, 140 mg of (5-chloro-2-methyl-4-nitrophenyl) acetonitrile was obtained from 0.86 g of 1-chloro-4-methyl-2-nitrobenzene.
1 H-NMR (CDCl 3 ) δ value: 2.41 (3H, s), 3.73 (2H, s), 7.60 (1H, s), 7.77 (1H, s).
参考例62
Figure JPOXMLDOC01-appb-I000076
参考例15と同様にして、(5-クロロ-2-メチル-4-ニトロフェニル)アセトニトリル140mgより、2-(5-クロロ-2-メチル-4-ニトロフェニル)エタンチオアミド150mgを得た。
1H-NMR(CDCl3)δ値:2.38(3H,s),4.08(2H,s),6.40-6.80(1H,broad),7.41(1H,s),7.42-7.58(1H,broad),7.77(1H,s).
Reference Example 62
Figure JPOXMLDOC01-appb-I000076
In the same manner as in Reference Example 15, 150 mg of 2- (5-chloro-2-methyl-4-nitrophenyl) ethanethioamide was obtained from 140 mg of (5-chloro-2-methyl-4-nitrophenyl) acetonitrile.
1 H-NMR (CDCl 3 ) δ value: 2.38 (3H, s), 4.08 (2H, s), 6.40-6.80 (1H, broad), 7.41 (1H, s), 7.42-7.58 (1H, broad), 7.77 (1H, s).
参考例63
Figure JPOXMLDOC01-appb-I000077
参考例21と同様にして、2-(5-クロロ-2-メチル-4-ニトロフェニル)エタンチオアミド150mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン156mgより、2-(5-クロロ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール180mgを得た。
1H-NMR(DMSO-d6)δ値:1.66-1.80(4H,m),2.39(3H,s),2.64-2.82(4H,m),4.52(2H,s),7.09(1H,d,J=8.3Hz),7.56-7.64(2H,m),7.75(1H,s),7.90(1H,s),8.00(1H,s).
Reference Example 63
Figure JPOXMLDOC01-appb-I000077
In the same manner as in Reference Example 21, 150 mg of 2- (5-chloro-2-methyl-4-nitrophenyl) ethanethioamide and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) From 156 mg of ethanone, 180 mg of 2- (5-chloro-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.66-1.80 (4H, m), 2.39 (3H, s), 2.64-2.82 (4H, m), 4.52 (2H, s), 7.09 (1H, d , J = 8.3Hz), 7.56-7.64 (2H, m), 7.75 (1H, s), 7.90 (1H, s), 8.00 (1H, s).
参考例64
Figure JPOXMLDOC01-appb-I000078
参考例10と同様にして、2-(5-クロロ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール90mgより、2-クロロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン37mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.86(4H,m),2.21(3H,s),2.74-2.88(4H,m),3.88-4.06(2H,broad),4.23(2H,s),6.63(1H,s),7.10(1H,d,J=7.8Hz),7.16(1H,s),7.24(1H,s),7.56(1H,dd,J=7.8,1.7Hz),7.61(1H,s).
Reference Example 64
Figure JPOXMLDOC01-appb-I000078
In the same manner as in Reference Example 10, 2- (5-chloro-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 90 mg Thus, 37 mg of 2-chloro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.76-1.86 (4H, m), 2.21 (3H, s), 2.74-2.88 (4H, m), 3.88-4.06 (2H, broad), 4.23 (2H, s ), 6.63 (1H, s), 7.10 (1H, d, J = 7.8Hz), 7.16 (1H, s), 7.24 (1H, s), 7.56 (1H, dd, J = 7.8, 1.7Hz), 7.61 (1H, s).
参考例65
Figure JPOXMLDOC01-appb-I000079
参考例31と同様にして、1-メトキシ-4-メチル-2-ニトロベンゼン0.84gより、(5-メトキシ-2-メチル-4-ニトロフェニル)アセトニトリル0.62gを得た。
1H-NMR(CDCl3)δ値:2.32(3H,s),3.73(2H,s),3.99(3H,s),7.15(1H,s),7.73(1H,s).
Reference Example 65
Figure JPOXMLDOC01-appb-I000079
In the same manner as in Reference Example 31, 0.62 g of (5-methoxy-2-methyl-4-nitrophenyl) acetonitrile was obtained from 0.84 g of 1-methoxy-4-methyl-2-nitrobenzene.
1 H-NMR (CDCl 3 ) δ value: 2.32 (3H, s), 3.73 (2H, s), 3.99 (3H, s), 7.15 (1H, s), 7.73 (1H, s).
参考例66
Figure JPOXMLDOC01-appb-I000080
参考例15と同様にして、(5-メトキシ-2-メチル-4-ニトロフェニル)アセトニトリル0.62gより、2-(5-メトキシ-2-メチル-4-ニトロフェニル)エタンチオアミド0.53gを得た。
1H-NMR(CDCl3)δ値:2.30(3H,s),3.96(3H,s),4.12(2H,s),6.48-6.70(1H,broad),6.72(1H,s),7.42-7.63(1H,broad),7.73(1H,s).
Reference Example 66
Figure JPOXMLDOC01-appb-I000080
In the same manner as in Reference Example 15, 0.53 g of 2- (5-methoxy-2-methyl-4-nitrophenyl) ethanethioamide was obtained from 0.62 g of (5-methoxy-2-methyl-4-nitrophenyl) acetonitrile. .
1 H-NMR (CDCl 3 ) δ value: 2.30 (3H, s), 3.96 (3H, s), 4.12 (2H, s), 6.48-6.70 (1H, broad), 6.72 (1H, s), 7.42 7.63 (1H, broad), 7.73 (1H, s).
参考例67
Figure JPOXMLDOC01-appb-I000081
参考例21と同様にして、2-(5-メトキシ-2-メチル-4-ニトロフェニル)エタンチオアミド240mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン253mgより、2-(5-メトキシ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール310mgを得た。
1H-NMR(DMSO-d6)δ値:1.70-1.80(4H,m),2.29(3H,s),2.64-2.82(4H,m),3.90(3H,s),4.48(2H,s),7.09(1H,d,J=7.6Hz),7.44(1H,s),7.58-7.66(2H,m),7.78(1H,s),7.88(1H,s).
Reference Example 67
Figure JPOXMLDOC01-appb-I000081
In the same manner as in Reference Example 21, 240 mg of 2- (5-methoxy-2-methyl-4-nitrophenyl) ethanethioamide and 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) From 253 mg of ethanone, 310 mg of 2- (5-methoxy-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.70-1.80 (4H, m), 2.29 (3H, s), 2.64-2.82 (4H, m), 3.90 (3H, s), 4.48 (2H, s ), 7.09 (1H, d, J = 7.6Hz), 7.44 (1H, s), 7.58-7.66 (2H, m), 7.78 (1H, s), 7.88 (1H, s).
参考例68
Figure JPOXMLDOC01-appb-I000082
参考例10と同様にして、2-(5-メトキシ-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール90mgより、2-メトキシ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン77mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.19(3H,s),2.73-2.88(4H,m),3.68-3.80(2H,broad),3.82(3H,s),4.26(2H,s),6.58(1H,s),6.72(1H,s),7.10(1H,d,J=7.8Hz),7.23(1H,s),7.56(1H,dd,J=7.8,1.7Hz),7.62(1H,s).
Reference Example 68
Figure JPOXMLDOC01-appb-I000082
In the same manner as in Reference Example 10, 90 mg of 2- (5-methoxy-2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole As a result, 77 mg of 2-methoxy-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained. .
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.19 (3H, s), 2.73-2.88 (4H, m), 3.68-3.80 (2H, broad), 3.82 (3H, s ), 4.26 (2H, s), 6.58 (1H, s), 6.72 (1H, s), 7.10 (1H, d, J = 7.8Hz), 7.23 (1H, s), 7.56 (1H, dd, J = 7.8, 1.7Hz), 7.62 (1H, s).
参考例69
Figure JPOXMLDOC01-appb-I000083
参考例31と同様にして、4-メチル-2-ニトロフェニル=プロパン-2-イル=エーテル2.66gより、(2-メチル-4-ニトロ-5-(プロパン-2-イルオキシ)フェニル)アセトニトリル1.80gを得た。
1H-NMR(CDCl3)δ値:1.40(6H,d,J=6.1Hz),2.30(3H,s),3.70(2H,s),4.63-4.76(1H,m),7.14(1H,s),7.65(1H,s).
Reference Example 69
Figure JPOXMLDOC01-appb-I000083
In the same manner as in Reference Example 31, from 2.66 g of 4-methyl-2-nitrophenyl = propan-2-yl ether, (2-methyl-4-nitro-5- (propan-2-yloxy) phenyl) acetonitrile 1.80 g was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.40 (6H, d, J = 6.1 Hz), 2.30 (3H, s), 3.70 (2H, s), 4.63-4.76 (1H, m), 7.14 (1H, s), 7.65 (1H, s).
参考例70
Figure JPOXMLDOC01-appb-I000084
(2-メチル-4-ニトロ-5-(プロパン-2-イルオキシ)フェニル)アセトニトリル0.60g、ジチオリン酸 O,O’-ジエチル0.61mLおよび5mol/L塩化水素-酢酸エチル溶液6.0mLの混合物を、室温で1時間15分間撹拌し、12時間静置した。減圧下で反応混合物の溶媒を留去し、黄色固体を得た。得られた黄色固体、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.78gおよびエタノール6.0mLの混合物を、2時間30分間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物にジイソプロピルエーテルを加え、固形物を濾取し、淡黄色固体の2-(2-メチル-4-ニトロ-5-(プロパン-2-イルオキシ)ベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール1.14gを得た。
1H-NMR(DMSO-d6)δ値:1.29(6H,d,J=6.1Hz),1.69-1.82(4H,m),2.28(3H,s),2.68-2.82(4H,m),4.45(2H,s),4.58-4.90(1H,m),7.06-7.14(1H,m),7.45(1H,s),7.59-7.68(2H,m),7.71(1H,s),7.87(1H,s).
Reference Example 70
Figure JPOXMLDOC01-appb-I000084
A mixture of 0.60 g of (2-methyl-4-nitro-5- (propan-2-yloxy) phenyl) acetonitrile, 0.61 mL of dithiophosphoric acid O, O′-diethyl and 6.0 mL of 5 mol / L hydrogen chloride-ethyl acetate solution The mixture was stirred at room temperature for 1 hour and 15 minutes and allowed to stand for 12 hours. The solvent of the reaction mixture was distilled off under reduced pressure to obtain a yellow solid. A mixture of the obtained yellow solid, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 0.78 g and ethanol 6.0 mL was heated to reflux for 2 hours 30 minutes. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. Diisopropyl ether was added to the obtained residue, and the solid was collected by filtration to give 2- (2-methyl-4-nitro-5- (propan-2-yloxy) benzyl) -4- (5, a pale yellow solid. There was obtained 1.14 g of 6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole.
1 H-NMR (DMSO-d 6 ) δ value: 1.29 (6H, d, J = 6.1 Hz), 1.69-1.82 (4H, m), 2.28 (3H, s), 2.68-2.82 (4H, m), 4.45 (2H, s), 4.58-4.90 (1H, m), 7.06-7.14 (1H, m), 7.45 (1H, s), 7.59-7.68 (2H, m), 7.71 (1H, s), 7.87 ( 1H, s).
参考例71
Figure JPOXMLDOC01-appb-I000085
参考例4と同様にして、2-(2-メチル-4-ニトロ-5-(プロパン-2-イルオキシ)ベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.50gより、5-メチル-2-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン320mgを得た。
1H-NMR(CDCl3)δ値:1.33(6H,d,J=6.1Hz),1.74-1.89(4H,m),2.19(3H,s),2.68-2.90(4H,m),3.60-3.86(2H,broad),4.24(2H,s),4.42-4.55(1H,m),6.59(1H,s),6.75(1H,s),7.10(1H,d,J=8.2Hz),7.23(1H,s),7.56(1H,d,J=8.2Hz),7.62(1H,s).
Reference Example 71
Figure JPOXMLDOC01-appb-I000085
In the same manner as in Reference Example 4, 2- (2-methyl-4-nitro-5- (propan-2-yloxy) benzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl)- From 0.50 g of 1,3-thiazole, 5-methyl-2- (propan-2-yloxy) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- 320 mg of thiazol-2-yl) methyl) aniline were obtained.
1 H-NMR (CDCl 3 ) δ value: 1.33 (6H, d, J = 6.1 Hz), 1.74-1.89 (4H, m), 2.19 (3H, s), 2.68-2.90 (4H, m), 3.60- 3.86 (2H, broad), 4.24 (2H, s), 4.42-4.55 (1H, m), 6.59 (1H, s), 6.75 (1H, s), 7.10 (1H, d, J = 8.2Hz), 7.23 (1H, s), 7.56 (1H, d, J = 8.2Hz), 7.62 (1H, s).
参考例72
Figure JPOXMLDOC01-appb-I000086
1-(ジフルオロメトキシ)-4-メチル-2-ニトロベンゼン2.54g、水酸化ナトリウム5.00g、2-((シアノメチル)スルファニル)安息香酸2.90gおよびジメチルスルホキシド25mLの混合物を、30~40℃で2時間撹拌した。反応混合物を氷冷し、水および酢酸エチルを加え、不溶物を濾去した。濾液の有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=3:1]で精製し、褐色油状物の(5-(ジフルオロメトキシ)-2-メチル-4-ニトロフェニル)アセトニトリル2.07gを得た。
1H-NMR(CDCl3)δ値:2.42(3H,s),3.74(2H,s),6.62(1H,t,J=72.8Hz),7.44(1H,s),7.82(1H,s).
Reference Example 72
Figure JPOXMLDOC01-appb-I000086
A mixture of 2.54 g of 1- (difluoromethoxy) -4-methyl-2-nitrobenzene, 5.00 g of sodium hydroxide, 2.90 g of 2-((cyanomethyl) sulfanyl) benzoic acid and 25 mL of dimethyl sulfoxide is stirred at 30 to 40 ° C. for 2 hours. Stir. The reaction mixture was ice-cooled, water and ethyl acetate were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 3: 1] to obtain 2.07 g of (5- (difluoromethoxy) -2-methyl-4-nitrophenyl) acetonitrile as a brown oil. It was.
1 H-NMR (CDCl 3 ) δ value: 2.42 (3H, s), 3.74 (2H, s), 6.62 (1H, t, J = 72.8Hz), 7.44 (1H, s), 7.82 (1H, s) .
参考例73
Figure JPOXMLDOC01-appb-I000087
参考例29と同様にして、(5-(ジフルオロメトキシ)-2-メチル-4-ニトロフェニル)アセトニトリル0.68gより、2-(5-(ジフルオロメトキシ)-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.73gを得た。
1H-NMR(CDCl3)δ値:1.78-1.87(4H,m),2.44(3H,s),2.76-2.88(4H,m),4.54(2H,s),6.61(1H,t,J=73.3Hz),7.12(1H,d,J=7.8Hz),7.31(1H,s),7.52-7.60(2H,m),7.78(1H,s),7.81(1H,s).
Reference Example 73
Figure JPOXMLDOC01-appb-I000087
In the same manner as in Reference Example 29, from 0.68 g of (5- (difluoromethoxy) -2-methyl-4-nitrophenyl) acetonitrile, 2- (5- (difluoromethoxy) -2-methyl-4-nitrobenzyl)- There was obtained 0.73 g of 4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.87 (4H, m), 2.44 (3H, s), 2.76-2.88 (4H, m), 4.54 (2H, s), 6.61 (1H, t, J = 73.3Hz), 7.12 (1H, d, J = 7.8Hz), 7.31 (1H, s), 7.52-7.60 (2H, m), 7.78 (1H, s), 7.81 (1H, s).
参考例74
Figure JPOXMLDOC01-appb-I000088
2-(5-(ジフルオロメトキシ)-2-メチル-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール0.73g、エタノール12mLおよび水3mLの混合物に、鉄粉0.33gおよび塩化アンモニウム54mgを加え、30分間加熱還流した。反応混合物を室温まで冷却し、不溶物を濾去し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=7:1-3:1]で精製し、黄色油状物の2-(ジフルオロメトキシ)-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン460mgを得た。
1H-NMR(CDCl3)δ値:1.77-1.86(4H,m),2.22(3H,s),2.74-2.88(4H,m),3.49(2H,s),4.24(2H,s),6.44(1H,t,J=74.5Hz),6.64(1H,s),6.98(1H,s),7.10(1H,d,J=8.0Hz),7.23-7.30(1H,m),7.53-7.59(1H,m),7.60(1H,s).
Reference Example 74
Figure JPOXMLDOC01-appb-I000088
2- (5- (difluoromethoxy) -2-methyl-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole 0.73 g, ethanol 12 mL and To a mixture of 3 mL of water, 0.33 g of iron powder and 54 mg of ammonium chloride were added and heated to reflux for 30 minutes. The reaction mixture was cooled to room temperature, insolubles were filtered off, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 7: 1-3: 1], and 2- (difluoromethoxy) -5-methyl-4-(( 460 mg of 4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.77-1.86 (4H, m), 2.22 (3H, s), 2.74-2.88 (4H, m), 3.49 (2H, s), 4.24 (2H, s), 6.44 (1H, t, J = 74.5Hz), 6.64 (1H, s), 6.98 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.23-7.30 (1H, m), 7.53-7.59 (1H, m), 7.60 (1H, s).
参考例75
Figure JPOXMLDOC01-appb-I000089
4-ブロモ-5-メチル-2-(プロパン-2-イル)アニリン500mg、シアノ酢酸エチル702μL、ビス(トリ-tert-ブチルホスフィン)パラジウム(0)56mg、リン酸三カリウム1.40gおよびトルエン10mLの混合物を、窒素雰囲気下、5時間加熱還流した。反応混合物を室温まで冷却し、水および酢酸エチルを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=4:1]で精製し、淡黄色油状物のエチル=(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)(シアノ)アセタート470mgを得た。
1H-NMR(CDCl3)δ値:1.15-1.31(9H,m),2.28(3H,s),2.77-2.90(1H,m),3.68-3.76(2H,broad),4.16-4.32(2H,m),4.76(1H,s),6.51(1H,s),7.15(1H,s).
Reference Example 75
Figure JPOXMLDOC01-appb-I000089
4-bromo-5-methyl-2- (propan-2-yl) aniline 500 mg, ethyl cyanoacetate 702 μL, bis (tri-tert-butylphosphine) palladium (0) 56 mg, tripotassium phosphate 1.40 g and toluene 10 mL The mixture was heated to reflux under a nitrogen atmosphere for 5 hours. The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 4: 1], and light yellow oily ethyl = (4-amino-2-methyl-5- (propan-2-yl) phenyl ) 470 mg of (cyano) acetate was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.15-1.31 (9H, m), 2.28 (3H, s), 2.77-2.90 (1H, m), 3.68-3.76 (2H, broad), 4.16-4.32 (2H , m), 4.76 (1H, s), 6.51 (1H, s), 7.15 (1H, s).
参考例76
Figure JPOXMLDOC01-appb-I000090
エチル=(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)(シアノ)アセタート460mg、塩化ナトリウム0.74g、水1mLおよびジメチルスルホキシド16mLの混合物を、140℃で4時間撹拌した。反応混合物を室温まで冷却し、水および酢酸エチルを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチル=5:1]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、黄色固体の(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)アセトニトリルの塩酸塩110mgを得た。
1H-NMR(DMSO-d6)δ値:1.18(6H,d,J=6.8Hz),2.26(3H,s),3.01-3.12(1H,m),3.96(2H,s),7.07(1H,s),7.34(1H,s).
Reference Example 76
Figure JPOXMLDOC01-appb-I000090
A mixture of ethyl = (4-amino-2-methyl-5- (propan-2-yl) phenyl) (cyano) acetate 460 mg, sodium chloride 0.74 g, water 1 mL and dimethyl sulfoxide 16 mL was stirred at 140 ° C. for 4 hours. . The reaction mixture was cooled to room temperature and water and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane: ethyl acetate = 5: 1], 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration to give a yellow solid (4-amino 110 mg of hydrochloride of -2-methyl-5- (propan-2-yl) phenyl) acetonitrile was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.18 (6H, d, J = 6.8 Hz), 2.26 (3H, s), 3.01-3.12 (1H, m), 3.96 (2H, s), 7.07 ( 1H, s), 7.34 (1H, s).
参考例77
Figure JPOXMLDOC01-appb-I000091
(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)アセトニトリルの塩酸塩110mg、ジチオリン酸 O,O’-ジエチル116μLおよび5mol/L塩化水素-酢酸エチル溶液3mLの混合物を室温で19時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル116μLを加え、6時間撹拌した。反応混合物に酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取した。得られた固形物に、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去し、褐色固体の2-(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)エタンチオアミド91mgを得た。
1H-NMR(CDCl3)δ値:1.24(6H,d,J=6.8Hz),2.16(3H,s),2.80-2.91(1H,m),3.60-3.72(2H,broad),4.03(2H,s),6.55(1H,s),6.66-6.78(1H,broad),6.88(1H,s),7.35-7.48(1H,broad).
Reference Example 77
Figure JPOXMLDOC01-appb-I000091
A mixture of 110 mg of hydrochloride of (4-amino-2-methyl-5- (propan-2-yl) phenyl) acetonitrile, 116 μL of dithiophosphoric acid O, O′-diethyl and 3 mL of 5 mol / L hydrogen chloride-ethyl acetate solution at room temperature For 19 hours. To the reaction mixture, 116 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 6 hours. Ethyl acetate and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. A 4 mol / L hydrogen chloride-ethyl acetate solution was added to the obtained residue, and the solid was collected by filtration. Ethyl acetate and 10% aqueous potassium carbonate solution were added to the obtained solid. The organic layer was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to give 2- (4-amino-2-methyl-5- (propan-2-yl) phenyl) ethanethioamide as a brown solid. 91 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.24 (6H, d, J = 6.8 Hz), 2.16 (3H, s), 2.80-2.91 (1H, m), 3.60-3.72 (2H, broad), 4.03 ( 2H, s), 6.55 (1H, s), 6.66-6.78 (1H, broad), 6.88 (1H, s), 7.35-7.48 (1H, broad).
参考例78
Figure JPOXMLDOC01-appb-I000092
2-(tert-ブチル)-5-メチルフェノール2.0g、トリフルオロメタンスルホン酸無水物2.4mL、ピリジン1.47mLおよび塩化メチレン25mLの混合物を、氷冷下で2時間30分間撹拌した。反応混合物に2mol/L塩酸を加えた。有機層を分取し、飽和炭酸水素ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン]で精製し、無色油状物の2-(tert-ブチル)-5-メチルフェニル=トリフルオロメタンスルホナート3.42gを得た。
1H-NMR(CDCl3)δ値:1.40(9H,s),2.35(3H,s),7.06-7.10(1H,m),7.14-7.16(1H,m),7.34(1H,d,J=8.0Hz).
Reference Example 78
Figure JPOXMLDOC01-appb-I000092
A mixture of 2- (tert-butyl) -5-methylphenol (2.0 g), trifluoromethanesulfonic anhydride (2.4 mL), pyridine (1.47 mL) and methylene chloride (25 mL) was stirred for 2 hours and 30 minutes under ice cooling. 2 mol / L hydrochloric acid was added to the reaction mixture. The organic layer was separated, washed with a saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [hexane] to obtain 3.42 g of colorless oily 2- (tert-butyl) -5-methylphenyl = trifluoromethanesulfonate.
1 H-NMR (CDCl 3 ) δ value: 1.40 (9H, s), 2.35 (3H, s), 7.06-7.10 (1H, m), 7.14-7.16 (1H, m), 7.34 (1H, d, J = 8.0Hz).
参考例79
Figure JPOXMLDOC01-appb-I000093
2-(tert-ブチル)-5-メチルフェニル=トリフルオロメタンスルホナート3.0g、ベンゾフェノン=イミン2.04mL、酢酸パラジウム(II)68mg、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフチル284mg、炭酸セシウム4.62gおよびジオキサン30mLの混合物を、窒素雰囲気下、4時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび水を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=100:0-25:1]で精製し、黄色固体のN-(2-(tert-ブチル)-5-メチルフェニル)-1,1-ジフェニルメタンイミン3.04gを得た。
1H-NMR(CDCl3)δ値:1.47(9H,s),1.96(3H,s),5.97-6.00(1H,m),6.67-6.72(1H,m),7.05-7.49(9H,m),7.76-7.82(2H,m).
Reference Example 79
Figure JPOXMLDOC01-appb-I000093
2- (tert-butyl) -5-methylphenyl = trifluoromethanesulfonate 3.0 g, benzophenone = imine 2.04 mL, palladium (II) acetate 68 mg, 2,2′-bis (diphenylphosphino) -1,1′- A mixture of 284 mg of binaphthyl, 4.62 g of cesium carbonate and 30 mL of dioxane was heated to reflux for 4 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and ethyl acetate and water were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 100: 0-25: 1], and N- (2- (tert-butyl) -5-methylphenyl) as a yellow solid As a result, 3.04 g of 1,1-diphenylmethanimine was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.47 (9H, s), 1.96 (3H, s), 5.97-6.00 (1H, m), 6.67-6.72 (1H, m), 7.05-7.49 (9H, m ), 7.76-7.82 (2H, m).
参考例80
Figure JPOXMLDOC01-appb-I000094
N-(2-(tert-ブチル)-5-メチルフェニル)-1,1-ジフェニルメタンイミン3.0g、2mol/L塩酸2.5mLおよびテトラヒドロフラン30mLの混合物を、室温で4時間30分間撹拌した。反応混合物に6mol/L塩酸2mLを加え、9時間撹拌した。反応混合物に6mol/L塩酸2mLを加え、15時間静置した。反応混合物にトルエンおよび水を加えた。水層を分取し、有機層を1mol/L塩酸で抽出した。水層と抽出液を併せ、10%炭酸カリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去し、淡赤色油状物の2-(tert-ブチル)-5-メチルアニリン0.78gを得た。
1H-NMR(CDCl3)δ値:1.40(9H,s),2.23(3H,s),3.57-3.94(2H,broad),6.46-6.50(1H,m),6.53-6.58(1H,m),7.12(1H,d,J=7.8Hz).
Reference Example 80
Figure JPOXMLDOC01-appb-I000094
A mixture of N- (2- (tert-butyl) -5-methylphenyl) -1,1-diphenylmethanimine (3.0 g), 2 mol / L hydrochloric acid (2.5 mL) and tetrahydrofuran (30 mL) was stirred at room temperature for 4 hours and 30 minutes. To the reaction mixture, 2 mL of 6 mol / L hydrochloric acid was added and stirred for 9 hours. To the reaction mixture was added 2 mL of 6 mol / L hydrochloric acid, and the mixture was allowed to stand for 15 hours. Toluene and water were added to the reaction mixture. The aqueous layer was separated, and the organic layer was extracted with 1 mol / L hydrochloric acid. The aqueous layer and the extract were combined, and 10% aqueous potassium carbonate solution and ethyl acetate were added. The organic layer was separated and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure to obtain 0.78 g of 2- (tert-butyl) -5-methylaniline as a pale red oil.
1 H-NMR (CDCl 3 ) δ value: 1.40 (9H, s), 2.23 (3H, s), 3.57-3.94 (2H, broad), 6.46-6.50 (1H, m), 6.53-6.58 (1H, m ), 7.12 (1H, d, J = 7.8Hz).
参考例81
Figure JPOXMLDOC01-appb-I000095
参考例44と同様にして、2-(tert-ブチル)-5-メチルアニリン0.78gより、4-ブロモ-2-(tert-ブチル)-5-メチルアニリン650mgを得た。
1H-NMR(CDCl3)δ値:1.39(9H,s),2.26(3H,s),6.61(1H,s),7.33(1H,s).
Reference Example 81
Figure JPOXMLDOC01-appb-I000095
In the same manner as in Reference Example 44, 650 mg of 4-bromo-2- (tert-butyl) -5-methylaniline was obtained from 0.78 g of 2- (tert-butyl) -5-methylaniline.
1 H-NMR (CDCl 3 ) δ value: 1.39 (9H, s), 2.26 (3H, s), 6.61 (1H, s), 7.33 (1H, s).
参考例82
Figure JPOXMLDOC01-appb-I000096
参考例75と同様にして、4-ブロモ-2-(tert-ブチル)-5-メチルアニリン400mgより、エチル=(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)(シアノ)アセタート502mgを得た。
1H-NMR(CDCl3)δ値:1.16-1.41(3H,m),1.40(9H,s),2.26(3H,s),3.79-3.94(2H,m),4.19-4.32(2H,m),4.75(1H,s),6.47(1H,s),7.24(1H,s).
Reference Example 82
Figure JPOXMLDOC01-appb-I000096
In the same manner as in Reference Example 75, from 400 mg of 4-bromo-2- (tert-butyl) -5-methylaniline, ethyl = (4-amino-5- (tert-butyl) -2-methylphenyl) (cyano) Acetate 502 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.16-1.41 (3H, m), 1.40 (9H, s), 2.26 (3H, s), 3.79-3.94 (2H, m), 4.19-4.32 (2H, m ), 4.75 (1H, s), 6.47 (1H, s), 7.24 (1H, s).
参考例83
Figure JPOXMLDOC01-appb-I000097
参考例76と同様にして、エチル=(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)(シアノ)アセタート500mgより、(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)アセトニトリルの塩酸塩150mgを得た。
1H-NMR(DMSO-d6)δ値:1.35(9H,s),2.21(3H,s),3.88(2H,s),6.89(1H,s),7.27(1H,s).
Reference Example 83
Figure JPOXMLDOC01-appb-I000097
In the same manner as in Reference Example 76, from 500 mg of ethyl = (4-amino-5- (tert-butyl) -2-methylphenyl) (cyano) acetate, (4-amino-5- (tert-butyl) -2- 150 mg of methylphenyl) acetonitrile hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.35 (9H, s), 2.21 (3H, s), 3.88 (2H, s), 6.89 (1H, s), 7.27 (1H, s).
参考例84
Figure JPOXMLDOC01-appb-I000098
参考例42と同様にして、(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)アセトニトリルの塩酸塩150mgより、2-(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)エタンチオアミドの塩酸塩50mgを得た。
1H-NMR(DMSO-d6)δ値:1.36(9H,s),2.25(3H,s),3.80(2H,s),7.03(1H,s),7.34(1H,s),9.24-9.35(1H,broad),9.46-9.56(1H,broad).
Reference Example 84
Figure JPOXMLDOC01-appb-I000098
In the same manner as in Reference Example 42, from 150 mg of hydrochloride of (4-amino-5- (tert-butyl) -2-methylphenyl) acetonitrile, 2- (4-amino-5- (tert-butyl) -2- 50 mg of methylphenyl) ethanethioamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.36 (9H, s), 2.25 (3H, s), 3.80 (2H, s), 7.03 (1H, s), 7.34 (1H, s), 9.24 9.35 (1H, broad), 9.46-9.56 (1H, broad).
参考例85
Figure JPOXMLDOC01-appb-I000099
1,4-ジフルオロ-2-ニトロベンゼン318mg、4-クロロフェノキシアセトニトリル402mgおよびN,N-ジメチルホルムアミド4.0mLの混合物に、-20~-10℃で、カリウムtert-ブトキシド561mgおよびN,N-ジメチルホルムアミド4.0mLを加え、-20~-10℃で15分間撹拌した。反応混合物に、酢酸エチルおよび水を加えた。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=4:1-2:1]で精製し、黒色油状物を得た。得られた黒色油状物、ジチオリン酸 O,O’-ジエチル0.47mLおよび5mol/L塩化水素-酢酸エチル溶液4mLの混合物を、室温で19時間撹拌した。反応混合物に、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=9:1-2:1]で精製し、黄色固体の2-(2,5-ジフルオロ-4-ニトロフェニル)エタンチオアミド60mgを得た。
1H-NMR(CDCl3)δ値:4.05(2H,s),7.43(1H,dd,J=10.6,6.0Hz),7.85(1H,dd,J=8.7,6.0Hz).
Reference Example 85
Figure JPOXMLDOC01-appb-I000099
To a mixture of 318 mg of 1,4-difluoro-2-nitrobenzene, 402 mg of 4-chlorophenoxyacetonitrile and 4.0 mL of N, N-dimethylformamide at −20 to −10 ° C., 561 mg of potassium tert-butoxide and N, N-dimethylformamide 4.0 mL was added and stirred at −20 to −10 ° C. for 15 minutes. To the reaction mixture was added ethyl acetate and water. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 4: 1-2: 1] to obtain a black oily substance. A mixture of the obtained black oily substance, 0.47 mL of dithiophosphoric acid O, O′-diethyl and 4 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 19 hours. To the reaction mixture were added ethyl acetate and saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 9: 1-2: 1] to give 2- (2,5-difluoro-4-nitrophenyl) ethanethioamide as a yellow solid 60 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 4.05 (2H, s), 7.43 (1H, dd, J = 10.6, 6.0 Hz), 7.85 (1H, dd, J = 8.7, 6.0 Hz).
参考例86
Figure JPOXMLDOC01-appb-I000100
2-(2,5-ジフルオロ-4-ニトロフェニル)エタンチオアミド60mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン72mgおよびメタノール2mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=99:1-9:1]で精製し、黄色固体の2-(2,5-ジフルオロ-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール66mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.88(4H,m),2.72-2.90(4H,m),4.46(2H,s),7.11(1H,d,J=7.8Hz),7.32-7.40(2H,m),7.52-7.63(2H,m),7.84(1H,dd,J=8.5,6.1Hz).
Reference Example 86
Figure JPOXMLDOC01-appb-I000100
A mixture of 60 mg of 2- (2,5-difluoro-4-nitrophenyl) ethanethioamide, 72 mg of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 2 mL of methanol Heated to reflux for hours. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 99: 1-9: 1] to give 2- (2,5-difluoro-4-nitrobenzyl) -4 as a yellow solid. 66 mg of (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.76-1.88 (4H, m), 2.72-2.90 (4H, m), 4.46 (2H, s), 7.11 (1H, d, J = 7.8Hz), 7.32 7.40 (2H, m), 7.52-7.63 (2H, m), 7.84 (1H, dd, J = 8.5,6.1Hz).
参考例87
Figure JPOXMLDOC01-appb-I000101
参考例4と同様にして、2-(2,5-ジフルオロ-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール66mgより、2,5-ジフルオロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン42mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.86(4H,m),2.72-2.88(4H,m),3.68-3.92(2H,broad),4.27(2H,d,J=1.0Hz),6.51(1H,dd,J=10.4,7.4Hz),6.96(1H,dd,J=11.0,6.8Hz),7.10(1H,d,J=7.8Hz),7.27(1H,s),7.56(1H,dd,J=7.8,1.7Hz),7.60(1H,s).
Reference Example 87
Figure JPOXMLDOC01-appb-I000101
In the same manner as in Reference Example 4, from 66 mg of 2- (2,5-difluoro-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole, 42 mg of 2,5-difluoro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.76-1.86 (4H, m), 2.72-2.88 (4H, m), 3.68-3.92 (2H, broad), 4.27 (2H, d, J = 1.0Hz), 6.51 (1H, dd, J = 10.4,7.4Hz), 6.96 (1H, dd, J = 11.0,6.8Hz), 7.10 (1H, d, J = 7.8Hz), 7.27 (1H, s), 7.56 (1H , dd, J = 7.8,1.7Hz), 7.60 (1H, s).
参考例88
Figure JPOXMLDOC01-appb-I000102
参考例19と同様にして、1,4-ジクロロ-2-ニトロベンゼン1.92gより、(2,5-ジクロロ-4-ニトロフェニル)アセトニトリル0.31gを得た。
1H-NMR(CDCl3)δ値:3.91(2H,d,J=0.5Hz),7.78(1H,s),8.01(1H,s).
Reference Example 88
Figure JPOXMLDOC01-appb-I000102
In the same manner as in Reference Example 19, 0.31 g of (2,5-dichloro-4-nitrophenyl) acetonitrile was obtained from 1.92 g of 1,4-dichloro-2-nitrobenzene.
1 H-NMR (CDCl 3 ) δ value: 3.91 (2H, d, J = 0.5 Hz), 7.78 (1H, s), 8.01 (1H, s).
参考例89
Figure JPOXMLDOC01-appb-I000103
参考例24と同様にして、(2,5-ジクロロ-4-ニトロフェニル)アセトニトリル0.30gより、2-(2,5-ジクロロ-4-ニトロフェニル)エタンチオアミド0.28gを得た。
1H-NMR(CDCl3)δ値:4.14(2H,s),6.76-7.04(1H,broad),7.32-7.60(1H,broad),7.68(1H,s),7.98(1H,s).
Reference Example 89
Figure JPOXMLDOC01-appb-I000103
In the same manner as in Reference Example 24, 0.28 g of 2- (2,5-dichloro-4-nitrophenyl) ethanethioamide was obtained from 0.30 g of (2,5-dichloro-4-nitrophenyl) acetonitrile.
1 H-NMR (CDCl 3 ) δ value: 4.14 (2H, s), 6.76-7.04 (1H, broad), 7.32-7.60 (1H, broad), 7.68 (1H, s), 7.98 (1H, s).
参考例90
Figure JPOXMLDOC01-appb-I000104
参考例21と同様にして、2-(2,5-ジクロロ-4-ニトロフェニル)エタンチオアミド133mgおよび2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン127mgより、2-(2,5-ジクロロ-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール190mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.88(4H,m),2.76-2.94(4H,m),5.41(2H,s),7.22(1H,d,J=8.1Hz),7.52(1H,s),7.75(1H,dd,J=8.1,1.9Hz),7.89(1H,s),8.00(1H,s),8.40(1H,s).
Reference Example 90
Figure JPOXMLDOC01-appb-I000104
In the same manner as in Reference Example 21, 133 mg of 2- (2,5-dichloro-4-nitrophenyl) ethanethioamide and 127 mg of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone As a result, 190 mg of 2- (2,5-dichloro-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.88 (4H, m), 2.76-2.94 (4H, m), 5.41 (2H, s), 7.22 (1H, d, J = 8.1 Hz), 7.52 ( 1H, s), 7.75 (1H, dd, J = 8.1, 1.9Hz), 7.89 (1H, s), 8.00 (1H, s), 8.40 (1H, s).
参考例91
Figure JPOXMLDOC01-appb-I000105
参考例10と同様にして、2-(2,5-ジクロロ-4-ニトロベンジル)-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール90mgより、2,5-ジクロロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン72mgを得た。
1H-NMR(CDCl3)δ値:1.76-1.86(4H,m),2.72-2.90(4H,m),4.02-4.16(2H,broad),4.37(2H,s),6.83(1H,s),7.10(1H,d,J=8.0Hz),7.22-7.30(2H,m),7.56(1H,dd,J=8.0,2.0Hz),7.61(1H,s).
Reference Example 91
Figure JPOXMLDOC01-appb-I000105
In the same manner as in Reference Example 10, from 90 mg of 2- (2,5-dichloro-4-nitrobenzyl) -4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole, 72 mg of 2,5-dichloro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.76-1.86 (4H, m), 2.72-2.90 (4H, m), 4.02-4.16 (2H, broad), 4.37 (2H, s), 6.83 (1H, s ), 7.10 (1H, d, J = 8.0Hz), 7.22-7.30 (2H, m), 7.56 (1H, dd, J = 8.0, 2.0Hz), 7.61 (1H, s).
参考例92
Figure JPOXMLDOC01-appb-I000106
N-エチル-N-メチルホルムアミド1.09gの塩化メチレン5mL溶液に、氷冷下で、塩化オキサリル1.07mLを加え、室温で30分間撹拌した。反応混合物に、氷冷下で、(4-アミノ-3,5-ジメチルフェニル)アセトニトリル1.00gの塩化メチレン5mL溶液を加え、室温で5時間撹拌した。反応混合物に、飽和炭酸水素ナトリウム水溶液および氷水を加えた。有機層を分取し、水層をクロロホルムで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、酢酸エチル、アセトンおよび4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体のN’-(4-(シアノメチル)-2,6-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩1.51gを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.29(3H,m),2.27(6H,s),3.25-3.30(3H,m),3.56-3.76(2H,m),4.02(2H,s),7.18(2H,s),8.12-8.30(1H,m),10.87-11.08(1H,m).
Reference Example 92
Figure JPOXMLDOC01-appb-I000106
To a solution of 1.09 g of N-ethyl-N-methylformamide in 5 mL of methylene chloride was added 1.07 mL of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 30 minutes. A solution of 1.00 g of (4-amino-3,5-dimethylphenyl) acetonitrile in 5 mL of methylene chloride was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 5 hours. To the reaction mixture were added saturated aqueous sodium hydrogen carbonate solution and ice water. The organic layer was separated and the aqueous layer was extracted with chloroform. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, ethyl acetate, acetone and a 4 mol / L hydrogen chloride-ethyl acetate solution were added, and the solid was collected by filtration to give N ′-(4- (cyanomethyl) -2,6-dimethylphenyl as a white solid. ) 1.51 g of hydrochloride salt of -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.29 (3H, m), 2.27 (6H, s), 3.25-3.30 (3H, m), 3.56-3.76 (2H, m), 4.02 (2H , s), 7.18 (2H, s), 8.12-8.30 (1H, m), 10.87-11.08 (1H, m).
参考例93
Figure JPOXMLDOC01-appb-I000107
N’-(4-(シアノメチル)-2,6-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩1.40g、5mol/L塩化水素-酢酸エチル溶液40mLおよびジチオリン酸 O,O’-ジエチル1.25mLの混合物を、室温で5時間撹拌し、14時間静置した。反応混合物に、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、水層をクロロホルムで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=4:1-1:1]で精製し、淡褐色固体の2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-3,5-ジメチルフェニル)エタンチオアミド690mgを得た。
1H-NMR(CDCl3)δ値:1.21(3H,t,J=7.1Hz),2.12(6H,s),2.99(3H,s),3.18-3.52(2H,broad),4.00(2H,s),6.71-6.81(1H,broad),6.87(2H,s),7.17(1H,s),7.41-7.57(1H,broad)
Reference Example 93
Figure JPOXMLDOC01-appb-I000107
1.40 g of N ′-(4- (cyanomethyl) -2,6-dimethylphenyl) -N-ethyl-N-methylimidoformamide hydrochloride, 40 mL of 5 mol / L hydrogen chloride-ethyl acetate solution and dithiophosphoric acid O, O ′ -A mixture of 1.25 mL of diethyl was stirred at room temperature for 5 hours and allowed to stand for 14 hours. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with chloroform. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL-type silica gel, hexane: ethyl acetate gradient elution = 4: 1-1: 1], and light brown solid 2- (4-((((ethyl (methyl 690 mg of amino) methylene) amino) -3,5-dimethylphenyl) ethanethioamide were obtained.
1 H-NMR (CDCl 3 ) δ value: 1.21 (3H, t, J = 7.1 Hz), 2.12 (6H, s), 2.99 (3H, s), 3.18-3.52 (2H, broad), 4.00 (2H, s), 6.71-6.81 (1H, broad), 6.87 (2H, s), 7.17 (1H, s), 7.41-7.57 (1H, broad)
参考例94
Figure JPOXMLDOC01-appb-I000108
4-ブロモ-2,3-ジメチルアニリン2.00g、シアノ酢酸エチル3.20mL、トリス(ジベンジリデンアセトン)二パラジウム(0)275mg、トリ-tert-ブチルホスホニウムテトラフルオロボラート348mg、リン酸三カリウム6.37gおよびトルエン40mLの混合物を、窒素雰囲気下、4時間10分間加熱還流した。反応混合物にビス(トリ-tert-ブチルホスフィン)パラジウム(0)260mgを加え、3時間加熱還流した。反応混合物を室温まで冷却し、氷水および酢酸エチルを加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、1mol/L塩酸および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、黄色固体のエチル=(4-アミノ-2,3-ジメチルフェニル)(シアノ)アセタートの塩酸塩2.11gを得た。 
1H-NMR(DMSO-d6)δ値:1.19(3H,t,J=7.1Hz),2.21(3H,s),2.23(3H,s),4.13-4.28(2H,m),5.86(1H,s),7.17-7.29(2H,m),8.80-10.80(3H,broad).
Reference Example 94
Figure JPOXMLDOC01-appb-I000108
4-bromo-2,3-dimethylaniline 2.00 g, ethyl cyanoacetate 3.20 mL, tris (dibenzylideneacetone) dipalladium (0) 275 mg, tri-tert-butylphosphonium tetrafluoroborate 348 mg, tripotassium phosphate 6.37 g The mixture of toluene and 40 mL was heated to reflux for 4 hours and 10 minutes under a nitrogen atmosphere. To the reaction mixture was added 260 mg of bis (tri-tert-butylphosphine) palladium (0), and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled to room temperature and ice water and ethyl acetate were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed successively with 1 mol / L hydrochloric acid and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. To the obtained residue, a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid matter was collected by filtration, and the yellow solid ethyl = (4-amino-2,3-dimethylphenyl) (cyano) acetate hydrochloride 2.11 g was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.19 (3H, t, J = 7.1 Hz), 2.21 (3H, s), 2.23 (3H, s), 4.13-4.28 (2H, m), 5.86 ( 1H, s), 7.17-7.29 (2H, m), 8.80-10.80 (3H, broad).
参考例95
Figure JPOXMLDOC01-appb-I000109
参考例76と同様にして、エチル=(4-アミノ-2,3-ジメチルフェニル)(シアノ)アセタートの塩酸塩0.50gより、(4-アミノ-2,3-ジメチルフェニル)アセトニトリルの塩酸塩180mgを得た。
1H-NMR(DMSO-d6)δ値:2.23(3H,s),2.24(3H,s),4.03(2H,s),7.25-7.28(2H,m),9.40-10.40(3H,broad).
Reference Example 95
Figure JPOXMLDOC01-appb-I000109
In the same manner as in Reference Example 76, from 0.50 g of ethyl = (4-amino-2,3-dimethylphenyl) (cyano) acetate hydrochloride, 180 mg of (4-amino-2,3-dimethylphenyl) acetonitrile hydrochloride Got.
1 H-NMR (DMSO-d 6 ) δ value: 2.23 (3H, s), 2.24 (3H, s), 4.03 (2H, s), 7.25-7.28 (2H, m), 9.40-10.40 (3H, broad ).
参考例96
Figure JPOXMLDOC01-appb-I000110
(4-アミノ-2,3-ジメチルフェニル)アセトニトリルの塩酸塩150mg、ジチオリン酸 O,O’-ジエチル181μLおよび5mol/L塩化水素-酢酸エチル溶液3mLの混合物を室温で5時間撹拌し、12時間静置した。反応混合物にジチオリン酸 O,O’-ジエチル97μLを加え3時間撹拌し、ジチオリン酸 O,O’-ジエチル97μLを加え、2時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル362μLを加え、14時間撹拌した。反応混合物にジチオリン酸 O,O’-ジエチル362μLを加え10時間撹拌した。反応混合物に、10%炭酸カリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=3:1-0:100]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡褐色固体の2-(4-アミノ-2,3-ジメチルフェニル)エタンチオアミドの塩酸塩83mgを得た。
1H-NMR(DMSO-d6)δ値:2.18-2.22(6H,m),3.87(2H,s),7.11-7.23(2H,m),9.21-9.33(1H,broad),9.51-9.59(1H,broad),9.68-10.19(3H,broad).
Reference Example 96
Figure JPOXMLDOC01-appb-I000110
A mixture of 150 mg of (4-amino-2,3-dimethylphenyl) acetonitrile hydrochloride, 181 μL of dithiophosphoric acid O, O′-diethyl and 3 mL of 5 mol / L hydrogen chloride-ethyl acetate solution was stirred at room temperature for 5 hours, and 12 hours Left to stand. To the reaction mixture, 97 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 3 hours, and 97 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 2 hours. To the reaction mixture was added 362 μL of dithiophosphoric acid O, O′-diethyl, and the mixture was stirred for 14 hours. To the reaction mixture, 362 μL of dithiophosphoric acid O, O′-diethyl was added and stirred for 10 hours. A 10% aqueous potassium carbonate solution and ethyl acetate were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 3: 1-0: 100], a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration. 83 mg of 2- (4-amino-2,3-dimethylphenyl) ethanethioamide hydrochloride as a light brown solid was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 2.18-2.22 (6H, m), 3.87 (2H, s), 7.11-7.23 (2H, m), 9.21-9.33 (1H, broad), 9.51-9.59 (1H, broad), 9.68-10.19 (3H, broad).
参考例97
Figure JPOXMLDOC01-appb-I000111
2-(4-アミノ-2,3-ジメチルフェニル)エタンチオアミドの塩酸塩70mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン77mgおよびエタノール5mLの混合物を1時間30分間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=15:1-4:1]で精製し、淡黄色油状物の2,3-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン87mgを得た。
1H-NMR(CDCl3)δ値:1.78-1.85(4H,m),2.11(3H,s),2.21(3H,s),2.74-2.86(4H,m),3.55-3.65(2H,broad),4.31(2H,s),6.59(1H,d,J=7.8Hz),6.99(1H,d,J=8.0Hz),7.10(1H,d,J=8.0Hz),7.22(1H,s),7.54-7.59(1H,m),7.60-7.64(1H,m).
Reference Example 97
Figure JPOXMLDOC01-appb-I000111
Mixture of 70 mg of 2- (4-amino-2,3-dimethylphenyl) ethanethioamide hydrochloride, 77 mg of 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone and 5 mL of ethanol Was heated to reflux for 1 hour 30 minutes. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 15: 1-4: 1] to give 2,3-dimethyl-4-((4- (5 , 6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.78-1.85 (4H, m), 2.11 (3H, s), 2.21 (3H, s), 2.74-2.86 (4H, m), 3.55-3.65 (2H, broad ), 4.31 (2H, s), 6.59 (1H, d, J = 7.8Hz), 6.99 (1H, d, J = 8.0Hz), 7.10 (1H, d, J = 8.0Hz), 7.22 (1H, s) ), 7.54-7.59 (1H, m), 7.60-7.64 (1H, m).
参考例98
Figure JPOXMLDOC01-appb-I000112
1,2,3,4-テトラヒドロ-1,4-メタノナフタレン0.40g、ブロモアセチルブロミド0.26mLおよび塩化メチレン8mLの混合物に、氷冷下で、塩化アルミニウム0.44gを加え、0~10℃で2時間撹拌した。氷水中に、反応混合物およびクロロホルムを加えた。有機層を分取し、水、飽和炭酸水素ナトリウム水溶液および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物を、シリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=100:0-90:10]で精製し、2-ブロモ-1-(1,2,3,4-テトラヒドロ-1,4-メタノナフタレン-6-イル)エタノン0.57gを得た。
1H-NMR(CDCl3)δ値:1.15-1.21(2H,m),1.52-1.61(1H,m),1.75-1.82(1H,m),1.92-2.00(2H,m),3.40-3.46(2H,m),4.44(2H,s),7.24-7.28(1H,m),7.73-7.80(2H,m).
Reference Example 98
Figure JPOXMLDOC01-appb-I000112
To a mixture of 0.40 g of 1,2,3,4-tetrahydro-1,4-methanonaphthalene, 0.26 mL of bromoacetyl bromide and 8 mL of methylene chloride, 0.44 g of aluminum chloride was added under ice cooling, and the mixture was heated at 0-10 ° C. Stir for hours. The reaction mixture and chloroform were added to ice water. The organic layer was separated, washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 100: 0-90: 10] to give 2-bromo-1- (1,2,3,4-tetrahydro-1 , 4-Methanonaphthalen-6-yl) ethanone 0.57 g was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.15-1.21 (2H, m), 1.52-1.61 (1H, m), 1.75-1.82 (1H, m), 1.92-2.00 (2H, m), 3.40-3.46 (2H, m), 4.44 (2H, s), 7.24-7.28 (1H, m), 7.73-7.80 (2H, m).
参考例99
Figure JPOXMLDOC01-appb-I000113
2-メチル-2,3-ジヒドロ-1H-インデン0.22gの塩化メチレン2.2mL溶液に、氷冷下でブロモアセチルブロミド0.16mLおよび塩化アルミニウム0.26gを加え、室温で2時間撹拌した。反応混合物に、氷およびクロロホルムを加えた。有機層を分取し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去し、白色固体の2-ブロモ-1-(2-メチル-2,3-ジヒドロ-1H-インデン-5-イル)エタノン0.47gを得た。
1H-NMR(CDCl3)δ値:1.12-1.20(3H,m),2.50-2.68(3H,m),3.02-3.17(2H,m),4.44(2H,s),7.26-7.31(1H,m),7.75-7.83(2H,m).
Reference Example 99
Figure JPOXMLDOC01-appb-I000113
To a solution of 0.22 g of 2-methyl-2,3-dihydro-1H-indene in 2.2 mL of methylene chloride were added 0.16 mL of bromoacetyl bromide and 0.26 g of aluminum chloride under ice cooling, and the mixture was stirred at room temperature for 2 hours. Ice and chloroform were added to the reaction mixture. The organic layer was separated and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to give 2-bromo-1- (2-methyl-2,3-dihydro-1H-inden-5-yl as a white solid. ) 0.47 g of ethanone was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.12-1.20 (3H, m), 2.50-2.68 (3H, m), 3.02-3.17 (2H, m), 4.44 (2H, s), 7.26-7.31 (1H , m), 7.75-7.83 (2H, m).
参考例100
Figure JPOXMLDOC01-appb-I000114
5-ブロモ-2,2-ジメチル-2,3-ジヒドロ-1H-インデン0.10g、ブチルビニルエーテル0.15mL、炭酸カリウム0.08g、(1,1’-ビス(ジフェニルホスフィノ)フェロセン)ジクロロパラジウム(II)8.7mg,水0.2mLおよびN,N-ジメチルホルムアミド1.8mLの混合物を、マイクロウェーブ反応装置を使用して100℃で20分間、120℃で20分間処理した。反応混合物に、酢酸エチルおよび水を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、N-ブロモスクシンイミド0.12g、テトラヒドロフラン1.0mLおよび水1.0mLを加え、室温で10分間撹拌した。反応混合物に酢酸エチルおよび水を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=99:1-9:1]で精製し、無色油状物の2-ブロモ-1-(2,2-ジメチル-2,3-ジヒドロ-1H-インデン-5-イル)エタノン53mgを得た。
1H-NMR(CDCl3)δ値:1.16(6H,s),2.77(4H,s),4.44(2H,s),7.25-7.28(1H,m),7.74-7.81(2H,m).
Reference Example 100
Figure JPOXMLDOC01-appb-I000114
5-bromo-2,2-dimethyl-2,3-dihydro-1H-indene 0.10 g, butyl vinyl ether 0.15 mL, potassium carbonate 0.08 g, (1,1′-bis (diphenylphosphino) ferrocene) dichloropalladium (II ) A mixture of 8.7 mg, water 0.2 mL and N, N-dimethylformamide 1.8 mL was treated at 100 ° C. for 20 minutes and 120 ° C. for 20 minutes using a microwave reactor. To the reaction mixture was added ethyl acetate and water. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, N-bromosuccinimide (0.12 g), tetrahydrofuran (1.0 mL) and water (1.0 mL) were added, and the mixture was stirred at room temperature for 10 minutes. Ethyl acetate and water were added to the reaction mixture. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 99: 1-9: 1], and colorless oily 2-bromo-1- (2,2-dimethyl-2, 3-Dihydro-1H-inden-5-yl) ethanone 53 mg was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.16 (6H, s), 2.77 (4H, s), 4.44 (2H, s), 7.25-7.28 (1H, m), 7.74-7.81 (2H, m).
参考例101
Figure JPOXMLDOC01-appb-I000115
ビシクロ[4.2.0]オクタ-1,3,5-トリエン0.22gの塩化メチレン2.0mL溶液に、氷冷下で、ブロモアセチルブロミド0.20mLおよび塩化アルミニウム0.34gを加え、室温で3時間撹拌した。反応混合物に、氷およびクロロホルムを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=99:1-93:7]で精製し、白色固体の1-(ビシクロ[4.2.0]オクタ-1,3,5-トリエン-3-イル)-2-ブロモエタノン0.22gを得た。
1H-NMR(CDCl3)δ値:3.24(4H,s),4.44(2H,s),7.17(1H,d,J=7.6Hz),7.67(1H,s),7.87(1H,dd,J=7.6,1.4Hz).
Reference Example 101
Figure JPOXMLDOC01-appb-I000115
To a solution of 0.22 g of bicyclo [4.2.0] octa-1,3,5-triene in 2.0 mL of methylene chloride was added 0.20 mL of bromoacetyl bromide and 0.34 g of aluminum chloride under ice cooling, and the mixture was stirred at room temperature for 3 hours. did. Ice and chloroform were added to the reaction mixture. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 99: 1-93: 7] to give 1- (bicyclo [4.2.0] octa-1,3 as a white solid. , 5-trien-3-yl) -2-bromoethanone was obtained.
1 H-NMR (CDCl 3 ) δ value: 3.24 (4H, s), 4.44 (2H, s), 7.17 (1H, d, J = 7.6 Hz), 7.67 (1H, s), 7.87 (1H, dd, J = 7.6,1.4Hz).
参考例102
Figure JPOXMLDOC01-appb-I000116
5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-カルボン酸0.40gのクロロホルム4.0mL溶液に、塩化オキサリル0.20mLおよびN,N-ジメチルホルムアミド10μLを加え、1時間20分間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物に、トルエン0.80mLおよび2,2,7,7-テトラメチル-4-((トリメチルシリル)オキシ)-3,6-ジオキサ-2,7-ジシラオクト-4-エン1.1mLを加え、90~100℃で1時間撹拌した。反応混合物に、2,2,7,7-テトラメチル-4-((トリメチルシリル)オキシ)-3,6-ジオキサ-2,7-ジシラオクト-4-エン0.12mLを加え、90~100℃で3時間30分間撹拌した。反応混合物に、ジオキサン1.6mLおよび1mol/L塩酸0.80mLを加え、70~80℃で1時間撹拌した。反応混合物を室温まで冷却し、1mol/L水酸化ナトリウム水溶液でpH2に調整し、反応混合物に酢酸エチルを加えた。有機層を分取し、飽和炭酸水素ナトリウム水溶液および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=47:3-4:1]で精製し、白色固体の1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)-2-ヒドロキシエタノン0.19gを得た。
1H-NMR(CDCl3)δ値:1.30-1.40(4H,m),1.66-1.76(4H,m),2.78-2.86(4H,m),3.40-3.74(1H,broad),4.86(2H,s),7.18-7.24(1H,m),7.66-7.70(1H,m),7.83-7.88(1H,m).
Reference Example 102
Figure JPOXMLDOC01-appb-I000116
To a solution of 0.40 g of 5,6,7,8,9,10-hexahydrobenzo [8] annulene-2-carboxylic acid in 4.0 mL of chloroform was added 0.20 mL of oxalyl chloride and 10 μL of N, N-dimethylformamide for 1 hour. Heated to reflux for 20 minutes. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. To the obtained residue, 0.80 mL of toluene and 1.1 mL of 2,2,7,7-tetramethyl-4-((trimethylsilyl) oxy) -3,6-dioxa-2,7-disilaoct-4-ene were added. The mixture was stirred at 90-100 ° C. for 1 hour. To the reaction mixture was added 0.12 mL of 2,2,7,7-tetramethyl-4-((trimethylsilyl) oxy) -3,6-dioxa-2,7-disilaoct-4-ene, and the mixture was stirred at 90-100 ° C. for 3 hours. Stir for 30 minutes. To the reaction mixture, 1.6 mL of dioxane and 0.80 mL of 1 mol / L hydrochloric acid were added, and the mixture was stirred at 70 to 80 ° C. for 1 hour. The reaction mixture was cooled to room temperature, adjusted to pH 2 with a 1 mol / L aqueous sodium hydroxide solution, and ethyl acetate was added to the reaction mixture. The organic layer was separated, washed successively with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 47: 3-4: 1] to give 1- (5,6,7,8,9,10-hexa of white solid. 0.19 g of hydrobenzo [8] annulen-2-yl) -2-hydroxyethanone was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.30-1.40 (4H, m), 1.66-1.76 (4H, m), 2.78-2.86 (4H, m), 3.40-3.74 (1H, broad), 4.86 (2H , s), 7.18-7.24 (1H, m), 7.66-7.70 (1H, m), 7.83-7.88 (1H, m).
参考例103
Figure JPOXMLDOC01-appb-I000117
反応A:1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)-2-ヒドロキシエタノン20mgのアセトニトリル0.16mL懸濁液に、氷冷下で、トリフェニルホスフィン27mgおよび四臭化炭素33mgを加え、氷冷下で10分間、室温で15分間撹拌した後、酢酸エチルおよび水を加え、反応混合物Aを得た。
反応B:1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)-2-ヒドロキシエタノン170mgのアセトニトリル1.4mL懸濁液に、氷冷下で、トリフェニルホスフィン0.23gおよび四臭化炭素0.28gを加え、氷冷下で20分間、室温で15分間撹拌した後、酢酸エチルおよび水を加え、反応混合物Bを得た。
反応混合物Aおよび反応混合物Bを併せた。有機層を分取し、水および飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=49:1-9:1]で精製し、黄色油状物の2-ブロモ-1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)エタノン0.26gを得た。
1H-NMR(CDCl3)δ値:1.30-1.80(8H,m),2.77-2.87(2H,m),4.45(2H,s),7.16-7.24(1H,m),7.70-7.78(2H,m).
Reference Example 103
Figure JPOXMLDOC01-appb-I000117
Reaction A: 1- (5,6,7,8,9,10-Hexahydrobenzo [8] annulen-2-yl) -2-hydroxyethanone 20 mg of acetonitrile in a suspension of 0.16 mL under ice cooling Then, 27 mg of triphenylphosphine and 33 mg of carbon tetrabromide were added, and the mixture was stirred for 10 minutes under ice-cooling and at room temperature for 15 minutes, and then ethyl acetate and water were added to obtain a reaction mixture A.
Reaction B: 1- (5,6,7,8,9,10-hexahydrobenzo [8] annulen-2-yl) -2-hydroxyethanone in a suspension of 170 mg of acetonitrile in 1.4 mL of acetonitrile under ice cooling Then, 0.23 g of triphenylphosphine and 0.28 g of carbon tetrabromide were added, and the mixture was stirred for 20 minutes under ice-cooling and for 15 minutes at room temperature, and then ethyl acetate and water were added to obtain a reaction mixture B.
Reaction mixture A and reaction mixture B were combined. The organic layer was separated, washed with water and a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 49: 1-9: 1] to give 2-bromo-1- (5,6,7,8, 0.26 g of 9,10-hexahydrobenzo [8] annulen-2-yl) ethanone was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.30-1.80 (8H, m), 2.77-2.87 (2H, m), 4.45 (2H, s), 7.16-7.24 (1H, m), 7.70-7.78 (2H , m).
実施例1
Figure JPOXMLDOC01-appb-I000118
窒素雰囲気下、N-エチル-N-メチルホルムアミド55mgのクロロホルム1.0mL溶液に、塩化オキサリル54μLを加え、室温で10分間撹拌した。反応混合物に、5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン131mgのクロロホルム1.0mL溶液を加え、室温で1時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチル=10:1]で精製し、4.9mol/L塩化水素-酢酸エチル溶液0.17mLを加え、固形物を濾取し、白色固体のN’-(5-ブロモ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩115mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.30(3H,m),1.71-1.79(4H,m),2.30-2.35(3H,m),2.69-2.80(4H,m),3.23-3.31(3H,m),3.55-3.68(2H,m),4.48(2H,s),7.10(1H,d,J=7.8Hz),7.51(1H,s),7.60-7.65(2H,m),7.77-7.81(1H,m),7.86(1H,m),8.32-8.50(1H,m),10.78-11.05(1H,m).
Example 1
Figure JPOXMLDOC01-appb-I000118
Under a nitrogen atmosphere, 54 μL of oxalyl chloride was added to a solution of N-ethyl-N-methylformamide 55 mg in chloroform 1.0 mL, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 131 mg of 5-bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A chloroform 1.0 mL solution was added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate = 10: 1], 0.17 mL of a 4.9 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration. N ′-(5-Bromo-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) as a white solid Phenyl) -N-ethyl-N-methylimidoformamide hydrochloride 115 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.30 (3H, m), 1.71-1.79 (4H, m), 2.30-2.35 (3H, m), 2.69-2.80 (4H, m), 3.23 -3.31 (3H, m), 3.55-3.68 (2H, m), 4.48 (2H, s), 7.10 (1H, d, J = 7.8Hz), 7.51 (1H, s), 7.60-7.65 (2H, m ), 7.77-7.81 (1H, m), 7.86 (1H, m), 8.32-8.50 (1H, m), 10.78-11.05 (1H, m).
実施例2
Figure JPOXMLDOC01-appb-I000119
実施例1と同様の手法により、5-シクロプロピル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン90mgから、N’-(5-シクロプロピル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩70mgを得た。
1H-NMR(CDCl3)δ値:0.57-0.69(2H,m),0.87-0.96(2H,m),1.37-1.53(3H,m),1.79-1.90(5H,m),2.46-2.62(3H,m),2.76-2.91(4H,m),3.36-3.48(1H,m),3.63-3.77(3H,m),4.16-4.28(1H,m),4.93-5.02(2H,m),6.88-6.99(1H,m),7.17-7.23(2H,m),7.45-7.54(1H,m),7.71-7.87(3H,m),8.50-8.85(1H,m).
Example 2
Figure JPOXMLDOC01-appb-I000119
In the same manner as in Example 1, 5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl ) Methyl) aniline from 90 mg, N ′-(5-cyclopropyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole-2) 70 mg of hydrochloride of -yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 0.57-0.69 (2H, m), 0.87-0.96 (2H, m), 1.37-1.53 (3H, m), 1.79-1.90 (5H, m), 2.46-2.62 (3H, m), 2.76-2.91 (4H, m), 3.36-3.48 (1H, m), 3.63-3.77 (3H, m), 4.16-4.28 (1H, m), 4.93-5.02 (2H, m) , 6.88-6.99 (1H, m), 7.17-7.23 (2H, m), 7.45-7.54 (1H, m), 7.71-7.87 (3H, m), 8.50-8.85 (1H, m).
実施例3
Figure JPOXMLDOC01-appb-I000120
2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン0.13gおよびN-メチルホルムアミド2.6mLの混合物に、p-トルエンスルホニルクロリド0.11gを加え、室温で16時間撹拌した。反応混合物に酢酸エチル、飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、水および飽和塩化ナトリウム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチル=3:1]で精製後、4mol/L塩化水素-酢酸エチル溶液0.20mL、アセトンを加え、固形物を濾取し、白色固体のN’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩60mgを得た。
1H-NMR(DMSO-d6)δ値:1.72-1.79(4H,m),2.26-2.35(6H,m),2.69-2.81(4H,m),2.98-3.15(3H,m),4.33-4.41(2H,m),7.07-7.34(3H,m),7.60-7.65(2H,m),7.82-7.88(1H,m),8.24-8.62(1H,m),8.90-10.30(1H,m),10.77-11.29(1H,m).
Example 3
Figure JPOXMLDOC01-appb-I000120
2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.13 g and N-methylformamide 2.6 To the mL mixture, 0.11 g of p-toluenesulfonyl chloride was added and stirred at room temperature for 16 hours. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate = 3: 1], 0.20 mL of 4 mol / L hydrogen chloride-ethyl acetate solution and acetone were added, and the solid was collected by filtration. N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl as a white solid ) -N-methylimidoformamide hydrochloride 60 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.72-1.79 (4H, m), 2.26-2.35 (6H, m), 2.69-2.81 (4H, m), 2.98-3.15 (3H, m), 4.33 -4.41 (2H, m), 7.07-7.34 (3H, m), 7.60-7.65 (2H, m), 7.82-7.88 (1H, m), 8.24-8.62 (1H, m), 8.90-10.30 (1H, m), 10.77-11.29 (1H, m).
実施例4
Figure JPOXMLDOC01-appb-I000121
実施例3と同様の手法により、2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン114mgから白色固体のN’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチルイミドホルムアミドの塩酸塩66mgを得た。
1H-NMR(DMSO-d6)δ値:1.11-1.27(3H,m),1.71-1.79(4H,m),2.15-2.36(6H,m),2.69-2.80(4H,m),3.33-3.57(2H,m),4.33-4.42(2H,m),7.07-7.36(3H,m),7.60-7.65(2H,m),7.82-7.88(1H,m),8.16-8.70(1H,m),9.07-10.38(1H,m),10.93-11.46(1H,m).
Example 4
Figure JPOXMLDOC01-appb-I000121
In the same manner as in Example 3, 2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) From 114 mg of aniline to N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl as a white solid 66 mg of phenyl) -N-ethylimidoformamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.11-1.27 (3H, m), 1.71-1.79 (4H, m), 2.15-2.36 (6H, m), 2.69-2.80 (4H, m), 3.33 -3.57 (2H, m), 4.33-4.42 (2H, m), 7.07-7.36 (3H, m), 7.60-7.65 (2H, m), 7.82-7.88 (1H, m), 8.16-8.70 (1H, m), 9.07-10.38 (1H, m), 10.93-11.46 (1H, m).
実施例5
Figure JPOXMLDOC01-appb-I000122
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩200mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン186mgおよびメタノール2mLの混合物を1時間加熱還流した。反応混合物を室温まで冷却し、水、酢酸エチルを加え、飽和炭酸水素ナトリウム水溶液でpH9.5に調整した。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DNH型シリカゲル、ヘキサン:酢酸エチル=8:1]で精製し、4.9mol/L塩化水素-酢酸エチル溶液0.20mLを加え、固形物を濾取し、白色固体のN’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩252mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.29(3H,m),1.70-1.79(4H,m),2.28-2.32(6H,s),2.67-2.81(4H,m),3.23-3.30(3H,m),3.58-3.74(2H,m),4.37(2H,s),7.10(1H,d,J=8.0Hz),7.21-7.25(1H,m),7.28(1H,s),7.60-7.64(2H,m),7.84(1H,s),8.27-8.46(1H,m),10.82-11.05(1H,m).
Example 5
Figure JPOXMLDOC01-appb-I000122
2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 200 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalene A mixture of -2-yl) ethanone 186 mg and methanol 2 mL was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, water and ethyl acetate were added, and the pH was adjusted to 9.5 with a saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DNH type silica gel, hexane: ethyl acetate = 8: 1], 0.20 mL of a 4.9 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration. N ′-(2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) as a white solid 252 mg of hydrochloride salt of -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.29 (3H, m), 1.70-1.79 (4H, m), 2.28-2.32 (6H, s), 2.67-2.81 (4H, m), 3.23 -3.30 (3H, m), 3.58-3.74 (2H, m), 4.37 (2H, s), 7.10 (1H, d, J = 8.0Hz), 7.21-7.25 (1H, m), 7.28 (1H, s ), 7.60-7.64 (2H, m), 7.84 (1H, s), 8.27-8.46 (1H, m), 10.82-11.05 (1H, m).
実施例6
Figure JPOXMLDOC01-appb-I000123
実施例5と同様の手法により、2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩0.36g、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)プロパン-1-オン0.48gから白色固体のN’-(2,5-ジメチル-4-((5-メチル-4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩0.25gを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.28(3H,m),1.71-1.79(4H,m),2.27-2.32(6H,m),2.44(3H,s),2.70-2.79(4H,m),3.22-3.29(3H,m),3.46-3.84(2H,m),4.27(2H,s),7.09-7.14(1H,m),7.20-7.23(1H,m),7.27(1H,s),7.30-7.34(2H,m),8.26-8.44(1H,m),10.80-11.01(1H,m).
Example 6
Figure JPOXMLDOC01-appb-I000123
According to the same procedure as in Example 5, 0.36 g of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- ( From 0.48 g of 5,6,7,8-tetrahydronaphthalen-2-yl) propan-1-one to N ′-(2,5-dimethyl-4-((5-methyl-4- (5,6 , 7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide hydrochloride 0.25 g was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.28 (3H, m), 1.71-1.79 (4H, m), 2.27-2.32 (6H, m), 2.44 (3H, s), 2.70-2.79 (4H, m), 3.22-3.29 (3H, m), 3.46-3.84 (2H, m), 4.27 (2H, s), 7.09-7.14 (1H, m), 7.20-7.23 (1H, m), 7.27 (1H, s), 7.30-7.34 (2H, m), 8.26-8.44 (1H, m), 10.80-11.01 (1H, m).
実施例7
Figure JPOXMLDOC01-appb-I000124
実施例5と同様の手法により、2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩100mg、2-ブロモ-1-(5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン108mgから白色固体のN’-(2,5-ジメチル-4-((4-(5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩142mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.32(15H,m),1.63-1.69(4H,m),2.31(3H,s),2.33(3H,s),3.23-3.30(3H,m),3.58-3.73(2H,m),4.39(2H,s),7.21-7.25(1H,m),7.29(1H,s),7.36(1H,d,J=8.2Hz),7.64(1H,dd,J=8.2,1.9Hz),7.86(1H,d,J=1.9Hz),7.90(1H,s),8.26-8.44(1H,m),10.82-11.04(1H,m).
Example 7
Figure JPOXMLDOC01-appb-I000124
In the same manner as in Example 5, 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 100 mg, 2-bromo-1- (5 , 5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) ethanone from 108 mg of white solid N ′-(2,5-dimethyl-4-((4- (5 Of 5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide 142 mg of hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.32 (15H, m), 1.63-1.69 (4H, m), 2.31 (3H, s), 2.33 (3H, s), 3.23-3.30 (3H , m), 3.58-3.73 (2H, m), 4.39 (2H, s), 7.21-7.25 (1H, m), 7.29 (1H, s), 7.36 (1H, d, J = 8.2Hz), 7.64 ( 1H, dd, J = 8.2,1.9Hz), 7.86 (1H, d, J = 1.9Hz), 7.90 (1H, s), 8.26-8.44 (1H, m), 10.82-11.04 (1H, m).
実施例8
Figure JPOXMLDOC01-appb-I000125
実施例5と同様の手法により、2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩200mg、2-ブロモ-1-(インダン-5-イル)エタノン175mgから淡黄色固体のN’-(4-((4-(インダン-5-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩245mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.28(3H,m),1.98-2.09(2H,m),2.28-2.35(6H,m),2.83-2.93(4H,m),3.21-3.30(3H,m),3.58-3.68(2H,m),4.37(2H,s),7.21-7.25(1H,m),7.27(1H,d,J=7.7Hz),7.29(1H,s),7.69(1H,d,J=7.7Hz),7.78(1H,s),7.85(1H,s),8.27-8.45(1H,m),10.69-10.94(1H,m).
Example 8
Figure JPOXMLDOC01-appb-I000125
In the same manner as in Example 5, 200 mg of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (indane -5-yl) ethanone to 175 mg of light yellow solid N ′-(4-((4- (indan-5-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) 245 mg of hydrochloride salt of -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.28 (3H, m), 1.98-2.09 (2H, m), 2.28-2.35 (6H, m), 2.83-2.93 (4H, m), 3.21 -3.30 (3H, m), 3.58-3.68 (2H, m), 4.37 (2H, s), 7.21-7.25 (1H, m), 7.27 (1H, d, J = 7.7Hz), 7.29 (1H, s ), 7.69 (1H, d, J = 7.7Hz), 7.78 (1H, s), 7.85 (1H, s), 8.27-8.45 (1H, m), 10.69-10.94 (1H, m).
実施例9
Figure JPOXMLDOC01-appb-I000126
実施例5と同様の手法により、2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩100mg、2-ブロモ-1-(ベンゾシクロヘプタン-2-イル)エタノン94mgから白色固体のN’-(2,5-ジメチル-4-((4-(ベンゾシクロヘプタン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩124mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.30(3H,m),1.51-1.65(4H,m),1.75-1.86(2H,m),2.26-2.35(6H,m),2.73-2.85(4H,m),3.20-3.30(3H,m),3.58-3.66(2H,m),4.38(2H,s),7.16(1H,d,J=7.8Hz),7.21-7.25(1H,m),7.29(1H,s),7.61(1H,dd,J=7.8,1.7Hz),7.66-7.69(1H,m),7.85(1H,s),8.27-8.46(1H,m),10.67-10.88(1H,m).
Example 9
Figure JPOXMLDOC01-appb-I000126
In the same manner as in Example 5, 100 mg of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (benzo From 94 mg of cycloheptan-2-yl) ethanone to N ′-(2,5-dimethyl-4-((4- (benzocycloheptan-2-yl) -1,3-thiazol-2-yl) methyl as a white solid 124 mg of phenyl) -N-ethyl-N-methylimidoformamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.30 (3H, m), 1.51-1.65 (4H, m), 1.75-1.86 (2H, m), 2.26-2.35 (6H, m), 2.73 -2.85 (4H, m), 3.20-3.30 (3H, m), 3.58-3.66 (2H, m), 4.38 (2H, s), 7.16 (1H, d, J = 7.8Hz), 7.21-7.25 (1H , m), 7.29 (1H, s), 7.61 (1H, dd, J = 7.8, 1.7Hz), 7.66-7.69 (1H, m), 7.85 (1H, s), 8.27-8.46 (1H, m), 10.67-10.88 (1H, m).
実施例10
Figure JPOXMLDOC01-appb-I000127
N-イソプロピル-N-メチルホルムアミド0.14gのクロロホルム2.4mL溶液に、塩化オキサリル0.12mLを加え、室温で20分間撹拌した。反応混合物に、2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン0.24gのクロロホルム2.4mL溶液を加え、室温で4時間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物にエタノールを加え、減圧下で溶媒を留去した。得られた残留物に、ジエチルエーテルおよび酢酸エチルを加え、固形物を濾取し、アセトンで洗浄し、白色固体のN’-(2,5-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチル-N-(プロパン-2-イル)イミドホルムアミドのZ塩酸塩0.17gを得た。
1H-NMR(DMSO-d6)δ値:1.25-1.31(6H,m),1.70-1.79(4H,m),2.30(3H,s),2.32(3H,s),2.66-2.80(4H,m),3.12-3.18(3H,m),4.08-4.17(1H,m),4.37(2H,s),7.10(1H,d,J=8.6Hz),7.22-7.31(2H,m),7.59-7.65(2H,m),7.84(1H,s),8.23-8.46(1H,m),10.63-10.93(1H,m).
Example 10
Figure JPOXMLDOC01-appb-I000127
0.12 mL of oxalyl chloride was added to a 2.4 mL chloroform solution of 0.14 g N-isopropyl-N-methylformamide and stirred at room temperature for 20 minutes. To the reaction mixture, 2,5-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 0.24 g of chloroform was added. 2.4 mL solution was added and stirred at room temperature for 4 hours. The solvent of the reaction mixture was distilled off under reduced pressure. Ethanol was added to the obtained residue, and the solvent was distilled off under reduced pressure. Diethyl ether and ethyl acetate were added to the obtained residue, the solid was collected by filtration, washed with acetone, and white solid N ′-(2,5-dimethyl-4-((4- (5,6 , 7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methyl-N- (propan-2-yl) imidoformamide 0.17 g of Z hydrochloride Obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.25-1.31 (6H, m), 1.70-1.79 (4H, m), 2.30 (3H, s), 2.32 (3H, s), 2.66-2.80 (4H , m), 3.12-3.18 (3H, m), 4.08-4.17 (1H, m), 4.37 (2H, s), 7.10 (1H, d, J = 8.6Hz), 7.22-7.31 (2H, m), 7.59-7.65 (2H, m), 7.84 (1H, s), 8.23-8.46 (1H, m), 10.63-10.93 (1H, m).
実施例11
Figure JPOXMLDOC01-appb-I000128
実施例1と同様の手法により、2,5-ジメチル-4-(2-(4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)エチル)アニリン82mgから白色固体のN’-(2,5-ジメチル-4-(2-(4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)エチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩87mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.30(3H,m),1.71-1.80(4H,m),2.23-2.32(6H,m),2.67-2.82(4H,m),3.02-3.12(2H,m),3.20-3.33(5H,m),3.48-3.70(2H,m),7.07-7.18(2H,m),7.22(1H,s),7.61-7.68(2H,m),7.84(1H,s),8.22-8.43(1H,m),10.68-10.91(1H,m).
Example 11
Figure JPOXMLDOC01-appb-I000128
In the same manner as in Example 1, 2,5-dimethyl-4- (2- (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) N '-(2,5-dimethyl-4- (2- (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole-2) from 82 mg of ethyl) aniline 87 mg of hydrochloride of -yl) ethyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.30 (3H, m), 1.71-1.80 (4H, m), 2.23-2.32 (6H, m), 2.67-2.82 (4H, m), 3.02 -3.12 (2H, m), 3.20-3.33 (5H, m), 3.48-3.70 (2H, m), 7.07-7.18 (2H, m), 7.22 (1H, s), 7.61-7.68 (2H, m) 7.84 (1H, s), 8.22-8.43 (1H, m), 10.68-10.91 (1H, m).
実施例12
Figure JPOXMLDOC01-appb-I000129
N-エチル-N-メチルホルムアミド48mgのクロロホルム1.0mL溶液に、塩化オキサリル48μLを加え、室温で15分間撹拌した。反応混合物に、5-アミノ-4-メチル-2-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル0.10gのクロロホルム3.0mL溶液を加え、室温で1時間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルおよびアセトンを加え、固形物を濾取し、黄色固体のN’-(5-シアノ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩88mgを得た。
1H-NMR(DMSO-d6)δ値:1.23-1.33(3H,m),1.71-1.80(4H,m),2.42-2.51(3H,m),2.65-2.81(4H,m),3.25-3.34(3H,m),3.59-3.75(2H,m),4.58(2H,s),7.09(1H,d,J=8.3Hz),7.59-7.64(3H,m),7.91(1H,s),7.96-8.04(1H,m),8.34-8.53(1H,m),10.93-11.16(1H,m).
Example 12
Figure JPOXMLDOC01-appb-I000129
To a solution of N-ethyl-N-methylformamide 48 mg in chloroform 1.0 mL was added oxalyl chloride 48 μL, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 5-amino-4-methyl-2-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile 0.10. A solution of g in chloroform (3.0 mL) was added, and the mixture was stirred at room temperature for 1 hour. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and acetone were added to the obtained residue, and the solid matter was collected by filtration, and N ′-(5-cyano-2-methyl-4-((4- (5,6,7,8- 88 mg of hydrochloride of tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.23-1.33 (3H, m), 1.71-1.80 (4H, m), 2.42-2.51 (3H, m), 2.65-2.81 (4H, m), 3.25 -3.34 (3H, m), 3.59-3.75 (2H, m), 4.58 (2H, s), 7.09 (1H, d, J = 8.3Hz), 7.59-7.64 (3H, m), 7.91 (1H, s ), 7.96-8.04 (1H, m), 8.34-8.53 (1H, m), 10.93-11.16 (1H, m).
実施例13
Figure JPOXMLDOC01-appb-I000130
N-エチル-N-メチルホルムアミド33mgのクロロホルム1mL溶液に、塩化オキサリル32μLを加え、室温で10分間撹拌した。反応混合物に、5-クロロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン92mgのクロロホルム2mL溶液を加え、室温で15分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN’-(5-クロロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩102mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.31(3H,m),1.67-1.81(4H,m),2.34(3H,s),2.65-2.81(4H,m),3.20-3.32(3H,m),3.55-3.77(2H,m),4.48(2H,s),7.10(1H,d,J=8.3Hz),7.51(1H,s),7.56-7.68(3H,m),7.86(1H,s),8.30-8.54(1H,m).
Example 13
Figure JPOXMLDOC01-appb-I000130
To a solution of 33 mg of N-ethyl-N-methylformamide in 1 mL of chloroform was added 32 μL of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture, 92 mg of 5-chloro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 15 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid matter was collected by filtration, and a pale yellow solid N ′-(5-chloro-2-methyl-4-((4- (5,6,7,8-tetrahydro 102 mg of the hydrochloride salt of naphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.31 (3H, m), 1.67-1.81 (4H, m), 2.34 (3H, s), 2.65-2.81 (4H, m), 3.20-3.32 (3H, m), 3.55-3.77 (2H, m), 4.48 (2H, s), 7.10 (1H, d, J = 8.3Hz), 7.51 (1H, s), 7.56-7.68 (3H, m), 7.86 (1H, s), 8.30-8.54 (1H, m).
実施例14
Figure JPOXMLDOC01-appb-I000131
N-エチル-N-メチルホルムアミド30mgのクロロホルム1mL溶液に、塩化オキサリル30μLを加え、室温で10分間撹拌した。反応混合物に、5-フルオロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン82mgのクロロホルム2mL溶液を加え、室温で10分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN-エチル-N’-(5-フルオロ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩95mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.30(3H,m),1.69-1.81(4H,m),2.33(3H,s),2.65-2.83(4H,m),3.21-3.34(3H,m),3.56-3.80(2H,m),4.40(2H,s),7.09(1H,d,J=7.6Hz),7.38-7.50(2H,m),7.57-7.67(2H,m),8.29-8.51(1H,m),11.00-11.33(1H,m).
Example 14
Figure JPOXMLDOC01-appb-I000131
30 μL of oxalyl chloride was added to 1 mL of chloroform in 30 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 82 mg of 5-fluoro-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid substance was collected by filtration, and a light yellow solid N-ethyl-N ′-(5-fluoro-2-methyl-4-((4- (5,6,7 , 8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide hydrochloride 95 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.30 (3H, m), 1.69-1.81 (4H, m), 2.33 (3H, s), 2.65-2.83 (4H, m), 3.21-3.34 (3H, m), 3.56-3.80 (2H, m), 4.40 (2H, s), 7.09 (1H, d, J = 7.6Hz), 7.38-7.50 (2H, m), 7.57-7.67 (2H, m ), 8.29-8.51 (1H, m), 11.00-11.33 (1H, m).
実施例15
Figure JPOXMLDOC01-appb-I000132
N-エチル-N-メチルホルムアミド36mgの塩化メチレン5mL溶液に、氷冷下で、塩化オキサリル36μLを加え、室温で15分間撹拌した。反応混合物に、4-メチル-6-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ビフェニル-3-アミン85mgの塩化メチレン2mL溶液を加え、室温で3時間撹拌した。反応混合物に、氷水および飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡黄色固体のN-エチル-N-メチル-N’-(4-メチル-6-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ビフェニル-3-イル)イミドホルムアミドの塩酸塩82mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.29(3H,m),1.70-1.79(4H,m),2.35-2.41(3H,m),2.66-2.80(4H,m),3.21-3.29(3H,m),3.54-3.70(2H,m),4.33(2H,s),7.08(1H,d,J=8.3Hz),7.33-7.49(7H,m),7.53-7.59(2H,m),7.80(1H,s),8.31-8.51(1H,m),10.64-10.87(1H,m).
Example 15
Figure JPOXMLDOC01-appb-I000132
To a solution of 36 mg of N-ethyl-N-methylformamide in 5 mL of methylene chloride was added 36 μL of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 85 mg of 4-methyl-6-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) biphenyl-3-amine. Methylene chloride (2 mL) was added, and the mixture was stirred at room temperature for 3 hours. Ice water and saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. A 5 mol / L hydrogen chloride-ethyl acetate solution was added to the obtained residue, and the solid substance was collected by filtration, and a light yellow solid N-ethyl-N-methyl-N ′-(4-methyl-6-((4 There was obtained 82 mg of hydrochloride salt of-(5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) biphenyl-3-yl) imidoformamide.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.29 (3H, m), 1.70-1.79 (4H, m), 2.35-2.41 (3H, m), 2.66-2.80 (4H, m), 3.21 -3.29 (3H, m), 3.54-3.70 (2H, m), 4.33 (2H, s), 7.08 (1H, d, J = 8.3Hz), 7.33-7.49 (7H, m), 7.53-7.59 (2H , m), 7.80 (1H, s), 8.31-8.51 (1H, m), 10.64-10.87 (1H, m).
実施例16
Figure JPOXMLDOC01-appb-I000133
N-エチル-N-メチルホルムアミド34mgのクロロホルム1mL溶液に、塩化オキサリル34μLを加え、室温で30分間撹拌した。反応混合物に、5-(ジフルオロメトキシ)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン79mgのクロロホルム1mL溶液を加え、室温で30分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルおよびアセトンを加え、固形物を濾取し、淡褐色固体のN’-(5-(ジフルオロメトキシ)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩73mgを得た。
1H-NMR(DMSO-d6)δ値:1.23-1.30(3H,m),1.71-1.79(4H,m),2.29-2.34(3H,m),2.66-2.80(4H,m),3.22-3.31(3H,m),3.60-3.70(2H,m),4.37(2H,s),7.09(1H,d,J=7.8Hz),7.23(1H,t,J=73.7Hz),7.35(1H,s),7.45(1H,s),7.58-7.64(2H,m),7.85(1H,s),8.30-8.49(1H,m),10.72-10.90(1H,m).
Example 16
Figure JPOXMLDOC01-appb-I000133
34 μL of oxalyl chloride was added to 1 mL of chloroform in 34 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture, 5- (difluoromethoxy) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) A solution of 79 mg of aniline in 1 mL of chloroform was added, and the mixture was stirred at room temperature for 30 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and acetone were added to the obtained residue, and the solid substance was collected by filtration, and N ′-(5- (difluoromethoxy) -2-methyl-4-((4- (5,6, 73 mg of 7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.23-1.30 (3H, m), 1.71-1.79 (4H, m), 2.29-2.34 (3H, m), 2.66-2.80 (4H, m), 3.22 -3.31 (3H, m), 3.60-3.70 (2H, m), 4.37 (2H, s), 7.09 (1H, d, J = 7.8Hz), 7.23 (1H, t, J = 73.7Hz), 7.35 ( 1H, s), 7.45 (1H, s), 7.58-7.64 (2H, m), 7.85 (1H, s), 8.30-8.49 (1H, m), 10.72-10.90 (1H, m).
実施例17
Figure JPOXMLDOC01-appb-I000134
N-エチル-N-メチルホルムアミド27mgのクロロホルム1mL溶液に、塩化オキサリル26μLを加え、室温で10分間撹拌した。反応混合物に、5-メトキシ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン75mgのクロロホルム2mL溶液を加え、室温で5分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN-エチル-N’-(5-メトキシ-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩97mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.33(3H,m),1.66-1.82(4H,m),2.20-2.30(3H,m),2.63-2.83(4H,m),3.20-3.36(3H,m),3.57-3.73(2H,m),3.84(3H,s),4.29(2H,s),7.02-7.18(2H,m),7.28(1H,s),7.57-7.69(2H,m),7.80(1H,s),8.26-8.53(1H,m),10.70-11.01(1H,m).
Example 17
Figure JPOXMLDOC01-appb-I000134
To a solution of 27 mg of N-ethyl-N-methylformamide in 1 mL of chloroform was added 26 μL of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 75 mg of 5-methoxy-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. Chloroform 2mL solution was added and stirred at room temperature for 5 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid substance was collected by filtration, and a pale yellow solid N-ethyl-N ′-(5-methoxy-2-methyl-4-((4- (5,6,7 , 8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide hydrochloride 97 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.33 (3H, m), 1.66-1.82 (4H, m), 2.20-2.30 (3H, m), 2.63-2.83 (4H, m), 3.20 -3.36 (3H, m), 3.57-3.73 (2H, m), 3.84 (3H, s), 4.29 (2H, s), 7.02-7.18 (2H, m), 7.28 (1H, s), 7.57-7.69 (2H, m), 7.80 (1H, s), 8.26-8.53 (1H, m), 10.70-11.01 (1H, m).
実施例18
Figure JPOXMLDOC01-appb-I000135
2-(5-メチル-4-ニトロ-2-(トリフルオロメチル)フェニル)エタンチオアミド0.12g、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン0.16gおよびエタノール2.0mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物に、ヘキサンを加え、固形物を濾取し、淡褐色固体を得た。得られた淡褐色固体、水0.6mL、エタノール2.4mL、鉄粉58mgおよび塩化アンモニウム11mgの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加え、不溶物を濾去した。濾液の有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、活性炭を加えた。不溶物を濾去後、減圧下で溶媒を留去し、黄色油状物を得た。N-エチル-N-メチルホルムアミド18mgのクロロホルム1.0mL溶液に、塩化オキサリル17μLを加え、室温で10分間撹拌した。反応混合物に、得られた黄色油状物のクロロホルム1.0mL溶液を加え、室温で1時間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物にジエチルエーテルおよび酢酸エチルを加え、固形物を濾取し、アセトンで洗浄し、淡黄色固体のN-エチル-N-メチル-N’-(2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)-5-(トリフルオロメチル)フェニル)イミドホルムアミドの塩酸塩24mgを得た。
1H-NMR(DMSO-d6)δ値:1.23-1.31(3H,m),1.71-1.79(4H,m),2.42(3H,s),2.65-2.82(4H,m),3.24-3.31(3H,m),3.60-3.72(2H,m),4.54(2H,s),7.10(1H,d,J=7.8Hz),7.59-7.65(3H,m),7.86(1H,s),7.88(1H,s),8.35-8.55(1H,m),10.88-11.09(1H,m).
Example 18
Figure JPOXMLDOC01-appb-I000135
2- (5-Methyl-4-nitro-2- (trifluoromethyl) phenyl) ethanethioamide 0.12 g, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl) ethanone 0.16 g A mixture of ethanol and 2.0 mL was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. Hexane was added to the obtained residue, and the solid was collected by filtration to obtain a light brown solid. A mixture of the obtained light brown solid, water 0.6 mL, ethanol 2.4 mL, iron powder 58 mg and ammonium chloride 11 mg was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added, and the insoluble material was removed by filtration. The organic layer of the filtrate was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and activated carbon was added. The insoluble material was removed by filtration, and the solvent was evaporated under reduced pressure to give a yellow oil. 17 μL of oxalyl chloride was added to a 1.0 mL chloroform solution of 18 mg N-ethyl-N-methylformamide and stirred at room temperature for 10 minutes. To the reaction mixture was added a 1.0 mL solution of the obtained yellow oil in chloroform, and the mixture was stirred at room temperature for 1 hour. The solvent of the reaction mixture was distilled off under reduced pressure. Diethyl ether and ethyl acetate were added to the obtained residue, and the solid was collected by filtration, washed with acetone, and pale yellow solid N-ethyl-N-methyl-N ′-(2-methyl-4-(( 4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) -5- (trifluoromethyl) phenyl) imidoformamide hydrochloride 24 mg was obtained. .
1 H-NMR (DMSO-d 6 ) δ value: 1.23-1.31 (3H, m), 1.71-1.79 (4H, m), 2.42 (3H, s), 2.65-2.82 (4H, m), 3.24-3.31 (3H, m), 3.60-3.72 (2H, m), 4.54 (2H, s), 7.10 (1H, d, J = 7.8Hz), 7.59-7.65 (3H, m), 7.86 (1H, s), 7.88 (1H, s), 8.35-8.55 (1H, m), 10.88-11.09 (1H, m).
実施例19
Figure JPOXMLDOC01-appb-I000136
N-エチル-N-メチルホルムアミド107mgのクロロホルム1.5mL溶液に、塩化オキサリル105μLを加え、室温で15分間撹拌した。反応混合物に、2-メチル-5-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン240mgのクロロホルム1.5mL溶液を加え、室温で20分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄後、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に5mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に酢酸エチルおよびジイソプロピルエーテルを加え、固形物を濾取し、淡褐色固体のN-エチル-N-メチル-N’-(2-メチル-5-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)イミドホルムアミドの塩酸塩220mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.32(9H,m),1.70-1.82(4H,m),2.20-2.32(3H,m),2.74-2.84(4H,m),3.20-3.34(3H,m),3.57-3.71(2H,m),4.26(2H,s),4.59-4.72(1H,m),7.06-7.14(2H,m),7.28(1H,s),7.58-7.68(2H,m),7.80(1H,s),8.24-8.46(1H,m),10.64-10.84(1H,m).
Example 19
Figure JPOXMLDOC01-appb-I000136
To a solution of 107 mg of N-ethyl-N-methylformamide in 1.5 mL of chloroform was added 105 μL of oxalyl chloride, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture was added 2-methyl-5- (propan-2-yloxy) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl. ) Methyl) aniline (240 mg) in chloroform (1.5 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the obtained residue. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. A 5 mol / L hydrogen chloride-ethyl acetate solution was added to the obtained residue, and the solvent was distilled off under reduced pressure. Ethyl acetate and diisopropyl ether were added to the obtained residue, the solid was collected by filtration, and a light brown solid N-ethyl-N-methyl-N ′-(2-methyl-5- (propan-2-yloxy) 220 mg of hydrochloride of -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) imidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.32 (9H, m), 1.70-1.82 (4H, m), 2.20-2.32 (3H, m), 2.74-2.84 (4H, m), 3.20 -3.34 (3H, m), 3.57-3.71 (2H, m), 4.26 (2H, s), 4.59-4.72 (1H, m), 7.06-7.14 (2H, m), 7.28 (1H, s), 7.58 -7.68 (2H, m), 7.80 (1H, s), 8.24-8.46 (1H, m), 10.64-10.84 (1H, m).
実施例20
Figure JPOXMLDOC01-appb-I000137
N-エチル-N-メチルホルムアミド27mgのクロロホルム1mL溶液に、塩化オキサリル27μLを加え、室温で15分間撹拌した。反応混合物に、5-エチニル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン56mgのクロロホルム1mL溶液を加え、室温で30分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物にアセトン、酢酸エチルおよびジエチルエーテルを加え、固形物を濾取し、褐色固体のN-エチル-N’-(5-エチニル-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩45mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.30(3H,m),1.72-1.79(4H,m),2.32-2.37(3H,m),2.65-2.81(4H,m),3.20-3.31(3H,m),3.58-3.72(2H,m),4.50(2H,s),4.53(1H,s),7.10(1H,d,J=8.0Hz),7.45(1H,s),7.60-7.65(3H,m),7.85(1H,m),8.32-8.50(1H,m),10.58-10.76(1H,m).
Example 20
Figure JPOXMLDOC01-appb-I000137
To a solution of N-ethyl-N-methylformamide 27 mg in 1 mL of chloroform was added 27 μL of oxalyl chloride, and the mixture was stirred at room temperature for 15 minutes. To the reaction mixture, 56 mg of 5-ethynyl-2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline Chloroform 1mL solution was added and stirred at room temperature for 30 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Acetone, ethyl acetate and diethyl ether were added to the obtained residue, and the solid was collected by filtration, and N-ethyl-N ′-(5-ethynyl-2-methyl-4-((4- (5 , 6,7,8-Tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide hydrochloride 45 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.30 (3H, m), 1.72-1.79 (4H, m), 2.32-2.37 (3H, m), 2.65-2.81 (4H, m), 3.20 -3.31 (3H, m), 3.58-3.72 (2H, m), 4.50 (2H, s), 4.53 (1H, s), 7.10 (1H, d, J = 8.0Hz), 7.45 (1H, s), 7.60-7.65 (3H, m), 7.85 (1H, m), 8.32-8.50 (1H, m), 10.58-10.76 (1H, m).
実施例21
Figure JPOXMLDOC01-appb-I000138
N-エチル-N-メチルホルムアミド42mgの塩化メチレン1mL溶液に、氷冷下で、塩化オキサリル42μLを加え、室温で20分間撹拌した。反応混合物に、氷冷下で、2-メチル-5-(プロパン-2-イル)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリンの塩酸塩100mgの塩化メチレン10mL溶液を加え、室温で50分間撹拌した。反応混合物に、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=2:1-0:100]で精製し、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体のN-エチル-N-メチル-N’-(2-メチル-5-(プロパン-2-イル)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)イミドホルムアミドの塩酸塩87mgを得た。
1H-NMR(DMSO-d6)δ値:1.16(6H,d,J=6.8Hz),1.23-1.30(3H,m),1.70-1.79(4H,m),2.28-2.31(3H,m),2.66-2.79(4H,m),3.22-3.31(4H,m),3.59-3.77(2H,m),4.42(2H,s),7.09(1H,d,J=8.0Hz),7.28-7.34(2H,m),7.59-7.65(2H,m),7.83(1H,s),8.22-8.43(1H,m),10.67-10.89(1H,m).
Example 21
Figure JPOXMLDOC01-appb-I000138
To a solution of 42 mg of N-ethyl-N-methylformamide in 1 mL of methylene chloride was added 42 μL of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture was added 2-methyl-5- (propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3- under ice cooling. A solution of thiazol-2-yl) methyl) aniline hydrochloride (100 mg) in methylene chloride (10 mL) was added, and the mixture was stirred at room temperature for 50 minutes. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 2: 1-0: 100], a 5 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was collected by filtration. White solid N-ethyl-N-methyl-N ′-(2-methyl-5- (propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) 87 mg of hydrochloride salt of) -1,3-thiazol-2-yl) methyl) phenyl) imidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.16 (6H, d, J = 6.8 Hz), 1.23-1.30 (3H, m), 1.70-1.79 (4H, m), 2.28-2.31 (3H, m ), 2.66-2.79 (4H, m), 3.22-3.31 (4H, m), 3.59-3.77 (2H, m), 4.42 (2H, s), 7.09 (1H, d, J = 8.0Hz), 7.28- 7.34 (2H, m), 7.59-7.65 (2H, m), 7.83 (1H, s), 8.22-8.43 (1H, m), 10.67-10.89 (1H, m).
実施例22
Figure JPOXMLDOC01-appb-I000139
反応A:N-エチル-N-メチルホルムアミド41mgの塩化メチレン1mL溶液に、氷冷下で、塩化オキサリル40μLを加え、室温で20分間撹拌した。反応混合物に、氷冷下で、5-(tert-ブチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリンの塩酸塩100mgの塩化メチレン10mL溶液を加え、室温で50分間撹拌した。反応混合物に、氷冷下で、トリエチルアミン130μLを加え、室温で1時間30分間撹拌し、反応混合物Aを得た。
反応B:N-エチル-N-メチルホルムアミド41mgの塩化メチレン2mL溶液に、塩化オキサリル40μLを加え、室温で20分間撹拌し、反応混合物Bを得た。
氷冷下で、反応混合物Aに反応混合物Bを加え、室温で10分間撹拌した。反応混合物に、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DNH型シリカゲル、ヘキサン:トルエンの勾配溶離=100:0-20:1]で精製し、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体のN’-(5-(tert-ブチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩67mgを得た。
1H-NMR(DMSO-d6)δ値:1.23-1.29(3H,m),1.40(9H,s),1.71-1.79(4H,m),2.25-2.29(3H,m),2.65-2.81(4H,m),3.21-3.31(3H,m),3.60-3.72(2H,m),4.62(2H,s),7.10(1H,d,J=7.8Hz),7.27-7.32(2H,m),7.61-7.66(2H,m),7.83(1H,s),8.27-8.47(1H,m),10.68-10.87(1H,m).
Example 22
Figure JPOXMLDOC01-appb-I000139
Reaction A: To 1 mL of methylene chloride in 41 mg of N-ethyl-N-methylformamide was added 40 μL of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was stirred under ice cooling with 5- (tert-butyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole- 2-yl) methyl) aniline hydrochloride (100 mg) in methylene chloride (10 mL) was added, and the mixture was stirred at room temperature for 50 minutes. To the reaction mixture, 130 μL of triethylamine was added under ice-cooling, and the mixture was stirred at room temperature for 1 hour and 30 minutes to obtain reaction mixture A.
Reaction B: 40 μL of oxalyl chloride was added to 2 mL of methylene chloride in 41 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 20 minutes to obtain a reaction mixture B.
Under ice-cooling, reaction mixture B was added to reaction mixture A and stirred at room temperature for 10 minutes. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DNH type silica gel, hexane: toluene gradient elution = 100: 0-20: 1], 5 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was filtered. N ′-(5- (tert-butyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazole) 67 mg of hydrochloride of -2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.23-1.29 (3H, m), 1.40 (9H, s), 1.71-1.79 (4H, m), 2.25-2.29 (3H, m), 2.65-2.81 (4H, m), 3.21-3.31 (3H, m), 3.60-3.72 (2H, m), 4.62 (2H, s), 7.10 (1H, d, J = 7.8Hz), 7.27-7.32 (2H, m ), 7.61-7.66 (2H, m), 7.83 (1H, s), 8.27-8.47 (1H, m), 10.68-10.87 (1H, m).
実施例23
Figure JPOXMLDOC01-appb-I000140
N-エチル-N-メチルホルムアミド26mgのクロロホルム1.0mL溶液に、塩化オキサリル26μLを加え、室温で20分間撹拌した。反応混合物に、5-(ジフルオロメチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン58mgのクロロホルム1.0mL溶液を加え、室温で20分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルおよびアセトンを加え、固形物を濾取し、淡褐色固体のN’-(5-(ジフルオロメチル)-2-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩28mgを得た。
1H-NMR(CD3OD)δ値:1.34-1.41(3H,m),1.78-1.86(4H,m),2.41(3H,m),2.73-2.86(4H,m),3.20-3.40(3H,m),3.63-3.73(2H,m),4.56(2H,s),7.08(1H,d,J=7.8Hz),7.18(1H,t,J=54.8Hz),7.48(1H,s),7.53-7.58(2H,m),7.60(1H,s),7.63(1H,s),8.22-8.39(1H,m).
Example 23
Figure JPOXMLDOC01-appb-I000140
To a 1.0 mL chloroform solution of 26 mg N-ethyl-N-methylformamide was added 26 μL oxalyl chloride, and the mixture was stirred at room temperature for 20 minutes. To the reaction mixture, 5- (difluoromethyl) -2-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) A solution of aniline (58 mg) in chloroform (1.0 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and acetone were added to the obtained residue, and the solid matter was collected by filtration, and N ′-(5- (difluoromethyl) -2-methyl-4-((4- (5,6, There was obtained 28 mg of hydrochloride salt of 7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide.
1 H-NMR (CD 3 OD) δ value: 1.34-1.41 (3H, m), 1.78-1.86 (4H, m), 2.41 (3H, m), 2.73-2.86 (4H, m), 3.20-3.40 ( 3H, m), 3.63-3.73 (2H, m), 4.56 (2H, s), 7.08 (1H, d, J = 7.8Hz), 7.18 (1H, t, J = 54.8Hz), 7.48 (1H, s ), 7.53-7.58 (2H, m), 7.60 (1H, s), 7.63 (1H, s), 8.22-8.39 (1H, m).
実施例24
Figure JPOXMLDOC01-appb-I000141
N-エチル-N-メチルホルムアミド32mgのクロロホルム1mL溶液に、塩化オキサリル31μLを加え、室温で10分間撹拌した。反応混合物に、2-フルオロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン85mgのクロロホルム2mL溶液を加え、室温で10分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN-エチル-N’-(2-フルオロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩92mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.30(3H,m),1.67-1.80(4H,m),2.32(3H,s),2.64-2.82(4H,m),3.22-3.34(3H,m),3.58-3.75(2H,m),4.43(2H,s),7.10(1H,d,J=8.3Hz),7.38-7.48(2H,m),7.58-7.65(2H,m),7.87(1H,s),8.43-8.64(1H,m),11.15-11.39(1H,m).
Example 24
Figure JPOXMLDOC01-appb-I000141
To a solution of N-ethyl-N-methylformamide 32 mg in 1 mL of chloroform was added 31 μL of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 85 mg of 2-fluoro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid matter was collected by filtration, and light yellow solid N-ethyl-N ′-(2-fluoro-5-methyl-4-((4- (5,6,7 , 8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide hydrochloride 92 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.30 (3H, m), 1.67-1.80 (4H, m), 2.32 (3H, s), 2.64-2.82 (4H, m), 3.22-3.34 (3H, m), 3.58-3.75 (2H, m), 4.43 (2H, s), 7.10 (1H, d, J = 8.3Hz), 7.38-7.48 (2H, m), 7.58-7.65 (2H, m ), 7.87 (1H, s), 8.43-8.64 (1H, m), 11.15-11.39 (1H, m).
実施例25
Figure JPOXMLDOC01-appb-I000142
N-エチル-N-メチルホルムアミド25mgのクロロホルム1mL溶液に、塩化オキサリル25μLを加え、室温で30分間撹拌した。反応混合物を、2-アミノ-4-メチル-5-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)ベンゾニトリル52mgのクロロホルム2mL懸濁液に加え、室温で2時間撹拌した。反応混合物に、クロロホルムおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[ヘキサン:酢酸エチルの勾配溶離=4:1-1:1]で精製し、無色油状物のN’-(2-シアノ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミド8mgを得た。
1H-NMR(CDCl3)δ値:1.22-1.29(3H,m),1.78-1.86(4H,m),2.31(3H,s),2.76-2.87(4H,m),3.01-3.11(3H,m),3.31-3.63(2H,m),4.30(2H,s),6.77-6.87(1H,m),7.10(1H,d,J=8.0Hz),7.25-7.29(1H,m),7.43(1H,s),7.53-7.69(3H,m).
Example 25
Figure JPOXMLDOC01-appb-I000142
To a solution of N-ethyl-N-methylformamide 25 mg in 1 mL of chloroform was added 25 μL of oxalyl chloride, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was charged with 2-amino-4-methyl-5-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) benzonitrile 52 mg. In chloroform (2 mL) and stirred at room temperature for 2 hours. To the reaction mixture, chloroform and a saturated aqueous sodium hydrogen carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [gradient elution of hexane: ethyl acetate = 4: 1-1: 1], and N ′-(2-cyano-5-methyl-4- ( 8 mg of (4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.22-1.29 (3H, m), 1.78-1.86 (4H, m), 2.31 (3H, s), 2.76-2.87 (4H, m), 3.01-3.11 (3H , m), 3.31-3.63 (2H, m), 4.30 (2H, s), 6.77-6.87 (1H, m), 7.10 (1H, d, J = 8.0Hz), 7.25-7.29 (1H, m), 7.43 (1H, s), 7.53-7.69 (3H, m).
実施例26
Figure JPOXMLDOC01-appb-I000143
N-エチル-N-メチルホルムアミド13mgのクロロホルム1mL溶液に、塩化オキサリル13μLを加え、室温で10分間撹拌した。反応混合物に、2-クロロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン37mgのクロロホルム2mL溶液を加え、室温で5分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN’-(2-クロロ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩27mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.30(3H,m),1.70-1.80(4H,m),2.35(3H,s),2.66-2.81(4H,m),3.22-3.33(3H,m),3.60-3.80(2H,m),4.45(2H,s),7.10(1H,d,J=8.6Hz),7.49(1H,s),7.57-7.65(3H,m),7.87(1H,s),8.38-8.60(1H,m),10.95-11.18(1H,m).
Example 26
Figure JPOXMLDOC01-appb-I000143
To a solution of N-ethyl-N-methylformamide 13 mg in 1 mL of chloroform was added 13 μL of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 37 mg of 2-chloro-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline. Chloroform 2mL solution was added and stirred at room temperature for 5 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid substance was collected by filtration, and the pale yellow solid N ′-(2-chloro-5-methyl-4-((4- (5,6,7,8-tetrahydro 27 mg of hydrochloride of naphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.30 (3H, m), 1.70-1.80 (4H, m), 2.35 (3H, s), 2.66-2.81 (4H, m), 3.22-3.33 (3H, m), 3.60-3.80 (2H, m), 4.45 (2H, s), 7.10 (1H, d, J = 8.6Hz), 7.49 (1H, s), 7.57-7.65 (3H, m), 7.87 (1H, s), 8.38-8.60 (1H, m), 10.95-11.18 (1H, m).
実施例27
Figure JPOXMLDOC01-appb-I000144
N-エチル-N-メチルホルムアミド28mgのクロロホルム1mL溶液に、塩化オキサリル27μLを加え、室温で5分間撹拌した。反応混合物に、2-メトキシ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン77mgのクロロホルム2mL溶液を加え、室温で10分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN-エチル-N’-(2-メトキシ-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-メチルイミドホルムアミドの塩酸塩93mgを得た。
1H-NMR(DMSO-d6)δ値:1.19-1.28(3H,m),1.70-1.80(4H,m),2.27(3H,s),2.65-2.81(4H,m),3.18-3.31(3H,m),3.57-3.68(2H,m),3.85(3H,s),4.41(2H,s),7.10(1H,d,J=7.6Hz),7.22-7.29(2H,m),7.59-7.66(2H,m),7.84(1H,s),8.34-8.54(1H,m),10.62-10.84(1H,m).
Example 27
Figure JPOXMLDOC01-appb-I000144
27 μL of oxalyl chloride was added to 1 mL of chloroform in 28 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 5 minutes. To the reaction mixture, 77 mg of 2-methoxy-5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline A 2 mL solution of chloroform was added, and the mixture was stirred at room temperature for 10 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid matter was collected by filtration, and light yellow solid N-ethyl-N ′-(2-methoxy-5-methyl-4-((4- (5,6,7 , 8-Tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-methylimidoformamide hydrochloride 93 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.19-1.28 (3H, m), 1.70-1.80 (4H, m), 2.27 (3H, s), 2.65-2.81 (4H, m), 3.18-3.31 (3H, m), 3.57-3.68 (2H, m), 3.85 (3H, s), 4.41 (2H, s), 7.10 (1H, d, J = 7.6Hz), 7.22-7.29 (2H, m), 7.59-7.66 (2H, m), 7.84 (1H, s), 8.34-8.54 (1H, m), 10.62-10.84 (1H, m).
実施例28
Figure JPOXMLDOC01-appb-I000145
N-エチル-N-メチルホルムアミド84mgのクロロホルム2.0mL溶液に、塩化オキサリル82μLを加え、室温で10分間撹拌した。反応混合物に、5-メチル-2-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリンの塩酸塩206mgを加え、室温で20分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物にアセトンおよびジイソプロピルエーテルを加え、固形物を濾取し、白色固体のN-エチル-N-メチル-N’-(5-メチル-2-(プロパン-2-イルオキシ)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)イミドホルムアミドの塩酸塩216mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.34(9H,m),1.70-1.81(4H,m),2.26(3H,s),2.68-2.86(4H,m),3.20-3.32(3H,m),3.58-3.70(2H,m),4.39(2H,s),4.56-4.68(1H,m),7.10(1H,d,J=7.8Hz),7.20-7.32(2H,m),7.59-7.67(2H,m),7.84(1H,s),8.32-8.54(1H,m),10.56-10.71(1H,m).
Example 28
Figure JPOXMLDOC01-appb-I000145
To a 2.0 mL solution of 84 mg of N-ethyl-N-methylformamide in chloroform was added 82 μL of oxalyl chloride, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 5-methyl-2- (propan-2-yloxy) -4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl. ) 206 mg of methyl) aniline hydrochloride was added and stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Acetone and diisopropyl ether are added to the obtained residue, and the solid is collected by filtration to give N-ethyl-N-methyl-N ′-(5-methyl-2- (propan-2-yloxy) -4 as a white solid. 216 mg of hydrochloride of-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) imidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.34 (9H, m), 1.70-1.81 (4H, m), 2.26 (3H, s), 2.68-2.86 (4H, m), 3.20-3.32 (3H, m), 3.58-3.70 (2H, m), 4.39 (2H, s), 4.56-4.68 (1H, m), 7.10 (1H, d, J = 7.8Hz), 7.20-7.32 (2H, m ), 7.59-7.67 (2H, m), 7.84 (1H, s), 8.32-8.54 (1H, m), 10.56-10.71 (1H, m).
実施例29
Figure JPOXMLDOC01-appb-I000146
N-エチル-N-メチルホルムアミド101mgのクロロホルム1.5mL溶液に、塩化オキサリル100μLを加え、室温で5分間撹拌した。反応混合物に、2-(ジフルオロメトキシ)-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン233mgのクロロホルム1.5mL溶液を加え、室温で40分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に、酢酸エチルおよび飽和炭酸水素ナトリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、酢酸エチルおよび5mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に酢酸エチル、アセトンおよびジイソプロピルエーテルを加え、固形物を濾取し、淡黄色固体のN’-(2-(ジフルオロメトキシ)-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩196mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.30(3H,m),1.70-1.80(4H,m),2.35(3H,s),2.68-2.82(4H,m),3.20-3.34(3H,m),3.56-3.80(2H,m),4.44(2H,s),7.00-7.24(1H,m),7.38-7.46(2H,m),7.58-7.65(2H,m),7.87(1H,s),8.38-8.58(1H,m),10.92-11.10(1H,m).
Example 29
Figure JPOXMLDOC01-appb-I000146
To a 1.5 mL chloroform solution of 101 mg N-ethyl-N-methylformamide was added 100 μL oxalyl chloride, and the mixture was stirred at room temperature for 5 minutes. To the reaction mixture was added 2- (difluoromethoxy) -5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) A solution of aniline 233 mg in chloroform 1.5 mL was added, and the mixture was stirred at room temperature for 40 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate and saturated aqueous sodium hydrogen carbonate solution were added to the obtained residue. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Ethyl acetate and a 5 mol / L hydrogen chloride-ethyl acetate solution were added to the obtained residue, and the solvent was distilled off under reduced pressure. Ethyl acetate, acetone and diisopropyl ether were added to the obtained residue, and the solid matter was collected by filtration, and light yellow solid N ′-(2- (difluoromethoxy) -5-methyl-4-((4- (5 , 6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide hydrochloride 196 mg was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.30 (3H, m), 1.70-1.80 (4H, m), 2.35 (3H, s), 2.68-2.82 (4H, m), 3.20-3.34 (3H, m), 3.56-3.80 (2H, m), 4.44 (2H, s), 7.00-7.24 (1H, m), 7.38-7.46 (2H, m), 7.58-7.65 (2H, m), 7.87 (1H, s), 8.38-8.58 (1H, m), 10.92-11.10 (1H, m).
実施例30
Figure JPOXMLDOC01-appb-I000147
反応A:2-(4-アミノ-2-メチル-5-(プロパン-2-イル)フェニル)エタンチオアミド90mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン97mgおよびメタノール5mLの混合物を50分間加熱還流した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡黄色固体を得た。
反応B:N-エチル-N-メチルホルムアミド71mgの塩化メチレン2mL溶液に、塩化オキサリル70μLを加え、室温で1時間撹拌した。反応混合物に、氷冷下で、反応Aで得られた淡黄色固体の塩化メチレン2mL溶液およびトリエチルアミン28μLを加え、氷冷下で25分間撹拌した。反応混合物に、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DNH型シリカゲル、ヘキサン:トルエンの勾配溶離=100:0-10:1]で精製し、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、微赤色固体のN-エチル-N-メチル-N’-(5-メチル-2-(プロパン-2-イル)-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)イミドホルムアミドの塩酸塩100mgを得た。
1H-NMR(DMSO-d6)δ値:1.18(6H,d,J=6.8Hz),1.22-1.28(3H,m),1.70-1.79(4H,m),2.31(3H,s),2.66-2.80(4H,m),3.17-3.29(4H,m),3.57-3.70(2H,m),4.41(2H,s),7.10(1H,d,J=8.0Hz),7.20(1H,s),7.45(1H,s),7.59-7.65(2H,m),7.83(1H,s),8.27-8.45(1H,m),10.83-10.98(1H,m).
Example 30
Figure JPOXMLDOC01-appb-I000147
Reaction A: 2- (4-Amino-2-methyl-5- (propan-2-yl) phenyl) ethanethioamide 90 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalen-2-yl ) A mixture of 97 mg ethanone and 5 mL methanol was heated to reflux for 50 minutes. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. A 4 mol / L hydrogen chloride-ethyl acetate solution was added to the obtained residue, and the solid was collected by filtration to give a pale yellow solid.
Reaction B: 70 μL of oxalyl chloride was added to 2 mL of methylene chloride in 71 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 1 hour. To the reaction mixture, 2 mL of a methylene chloride solution of light yellow solid obtained in Reaction A and 28 μL of triethylamine were added under ice cooling, and the mixture was stirred for 25 minutes under ice cooling. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DNH type silica gel, hexane: toluene gradient elution = 100: 0-10: 1], 5 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was filtered. N-ethyl-N-methyl-N ′-(5-methyl-2- (propan-2-yl) -4-((4- (5,6,7,8-tetrahydronaphthalene) 100 mg of hydrochloride of -2-yl) -1,3-thiazol-2-yl) methyl) phenyl) imidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.18 (6H, d, J = 6.8 Hz), 1.22-1.28 (3H, m), 1.70-1.79 (4H, m), 2.31 (3H, s), 2.66-2.80 (4H, m), 3.17-3.29 (4H, m), 3.57-3.70 (2H, m), 4.41 (2H, s), 7.10 (1H, d, J = 8.0Hz), 7.20 (1H, s), 7.45 (1H, s), 7.59-7.65 (2H, m), 7.83 (1H, s), 8.27-8.45 (1H, m), 10.83-10.98 (1H, m).
実施例31
Figure JPOXMLDOC01-appb-I000148
反応A:2-(4-アミノ-5-(tert-ブチル)-2-メチルフェニル)エタンチオアミドの塩酸塩50mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン44mgおよびエタノール5mLの混合物を、70℃で2時間撹拌した。反応混合物を室温まで冷却し、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、淡黄色固体を得た。
反応B:N-エチル-N-メチルホルムアミド12mgの塩化メチレン1mL溶液に、塩化オキサリル12μLを加え、室温で30分間撹拌した。反応混合物を、反応Aで得られた淡黄色固体、トリエチルアミン12μLおよび塩化メチレン1mLの混合物に加え、室温で30分間撹拌し、反応混合物Bを得た。
反応C:N-エチル-N-メチルホルムアミド12mgの塩化メチレン1mL溶液に、塩化オキサリル12μLを加え、室温で15分間撹拌し、反応混合物Cを得た。
反応混合物Bに反応混合物Cを加え、室温で30分間撹拌した。反応混合物に、10%炭酸カリウム水溶液を加えた。有機層を分取し、水層をクロロホルムで抽出した。有機層および抽出液を併せ、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DNH型シリカゲル、ヘキサン]で精製し、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体のN’-(2-(tert-ブチル)-5-メチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩14mgを得た。
1H-NMR(DMSO-d6)δ値:1.21-1.29(3H,m),1.34(9H,s),1.72-1.78(4H,m),2.32(3H,s),2.66-2.79(4H,m),3.19-3.29(3H,m),3.54-3.66(2H,m),4.43(2H,s),7.10(1H,d,J=7.6Hz),7.15-7.19(1H,m),7.55(1H,s),7.59-7.65(2H,m),7.83(1H,s),8.26-8.44(1H,m),10.53-10.64(1H,m).
Example 31
Figure JPOXMLDOC01-appb-I000148
Reaction A: 2- (4-Amino-5- (tert-butyl) -2-methylphenyl) ethanethioamide hydrochloride 50 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalene-2- Yl) A mixture of 44 mg of ethanone and 5 mL of ethanol was stirred at 70 ° C. for 2 hours. The reaction mixture was cooled to room temperature and ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. A 4 mol / L hydrogen chloride-ethyl acetate solution was added to the obtained residue, and the solid was collected by filtration to give a pale yellow solid.
Reaction B: To 1 mL of methylene chloride in 12 mg of N-ethyl-N-methylformamide was added 12 μL of oxalyl chloride, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was added to a mixture of the pale yellow solid obtained in reaction A, 12 μL of triethylamine and 1 mL of methylene chloride, and stirred at room temperature for 30 minutes to obtain reaction mixture B.
Reaction C: 12 μL of oxalyl chloride was added to 1 mL of methylene chloride in 12 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 15 minutes to obtain a reaction mixture C.
Reaction mixture C was added to reaction mixture B and stirred at room temperature for 30 minutes. A 10% aqueous potassium carbonate solution was added to the reaction mixture. The organic layer was separated and the aqueous layer was extracted with chloroform. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DNH type silica gel, hexane], 5 mol / L hydrogen chloride-ethyl acetate solution was added, the solid was collected by filtration, and N ′-(2- (2- ( tert-butyl) -5-methyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl 14 mg of hydrochloride salt of -N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.21-1.29 (3H, m), 1.34 (9H, s), 1.72-1.78 (4H, m), 2.32 (3H, s), 2.66-2.79 (4H , m), 3.19-3.29 (3H, m), 3.54-3.66 (2H, m), 4.43 (2H, s), 7.10 (1H, d, J = 7.6Hz), 7.15-7.19 (1H, m), 7.55 (1H, s), 7.59-7.65 (2H, m), 7.83 (1H, s), 8.26-8.44 (1H, m), 10.53-10.64 (1H, m).
実施例32
Figure JPOXMLDOC01-appb-I000149
N-エチル-N-メチルホルムアミド15mgのクロロホルム1mL溶液に、塩化オキサリル15μLを加え、室温で10分間撹拌した。反応混合物に、2,5-ジフルオロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン41mgのクロロホルム2mL溶液を加え、室温で20分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、淡黄色固体のN’-(2,5-ジフルオロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩40mgを得た。
1H-NMR(DMSO-d6)δ値:1.18-1.35(3H,m),1.69-1.84(4H,m),2.65-2.84(4H,m),3.25-3.39(3H,m),3.61-3.78(2H,m),4.45(2H,s),7.09(1H,d,J=8.3Hz),7.56-7.73(4H,m),7.90(1H,s),8.47-8.70(1H,m),11.35-11.65(1H,m).
Example 32
Figure JPOXMLDOC01-appb-I000149
15 μL of oxalyl chloride was added to a solution of N-ethyl-N-methylformamide 15 mg in 1 mL of chloroform and stirred at room temperature for 10 minutes. To the reaction mixture, 2,5-difluoro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 41 mg chloroform 2 mL The solution was added and stirred at room temperature for 20 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid matter was collected by filtration, and light yellow solid N ′-(2,5-difluoro-4-((4- (5,6,7,8-tetrahydronaphthalene- 40 mg of hydrochloride of 2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.18-1.35 (3H, m), 1.69-1.84 (4H, m), 2.65-2.84 (4H, m), 3.25-3.39 (3H, m), 3.61 -3.78 (2H, m), 4.45 (2H, s), 7.09 (1H, d, J = 8.3Hz), 7.56-7.73 (4H, m), 7.90 (1H, s), 8.47-8.70 (1H, m ), 11.35-11.65 (1H, m).
実施例33
Figure JPOXMLDOC01-appb-I000150
N-エチル-N-メチルホルムアミド24mgのクロロホルム1mL溶液に、塩化オキサリル24μLを加え、室温で10分間撹拌した。反応混合物に、2,5-ジクロロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン72mgのクロロホルム2mL溶液を加え、室温で15分間撹拌した。減圧下で反応混合物の溶媒を留去した。得られた残留物に酢酸エチルを加え、固形物を濾取し、褐色固体のN’-(2,5-ジクロロ-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩90mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.32(3H,m),1.67-1.80(4H,m),2.64-2.81(4H,m),3.20-3.34(3H,m),3.58-3.73(2H,m),4.54(2H,s),7.10(1H,d,J=7.8Hz),7.56-7.66(2H,m),7.85-7.94(2H,m),8.42-8.65(1H,m).
Example 33
Figure JPOXMLDOC01-appb-I000150
24 μL of oxalyl chloride was added to 1 mL of chloroform in 24 mg of N-ethyl-N-methylformamide, and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture, 2,5-dichloro-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) aniline 72 mg chloroform 2 mL The solution was added and stirred at room temperature for 15 minutes. The solvent of the reaction mixture was distilled off under reduced pressure. Ethyl acetate was added to the obtained residue, and the solid matter was collected by filtration, and N ′-(2,5-dichloro-4-((4- (5,6,7,8-tetrahydronaphthalene-2) was obtained as a brown solid. 90 mg of hydrochloride of -yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.32 (3H, m), 1.67-1.80 (4H, m), 2.64-2.81 (4H, m), 3.20-3.34 (3H, m), 3.58 -3.73 (2H, m), 4.54 (2H, s), 7.10 (1H, d, J = 7.8Hz), 7.56-7.66 (2H, m), 7.85-7.94 (2H, m), 8.42-8.65 (1H , m).
実施例34
Figure JPOXMLDOC01-appb-I000151
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-3,5-ジメチルフェニル)エタンチオアミド100mg、2-ブロモ-1-(5,6,7,8-テトラヒドロナフタレン-2-イル)エタノン98mgおよびメタノール5mLの混合物を1時間加熱還流した。反応混合物を室温まで冷却し、減圧下で溶媒を留去した。得られた残留物に、酢酸エチルおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物に、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、凍結乾燥して淡黄色固体のN’-(2,6-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩148mgを得た。
1H-NMR(DMSO-d6)δ値:1.20-1.29(3H,m),1.71-1.79(4H,m),2.25(6H,s),2.66-2.81(4H,m),3.22-3.28(3H,m),3.54-3.69(2H,m),4.35(2H,s),7.10(1H,d,J=8.3Hz),7.22(2H,s),7.60-7.65(2H,m),7.85(1H,s),8.12-8.30(1H,m),10.56-10.73(1H,m).
Example 34
Figure JPOXMLDOC01-appb-I000151
2- (4-((((Ethyl (methyl) amino) methylene) amino) -3,5-dimethylphenyl) ethanethioamide 100 mg, 2-bromo-1- (5,6,7,8-tetrahydronaphthalene-2- Yl) A mixture of 98 mg of ethanone and 5 mL of methanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and the solvent was distilled off under reduced pressure. To the obtained residue, ethyl acetate and 10% aqueous potassium carbonate solution were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue, a 5 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid matter was collected by filtration, freeze-dried, and light yellow solid N ′-(2,6-dimethyl-4-((4- 148 mg of (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.20-1.29 (3H, m), 1.71-1.79 (4H, m), 2.25 (6H, s), 2.66-2.81 (4H, m), 3.22-3.28 (3H, m), 3.54-3.69 (2H, m), 4.35 (2H, s), 7.10 (1H, d, J = 8.3Hz), 7.22 (2H, s), 7.60-7.65 (2H, m), 7.85 (1H, s), 8.12-8.30 (1H, m), 10.56-10.73 (1H, m).
実施例35
Figure JPOXMLDOC01-appb-I000152
N-エチル-N-メチルホルムアミド42mgの塩化メチレン5mL溶液に、氷冷下で、塩化オキサリル42μLを加え、室温で40分間撹拌した。反応混合物に、氷冷下で、2,3-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)アニリン85mgの塩化メチレン5mL溶液を加え、氷冷下で、1時間30分間撹拌した。反応混合物に、クロロホルムおよび10%炭酸カリウム水溶液を加えた。有機層を分取し、無水硫酸ナトリウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DNH型シリカゲル、ヘキサン:クロロホルムの勾配溶離=100:0-15:1]で精製し、5mol/L塩化水素-酢酸エチル溶液を加え、固形物を濾取し、白色固体のN’-(2,3-ジメチル-4-((4-(5,6,7,8-テトラヒドロナフタレン-2-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩97mgを得た。
1H-NMR(DMSO-d6)δ値:1.26(3H,t,J=7.1Hz),1.71-1.80(4H,m),2.22-2.29(6H,m),2.66-2.82(4H,m),3.22-3.31(3H,m),3.62(2H,q,J=7.1Hz),4.45(2H,s),7.09(1H,d,J=7.7Hz),7.20-7.26(1H,m),7.33(1H,d,J=7.7Hz),7.60-7.66(2H,m),7.83(1H,s),8.24-8.44(1H,m),10.75-11.23(1H,m).
Example 35
Figure JPOXMLDOC01-appb-I000152
To a solution of 42 mg of N-ethyl-N-methylformamide in 5 mL of methylene chloride was added 42 μL of oxalyl chloride under ice cooling, and the mixture was stirred at room temperature for 40 minutes. To the reaction mixture was added 2,3-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl) under ice cooling. A solution of 85 mg of aniline in 5 mL of methylene chloride was added, and the mixture was stirred for 1 hour and 30 minutes under ice cooling. Chloroform and 10% aqueous potassium carbonate solution were added to the reaction mixture. The organic layer was separated, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography [DNH type silica gel, hexane: chloroform gradient elution = 100: 0-15: 1], 5 mol / L hydrogen chloride-ethyl acetate solution was added, and the solid was filtered. N ′-(2,3-dimethyl-4-((4- (5,6,7,8-tetrahydronaphthalen-2-yl) -1,3-thiazol-2-yl) methyl as a white solid 97 mg) of phenyl) -N-ethyl-N-methylimidoformamide hydrochloride was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.26 (3H, t, J = 7.1 Hz), 1.71-1.80 (4H, m), 2.22-2.29 (6H, m), 2.66-2.82 (4H, m ), 3.22-3.31 (3H, m), 3.62 (2H, q, J = 7.1Hz), 4.45 (2H, s), 7.09 (1H, d, J = 7.7Hz), 7.20-7.26 (1H, m) , 7.33 (1H, d, J = 7.7Hz), 7.60-7.66 (2H, m), 7.83 (1H, s), 8.24-8.44 (1H, m), 10.75-11.23 (1H, m).
実施例36
Figure JPOXMLDOC01-appb-I000153
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩0.10g、2-ブロモ-1-(1,2,3,4-テトラヒドロ-1,4-メタノナフタレン-6-イル)エタノン0.11gおよびメタノール2.0mLの混合物を2時間加熱還流した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸マグネシウムで乾燥後、活性炭を加えた。不溶物を濾去後、減圧下で溶媒を留去した。得られた残留物に、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=100:0-1:3]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に、アセトンおよび酢酸エチルを加え、固形物を濾取し、褐色固体のN’-(2,5-ジメチル-4-((4-(1,2,3,4-テトラヒドロ-1,4-メタノナフタレン-6-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩63mgを得た。
1H-NMR(DMSO-d6)δ値:1.04-1.11(2H,m),1.22-1.29(3H,m),1.49-1.55(1H,m),1.62-1.68(1H,m),1.89-1.96(2H,m),2.26-2.33(6H,m),3.20-3.71(7H,m),4.37(2H,s),7.14-7.25(2H,m),7.28(1H,s),7.62(1H,dd,J=7.6,1.5Hz),7.72(1H,s),7.80(1H,s),8.26-8.45(1H,m),10.63-10.82(1H,m).
Example 36
Figure JPOXMLDOC01-appb-I000153
0.10 g of hydrochloride of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide, 2-bromo-1- (1,2,3,4-tetrahydro A mixture of 0.11, 4-methanonaphthalen-6-yl) ethanone and 2.0 mL of methanol was heated to reflux for 2 hours. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated, dried over anhydrous magnesium sulfate, and activated carbon was added. The insoluble material was removed by filtration, and the solvent was distilled off under reduced pressure. To the obtained residue, a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate gradient elution = 100: 0-1: 3], a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the mixture was reduced under reduced pressure. The solvent was distilled off. Acetone and ethyl acetate are added to the obtained residue, and the solid matter is collected by filtration, and N ′-(2,5-dimethyl-4-((4- (1,2,3,4-tetrahydro 63 mg of hydrochloride of 1,4-methanonaphthalen-6-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.04-1.11 (2H, m), 1.22-1.29 (3H, m), 1.49-1.55 (1H, m), 1.62-1.68 (1H, m), 1.89 -1.96 (2H, m), 2.26-2.33 (6H, m), 3.20-3.71 (7H, m), 4.37 (2H, s), 7.14-7.25 (2H, m), 7.28 (1H, s), 7.62 (1H, dd, J = 7.6,1.5Hz), 7.72 (1H, s), 7.80 (1H, s), 8.26-8.45 (1H, m), 10.63-10.82 (1H, m).
実施例37
Figure JPOXMLDOC01-appb-I000154
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩0.12g、2-ブロモ-1-(2-メチル-2,3-ジヒドロ-1H-インデン-5-イル)エタノン0.10gおよびメタノール2.0mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、シリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=100:0-4:1]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に、アセトン、エタノールおよび酢酸エチルを加え、固形物を濾取し、青緑色固体のN’-(2,5-ジメチル-4-((4-(2-メチル-2,3-ジヒドロ-1H-インデン-5-イル)-1,3-チアゾール-2-イル)メチル)フェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩70mgを得た。
1H-NMR(DMSO-d6)δ値:1.11(3H,d,J=6.3Hz),1.22-1.29(3H,m),2.26-2.35(6H,m),2.45-2.58(3H,m),2.98-3.11(2H,m),3.22-3.29(3H,m),3.58-3.71(2H,m),4.37(2H,s),7.14-7.32(3H,m),7.66-7.70(1H,m),7.74(1H,s),7.83(1H,s),8.26-8.45(1H,m),10.72-10.92(1H,m).
Example 37
Figure JPOXMLDOC01-appb-I000154
0.12 g of 2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride, 2-bromo-1- (2-methyl-2,3-dihydro A mixture of −1 g-inden-5-yl) ethanone and 2.0 mL methanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature, purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate gradient elution = 100: 0-4: 1], 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the pressure was reduced. The solvent was distilled off under. Acetone, ethanol and ethyl acetate are added to the obtained residue, and the solid is collected by filtration, and N ′-(2,5-dimethyl-4-((4- (2-methyl-2,2, 70 mg of hydrochloride of 3-dihydro-1H-inden-5-yl) -1,3-thiazol-2-yl) methyl) phenyl) -N-ethyl-N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.11 (3H, d, J = 6.3 Hz), 1.22-1.29 (3H, m), 2.26-2.35 (6H, m), 2.45-2.58 (3H, m ), 2.98-3.11 (2H, m), 3.22-3.29 (3H, m), 3.58-3.71 (2H, m), 4.37 (2H, s), 7.14-7.32 (3H, m), 7.66-7.70 (1H) , m), 7.74 (1H, s), 7.83 (1H, s), 8.26-8.45 (1H, m), 10.72-10.92 (1H, m).
実施例38
Figure JPOXMLDOC01-appb-I000155
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩67mg、2-ブロモ-1-(2,2-ジメチル-2,3-ジヒドロ-1H-インデン-5-イル)エタノン53mgおよびメタノール2.0mLの混合物を、1時間加熱還流した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=99:1-17:3]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に、エタノール、アセトンおよび酢酸エチルを加え、固形物を濾取し、白色固体のN’-(4-((4-(2,2-ジメチル-2,3-ジヒドロ-1H-インデン-5-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミドの塩酸塩40mgを得た。
1H-NMR(CD3OD)δ値:1.16(6H,s),1.34-1.41(3H,m),2.33-2.38(6H,m),2.74(2H,s),2.76(2H,s),3.26-3.38(3H,m),3.63-3.72(2H,m),4.42(2H,s),7.18-7.22(2H,m),7.31(1H,s),7.58-7.66(3H,m),8.16-8.34(1H,m).
Example 38
Figure JPOXMLDOC01-appb-I000155
2- (4-(((ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 67 mg, 2-bromo-1- (2,2-dimethyl-2,3- A mixture of 53 mg of dihydro-1H-inden-5-yl) ethanone and 2.0 mL of methanol was heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated, washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate gradient elution = 99: 1-17: 3], a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the mixture was reduced under reduced pressure. The solvent was distilled off. Ethanol, acetone and ethyl acetate were added to the obtained residue, and the solid was collected by filtration, and white solid N ′-(4-((4- (2,2-dimethyl-2,3-dihydro-1H -Inden-5-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N-ethyl-N-methylimidoformamide hydrochloride 40 mg was obtained.
1 H-NMR (CD 3 OD) δ value: 1.16 (6H, s), 1.34-1.41 (3H, m), 2.33-2.38 (6H, m), 2.74 (2H, s), 2.76 (2H, s) , 3.26-3.38 (3H, m), 3.63-3.72 (2H, m), 4.42 (2H, s), 7.18-7.22 (2H, m), 7.31 (1H, s), 7.58-7.66 (3H, m) , 8.16-8.34 (1H, m).
実施例39
Figure JPOXMLDOC01-appb-I000156
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩0.29g、1-(ビシクロ[4.2.0]オクタ-1,3,5-トリエン-3-イル)-2-ブロモエタノン0.22gおよびメタノール4.4mLの混合物を1時間加熱還流した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、無水硫酸マグネシウムで乾燥し、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=99:1-4:1]で精製し、白色固体のN’-(4-((4-(ビシクロ[4.2.0]オクタ-1,3,5-トリエン-3-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-エチル-N-メチルイミドホルムアミド0.16gを得た。
1H-NMR(CDCl3)δ値:1.21(3H,t,J=7.1Hz),2.24(3H,s),2.25(3H,s),2.99(3H,s),3.20(4H,s),3.27-3.47(2H,m),4.28(2H,s),6.59(1H,s),7.05(1H,s),7.08(1H,d,J=8.0Hz),7.20(1H,s),7.44(1H,s),7.57(1H,s),7.74(1H,dd,J=8.0,1.5Hz).
Example 39
Figure JPOXMLDOC01-appb-I000156
2- (4-(((Ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 0.29 g, 1- (bicyclo [4.2.0] octa-1,3 , 5-trien-3-yl) -2-bromoethanone and 4.4 mL of methanol were heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and saturated aqueous sodium bicarbonate and ethyl acetate were added. The organic layer was separated and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate gradient elution = 99: 1-4: 1], and white solid N ′-(4-((4- (bicyclo [4.2.0] octa-1,3,5-trien-3-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N-ethyl-N-methyl 0.16 g of imidoformamide was obtained.
1 H-NMR (CDCl 3 ) δ value: 1.21 (3H, t, J = 7.1 Hz), 2.24 (3H, s), 2.25 (3H, s), 2.99 (3H, s), 3.20 (4H, s) , 3.27-3.47 (2H, m), 4.28 (2H, s), 6.59 (1H, s), 7.05 (1H, s), 7.08 (1H, d, J = 8.0Hz), 7.20 (1H, s), 7.44 (1H, s), 7.57 (1H, s), 7.74 (1H, dd, J = 8.0,1.5Hz).
実施例40
Figure JPOXMLDOC01-appb-I000157
2-(4-(((エチル(メチル)アミノ)メチレン)アミノ)-2,5-ジメチルフェニル)エタンチオアミドの塩酸塩0.14g、2-ブロモ-1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)エタノン0.13gおよびメタノール2.0mLの混合物を1時間35分間加熱還流した。反応混合物を室温まで冷却し、2-ブロモ-1-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)エタノン0.13gおよびメタノール2.0mLを加え、1時間加熱還流した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液、飽和塩化ナトリウム水溶液および酢酸エチルを加えた。有機層を分取し、水層を酢酸エチルで抽出した。有機層および抽出液を併せ、無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。得られた残留物をシリカゲルカラムクロマトグラフィー[DIOL型シリカゲル、ヘキサン:酢酸エチルの勾配溶離=99:1-17:3]で精製し、4mol/L塩化水素-酢酸エチル溶液を加え、減圧下で溶媒を留去した。得られた残留物に、エタノールおよび酢酸エチルを加え、固形物を濾取した。得られた固形物にアセトンを加え、濾取し、白色固体のN-エチル-N’-(4-((4-(5,6,7,8,9,10-ヘキサヒドロベンゾ[8]アヌレン-2-イル)-1,3-チアゾール-2-イル)メチル)-2,5-ジメチルフェニル)-N-メチルイミドホルムアミドの塩酸塩61mgを得た。
1H-NMR(DMSO-d6)δ値:1.22-1.36(7H,m),1.58-1.68(4H,m),2.27-2.34(6H,m),2.71-2.80(4H,m),3.20-3.29(3H,m),3.35-3.67(2H,m),4.38(2H,s),7.16(1H,d,J=7.6Hz),7.21-7.25(1H,m),7.30(1H,s),7.65-7.69(2H,m),7.85(1H,s),8.26-8.44(1H,m),10.56-10.72(1H,m).
Example 40
Figure JPOXMLDOC01-appb-I000157
2- (4-((((Ethyl (methyl) amino) methylene) amino) -2,5-dimethylphenyl) ethanethioamide hydrochloride 0.14 g, 2-bromo-1- (5,6,7,8,9 , 10-hexahydrobenzo [8] annulen-2-yl) ethanone and a mixture of methanol 2.0 mL were heated to reflux for 1 hour 35 minutes. The reaction mixture is cooled to room temperature, 0.13 g of 2-bromo-1- (5,6,7,8,9,10-hexahydrobenzo [8] annulen-2-yl) ethanone and 2.0 mL of methanol are added, and 1 Heated to reflux for hours. The reaction mixture was cooled to room temperature, and saturated aqueous sodium hydrogen carbonate solution, saturated aqueous sodium chloride solution and ethyl acetate were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [DIOL type silica gel, hexane: ethyl acetate gradient elution = 99: 1-17: 3], a 4 mol / L hydrogen chloride-ethyl acetate solution was added, and the mixture was reduced under reduced pressure. The solvent was distilled off. Ethanol and ethyl acetate were added to the obtained residue, and the solid was collected by filtration. Acetone was added to the obtained solid substance, and the mixture was collected by filtration. 61 mg of hydrochloride of annulen-2-yl) -1,3-thiazol-2-yl) methyl) -2,5-dimethylphenyl) -N-methylimidoformamide was obtained.
1 H-NMR (DMSO-d 6 ) δ value: 1.22-1.36 (7H, m), 1.58-1.68 (4H, m), 2.27-2.34 (6H, m), 2.71-2.80 (4H, m), 3.20 -3.29 (3H, m), 3.35-3.67 (2H, m), 4.38 (2H, s), 7.16 (1H, d, J = 7.6Hz), 7.21-7.25 (1H, m), 7.30 (1H, s ), 7.65-7.69 (2H, m), 7.85 (1H, s), 8.26-8.44 (1H, m), 10.56-10.72 (1H, m).
 一般式[1]で表される化合物またはその塩は、優れた抗真菌活性を有し、抗真菌剤として有用である。また、別の態様では、一般式[1]で表される化合物またはその塩は、安全性にも優れ、カンジダ属菌、アスペルギルス属菌および白癬菌属菌に対する抗真菌剤として有用である。 The compound represented by the general formula [1] or a salt thereof has excellent antifungal activity and is useful as an antifungal agent. In another embodiment, the compound represented by the general formula [1] or a salt thereof is excellent in safety and is useful as an antifungal agent against Candida, Aspergillus, and Trichophyton.

Claims (14)

  1. 一般式
    Figure JPOXMLDOC01-appb-C000001
    「式中、RおよびRは、同一または異なって、水素原子、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基を;
    は、置換されていてもよいジヒドロベンゾシクロブテニル基、置換されていてもよいインダニル基、置換されていてもよいインデニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいジヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいジヒドロ-5H-ベンゾシクロヘプテニル基、置換されていてもよい5H-ベンゾシクロヘプテニル基、置換されていてもよいヘキサヒドロベンゾシクロオクテニル基、置換されていてもよいテトラヒドロベンゾシクロオクテニル基、置換されていてもよいジヒドロベンゾシクロオクテニル基、置換されていてもよいテトラヒドロメタノナフチル基または置換されていてもよいテトラヒドロエタノナフチル基を;
    およびRは、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいアリール基または置換されていてもよい単環の複素環式基;または、
    およびRは、それらが結合する窒素原子と一緒になって形成される、置換されていてもよい環状アミノ基を;
    は、硫黄原子、C1-6アルキレン基または一般式NR「式中、Rは、水素原子、置換されていてもよいC1-6アルキル基またはイミノ保護基を示す。」で表される基を;
    およびZは、同一または異なって、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基を示す。」で-表される基を;
    は、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子または置換されていてもよいC1-6アルキル基を示す。」で表される基を意味する。」で表される化合物またはその塩。
    General formula
    Figure JPOXMLDOC01-appb-C000001
    In the formula, R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, or an optionally substituted C 2- 6 alkenyl group, optionally substituted C 2-6 alkynyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 alkoxy group, optionally substituted A C 1-6 alkylamino group, an optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, a substituted Arylthio group which may be substituted, aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, protected Good amino group, An optionally protected hydroxyl group or an optionally protected carboxyl group;
    R 3 is an optionally substituted dihydrobenzocyclobutenyl group, an optionally substituted indanyl group, an optionally substituted indenyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted Good dihydronaphthyl group, optionally substituted benzocycloheptyl group, optionally substituted dihydro-5H-benzocycloheptenyl group, optionally substituted 5H-benzocycloheptenyl group, substituted May be a hexahydrobenzocyclooctenyl group, an optionally substituted tetrahydrobenzocyclooctenyl group, an optionally substituted dihydrobenzocyclooctenyl group, an optionally substituted tetrahydromethanonaphthyl group or a substituted An optionally tetrahydroethanonaphthyl group;
    R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− A 6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted monocyclic heterocyclic group; or
    R 4 and R 5 are an optionally substituted cyclic amino group formed together with the nitrogen atom to which they are attached;
    X 1 represents a sulfur atom, a C 1-6 alkylene group or a general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group. The group represented;
    Z 1 and Z 2 are the same or different and are each a nitrogen atom or a general formula CR c wherein R c is a hydrogen atom, a halogen atom, a cyano group, a nitro group, or an optionally substituted C 1-6 alkyl. A group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1 -6 alkoxy group, optionally substituted C 1-6 alkylamino group, optionally substituted di (C 1-6 alkyl) amino group, optionally substituted C 1-6 alkylthio group, substituted Aryloxy group which may be substituted, arylthio group which may be substituted, aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic which may be substituted Heterocyclic A group, an amino group which may be protected, a hydroxyl group which may be protected or a carboxyl group which may be protected;
    Z 3 represents a nitrogen atom or a group represented by the general formula CR b wherein R b represents a hydrogen atom, a halogen atom or an optionally substituted C 1-6 alkyl group. Or a salt thereof.
  2. およびRが、同一または異なって、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基;
    が、置換されていてもよいインダニル基、置換されていてもよいインデニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいジヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいジヒドロ-5H-ベンゾシクロヘプテニル基または置換されていてもよい5H-ベンゾシクロヘプテニル基;
    およびRが、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいアリール基または置換されていてもよい単環の複素環式基;または、
    およびRが、それらが結合する窒素原子と一緒になって形成される、置換されていてもよい環状アミノ基;
    が、硫黄原子、メチレン基または一般式NR「式中、Rは、水素原子、置換されていてもよいC1-6アルキル基またはイミノ保護基を示す。」で表される基;
    およびZが、同一または異なって、窒素原子または式CHで表される基;
    が、窒素原子または一般式CR「式中、Rは、水素原子、ハロゲン原子または置換されていてもよいC1-6アルキル基を示す。」で表される基である請求項1に記載の化合物またはその塩。
    R 1 and R 2 are the same or different and are each a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, a substituted An optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted C 1-6 alkylamino group , An optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, an optionally substituted aryloxy group, an optionally substituted arylthio group, Aryl group which may be substituted, monocyclic heterocyclic group which may be substituted, bicyclic heterocyclic group which may be substituted, amino group which may be protected, protected May A hydroxyl group or an optionally protected carboxyl group;
    R 3 is an optionally substituted indanyl group, an optionally substituted indenyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted dihydronaphthyl group, an optionally substituted benzocyclo group. A heptyl group, an optionally substituted dihydro-5H-benzocycloheptenyl group or an optionally substituted 5H-benzocycloheptenyl group;
    R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− A 6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted aryl group or an optionally substituted monocyclic heterocyclic group; or
    An optionally substituted cyclic amino group formed by R 4 and R 5 together with the nitrogen atom to which they are attached;
    X 1 is a sulfur atom, a methylene group, or a group represented by the general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group. ;
    Z 1 and Z 2 are the same or different and are a nitrogen atom or a group represented by the formula CH;
    Z 3 is a nitrogen atom or a group represented by the general formula CR b , wherein R b represents a hydrogen atom, a halogen atom or an optionally substituted C 1-6 alkyl group. 2. The compound or a salt thereof according to 1.
  3. およびZが、同一または異なって、一般式CR「式中、Rは、水素原子、ハロゲン原子、シアノ基、ニトロ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基、置換されていてもよいC1-6アルキルアミノ基、置換されていてもよいジ(C1-6アルキル)アミノ基、置換されていてもよいC1-6アルキルチオ基、置換されていてもよいアリールオキシ基、置換されていてもよいアリールチオ基、置換されていてもよいアリール基、置換されていてもよい単環の複素環式基、置換されていてもよい二環式の複素環式基、保護されていてもよいアミノ基、保護されていてもよいヒドロキシル基または保護されていてもよいカルボキシル基を示す。」で表される基である請求項1に記載の化合物またはその塩。 Z 1 and Z 2 may be the same or different and have the general formula CR c , wherein R c is a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally substituted C 1-6 alkyl group, a substituted group An optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, optionally substituted C 1-6 alkylamino group, optionally substituted di (C 1-6 alkyl) amino group, an optionally substituted C 1-6 alkylthio group, substituted An aryloxy group which may be substituted, an arylthio group which may be substituted, an aryl group which may be substituted, a monocyclic heterocyclic group which may be substituted, a bicyclic heterocyclic ring which may be substituted Formula group, protected The compound or a salt thereof according to claim 1, which is a group represented by “an amino group which may be protected, a hydroxyl group which may be protected or a carboxyl group which may be protected.”
  4. およびZが、式CHで表される基である請求項1または2に記載の化合物またはその塩。 The compound or a salt thereof according to claim 1 or 2, wherein Z 1 and Z 2 are a group represented by the formula CH.
  5. およびRが、同一または異なって、水素原子、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基、置換されていてもよいC3-8シクロアルキル基、置換されていてもよいC1-6アルコキシ基または置換されていてもよいアリール基である請求項1、3および4のいずれか一項に記載の化合物またはその塩。 R 1 and R 2 are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or a substituted 2. An optionally substituted C 2-6 alkynyl group, an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, or an optionally substituted aryl group. 5. The compound or a salt thereof according to any one of 3 and 4.
  6. およびRが、同一または異なって、ハロゲン原子、シアノ基、置換されていてもよいC1-6アルキル基、置換されていてもよいC3-8シクロアルキル基または置換されていてもよいC1-6アルコキシ基である請求項1~4のいずれか一項に記載の化合物またはその塩。 R 1 and R 2 may be the same or different and each may be a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-8 cycloalkyl group or an optionally substituted The compound or a salt thereof according to any one of claims 1 to 4, which is a good C 1-6 alkoxy group.
  7. が、C1-6アルキレン基または一般式NR「式中、Rは、水素原子、置換されていてもよいC1-6アルキル基またはイミノ保護基を示す。」で表される基である請求項1、3、4、5および6のいずれか一項に記載の化合物またはその塩。 X 1 represents a C 1-6 alkylene group or a general formula NR a , wherein R a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or an imino protecting group. The compound or a salt thereof according to any one of claims 1, 3, 4, 5, and 6, which is a group.
  8. が、メチレン基または一般式NRa1「式中、Ra1は、水素原子またはイミノ保護基を示す。」で表される基である請求項1~6のいずれか一項に記載の化合物またはその塩。 The compound according to any one of claims 1 to 6, wherein X 1 is a methylene group or a group represented by the general formula NR a1 , wherein R a1 represents a hydrogen atom or an imino protecting group. Or its salt.
  9. が、メチレン基である請求項1~6のいずれか一項に記載の化合物またはその塩。 The compound or a salt thereof according to any one of claims 1 to 6, wherein X 1 is a methylene group.
  10. およびRが、同一または異なって、水素原子、置換されていてもよいC1-6アルキル基、置換されていてもよいC2-6アルケニル基、置換されていてもよいC2-6アルキニル基または置換されていてもよいC3-8シクロアルキル基である請求項1~9のいずれか一項に記載の化合物またはその塩。 R 4 and R 5 are the same or different and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, or an optionally substituted C 2− The compound or a salt thereof according to any one of claims 1 to 9, which is a 6 alkynyl group or an optionally substituted C 3-8 cycloalkyl group.
  11. およびRが、同一または異なって、水素原子またはC1-6アルキル基である請求項1~9のいずれか一項に記載の化合物またはその塩。 The compound or a salt thereof according to any one of claims 1 to 9, wherein R 4 and R 5 are the same or different and each is a hydrogen atom or a C 1-6 alkyl group.
  12. が、置換されていてもよいジヒドロベンゾシクロブテニル基、置換されていてもよいインダニル基、置換されていてもよいテトラヒドロナフチル基、置換されていてもよいベンゾシクロヘプチル基、置換されていてもよいヘキサヒドロベンゾシクロオクテニル基または置換されていてもよいテトラヒドロメタノナフチル基である請求項1および3~11のいずれか一項に記載の化合物またはその塩。 R 3 is an optionally substituted dihydrobenzocyclobutenyl group, an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group, an optionally substituted benzocycloheptyl group, a substituted The compound or a salt thereof according to any one of claims 1 and 3 to 11, which is an optionally substituted hexahydrobenzocyclooctenyl group or an optionally substituted tetrahydromethanonaphthyl group.
  13. が、置換されていてもよいインダニル基、置換されていてもよいテトラヒドロナフチル基または置換されていてもよいベンゾシクロヘプチル基である請求項1~11のいずれか一項に記載の化合物またはその塩。 The compound according to any one of claims 1 to 11, wherein R 3 is an optionally substituted indanyl group, an optionally substituted tetrahydronaphthyl group, or an optionally substituted benzocycloheptyl group. Its salt.
  14. 請求項1~13のいずれか一項に記載の化合物またはその塩を含有する抗真菌剤。 An antifungal agent comprising the compound according to any one of claims 1 to 13 or a salt thereof.
PCT/JP2014/051966 2013-01-30 2014-01-29 Amidine compound and salt thereof WO2014119617A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013015066 2013-01-30
JP2013-015066 2013-01-30

Publications (1)

Publication Number Publication Date
WO2014119617A1 true WO2014119617A1 (en) 2014-08-07

Family

ID=51262329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/051966 WO2014119617A1 (en) 2013-01-30 2014-01-29 Amidine compound and salt thereof

Country Status (1)

Country Link
WO (1) WO2014119617A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025962A1 (en) * 2013-08-23 2015-02-26 富山化学工業株式会社 Amidine compound or salt thereof
WO2016043260A1 (en) * 2014-09-19 2016-03-24 塩野義製薬株式会社 Cyclic guanidine or amidine compound
WO2016095870A1 (en) * 2014-12-19 2016-06-23 中国科学院上海有机化学研究所 Bisphenol and diamine containing benzocyclobutene structural unit, and preparation and application thereof
WO2018069841A1 (en) * 2016-10-14 2018-04-19 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
WO2018211442A1 (en) 2017-05-18 2018-11-22 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
WO2019202459A1 (en) 2018-04-16 2019-10-24 Pi Industries Ltd. Use of 4-substituted phenylamidine compounds for controlling disease rust diseases in plants
CN113387842A (en) * 2021-07-08 2021-09-14 成都泰和伟业生物科技有限公司 Method for synthesizing aromatic primary amine through OTf amine
RU2796397C2 (en) * 2016-10-14 2023-05-23 Пи Индастриз Лтд 4-substituted phenylamine derivatives and their use to protect crops against undesirable phytopathogenic microorganisms

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009185020A (en) * 2008-01-11 2009-08-20 Ishihara Sangyo Kaisha Ltd Pyridylamidine derivative or salt thereof, and agricultural or horticultural fungicide containing the same as active ingredient
JP2010520901A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 3,4-disubstituted phenoxyphenylamidines and their use as fungicides
JP2010520898A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Use of N2-phenylamidine as a herbicide
JP2010520905A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Fluoroalkylphenylamidines and their use as fungicides
JP2011525505A (en) * 2008-06-27 2011-09-22 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Thiadiazolyloxyphenylamidines and their use as fungicides
WO2013018735A1 (en) * 2011-07-29 2013-02-07 大正製薬株式会社 Amidine compound or salt thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520901A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 3,4-disubstituted phenoxyphenylamidines and their use as fungicides
JP2010520898A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Use of N2-phenylamidine as a herbicide
JP2010520905A (en) * 2007-03-12 2010-06-17 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Fluoroalkylphenylamidines and their use as fungicides
JP2009185020A (en) * 2008-01-11 2009-08-20 Ishihara Sangyo Kaisha Ltd Pyridylamidine derivative or salt thereof, and agricultural or horticultural fungicide containing the same as active ingredient
JP2011525505A (en) * 2008-06-27 2011-09-22 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Thiadiazolyloxyphenylamidines and their use as fungicides
WO2013018735A1 (en) * 2011-07-29 2013-02-07 大正製薬株式会社 Amidine compound or salt thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROSHI NAGASE, THE PRACTICE OF MEDICINAL CHEMISTRY JOKAN, vol. 1ST ED., 15 August 1998 (1998-08-15), TECHNOMICS, INC., pages 236 - 240 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025962A1 (en) * 2013-08-23 2015-02-26 富山化学工業株式会社 Amidine compound or salt thereof
WO2016043260A1 (en) * 2014-09-19 2016-03-24 塩野義製薬株式会社 Cyclic guanidine or amidine compound
WO2016095870A1 (en) * 2014-12-19 2016-06-23 中国科学院上海有机化学研究所 Bisphenol and diamine containing benzocyclobutene structural unit, and preparation and application thereof
CN105777519A (en) * 2014-12-19 2016-07-20 中国科学院上海有机化学研究所 Bisphenol or dual amine containing benzocyclobutene structure unit, preparation and application thereof
CN105777519B (en) * 2014-12-19 2019-05-17 中国科学院上海有机化学研究所 Bis-phenol, diamine and its preparation and application of one kind structural unit containing benzocyclobutene
WO2018069841A1 (en) * 2016-10-14 2018-04-19 Pi Industries Ltd 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
CN109843056A (en) * 2016-10-14 2019-06-04 印度商皮埃企业有限公司 Phenyl amine derivative that 4- is substituted and its by confrontation should not phytopathogenic microorganisms cover crop purposes
RU2796397C9 (en) * 2016-10-14 2024-03-26 Пи Индастриз Лтд 4-substituted phenylamine derivatives and their use to protect crops against undesirable phytopathogenic microorganisms
RU2796397C2 (en) * 2016-10-14 2023-05-23 Пи Индастриз Лтд 4-substituted phenylamine derivatives and their use to protect crops against undesirable phytopathogenic microorganisms
US11155517B2 (en) 2016-10-14 2021-10-26 Pi Industries Ltd. 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
US11524934B2 (en) 2017-04-20 2022-12-13 Pi Industries Ltd Phenylamine compounds
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
WO2018211442A1 (en) 2017-05-18 2018-11-22 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
WO2019202459A1 (en) 2018-04-16 2019-10-24 Pi Industries Ltd. Use of 4-substituted phenylamidine compounds for controlling disease rust diseases in plants
CN113387842A (en) * 2021-07-08 2021-09-14 成都泰和伟业生物科技有限公司 Method for synthesizing aromatic primary amine through OTf amine

Similar Documents

Publication Publication Date Title
WO2014119617A1 (en) Amidine compound and salt thereof
JP6160613B2 (en) Trk inhibitory compound
TWI583670B (en) Partially saturated nitrogenous heterocyclic compounds
CN102099355B (en) Phenyl and benzodioxinyl substituted indazoles derivatives
JP6569792B2 (en) Halogen-substituted heterocyclic compounds
TWI359810B (en) Carboxylic acid derivative containing thiazole rin
TWI706939B (en) Novel disubstituted 1,2,4-triazine compounds
KR102212981B1 (en) 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CA2958503A1 (en) Indazole compounds as fgfr kinase inhibitor, preparation and use thereof
JP2010514689A (en) Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
TW200417546A (en) New compounds
TW201036946A (en) N-acylanthranilic acid derivative or salt thereof
CN101605783A (en) As medicine, pharmaceutical composition especially as the novel N of IKK inhibitor, N '-2,4-hexichol amine pyrimidine derivates and preparation thereof
WO2022028346A1 (en) Aromatic compound and application thereof in antitumor drug
TW201138772A (en) Aroylquinoline compounds
CN111051300B (en) Novel heteroaryl amide derivatives as selective inhibitors of histone deacetylase 1 and/or 2 (HDAC 1-2)
TW201139400A (en) Process for the synthesis of ketobenzofuran derivatives
WO2015025962A1 (en) Amidine compound or salt thereof
KR20150126620A (en) Drug for respiratory diseases
WO2021239133A1 (en) Pyrimidine compound as axl inhibitor
HUE031639T2 (en) Condensed pyridine compounds as cb2 cannabinoid receptor ligands
Revelant et al. Exploring S1 plasticity and probing S1′ subsite of mammalian aminopeptidase N/CD13 with highly potent and selective aminobenzosuberone inhibitors
CN102300847A (en) Ppar Agonist Compositions And Methods Of Use
WO2010057418A1 (en) A phenoxypyrimidine derivative, its preparation method and the use thereof
TWI755418B (en) Biaryl compositions and methods for modulating a kinase cascade

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14746868

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14746868

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP